---
document_datetime: 2023-09-21 19:40:09
document_pages: 148
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf
document_name: lorviqua-epar-public-assessment-report_en.pdf
version: success
processing_time: 248.3923665
conversion_datetime: 2025-12-23 07:27:10.479
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 February 2019 EMA/CHMP/182840/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lorviqua

International non-proprietary name: lorlatinib

Procedure No. EMEA/H/C/004646/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | ..............................................7                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................8              |                                                                                                          |
| 2. Scientific discussion                                                                                                  | ..............................................................................10                         |
| 2.1. Problem statement                                                                                                    | .............................................................................................10          |
| 2.1.1. Disease or condition.........................................................................................10    |                                                                                                          |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                          | ....................................10                                                                   |
| 2.1.3. Biologic features/Aetiology and pathogenesis                                                                       | ......................................................10                                                 |
| 2.1.4. Clinical presentation, diagnosis and stage...........................................................11            |                                                                                                          |
| 2.1.5. Management...................................................................................................11    |                                                                                                          |
| 2.2. Quality aspects                                                                                                      | ..................................................................................................16     |
| 2.2.1. Introduction....................................................................................................16 |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................16    |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                         | ................................................................................18                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................20                      |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................20                                                                                 |
| 2.2.6. Recommendation for future quality development.................................................20                   |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                 | ............................................................................................21           |
| 2.3.1. Introduction....................................................................................................21 |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                       | .................................................................................................21      |
| 2.3.3. Toxicology                                                                                                         | ......................................................................................................32 |
| 2.3.4. Ecotoxicity/environmental risk assessment                                                                          | .........................................................38                                              |
| 2.3.5. Discussion on non-clinical aspects......................................................................38         |                                                                                                          |
| 2.3.6. Conclusion on the non-clinical aspects................................................................40           |                                                                                                          |
| 2.4. Clinical aspects                                                                                                     | ..................................................................................................40     |
| 2.4.1. Introduction....................................................................................................40 |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................43    |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................62       |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................65           |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................68            |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                    | ..................................................................................................68     |
| 2.5.1. Dose response study(ies)                                                                                           | .................................................................................69                      |
| 2.5.2. Main study......................................................................................................70 |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy ..........................................................................         | 104                                                                                                      |
| 2.5.4. Conclusions on the clinical efficacy...................................................................            | 107                                                                                                      |
| 2.6. Clinical safety                                                                                                      | .................................................................................................. 108   |
| 2.6.1. Discussion on clinical safety ............................................................................         | 133                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................            | 135                                                                                                      |
| 2.7. Risk Management Plan ......................................................................................          | 135                                                                                                      |
| 2.8. Pharmacovigilance............................................................................................        | 137                                                                                                      |
| 2.9. New Active Substance.......................................................................................          | 138                                                                                                      |
| 2.10. Product information                                                                                                 | ........................................................................................ 138             |

<div style=\"page-break-after: always\"></div>

2.10.1. User consultation  .........................................................................................  138

2.10.2. Additional monitoring ...................................................................................  138

3. Benefit-Risk Balance............................................................................  138

3.1. Therapeutic Context .........................................................................................  138

3.1.1. Disease or condition  .......................................................................................  138

3.1.2. Available therapies and unmet medical need  ..................................................... 139

3.1.3. Main clinical studies .......................................................................................  139

3.2. Favourable effects ............................................................................................  139

3.3. Uncertainties and limitations about favourable effects  ........................................... 140

3.4. Unfavourable effects  .........................................................................................  140

3.5. Uncertainties and limitations about unfavourable effects ....................................... 140

3.6. Effects Table  ....................................................................................................  141

3.7. Benefit-risk assessment and discussion  ............................................................... 142

3.7.1. Importance of favourable and unfavourable effects  ............................................ 142

3.7.2. Balance of benefits and risks  ...........................................................................  143

3.7.3. Additional considerations on the benefit-risk balance ......................................... 143

3.8. Conclusions .....................................................................................................  144

4. Recommendations ...............................................................................  144

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AAG         |  1-acid glycoprotein                                                                                                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------|
| ADR         | adverse drug reaction                                                                                                      |
| AE          | adverse event                                                                                                              |
| AESI        | adverse events of special interest                                                                                         |
| AIFA        | Italian Medicine Agency                                                                                                    |
| AJCC        | American Joint Committee for Cancer                                                                                        |
| ALK         | anaplastic lymphoma kinase                                                                                                 |
| ALP         | alkaline phosphatase                                                                                                       |
| ALT         | alanine aminotransferase                                                                                                   |
| AST         | aspartate aminotransferase                                                                                                 |
| ATP         | adenosine triphosphate                                                                                                     |
| AUC         | area under the plasma concentration-time curve                                                                             |
| AUC inf     | area under the plasma concentration-time profile from time 0 extrapolated to infinite time profile from time 0 to 24 hours |
| AUC 24      | area under the                                                                                                             |
| AUC tau     | plasma concentration-time area under the plasma concentration versus time interval from time zero                          |
| AV          | through the dosing interval atrioventricular                                                                               |
| BA          | bioavailability                                                                                                            |
| BBB         | blood-brain barrier                                                                                                        |
| BCS         | biopharmaceutics classification system                                                                                     |
| BE          | bioequivalence                                                                                                             |
| BID         | twice a day                                                                                                                |
| BOR         | Best Overall Response                                                                                                      |
| BTD         | Breakthrough Therapy Designation                                                                                           |
| cfDNA CHMP  | circulating free deoxyribonucleic acid Committee for Medicinal Products for Human Use                                      |
| CI          | Confidence Interval                                                                                                        |
| CL          | clearance                                                                                                                  |
| CLI         | single-dose clearance                                                                                                      |
| CM          | Carcinomatous meningitis                                                                                                   |
| CMA         | Conditional Marketing Authorisation                                                                                        |
| C max       | mean peak plasma concentration                                                                                             |
| CNA         | circulating nucleic acid                                                                                                   |
| CNS         | central nervous system                                                                                                     |
| CO          | Clinical Overview                                                                                                          |
| CQA         | critical quality attribute                                                                                                 |
| CRM         | continual reassessment method                                                                                              |
| CR CSF      | complete response cerebrospinal fluid                                                                                      |
| CSR         | clinical study report                                                                                                      |
| CTD         | Common Technical Document                                                                                                  |
| CV          | coefficient of variation                                                                                                   |
| CYP         | cytochrome P450                                                                                                            |
| DDI         | drug-drug interaction                                                                                                      |
| DLT         | dose-limiting toxicity                                                                                                     |
| DoE         | design of experiments                                                                                                      |
| DOR         | duration of response                                                                                                       |
| IC DOR      | Intracranial duration of response                                                                                          |
| DMA         | Danish Medicine Agency                                                                                                     |
| EC          | European Commission                                                                                                        |
| ECG         | electrocardiogram                                                                                                          |
| ECOG        | Eastern Cooperative Oncology Group                                                                                         |
| ECOG PS     | Eastern Cooperative Oncology Group Performance Status Evaluation of Drug-Induced Serious Hepatotoxicity                    |
| eDISH ELISA | enzyme-linked immunosorbent assay                                                                                          |
| EMA         | European Medicines Agency                                                                                                  |
| EML4        | echinoderm microtubule-associated protein-like 4 End-of-Phase 1                                                            |
| EOP1 EORTC  | European Organization for Research and Treatment of Cancer Core                                                            |
| QLQ-        | Quality of                                                                                                                 |
| C30         | Life Questionnaire                                                                                                         |

E-R

exposure response

EU

European Union

EXP

expansion

FAL

Final Advice Letter

FDA

FISH

Food and Drug Administration

Fluorescence in situ hybridisation

GC

gas chromatography

GCP

Good Clinical Practice

hPXR

human Pregnane X Receptor

hCAR

human constitutive androstane receptor

HDL

high density lipoprotein

HDPE

high density polyethylene

HPLC

high performance liquid chromatography

HSA

human serum albumin

IC

intracranial

IC ORR

intracranial objective response rate

IC50

50% inhibitive concentration

ICH

International Council for Harmonisation

ICR

Independent Central Review

IHC

immunohistochemistry

ILD

interstitial lung disease

IR

infrared

ITT

intention-to-treat

IV

intravenous

IU

international units

KRAS

Kirsten rat sarcoma viral oncogene homologue

LC

liquid chromatography

LM

Leptomeningeal disease

LDPE

low density polyethylene

LDL

low density lipoprotein

LIC

Lead-in Cohort

LOAEL

lowest-observed-adverse-effect level

LVEF

left ventricular ejection fraction

MAA

Marketing Authorization Application

MA

Marketing Authorisation

MAH

Marketing Authorisation Holder

MDZ

midazolam

MTD

maximum tolerated dose

MUGA

multi-gated acquisition

NCA

non-compartmental analysis

NDA

New Drug Application

NE

not estimable

NOAEL

no-observed-adverse-effect-level

MNT

not more than

NR

not reached

NSCLC

non-small cell lung cancer

OAT

organic anion transporter

OCT

organic cation transporter

ORR

objective response rate

OS

overall survival

PD

progressive disease

PFS

progression-free survival

Ph. Eur

European Pharmacopoeia

PK

pharmacokinetic(s)

PMAR

Pharmacokinetic Modeling Analysis Report

popPK

population pharmacokinetics

PR

partial response

PRO

patient reported outcome

PS

Performance Status

PT

Preferred Term

PXRD

powder X-ray diffractometer

QbD

quality by design

QC

Quality control

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| QD       | once daily                                    |
|----------|-----------------------------------------------|
| QLQ-LC13 | Quality of Life Questionnaire Lung Cancer 13  |
| QoL      | Quality of Life                               |
| QTc      | QT interval corrected for heart rate          |
| QTTP     | Quality target product profile                |
| RECIST   | Response Evaluation Criteria in Solid Tumours |
| RH       | relative humidity                             |
| ROS1     | c-ros oncogene 1                              |
| RP2D     | recommended Phase 2 dose                      |
| SA       | scientific advice                             |
| SAE      | serious adverse event                         |
| SCE      | Summary of Clinical Efficacy                  |
| SCP      | Summary of Clinical Pharmacology              |
| SCS      | Summary of Clinical Safety                    |
| SmPC     | Summary of Product Characteristics            |
| TAMC     | Total aerobic microbial count                 |
| TDI      | time-dependent inhibition                     |
| TDOSE    | total daily dose                              |
| TKI      | tyrosine kinase inhibitor                     |
| T max    | time to peak concentration                    |
| TQT      | thorough QT                                   |
| TTR      | time to tumour response                       |
| TYMC     | total combined yeasts/moulds count            |
| UGT      | uridine diphosphate-glucuronosyltransferase   |
| ULN      | upper limit of normal                         |
| US       | United States                                 |
| USPI     | United States Prescribing Information         |
| UV       | ultraviolet                                   |
| V ss     | steady-state volume of distribution           |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pfizer Limited submitted on 9 January 2018 an application for marketing authorisation to the European Medicines Agency (EMA) for Lorviqua, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA / Committee for Medicinal Products for Human Use (CHMP) on 15 September 2016.

The applicant applied for the following indication: Lorviqua monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with one or more ALK tyrosine kinase inhibitors (TKIs), except for patients treated with crizotinib as the only ALK-TKI.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) EMA/60972/201717 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's request(s) for consideration

## Conditional marketing authorisation

The applicant requested consideration of its application for a Conditional marketing authorisation in accordance with Article 14-a of Regulation (EC) No 726/2004.

## New active Substance status

The applicant requested the active substance lorlatinib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal

<div style=\"page-break-after: always\"></div>

product previously authorised within the European Union.

## Scientific advice

The applicant received Scientific Advice on the development relevant for the approved indication from the CHMP on 28 April 2016 (EMEA/H/SA/3268/1/2016/II). The Scientific Advice pertained to the following clinical aspects of the dossier:

- An open-label, non-comparative Phase 1b/2 study: Adequacy of the approach to the primary efficacy analysis whereby data is pooled across different ALK-positive NSCLC cohorts; whether the pooled efficacy data generated from the study could be used to support a conditional Marketing Authorisation application.
- A Phase 3 randomised, open label study of lorlatinib with standard of care (SOC) therapy as comparator: overall study design and objectives; proposed patient population (ALK-positive advanced NSCLC), eligibility criteria, and approach to identify ALK-positive patients; choice of SOC comparator; primary endpoint of progression-free survival, and key secondary endpoints; statistical approach including sample size, power, statistical testing of primary endpoint including effect size and proposed interim analysis; use of proposed patient reported outcome data adequacy of the safety data to initiate the Phase 3 study.
- Pharmacokinetic (PK) and clinical pharmacology studies: Adequacy of plan and timing of study submission in relation Marketing Authorisation Application (MAA).
- Regulatory approach and submission strategy: Adequacy of the Phase 3 study to support MAA, and suitability for use as confirmatory study to convert CMA to full MA.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Sinan B. Sarac Co-Rapporteur:  Daniela Melchiorri

| The application was received by the EMA on                                                                                                                              | 9 January 2018   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                | 1 February 2018  |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                          | 24 April 2018    |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                       | 26 April 2018    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                     | 7 May 2018       |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                 | 31 May 2018      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                     | 16 August 2018   |
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product: |                  |

<div style=\"page-break-after: always\"></div>

| A GCP inspection at two investigator sites (in Australia and Italy) and at the sponsor site in the USA was performed between 16 April 2018 and 22 June 2018. The outcome of the inspection carried out was issued on:   | 30 July 2018      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                                                 | 26 September 2018 |
| The CHMP agreed on a list of outstanding issues to be addressed in writing and in an oral explanation sent to the applicant on                                                                                          | 18 October 2018   |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                                         | 18 December 2018  |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                                                        | 17 January 2019   |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                                                 | 29 January 2019   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Lorviqua on                                | 28 February 2019  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

Although most patients with ALK-positive NSCLC derive substantial clinical benefit from crizotinib, some patients with ALK-positive NSCLC will not respond to treatment (intrinsic resistance), and other patients who initially experience clinical benefit will later develop resistance (acquired resistance). Next-generation ALK-TKIs such as ceritinib, alectinib, and brigatinib have been developed to address crizotinib treatment failure. However, ALK-positive NSCLC remains an incurable disease, as patients ultimately develop resistance to second-generation ALK-TKIs, including but not limited to emergence of brain metastases. Therefore, there is a need for additional ALK-TKIs, in patients whose disease has progressed on a second-generation ALK-TKI, which can overcome resistance mutations and with central nervous system (CNS) penetration.

## 2.1.1. Disease or condition

Lorviqua (lorlatinib) is intended as monotherapy for the treatment of adult patients with ALK-positive advanced  NSCLC  previously  treated  with  one  or  more  ALK  TKIs,  except  for  patients  treated  with crizotinib as the only ALK-TKI.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Lung cancer is one of the most common cancers in the world (1.8 million new cases in 2012), 12.9% of all new cancers worldwide 1 . In Europe, the age standardised predicted mortality rate for lung cancer was 35.98 per 100,000 men and 14.24 per 100,000 women as of 2015.

About  85%-90%  of  lung  cancers  are  constituted  by  NSCLCs,  and  ALK-positive  NSCLC  represents approximately  4%-5%  of  all  NSCLC  patients  in  both  Caucasian  and  Asian  populations,  which represents potentially 40,000 new cases worldwide each year.

## 2.1.3. Biologic features/Aetiology and pathogenesis

ALK  is  a  tyrosine  kinase  encoded  on  chromosome  2  and  is  primarily  involved  in  developmental processes  and  expressed  at  low  levels  in  adults 2 .  The  first  genetic  rearrangement  of  ALK  seen  in NSCLC involved a fusion between the echinoderm microtubule-associated protein-like 4 (EML4) gene and  the  ALK  tyrosine  kinase  domain.  EML4-ALK  has  the  capacity  to  transform  fibroblasts  grown  in culture  and  as  subcutaneous  xenografts  to  induce  tumour  formation 3 .  A  number  of  additional  ALK fusion partners have been described in NSCLC that are believed to result in aberrant  signalling and oncogenic transformation 4,5 . ALK rearrangements are more common among patients with

1  Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Estimated Cancer Incidence, Mortality and Prevalence Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2012. Available from: http://globocan.iarc.fr

2 Camidge D, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268-77

3 Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-6.

4 Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-203.

5 Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res.2009;15(9):3143-9.

<div style=\"page-break-after: always\"></div>

adenocarcinoma histology, patients who have never smoked, and patients who have wild-type EGFR and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) 6 .

## 2.1.4. Clinical presentation, diagnosis and stage

Approximately, one third of the patients with Stage IIIA disease are considered operable. However, the majority of patients with Stage IIIA/B have inoperable (unresectable) disease, and are amenable to receiving curative intention chemoradiation treatment. The biological characteristics of locally advanced, Stage III disease are poorly defined; the clinical characteristics associated with prognosis are nodal station involvement, size of primary tumour, baseline pulmonary function, gender, presence or absence of significant weight loss, and performance status (PS).

Pathological diagnosis based on tumour samples includes immunohistochemistry (IHC) to identify adenocarcinoma or squamous cell carcinoma and cytogenetic analysis by fluorescence in situ hybridisation (FISH) test to detect ALK rearrangements. Molecular testing should be carried out to determine genetic alterations, such as EGFR mutations and ALK rearrangements which determine choice of targeted treatment.

## 2.1.5. Management

While the standard treatment algorithm for unselected NSCLC patients has historically involved frontline treatment with chemotherapy, recent clinical studies have demonstrated that patients with ALKpositive  locally  advanced  or  metastatic  NSCLC  respond  well  to  treatment  with  the  ALK  inhibitor crizotinib.

The  approval  of  crizotinib  was  based  on  results  from  2  single-arm  studies 7 .  Crizotinib  is  a  firstgeneration ALK-TKI is indicated for the treatment of ALK-positive advanced NSCLC (hereafter referred to  as  ALK-positive  NSCLC).  Crizotinib  significantly  prolonged  progression-free  survival  (PFS)  in previously untreated patients with ALK-positive advanced non-squamous NSCLC when compared with standard platinum-based chemotherapy regimens.

Resistance due to the emergence of various ALK kinase domain mutations and the activation of bypass resistance  mechanisms,  continues  to  present  a  treatment  challenge  with  the  use  of  ALK-TKIs.  ALK resistant mutations following treatment with a second-generation ALK-TKI have also been observed in the  clinic.  Among  them,  ALKG1202R  and  ALKI1171T  missense  mutations  are  common  resistance mutations after ceritinib and alectinib treatment, respectively 8 .

Among patients whose disease has progressed on second-generation TKIs used either in the first- or second-line setting,  chemotherapy  would  be  the fall back standard of care.  Outcomes  with chemotherapy  have  been  modest.  In  a  randomised  Phase  3  trial  of  ceritinib  vs  chemotherapy (docetaxel or pemetrexed) in patients with ALK-positive NSCLC who had been previously treated with chemotherapy and crizotinib, chemotherapy had an objective response rate (ORR) of 6.9% and median PFS of 1.6 months, as determined by blinded independent central review (ICR). Chemotherapy also has a limited intracranial (IC) ORR even in a treatment-naïve setting. In a randomised Phase 3 study of  first-line  ceritinib  versus  platinum-based  chemotherapy  in  advanced  ALK-rearranged  NSCLC,  the

6 Camidge D, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268-77.

7 Xalkori. crizotinib EPAR.

8  Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9(4):549-53.

<div style=\"page-break-after: always\"></div>

platinum doublet was reported to have an IC ORR by ICR of 21.2% (95% confidence interval [CI]: 11.1, 34.7).

## Unmet medical need

Because there are no agents approved that confer substantial benefit for ALK-positive advanced NSCLC previously  treated  with  2  or  more  ALK-TKIs,  there  is  a  substantial  unmet  medical  need  in  this treatment setting. Of note, this is a clinical situation that is similar to that in patients whose disease progressed after treatment with a second-generation ALK-TKI when used as the only ALK-TKI. Thus, additional drugs are needed to overcome resistance mechanisms, to impact patient outcomes through improved response rates and PFS, and to have significant antitumor activity against CNS metastases.

Chemotherapy  would  provide  another  treatment  option  in  patients  whose  disease  progressed  after treatment with a second-generation ALK-TKI (either as the only ALK-TKI or when used after crizotinib). Because there are no published clinical data available on the antitumor activity of chemotherapy in this particular  setting,  the  best  approximation  for  the  efficacy  of  chemotherapy  would  be  patients previously treated with a platinum doublet and crizotinib. Data in this setting have been reported for the chemotherapy control arms of the alectinib Phase 3 ALUR trial and the ceritinib Phase 3 ASCEND-5 trial.  In  the  ALUR  trial,  the  ORR  for  single-agent  chemotherapy  was  11.4%,  and  there  were  no  IC responses and median PFS was 1.4 months (95% CI not reported). In the ASCEND-5 trial, the ORR for single-agent  chemotherapy  was  6.9%  with  an  IC  ORR  of  5.0%  and  a  median  PFS  of  1.6  months (95%CI: 1.4, 2.8).

## About the product

Lorlatinib is a selective, adenosine triphosphate (ATP) -competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases.

In non-clinical studies, lorlatinib inhibited catalytic activities of non-mutated ALK and clinically relevant ALK mutant kinases in recombinant enzyme and cell-based assays. Lorlatinib demonstrated marked anti-tumour activity in mice bearing tumour xenografts that express echinoderm microtubule-associated protein-like 4 (EML4) fusions with ALK variant 1 (v1), including ALK mutations L1196M, G1269A, G1202R, and I1171T. Two (2) of these ALK mutants, G1202R and I1171T, are known to confer resistance to alectinib, brigatinib, ceritinib, and crizotinib. Lorlatinib was also capable of penetrating the blood-brain barrier. Lorlatinib demonstrated activity in mice bearing orthotopic EML4-ALK or EML4-ALK L1196M  brain tumour implants. The applicant applied for the following indication:

'Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with one or more ALK tyrosine kinase inhibitors (TKIs), except for patients treated with crizotinib as the only ALK TKI.'

The recommended indication for approval is:

Lorlatinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after:

-  alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
-  crizotinib and at least one other ALK TKI.

The recommended dose is 100 mg lorlatinib taken orally once daily.

Duration of treatment

<div style=\"page-break-after: always\"></div>

Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity.

## Delayed or missed doses

If a dose of lorlatinib is missed, then it should be taken as soon as the patient remembers unless it is less than 4 hours before the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose.

## Dose modifications

Dosing interruption or dose reduction may be required based on individual safety and tolerability. Lorlatinib dose reduction levels are summarised below:

-  First dose reduction: 75 mg taken orally once daily
-  Second dose reduction: 50 mg taken orally once daily

Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily.

Dose modification recommendations for toxicities and for patients who develop atrioventricular (AV) block are provided in Table 1.

## Table 1: Recommended lorlatinib dose modifications for adverse reactions

| Adverse reaction a                                                                                                                                                                                                                                                                                                                                                                                           | Lorlatinib dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypercholesterolaemia or hypertriglyceridaemia                                                                                                                                                                                                                                                                                                                                                               | Hypercholesterolaemia or hypertriglyceridaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Mild hypercholesterolaemia (cholesterol between ULN and 300 mg/dL or between ULN and 7.75 mmol/L) OR Moderate hypercholesterolaemia (cholesterol between 301 and 400 mg/dL or between 7.76 and 10.34 mmol/L) OR Mild hypertriglyceridaemia (triglycerides between 150 and 300 mg/dL or 1.71 and 3.42 mmol/L) Moderate hypertriglyceridaemia (triglycerides between 301 and 500 mg/dL or 3.43 and 5.7 mmol/L) | Introduce or modify lipid-lowering therapy b in accordance with respective prescribing information; continue lorlatinib at same dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Severe hypercholesterolaemia (cholesterol between 401 and 500 mg/dL or between 10.35 and 12.92 mmol/L) OR Severe hypertriglyceridaemia (triglycerides between 501 and 1,000 mg/dL or 5.71 and 11.4 mmol/L)                                                                                                                                                                                                   | Introduce the use of lipid-lowering therapy; b if currently on lipid-lowering therapy, increase the dose of this therapy b in accordance with respective prescribing information; or change to a new lipid-lowering therapy. Continue lorlatinib at the same dose without interruption.                                                                                                                                                                                                                                                                                                                                                                        |
| Life-threatening hypercholesterolaemia (cholesterol over 500 mg/dL or over 12.92 mmol/L) OR Life-threatening hypertriglyceridaemia (triglycerides over 1,000 mg/dL or over 11.4 mmol/L)                                                                                                                                                                                                                      | Introduce the use of lipid-lowering therapy b or increase the dose of this therapy a in accordance with respective prescribing information or change to a new lipid-lowering therapy. Withhold lorlatinib until recovery of hypercholesterolaemia and/or hypertriglyceridaemia to moderate or mild severity grade. Re-challenge at same lorlatinib dose while maximising lipid-lowering therapy b in accordance with respective prescribing information. If severe hypercholesterolaemia and/or hypertriglyceridaemia recur despite maximal lipid-lowering therapy b in accordance with respective prescribing information, reduce lorlatinib by 1 dose level. |
| Central nervous system effects (changes in cognition, mood or speech)                                                                                                                                                                                                                                                                                                                                        | Central nervous system effects (changes in cognition, mood or speech)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Grade 2: Moderate OR Grade 3: Severe                                                                                                                                                                                                                                                                                                                                                                         | Withhold dose until toxicity is less than or equal to Grade 1. Then resume lorlatinib at 1 reduced dose level.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Grade 4: Life-threatening/Urgent intervention                                                                                                                                                                                                                                                                                                                                                                | Permanently discontinue lorlatinib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Adverse reaction a                                      | Lorlatinib dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| indicated                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lipase/Amylase increase                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Grade 3: Severe                                         | Withhold lorlatinib until lipase or amylase returns to baseline. Then resume lorlatinib at 1 reduced dose level.                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OR                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Grade 4: Life-threatening/Urgent intervention indicated |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Interstitial lung disease (ILD)/Pneumonitis             | Interstitial lung disease (ILD)/Pneumonitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Grade 1: Mild OR                                        | Withhold lorlatinib until symptoms have returned to baseline and consider initiating corticosteroids. Resume lorlatinib at 1 reduced dose level. Permanently discontinue lorlatinib if ILD/pneumonitis recurs or fails to                                                                                                                                                                                                                                                                                                                                         |
| Grade 2: Moderate                                       | recover after 6 weeks of lorlatinib hold and steroid treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| OR                                                      | Permanently discontinue lorlatinib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Grade 4: Life-threatening/Urgent intervention indicated | (AV) block                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PR interval prolongation/Atrioventricular               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| First-degree AV block: Symptomatic                      | Withhold lorlatinib. Consider effects of concomitant medicinal products, and assess and correct electrolyte imbalance that may prolong PR interval. Monitor ECG/symptoms potentially related to AV block closely. If symptoms resolve, resume lorlatinib at 1 reduced dose level.                                                                                                                                                                                                                                                                                 |
| Second-degree AV block Asymptomatic                     | Withhold lorlatinib. Consider effects of concomitant medicinal products, and assess and correct electrolyte imbalance that may prolong PR interval. Monitor ECG/symptoms potentially related to AV block closely. If subsequent ECG does not show second degree AV block, resume lorlatinib at 1 reduced dose level.                                                                                                                                                                                                                                              |
| Second-degree AV block Symptomatic                      | Withhold lorlatinib. Consider effects of concomitant medicinal products, and assess and correct electrolyte imbalance that may prolong PR interval. Refer for cardiac observation and monitoring. Consider pacemaker placement if symptomatic AV block persists. If symptoms and the second degree AV block resolve or if patients revert to asymptomatic first degree AV block, resume lorlatinib at 1 reduced dose level.                                                                                                                                       |
| Complete AV block                                       | Withhold lorlatinib. Consider effects of concomitant medicinal products, and assess and correct electrolyte imbalance that may prolong PR interval. Refer for cardiac observation and monitoring. Pacemaker placement may be indicated for severe symptoms associated with AV block. If AV block does not resolve, placement of a permanent pacemaker may be considered. If pacemaker placed, resume lorlatinib at full dose. If no pacemaker placed, resume lorlatinib at 1 reduced dose level only when symptoms resolve and PR interval is less than 200 msec. |
| Other adverse reactions                                 | Other adverse reactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Grade 1: Mild OR                                        | Consider no dose modification or reduce by 1 dose level, as clinically indicated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Grade 2: Moderate                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Greater than or equal to Grade 3: Severe                | Withhold lorlatinib until symptoms resolve to less than or equal to Grade 2 or baseline. Then resume lorlatinib at 1 reduced dose level.                                                                                                                                                                                                                                                                                                                                                                                                                          |

Abbreviations: AV=atrioventricular; CTCAE=Common Terminology Criteria for Adverse Events; ECG=electrocardiogram;

HMG CoA=3-hydroxy-3-methylglutaryl coenzyme A; NCI=National Cancer Institute; ULN=upper limit of normal.

a  Grade categories are based on NCI CTCAE classifications.

b  Lipid-lowering therapy may include: HMG CoA reductase inhibitor, nicotinic acid, fibric acid, or ethyl esters of omega-3 fatty acids.

## Type of Application and aspects on development

The applicant requested consideration of its application for a conditional marketing authorisation in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria:

<div style=\"page-break-after: always\"></div>

-  The benefit-risk balance is positive.

The applicant claims that in pivotal Study B7461001 (also called study 1001), lorlatinib demonstrated clinically meaningful benefit in patients with ALK-positive NSCLC who previously received a range of treatments with prior ALK-TKIs and/or chemotherapy regimens, with tumour responses that were rapid, deep, and durable.

Importantly, lorlatinib also had activity against brain metastases and exhibited antitumor activity across a variety of ALK kinase domain resistance mutations, including the difficult-to-treat G1202R/G1202del mutations. Lorlatinib also evoked responses in tumours resistant to prior ALK-TKIs that did not contain detectable ALK resistance mutations.

Lorlatinib was generally tolerable, as AEs were primarily mild to moderate in severity and manageable by dosing interruption, dose reduction, and/or standard supportive medical therapy, as the rate of permanent treatment discontinuations associated with AEs was low without any treatment-related deaths. The safety profiles between the overall safety population and subgroups of baseline demographics (age, race, gender) were similar.

-  It is likely that the applicant will be able to provide comprehensive data.

The applicant claims that the confirmatory data will be provided with data from Study B7461006, an ongoing Phase 3, randomised, open-label trial of the safety and efficacy of lorlatinib and crizotinib for first-line treatment of subjects with advanced ALK-positive NSCLC. Study B7461006 is a global study with total of 280 subjects planned for enrolment. The First Patient First Dose was in May 2017, study enrolment is on schedule and planned to be completed by 4Q2018 with  clinical study report expected by 31 December 2021.

-  Unmet medical needs will be addressed

The applicant claims that the clinical benefit of lorlatinib in patients with ALK-positive advanced NSCLC previously treated with one or more ALK-TKIs was shown by the results of Study 1001 as evidenced by rapid, deep, and durable responses, also across subgroups of baseline demographics (age, race, gender) and ECOG PS.

Because there are no agents approved that confer substantial benefit for patients who have been previously treated with 2 or more ALK-TKIs, there is a substantial unmet need in this setting. Of note, this is a clinical situation that is similar to that in patients whose disease progressed after treatment with a second-generation ALK-TKI when used as the only ALK-TKI.

In contrast to the poor outcome with immune checkpoint inhibitors or chemotherapy, the ORR for lorlatinib after a second-generation ALK-TKI is compelling.

Lorlatinib exhibited antitumor activity across a variety of ALK kinase domain resistance mutations, including the difficult-to-treat G1202R/G1202del mutations, and also evoked responses in tumours resistant to prior ALK-TKIs that did not harbour ALK resistance mutations.

In addition to the systemic response, lorlatinib also exhibited rapid, deep, and durable intracranial responses consistent with its ability to cross the blood-brain barrier (BBB). Lorlatinib has the potential to fulfil an important unmet medical need in this heavily pre-treated patient population.

-  The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required.

The applicant claims that despite the introduction of effective ALK-TKIs over the past several years, ALK-positive NSCLC is a serious, life-threatening disease that remains incurable.

There is a high unmet medical need in patients for whom treatment with second-generation ALK-TKIs

<div style=\"page-break-after: always\"></div>

such as alectinib or ceritinib has failed, because available treatment options are not effective and no therapies exist that would be specifically indicated in that setting.

Consequently, new drugs are needed to overcome ALK-TKI resistance mechanisms and to enhance patient outcomes.

Overall, the safety, efficacy, and PK data make lorlatinib a useful therapeutic option that should be made available to the public immediately. Based on the current timeline projections, waiting for randomised data from Phase 3 Study B7461006 may translate into a 1- to 3-year delay in the availability of lorlatinib in the EU for patients with ALK-positive advanced NSCLC who have progressed after second generation ALK inhibitor.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product Lorviqua is presented as film-coated tablets in 2 strengths containing 25 mg and 100 mg lorlatinib as active substance.

Other ingredients are:

Tablet core: microcrystalline cellulose, calcium hydrogen phosphate, sodium starch glycollate, and magnesium stearate.

Film-coating: hypromellose, lactose monohydrate, macrogol, triacetin, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172).

The product is available in OPA/Al/PVC blisters with aluminium foil backing as described in Section 6.5 of the SmPC.

## 2.2.2. Active Substance

## General information

The chemical name of lorlatinib is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile corresponding to the molecular formula C21H19FN6O2. It has a relative molecular mass of 406.41 daltons and the following structure:

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Figure 1: Active substance structure

The chemical structure of the active substance was elucidated by a combination of IR spectroscopy, mass spectroscopy, nuclear magnetic resonance spectroscopy, X-Ray diffraction, ultraviolet/visible (UV/Vis) spectrum, and specific optical rotation. The solid state properties of the active substance were measured by X-Ray diffraction.

Lorlatinib is a non-hygroscopic white to off white powder. The aqueous solubility of lorlatinib is high at low pH (0.1 N HCl) and decreases with increasing pH. It has very low solubility above pH 4.5. It is classified as a BCS class 4 substance with low solubility and low permeability. Due to the low solubility of lorlatinib, the substance is milled and a requirement for particle size is included in the active substance specification.

The active substance exhibits stereoisomerism due to the presence of one chiral centre, giving 2 possible stereoisomers. For lorlatinib, the absolute configuration at the 10-position is the R-optical isomer.

Lorlatinib shows polymorphism.

## Manufacture, characterisation and process controls

The active substance is synthesised in 4 main steps using commercially available well defined starting materials with acceptable specifications.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised. An impurity risk assessment for mutagenicity according to International Council for Harmonisation (ICH) M7 guideline has been performed for all actual and potential impurities. No mutagenicity impurities were detected. An overall risk assessment for elemental impurities in accordance with ICH Q3D guideline is presented.

Elements of quality by design (QbD) (enhanced approach) have been applied during the development of  the  manufacturing  process  of  the  active  substance,  in  order  to  gain  manufacturing  process knowledge and to define operating ranges.

## Specification

The active substance specification includes tests for appearance (visual), identification (IR, HPLC, PXRD), assay (HPLC), residual solvents (GC), impurities (HPLC), particle size (laser light diffraction), water content (Ph. Eur.), and residue on ignition (Ph. Eur.).

The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data of the active substance are provided. The results are within the specifications and consistent from batch to batch.

<div style=\"page-break-after: always\"></div>

## Stability

Stability data of active substance stored in the intended commercial package for up to 18 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided.

The following parameters were tested: appearance, assay, degradation products, water content, solid form, particle size, and microbial quality. With the exception of the chiral purity method, the analytical methods used in the primary stability program are the same as the release methods.

There were no trends observed during the stability studies at any of the storage conditions.

Photostability testing following the ICH guideline Q1B was performed on one batch. As demonstrated by the photostability in packaging, the current packaging configuration, double antistatic low density polyethylene (LDPE) bags in high density polyethylene (HDPE) drum, adequately protects the active substance; therefore an additional light restriction is not required.

Samples of the active substance were subjected to forced degradation conditions. Overall, lorlatinib is stable under various stressed conditions. No significant degradation was observed.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 30 months with no recommendations on the storage temperature in the proposed container.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is formulated as immediate-release film coated tablets in 2 strengths (25 mg and 100 mg). The 25 mg tablet is presented as a round, light pink film-coated tablet debossed with 'Pfizer' in one side and '25' and 'LLN' on the other side. The 100 mg tablet is presented as an oval, dark pink film-coated tablet debossed with 'Pfizer' on one side and 'LLN 100' on the other side.

The formulation and process development of lorlatinib immediate-release film-coated tablets focused on the quality attributes defined in a Quality Target Product Profile (QTPP).

Lorlatinib is categorised as a BCS Class IV active substance (low solubility and low permeability) according to the Biopharmaceutics Classification System. Lorlatinib solubility is pH dependent, with solubility being highest under low pH gastric conditions in the fasted state. As such the impact of active substance particle size was an important consideration during finished product development.

The selection of excipients for the commercial tablet formulations was based on the evaluation of the compatibility of the active substance with platform formulations using an accelerated stability program. Accelerated stability studies comparing coated tablets and uncoated tablet found no impact on stability from film-coating. Supporting development data and registration stability studies showed that the excipients selected are suitable to enable the finished product to achieve acceptable stability. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards except Opadry II which complies with internal standards. However, the CHMP recommends submitting an appropriate variation application to establish or adopt a colour reference as part of the Opadry appearance acceptance criteria or alternatively develop an identity test that can distinguish between the two Opadry material types (Tan and Lavender). There are no novel excipients used in the finished product formulation. The list of excipients is included in Section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

<div style=\"page-break-after: always\"></div>

The finished product has been formulated as an immediate release film-coated tablet for oral administration. Bioequivalence study was performed showing bioequivalence between 25 mg lorlatinib used in Phase 2 clinical tablet and the proposed commercial 25 mg and 100 mg lorlatinib tablets. There were considered bioequivalent.

In vitro dissolution testing was performed to demonstrate the in vitro dissolution performance of the proposed commercial lorlatinib tablet strengths and the Phase 2 clinical tablet. The data are shown that there was no difference between the dissolution profiles of the formulations tested.

A risk based approach was taken during the development of the commercial manufacturing process to guide the design of experiments and to ensure that final finished products of acceptable quality and stability are consistently produced. A risk assessment was conducted, which identified potential relationships between manufacturing process parameters finished product quality attributes.

The primary packaging is OPA/Al/PVC foil blisters with aluminium foil backing. The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

Lorlatinib 25 mg and 100 mg immediate release film-coated tablets are manufactured using a conventional dry granulation process which consists of 8 main steps: de-agglomeration, blending, intragranular lubricant blending, dry granulation (roller compaction and milling), extra-granular lubricant blending, tableting, film-coating and packaging.

The manufacturing process for lorlatinib immediate release 25 mg and 100 mg film-coated tablets uses conventional manufacturing techniques and equipment. The in-process controls are adequate for this type of pharmaceutical form.

## Product specification

The  finished  product  release  specifications  include  appropriate  tests  for  this  kind  of  dosage  form: appearance (visual),  identification  (LC,  UV/DAD),  assay  (LC),  degradation  products  (LC),  dissolution (LC), content uniformity (LC), microbial limits (Ph. Eur.)

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market through traditional final product release testing.

## Stability of the product

Stability data from 3 commercial scale batches per strength of finished product stored in commercial packaging system for up to 18 months under long term conditions (25 ºC/60% RH and 30°C/75 % RH) and for up to 6 months under accelerated conditions (40 ºC/75% RH) according to the ICH guidelines were provided.

Samples  were  tested  for  appearance,  assay,  degradation  products,  dissolution,  water  content  and microbial purity.

<div style=\"page-break-after: always\"></div>

The long-term and accelerated stability studies have demonstrated that the finished has acceptable stability at the proposed storage condition in the proposed commercial packaging configurations.

In addition, one batch per strength packed in HDPE bottles and aluminum foil lidding was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. No  significant  changes  were  observed  in  appearance,  assay,  water  content  and  dissolution.  The degradation product increased under light exposure. No increase was observed in the control samples. Formation of this degradant is controlled by the protective packaging configurations used.

Based  on  available  stability  data,  the  proposed  shelf-life  of  24  months  when  stored  in  OPA/Al/PVC blisters with aluminium foil backing without special storage conditions as stated in the SmPC (Section 6.3) is acceptable .

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and Veterinary medicinal products.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

The applicant has applied QbD principles in the development of the active substance and/or finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the active substance, nor for the finished product

At the time of the CHMP opinion, there were minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data have been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendation for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

- To submit an appropriate variation application to establish or adopt a colour reference as part of the Opadry appearance acceptance criteria or alternatively develop an identity test that can distinguish between the 2 Opadry material types (Tan and Lavender).

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive small molecule inhibitor of the ALK and ROS1 receptor tyrosine kinase (RTK) that also potently inhibits ALK kinase domain mutations responsible for resistance to ALK inhibitors. Oncogenic fusions of ALK and ROS1 define 2 distinct subsets of human lung adenocarcinoma patients and play essential roles in regulation of tumour cell survival, growth and metastasis (Soda et al, 2007; Bergethon et al, 2012).

## 2.3.2. Pharmacology

Lorlatinib has been studied in a variety of in vitro and in vivo studies to determine activity by assessing inhibition of ALK or ROS1 tyrosine kinase activity, kinase selectivity, antitumor efficacy, PK/PD relationships, and mechanism of action. Lorlatinib was evaluated in in vitro , ex vivo , and in vivo safety pharmacology studies to identify potential effects on the cardiovascular, respiratory, and CNSs.

## Primary pharmacodynamic studies

## In vitro studies

## Inhibition of wild-type ALK, wild-type ROS1, and ALK mutant kinase activity in a biochemical enzyme assay (Study PF-06463922\\_12Mar13\\_174542)

Recombinant proteins of human ALK and ROS1 kinase domains, including various clinically relevant ALK  kinase  domain  mutants,  were  used  to  determine  lorlatinib  potency  against  RTK  targets  in biochemical enzyme assays.

Table 2: Biochemical potencies (Ki) of Lorlatinib for Target Kinases in Recombinant Enzyme Assays

| Recombinant Enzyme Assays                                     | K i , GMean (GCI95) a   | K i , GMean (GCI95) a   | K i , GMean (GCI95) a   | K i , GMean (GCI95) a   | K i , GMean (GCI95) a   | K i , GMean (GCI95) a   | K i Ratio    |
|---------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------|
|                                                               | Lorlatinib              | Lorlatinib              | Lorlatinib              | Crizotinib              | Crizotinib              | Crizotinib              | Crizotinib/  |
| Recombinant human ALK wild-type and ALK mutant kinase domains | nM (range)              | ng/mL                   | n                       | nM (range)              | ng/m L                  | n                       | Lorlatinib b |
| Wild-type ALK                                                 | <0.2                    | <0.08                   | 3                       | 0.72 (0.65-0.80)        | 0.3                     | 127                     | >4           |
| ALK L1196M                                                    | 0.7 (0.4-1.3)           | 0.3                     | 3                       | 8.1 (7.6-8.7)           | 3.6                     | 143                     | 12           |
| ALK G1269A                                                    | 0.9 (0.3-3.0)           | 0.4                     | 2                       | 20.1 (17.6-23.1)        | 9.1                     | 4                       | 22           |
| ALK F1174L                                                    | <0.1                    | <0.04                   | 1                       | 0.82 (0.74-0.90)        | 0.4                     | 3                       | >8           |
| ALK C1156Y                                                    | <0.1                    | <0.04                   | 1                       | 0.6 (0.1-3.3)           | 0.3                     | 3                       | >6           |
| ALK L1152R                                                    | <0.1                    | <0.04                   | 1                       | 2.2 (1.3-3.6)           | 1                       | 3                       | >22          |
| ALK 1151Tins                                                  | 0.1                     | 0.04                    | 1                       | 2.2                     | 1                       | 1                       | 22           |
| ALK S1206Y                                                    | 0.2                     | 0.08                    | 1                       | 1.3                     | 0.6                     | 1                       | 7            |
| Recombinant human ROS1 wild-type kinase domain                |                         |                         |                         |                         |                         |                         |              |
| Wild-type ROS1                                                | <0.005                  | <0.002                  | 2                       | 0.12 (0.08-0.19)        | 0.06                    | 3                       | >24          |

Ki = Inhibition constant; GMean = geometric mean; GCI95 = Geometric confidence level.

a. Ki values are geometric means with a geometric confidence 95% interval for n independent measurements.

b. Ki ratio was calculated based on GMean (in nM) of lorlatinib divided by crizotinib Ki.

Inhibition of Wild-type ALK and ALK I171T  Kinase Activity in a Biochemical Enzyme Assay

<div style=\"page-break-after: always\"></div>

Lorlatinib  inhibited  recombinant wild-type  ALK  and  ALK I1171T   kinase  domain  in  an  ATP-competitive enzymatic kinase assay resulting in Ki values of &lt;0.1 nM and 0.25 nM, respectively (Study PF-06463922\\_29Mar16\\_055600).

Table 3: Inhibition Constants, Ki and Kiapp (1 mM ATP), for Pre-activated Recombinant Wild-type ALK and ALKI1171T with Lorlatinib and Crizotinib in Biochemical Assays

| Compound   | K i , nM    | K i , nM    | K i , nM   | K i app (1 mM ATP), nM   | K i app (1 mM ATP), nM   | K i app (1 mM ATP), nM   |
|------------|-------------|-------------|------------|--------------------------|--------------------------|--------------------------|
|            | WT          | I1171T      | n          | WT                       | I1171T                   | n                        |
| Lorlatinib | <0.1        | 0.25  0.01 | 2          | 0.65  0.03              | 7.8  0.1                | 2                        |
| Crizotinib | 0.73  0.01 | 1.03  0.02 | 2          | 8.3  0.2                | 30.4  0.7               | 2                        |

The enzymes were preactivated and tested in microfluidic mobility-shift assays. Inhibition constants, Ki (with standard errors, n = 2), were derived using a competitive inhibition equation and experimentally determined ATP Km (97 and 35  M for wild-type and ALK I1171T , respectively). ATP = Adenosine triphosphate; Ki = Inhibition constant; Ki app  = Apparent inhibition constant; n = number of replicates; WT = Wild type.

## Biochemical Profile of Lorlatinib Major Metabolite, PF-06895751

The major metabolite of lorlatinib, PF-06895751, was inactive against wild-type ALK in a biochemical assay at 10, 1 and 0.1  M doses using a Km-level of ATP (Study PF-06463922\\_21Jul17\\_025806). The lorlatinib metabolite was also inactive against ROS1 and a diverse panel of 40 other kinases at 1  M.

## Kinase Selectivity of Lorlatinib in Biochemical and Cell-based Assays (Study PF-06463922\\_12Mar13\\_174542)

To investigate kinase selectivity of lorlatinib relative to its target kinases, ALK and ROS1, lorlatinib was evaluated in biochemical kinase screening assays against a panel of 206 recombinant kinases.

Eleven  (11)  kinases  were  identified  for  which  lorlatinib  exhibited  activity  and  showed  selectivity margins of less than 100x compared to the target ALK L1196M .

The selectivity of lorlatinib was further evaluated in a panel of cell-based assays for selected kinases that were identified as potential relevant hits in biochemical assays.

Table 4: Kinase Selectivity of lorlatinib in Cell-based Assays

| In vitro Cellular Activity Against Non-Target Kinases   | In vitro Cellular Activity Against Non-Target Kinases   | Mean Cell IC50 b   | Mean Cell IC50 b   | Selectivity vs c   |
|---------------------------------------------------------|---------------------------------------------------------|--------------------|--------------------|--------------------|
| Cells                                                   | Phosphorylation Target Assayed                          | nM                 | ng/mL              | ALK-L1196M         |
| NIH3T3-EML4- ALKv1 L1196M                               | Engineered EML4-ALKv1 L1196M phosphorylation            | 21                 | 8.5                | 1                  |
| TrkA-PAE                                                | NGF-stimulated TrkA phosphorylation                     | >10000             | >4064              | 476                |
| TrkB-PAE                                                | BDNF-stimulated TrkB phosphorylation                    | 229                | 93                 | 11                 |
| A549                                                    | EGF-stimulated wild-type EGFR phosphorylation           | >10000             | >4064              | >476               |
| PC9                                                     | Endogenous EGFR E746-A750 Del phosphorylation           | >10000             | >4064              | >476               |
| NCI-H3255                                               | Endogenous EGFR L858R phosphorylation                   | >10000             | >4064              | >476               |
| NCI-H1975                                               | Endogenous EGFR L858R/T790M phosphorylation             | >10000             | >4064              | >476               |

ALK = Anaplastic lymphoma kinase; BDNF = Brain-derived neurotrophic factor; EGF = Epidermal growth factor; EGFR = EGF receptor; IC50 = 50% inhibitory concentration; NGF = Nerve growth factor;

TrkA = Tropomyosin receptor kinase A; TrkB = Tropomyosin receptor kinase B; PAE = Porcine aortic endothelial cells.

a. Reported are either IC50 values at the Km-level of ATP or Ki (where shown).

b. RTK phosphorylation was determined by using ELISA capture methods.

c. Ratio of 476 does not match the study report due to a rounding error in the original report.

## Lorlatinib Inhibition of Phosphorylation of ALK and ROS Variants

To confirm inhibition of target kinases in cell lines, the ability of lorlatinib to inhibit the phosphorylation of  ALK fusion variants, clinically relevant crizotinib resistant ALK mutants, and ROS1 fusion variants

<div style=\"page-break-after: always\"></div>

were evaluated by capture enzyme-linked immunosorbent assay (ELISA) or Western Blot analysis and 50% inhibitive concentration (IC50) values were determined (Study PF-06463922\\_12Mar13\\_174542).

IC

50

:

= 101 nM

= 687 nM

= 479 nM

<!-- image -->

HC3122- Parental (endogenous EML4-ALKv1 expression) and HC3122 cells expressing exogenous EML4-ALKv1, EML4-ALKv1 L1196M , and  EML4-ALKv1 G11269A   were  treated  with  designated  concentrations  of  crizotinib  for  72  hours.    The  effect  of  crizotinib  on  cell proliferation was determined by utilizing a commercially available CellTiter-Glo  Assay kit (Promega).

Figure 2: Acquired Resistance to Crizotinib in H3122-EML4-ALK L1196M  and H3122-EML4-ALK G1269A  Models Clinically relevant mutations of EML4-ALK following ALK inhibitor treatment include L1196M, G1269A, F1174L, C1156Y, L1152R, G1202R, S1206Y, 1151Tins, and I1171T. In engineered NIH3T3 cell lines expressing EML4-ALKv1 mutations, lorlatinib inhibited ALK phosphorylation.

<div style=\"page-break-after: always\"></div>

Table 5: Lorlatinib potency against ALK fusion variants and ALK fusion mutations in cells (ALK Phosphorylation)

| Cell-based ALK phosphorylation (Y1604) ELISA Assay a   | IC 50 (Mean  SEM)   | IC 50 (Mean  SEM)   | IC 50 (Mean  SEM)   | IC 50 (Mean  SEM)   | IC 50 Ratio Crizotinib/ Lorlatinib   |
|--------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------------|
|                                                        | Lorlatinib           | Lorlatinib           | Crizotinib           | Crizotinib           |                                      |
|                                                        | nM                   | n                    | nM                   | n                    |                                      |
| Endogenous cell lines expressing:                      |                      |                      |                      |                      |                                      |
| EML4-ALKv1 in H3122 cells                              | 2.4  0.3            | 3                    | 87  8.9             | 29                   | 36                                   |
| EML4-ALKv3a/b in H2228 cells                           | 1.3  0.4            | 3                    | 206  41             | 3                    | 158                                  |
| NCI-H3122 engineered cells expressing:                 |                      |                      |                      |                      |                                      |
| H3122-EML4-ALKv1 L1196M                                | 11  0.3             | 7                    | 535  73             | 6                    | 49                                   |
| H3122-EML4-ALKv1 G1269A                                | 17  1.9             | 3                    | 504  135            | 3                    | 30                                   |
| NIH3T3 engineered cells expressing:                    |                      |                      |                      |                      |                                      |
| EML4-ALKv1                                             | 1.5  0.4            | 5                    | 80  37              | 101                  | 53                                   |
| EML4-ALKv2                                             | 1.4  0.1            | 2                    | 96  3.7             | 2                    | 69                                   |
| EML4-ALKv3a                                            | 0.9  <0.1           | 2                    | 55  2.8             | 2                    | 61                                   |
| EML4-ALKv3b                                            | 1.0  <0.1           | 2                    | 76  13              | 2                    | 76                                   |
| KIF5B-ALK                                              | 0.5  0.2            | 3                    | 29  6.4             | 3                    | 58                                   |
| EML4-ALKv1 L1196M                                      | 21  2.3             | 5                    | 843  382            | 101                  | 40                                   |
| EML4-ALKv1 G1269A                                      | 15  8.5             | 2                    | 605  90             | 4                    | 40                                   |
| EML4-ALKv1 F1174L                                      | 0.2  <0.1           | 2                    | 165  36             | 4                    | 825                                  |
| EML4-ALKv1 C1156Y                                      | 1.6  1.4            | 2                    | 478  153            | 4                    | 299                                  |
| EML4-ALKv1 L1152R                                      | 9  7                | 2                    | 1026  71            | 4                    | 114                                  |
| EML4-ALKv1 G1202R                                      | 65  23              | 4                    | 1148  471           | 4                    | 18                                   |
| EML4-ALKv1 1151Tins                                    | 46  0.7             | 2                    | 3039  39            | 2                    | 66                                   |
| EML4-ALKv1 S1206Y                                      | 4.2                  | 1                    | 626                  | 1                    | 149                                  |
| EML4-ALKv1 I1171T                                      | 7.1  2.0            | 3                    | 240  68             | 3                    | 34                                   |

ELISA = Enzyme-linked immunosorbent assay; IC50 = 50% inhibitory concentration; n = Number of replicates; SEM = Standard error of the mean.

a. The cells were treated with lorlatinib, crizotinib, or vehicle in the serum free media for 1 hour, and lysed by using the Cell

Lysis Buffer (Cell Signaling Technologies). The ALK-tyrosine 1604 (Y1604) phosphorylation in cell lysates was determined utilizing a commercially available PathScan® Phospho-ALK Chemiluminescent Sandwich ELISA Kit (Cell Signaling Technologies). IC50 values were calculated by concentration-response curve fitting utilizing a four-parameter analytical method.

Sources: Study PF-06463922\\_12Mar13\\_174542 and Study PF-06463922\\_29Mar16\\_055600.

In the panel of NIH3T3-ROS1 cell lines engineered to express ROS1 fusion proteins, lorlatinib inhibited ROS1 kinase activity with IC50 values ranging from 0.23 nM to 1.30 nM.

## Lorlatinib Inhibition of Cell Proliferation (Study PF-06463922\\_12Mar13\\_174542)

Lorlatinib was evaluated for its ability to inhibit ALK fusion or mutant ALK fusion dependent cancer cell growth in a panel of human NSCLC cells that harbour ALK fusion proteins.

<div style=\"page-break-after: always\"></div>

Table 6: Effect of lorlatinib on ALK Fusion or ROS1 Fusion Dependent Phenotypes

| Cell-based Functional Assays   |                                        | IC 50 (Mean  STD)   | IC 50 (Mean  STD)   | IC 50 (Mean  STD)   | IC 50 (Mean  STD)   | IC 50 Crizotinib/ Lorlatinib   |
|--------------------------------|----------------------------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------|
|                                |                                        | Lorlatinib           | Lorlatinib           | Crizotinib           | Crizotinib           |                                |
|                                |                                        | nM                   | n                    | nM                   | n                    |                                |
| Cell line                      | ALK or ROS1 Fusion                     |                      |                      |                      |                      |                                |
|                                | ALK fusion driven cell proliferation a |                      |                      |                      |                      |                                |
| H3122                          | Endogenous EML4-ALK v1                 | 2.4  0.3            | 4                    | 108  29             | 4                    | 45                             |
| H2228                          | Endogenous EML4-ALK v3a/b              | 1.3  0.1            | 3                    | 118  14             | 3                    | 91                             |
| H3122                          | Engineered EML4-ALK v1 L1196M          | 30  7               | 3                    | 838  154            | 3                    | 28                             |
| H3122                          | Engineered EML4-ALK v1 G1269A          | 30  16              | 4                    | 623  251            | 4                    | 21                             |
| Ba/F3                          | Engineered EML4-ALKv1 I1171T           | 14  12              | 5                    | 225  148            | 5                    | 16                             |
|                                | ALK fusion driven cell apoptosis b     |                      |                      |                      |                      |                                |
| H3122                          | Endogenous EML4-ALK v1                 | 4.9  0.2            | 3                    | 149  8              | 3                    | 30                             |
| H3122                          | Engineered EML4-ALK v1 L1196M          | 29  5.7             | 3                    | 1520  372           | 3                    | 52                             |
| H3122                          | Engineered c EML4-ALK v1 G1269A        | 28  4.9             | 3                    | 1526  291           | 3                    | 55                             |
|                                | ROS1 fusion driven cell proliferation  |                      |                      |                      |                      |                                |
| HCC78                          | Endogenous SLC34A2-ROS1                | 2.6  3              | 3                    | 41  14              | 3                    | 16                             |
| BaF3                           | Engineered CD74-ROS1(s)                | 0.6  0.5            | 4                    | 5.9  4.4            | 4                    | 10                             |

IC50 = 50% inhibitory concentration; n = Number of replicates; STD = Standard deviation.

a. Cell proliferation was determined by utilizing a commercially available CellTiter-Glo  Assay kit (Promega).

b. Cell apoptosis was determined by using a commercially available Caspase-Glo® 3/7 Assay kit (Promega).

c. Corrected typo where incorrect mutant number was written in study report.

Sources: Study PF-06463922\\_12Mar13\\_174542 and Study PF-06463922\\_29Mar16\\_055600.

## In vivo studies

Summary of in vivo primary pharmacodynamic studies

| Study Reference /Study Type                                                                                        | Species (Strain)                                                                                                                                                                   | Dose (mg/kg) Route                                                     | Results                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PF- 06463922_12Mar13_1747 36 Inhibition of ALK Phosphorilation in ALKv1, ALK L1196M , ALK G1269A Xenofraft Tumours | Human lung adenocarcinoma xenograft model nu/nu or anthymic mouse implanted with H3122 cells expressing active EML4- ALKv1, EML4-ALKv1 L1196M and EML4-ALKv1 G1269A fusion protein | 0.06 to 40 mg/kg/day 6 to 14 days PO BID or subcutaneous pump infusion | PF-06463922 dose-dependently inhibited ALK activity in the ALK fusion driven tumour xenograft models. EC 50 s of PF-06463922 against ALK phosphorylation in tumours: ALK in H3122 model = 4.4 nM ALK L1196M in H3122-EML4-ALK L1196M model = 36 nM (BID study) ALK L1196M in H3122-EML4-ALK L1196M model = 66 nM (SC infusion pump study) ALK G1269A in H3122-EML4-ALK G1269A model = 31 nM |
| PF- 06463922_29Mar16_0556 00 Inhibition of ALK Phosphorilation in, ALK I1171T Xenofraft Tumours                    | Lung adenocarcinoma xenograft model anthymic mouse implanted with NIH3T3 cells expressing active EML4- ALKv1 I1171T                                                                | 0.3, 1 and 3 mg/kg/day for 9 days Subcutaneous pump infusion           | ALK I1171T in H3122-EML4-ALK 1171T model = 6.4 nM                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Study Reference /Study Type                                                                    | Species (Strain)                                                                                                                                                                   | Dose (mg/kg) Route                                                        | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PF-06463922_22 Jun17_020236 Inhibition of ALK Phosphorilation in, ALK G1202R Xenofraft Tumours | Lung adenocarcinoma xenograft model nu/nu mouse implanted with NIH3T3 cells expressing active EML4- ALKv1 G1202R                                                                   | 0.75, 2.5, 7.5, 20, or 25 mg/kg/day for 6 days Subcutaneous pump infusion | ALK G1202R in H3122-EML4-ALK G1202R model = 190 nM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PF- 06463922_12Mar13_1747 36 Antitumor activity Xenofraft Tumours                              | Human lung adenocarcinoma xenograft model nu/nu or anthymic mouse implanted with H3122 cells expressing active EML4- ALKv1, EML4-ALKv1 L1196M and EML4-ALKv1 G1269A fusion protein | 0.06 to 40 mg/kg/day 12 to 13 days PO BID or subcutaneous pump infusion   | PF-06463922 dose-dependently inhibited tumour growth and induced tumour regression in ALK fusion driven tumour xenograft models. H3122 model: 59% regression at 3 mg/kg/day SC infusion; H3122-EML4-ALKv1 L1196M model: 63% regression at 20 mg/kg/day PO BID; 57% regression at 15 mg/kg/day SC infusion; H3122-EML4-ALKv1 G1269A model: 59% regression at 25 mg/kg/day SC infusion PF-06463922 plasma concentration to achieve tumour stasis: H3122 model = 6.5 nM H3122-EML4-ALKv1 L1196M model (PO, BID) = 51 nM H3122-EML4-ALKv1 L1196M model (SC |
| PF- 06463922_29Mar16_0556 00 Antitumor activity Xenofraft Tumours                              | Human lung adenocarcinoma xenograft model anthymic mouse implanted with NIH3T3 cells expressing active EML4- ALKv1 I1171T                                                          | 0.3, 1 and 3mg/kg/day for 9 days Subcutaneous pump infusion               | Dose dependent antitumor efficacy of PF-06463922 and correlation to inhibition of EML4-ALK I1171T phosphorylation observed. ALK I1171T phosphorylation (100% inhibition) and antitumor efficacy (50% regression) achieved in the 3 mg/kg/day dose group with a mean unbound plasma Cav of 118 nM. PF-06463922 plasma concentration to achieve tumour stasis:                                                                                                                                                                                           |
| PF-06463922_22 Jun17_020236 Antitumor activity Xenofraft Tumours                               | Lung adenocarcinoma xenograft model nu/nu mouse implanted with NIH3T3 cells expressing active EML4- ALKv1 G1202R                                                                   | 0.75, 2.5, 7.5, 20, or 25 mg/kg/day for 6 days Subcutaneous pump infusion | Dose dependent antitumor efficacy of PF-06463922 and correlation to inhibition of EML4-ALK G1202R phosphorylation observed. At 2.5 mg/kg/day, 71% TGI and tumour regression of 34%, 76%, and 77% at the 7.5, 20, and 25 mg/kg/day, respectively. EC 50 for tumour growth inhibition was 165 nM which correlated with tumour stasis concentration.                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Study Reference /Study Type                                                | Species (Strain)                                                                                                                                    | Dose (mg/kg) Route                                                                                                              | Results                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PF-06463922_12 Mar 13_174736 Antitumor activity Xenofraft Tumours          | Lung adenocarcinoma xenograft model anthymic mouse implanted with NIH3T3 cells expressing active ROS1 fusion protein                                | 0.02 to 6 mg/kg/day for 9 days PO BID                                                                                           | PF-06463922 dose-dependently inhibited tumour growth and induced tumour regression (85% regression at 6 mg/kg/day) in ROS1 fusion driven tumour xenograft model. PF-06463922 plasma concentration to achieve tumour stasis: NIH3T3-CD74-ROS1 model = 5.6 nM. |
| PF-06463922_12 Mar 13_174736 Antitumor activity in Brain Xenofraft Tumours | Human lung adenocarcinoma xenograft model anthymic mouse implanted with H3122 cells expressing active EML4- ALKv1, EML4-ALKv1 L1196M fusion protein | 6 mg/kg/day in h3122-luciferase model ;5, 10 and 20 mg/kg in H3122-EML4- ALK L1196M luciferase model Subcutaneous pump infusion | Lorlatinib reduced tumour burden at 6 mg/kg/day in H3122-luciferase and at 5, 10, and 20 mg/kg/day in H3122-EML4-ALK L1196M -luciferase model (with plasma exposure levels ranging from 215 nM to 571 nM of free drug).                                      |

## · Functional    Biomarker  Analysis  in  the  H3122-EML4-ALKv1 L1196M  and  NIH3T3-CD74ROS1 Tumour Models (Study PF-06463922\\_12Mar13\\_174736).

Significant dose-dependent induction of caspase 3 levels was observed at 3 and 10 mg/kg BID groups (doses  that  showed  significant  antitumor  efficacy)  coupled  with  an  upregulation  of  pre-apoptosis protein BIM. In addition, a dose-dependent inhibition of Ki67 was also observed in the 3 and 10 mg/kg treatment groups. Marked dose-dependent inhibition of phosphorylated ALK, ERK, AKT, and STAT3 was observed  at  dose  levels  of  1,  3,  and  10 mg/kg/day  at  1-hour  and  3-hour  time  points  post  dose following  4-days  of  lorlatinib  treatment  (PO,  BID).  Similar  effects  with  these  markers  were  also observed following 1 hour of lorlatinib treatment in cells, with the exception that AKT (S473) inhibition was  less  significant  than  in  tumour  tissues.  Furthermore,  a  significant  and  dose  dependent  downregulation of cell cycle protein cyclin D1 and transcription regulator Myc was observed in the 3 and 10 mg/kg/day  groups  in  the  H3122-EML4-ALKv1 L1196M   model  corresponding  to  inhibition  of  cell proliferation  (Ki67  and  cell  viability),  induction  of  apoptosis  (caspase  3),  and  significant  antitumor efficacy.

## Secondary pharmacodynamic studies

In the assessment of secondary pharmacology, lorlatinib was profiled in vitro against a broad panel of receptors, enzymes, transporters, and ion channels in a wide ligand screening panel at concentrations up  to  10  M.  Less  than  50%  inhibition  of  binding  or  enzymatic  activity  was  observed  against  most profiled targets with the exception of the following enzymes: acetylcholinesterase (73.0% inhibition), AurA/Aur2 kinase (87.0% inhibition), EGFR (73.6% inhibition), and Lck (53.4% inhibition), with the enzymatic 50% inhibitory concentration (IC50) values for these activities determined to be &gt;7000x the enzymatic IC50 value for the target ALKL 1196M  (0.7 nM, 0.3 ng/mL).

The kinase selectivity profile of lorlatinib was also evaluated in a broad biochemical kinase panel of 206 recombinant  kinases.  Eleven  (11)  kinases  were  identified  for  which  lorlatinib  exhibited  activity  and showed selectivity margins of less than 100x compared to the target ALKL1196M.

There was no binding or enzymatic activity at 10  M for the metabolite PF-06895751.

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

Lorlatinib was evaluated in in vitro , ex vivo , and/or in vivo safety pharmacology studies to identify potential effects on the cardiovascular, respiratory, and CNS.

## -Cardiovascular Effects

In vitro , lorlatinib inhibited hERG (IC50=82,489 ng/ml) and calcium currents (IC50 = 17,871 ng/ml), ICs50 that correspond to 350x and 76x the human clinical exposure at 100 mg once daily (Cmax = 236 ng/ml), respectively. Inhibition of the sodium current was not observed at doses ≤100 µM.

Antagonist effect on calcium channel was not observed in the isolated rat aorta model where lorlatinib did not produce vasoconstriction in aortic rings at ≤30 µM.

Ex vivo, lorlatinib induced an increase in PR interval in a concentration-dependent manner from 1 µM (406 ng/ml) to 30 µM (12,193 ng/ml). There were no effects on any other parameters evaluated such as dP/dt (contractility), left ventricular pressure, coronary perfusion pressure, QRS and QT intervals.

The in vivo study has been conducted in conscious animals. Oral administration of lorlatinib induced an increase in systolic, diastolic and mean blood pressure, an initial decrease and later increase in heart rate in rat at 10 and 30 mg/kg. No exposure measures were conducted in this study. In a previous single-dose rat toxicokinetic study, the administration of lorlatinib at 10 and 30 mg/kg resulted in unbound AUC24 values of 4700 and 16,200 ng∙h/ml, respectively, and unbound Cmax values of 524 and 1640 ng/ml, respectively. In dog, oral administration of lorlatinib at 15 mg/kg/day induced an increase in heart rate and decrease systolic blood pressure, PR and QRS interval prolongation and increase fractional shortening with unbound mean Cmax and AUC24 values of 519 ng/ml and 6690 ng∙h/ml, respectively. No cardiovascular changes were observed at doses of 2 mg/kg/day with associated unbound mean Cmax and AUC24 values of 68 ng/ml and 890 ng∙h/ml, respectively.

PF-06895751, a major human circulating metabolite of lorlatinib, did not inhibit hERG potassium ion channels with an IC50 &gt;300  M (55,260 ng/ml).

## -Neurofunctional Effects

Lorlatinib was shown to be a brain penetrable compound, with measurable concentrations in the brain and CSF in the rat, dog, and human.

Lorlatinib caused a significant reduction in amplitude of long term potentiation in hippocampal brain slices, a measure that is widely considered to be one of the cellular mechanisms that underlie learning and memory formation. This effect was observed at 1  M (406 ng/mL), a concentration above the cellbased TrkB IC50 of 93 ng/mL whereas the effect was not observed at 0.1  M (41 ng/ml).

In a contextual renewal model, lower memory recall scores were observed at ≥3 mg/kg/day following a single dose of lorlatinib. The unbound brain concentrations of lorlatinib (137 and 511 ng/g 4 ) at 10 and 30 mg/kg doses, respectively, exceeded both the wild-type cell-based ALK IC50 of 0.6 ng/ml (primary pharmacology) and was similar to the cell-based TrkB IC50 of 93 ng/ml (secondary pharmacology). At 3 mg/kg, variability in the pharmacologic sensitivity was identified between studies, with the unbound brain concentrations of lorlatinib (24.6 to 31.4 ng/g) below the cell based TrkB IC50. No effects were observed on cue-induced renewal responding or total number of nose pokes, other measurements of cognitive function, or indirect measures of activity.

In addition, after 14 days of lorlatinib administration to rats, on Day 3 and 13, functional effects were observed such as, abnormal behaviour (i.e. teeth chattering), involuntary movements (i.e. retropulsion and trembling), reduced handling reactivity, decreased arousal, abnormal gait, and reduced reflex responses (i.e. uncoordinated air righting-reflex, and reduced extensor thrust response). There were

<div style=\"page-break-after: always\"></div>

no lorlatinib-related FOB findings at  20 mg/kg/day. No functional observational effects were identified in the pivotal toxicity studies following 4 and 13 weeks of dosing. There were no microscopic findings observed in the CNS in any of the studies conducted in rats or dogs, although non-adverse lower brain weights were observed in rats after 13 weeks of lorlatinib administration. The no-observed-adverseeffect-level (NOAEL) in rats, 15 mg/kg/day with an associated unbound AUC24 exposure of 13,600 (males) and 39700 ng·h/ml (females) following 13 weeks of lorlatinib administration, provide a margin of 7.1x the unbound human steady-state AUC exposure (1920 ng∙h/ml) at the recommended dose of 100 mg QD.

- -Respiratory Effects

Lorlatinib was administered to male rats (6/group) at single doses of 0 (vehicle), 10, 30, or 100 mg/kg. Statistically significantly lower mean tidal volumes were observed at doses ≥30 mg/kg. There were no significant changes in respiratory rate or minute volume at ≤100 mg/kg.

## Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies with lorlatinib have been submitted (see non-clinical discussion).

## Pharmacokinetics

The non-clinical pharmacokinetic/toxicokinetic, absorption, distribution, metabolism, and excretion (ADME) properties of lorlatinib (PF-06463922) were evaluated in vivo in rats and dogs and to a lesser extent in rabbits using oral and/or intravenous (IV) routes of administration. In vitro studies were also conducted to assess plasma protein binding of lorlatinib, partitioning of lorlatinib into red blood cells, hepatic uptake properties by transporters, drug metabolism of lorlatinib, and to assess the effects of lorlatinib on selected cytochrome P450 (CYP) enzymes, uridine diphosphate glucuronosyltransferase (UGT) enzymes, and selected efflux and uptake transporter activities.

An LC-MS/MS method has been developed for quantification of lorlatinib in rat, rabbit and dog plasma. This method appears to be sufficiently validated for the TK studies. Furthermore, a non-validated LCMS/MS method has been used to measure lorlatinib concentrations in brain and CSF for both rats and dogs. An LC MS/MS method was also developed and validated for quantification of the metabolite, PF06895751 in both rat and dog plasma to be used in the 13-week toxicity studies. The applied analytical methods are considered appropriate and validated for their purpose.

## Absorption

In rats and dogs, following intravenous (IV) administration, lorlatinib exhibited low plasma clearance (CL) of 15.5 ml/min/kg in rats and 9 ml/min/kg in dogs, and a volume of distribution (Vss) of 2.66 L/kg in rats and 2.8 L/kg in dogs, which exceeded total body water, suggesting extensive distribution to tissues. Oral bioavailability was high (&gt;100% in rats and 96.6% in dogs).

The toxicokinetics of lorlatinib were evaluated as part of oral repeat-dose toxicity studies in rats and dogs, EFD studies in rats and rabbits, and in support of phototoxicity evaluation.

The systemic exposure to lorlatinib increased with increasing dose over the dose range evaluated in the toxicology studies.

PF-06895751 (or M8) was a major pharmacologically inactive metabolite in human plasma that was also observed in rat and dog plasma following oral administration of 13-week repeat doses of lorlatinib. However, the unbound plasma area under the concentration-time curve (AUC) of PF-06895751 in rat

<div style=\"page-break-after: always\"></div>

and dog plasma following oral administration of repeat doses of lorlatinib was &lt;4% of that observed in humans after oral administration of multiple doses of lorlatinib (100 mg once daily [QD]).

Lorlatinib was not a substrate for P-gp or BCRP, and these efflux mechanisms are expected to have minimal effect on the absorption of lorlatinib.

## Distribution

[ 14 C]Lorlatinib-derived radioactivity was well distributed to most tissues and organs in male pigmented Long Evans rats, and was consistent with a Vss for lorlatinib that exceeded total body water. The uptake and retention of [ 14 C]lorlatinib-derived radioactivity was particularly prominent in the pigmented uveal tract. Tissues with the highest Cmax values for radioequivalents were observed for the uveal tract, liver, intervertebral discs, adrenal gland, and Harderian gland. Radioactivity concentrations were observed for up to 24 hours post-dose in non-circumventricular CNS tissues protected by the blood-brain barrier. In the vast majority of tissues, the elimination of [ 14 C]lorlatinib-derived radioactivity was complete by 96 hours post-dose. However, the QWBA shows a high AUClast and a slow t½ (more than 10 days) in some tissues like the eyes, the kidneys and the thyroid after a single oral dose of 10 mg/kg. However, a rapid decline in lorlatinib concentration was seen during the first 48 hours pose dose, followed by a slow terminal t½ in these tissues.

Lorlatinib can cross the BBB and distribute to the CNS tissues in rats and dogs. In addition, quantifiable lorlatinib concentrations were also observed in brain and CSF samples obtained at necropsy in the 4week toxicity study in rats and dogs.

In HEK293 cells transfected with OATP1B1 or OATP1B3, lorlatinib was not a substrate for either of these hepatic uptake transporters.

Lorlatinib and its major pharmacologically inactive metabolite (M8, PF-06895751) in humans showed moderate binding to proteins in mouse, rat, rabbit, dog, and human plasma.

In vitro , lorlatinib showed similar partitioning between the blood cells and plasma compartments for mouse, rat, rabbit, dog, and human.

Placental transfer of lorlatinib was not studied.

## Metabolism

## In vivo

After oral administration, the major primary metabolic pathways of [ 14 C]lorlatinib in rats and humans involved oxidation and glucuronidation, while oxidation was mainly involved in dogs. Although the glucuronidation pathway for lorlatinib was observed in both rats and humans, the positions of the glucuronide conjugates on the lorlatinib molecule differed between rats (M1b) and humans (M1a).

Similarity in the oxidative metabolic pathways and the presence of the major human circulating metabolite (M8) supports the selection of rats and dogs as the non-clinical species for toxicology evaluations.

Lorlatinib (PF-06463922) and pyrazole N-desmethyl lorlatinib (M2a, PF-06648706) were the major circulating entities in rat and dog plasma.

In human plasma, lorlatinib was the most abundant drug-related component, representing 44.4% of plasma AUC of the circulating radioactivity. The major circulating metabolite for lorlatinib in humans was a cleaved product of lorlatinib (PF-06895751, M8), which likely was formed via multiple biotransformation steps and accounted for 21% of circulating radioactivity. This metabolite constituted a disproportionate circulating metabolite as the unbound plasma AUC in humans (854 ng·h/ml) following oral administration of multiple 100 mg QD doses of lorlatinib (CSR; Study B7461001)

<div style=\"page-break-after: always\"></div>

exceeded those observed in rats (32.1 ng·h/ml [male], 9.32 ng·h/ml [female]) and dogs (20.1 ng·h/ml) at the highest doses tested in the 13-week toxicity studies.

## In vitro

The in vitro metabolism of lorlatinib in liver microsomes and hepatocytes was generally low across the evaluated species (mouse, rat, rabbit, dog, monkey, and human).

CYP-mediated metabolism contributed approximately 67% to the clearance for lorlatinib based on parent drug disappearance, with ~33% of the clearance derived from non-CYP mediated process.

Lorlatinib was mainly metabolised by CYP3A4 and UGT1A4, with minor contributions from CYP2C8, CYP2C19, CYP1A2, CYP3A5, and UGT1A3. Formation of PF-06895751 likely involved, at least in part, CYP3A4/5 as administration of itraconazole with lorlatinib to humans reduced the plasma AUC for this metabolite compared to lorlatinib alone.

In in vitro studies, CYP3A4 was consistently identified to contribute to the formation of M6. Formation of M2a was mediated mainly by CYP3A4 and CYP3A5, with minor contributions from CYP2C8, CYP2C19, and CYP1A2.

Glucuronidation of lorlatinib constituted a major clearance pathway in humans, with the glucuronide conjugate (M1a, PF-06924938) comprising a mean of ~13.5% of dose in excreta (10.9% in urine, 2.6% in faeces). Results from in vitro evaluations using HLM and recombinant human (rh)UGT enzymes indicated that UGT1A4 was the primary enzyme mediating the glucuronidation of lorlatinib to form M1a, with minor contribution from UGT1A3.

## Excretion

Following oral administration of [ 14 C]lorlatinib, the primary route of elimination of radioactivity was via the faeces in rats and dogs, whereas in humans, elimination involved both the urinary (47% dose recovered) and faecal routes (40.9% dose recovered). Excretion in milk was not tested.

## Pharmacokinetic drug interactions

## Lorlatinib and cytochromes

In vitro , lorlatinib demonstrated little or no reversible or time dependent inhibition (TDI) of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzyme activities (half maximal inhibitory concentration [IC50] &gt;100 µM) except for CYP2C9 where IC50 for reversible inhibition was 44 µM and for CYP3A4/5 where IC50 were 23, 10 and 22 µM for testosterone 6β-hydroxylation, midazolam 1'hydroxylation, and nifedipine oxidation, respectively.

Although in vitro , lorlatinib showed reversible inhibition and TDI towards CYP3A4/5, in human hepatocytes, lorlatinib has also been shown to induce CYP3A4 and to activate human pregnane X receptor (hPXR).

PF-06895751, the major circulating metabolite of lorlatinib in humans, showed little or no reversible inhibition and no TDI for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at concentrations up to 100 µM. PF-06895751 showed weak TDI for CYP3A4/5.

In human hepatocytes, lorlatinib caused a dose-dependent induction of CYP3A4 at concentrations ≥0.1 µM, and the same for dose-dependent induction of CYP3A4/5 activity (midazolam 1' hydroxylation) at concentration up to 3 or 10 µM and it also caused activation of the hPXR in a dose-dependent manner over the concentration range of 0.01 to 100 µM, with the EC50 and the Emax of 2.76 and 13-fold, respectively, comparable to those observed with rifampin (2.76 µM and 13-fold, respectively).

<div style=\"page-break-after: always\"></div>

Treatment of human hepatocytes with lorlatinib caused ≥2-fold dose-dependent induction of CYP2B6 mRNA and enzymatic activity (bupropion hydroxylation) at concentrations of ≥0.5 µM. In addition, lorlatinib (0.01-50 µM) also caused dose-dependent hCAR1 activation up to 6.46-fold, while the positive controls phenobarbital (3.1 to 750 µM) and CITCO (0.005 to 20 µM) showed dose-dependent activation of up to 3.05 and 22.46-fold.

In vitro , lorlatinib showed an increase (≥2-fold) in CYP1A2 mRNA in 1 of 3 lots of human hepatocytes at concentrations ≥50 µM, but no induction of the enzymatic activity in all 3 lots. The lowest concentration associated with no induction of CYP1A2 messenger ribonucleic acid (mRNA) (30 µM) exceeded the 50x unbound Cmax (Cmax,u) value (~24 µM).

In vitro , PF 06895751 showed a low potential to cause induction of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.

## Lorlatinib and UGTs (UDP-glucoronyl transferase)

In vitro studies indicated a low likelihood of inhibitory DDI by lorlatinib with UGT1A4, UGT1A6, UGT1A9, UGT2B7 and UGT2B15 but the IC50 value obtained for inhibition of UGT1A1 (46 µM) indicates there may be a potential for lorlatinib to inhibit UGT1A1. PF-06895751 demonstrated little or no reversible inhibition of UGT1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 (IC50 &gt;100 µM) in HLM with or without the addition of 2% BSA.

## Lorlatinib and protein transporters

Lorlatinib showed a low potential to cause DDI by inhibiting BCRP (systemically), OAT1, OCT2 and MATE2K, but has the potential to inhibit P-gp (systemically and GI tract), BCRP (GI tract), OATP1B1, OATP1B3, OCT1, OAT3, and MATE1 at clinically relevant concentrations. Since lorlatinib is an activator of hPXR in vitro , which regulates the expression of P-gp (Urquhart et al., 2007), the net effect of lorlatinib on P-gp activity in vivo is not known.

In vitro , PF-06895751 did not inhibit the activities of Pgp and BCRP mediated efflux of respective substrates at concentrations up to 268 µM, OATP1B1, OATP1B3 or OCT1 at concentrations up to 50 or 100 µM and OAT1, OAT3, OCT2, MATE1, or MATE2K at concentrations up to 50 or 100 µM.

## 2.3.3. Toxicology

The oral route of administration was selected for these studies since it is the intended route of clinical exposure. Rats and dogs were dosed twice daily (BID), approximately 6 or 7 hours apart to ensure appropriate  exposure  in  a  24-hour  period  and  was  also  supportive  of  the  continuous  daily  dosing planned in the clinic. Due to a gender difference in exposure observed in rats, doses in the 4- and 13week rat toxicity studies were twice as high in male as in female animals, in an attempt to achieve comparable systemic exposures.

Most of the pivotal toxicity studies were conducted using the free base of lorlatinib (PF-06463922, anhydrous form); however, the genotoxicity studies and some of the pivotal and non-pivotal and investigational studies used the acetic acid solvate form of lorlatinib (PF-06463922-14), and the 14day non-pivotal toxicity study in dogs and electro-retinography study in rats used the hydrochloride salt form of lorlatinib (PF-06463922-01). The free base form of lorlatinib represents the form that will be commercially available for clinical use.

<div style=\"page-break-after: always\"></div>

## Single dose toxicity

| Study ID                          | Species/ Sex/Number/ Group   | Dose/Route                       | Approx. lethal dose / observed max non-lethal dose   | Major findings                                                                                                    |
|-----------------------------------|------------------------------|----------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| PF-06463922 Non- GLP              | Rat/3M                       | 0, 10, 30, 100 mg/kg Oral gavage | MTD: 100 mg/kg/day                                   | 100 mg/kg : Reduced activity, pancreas (minimal degeneration of islet cells,  vacuolation, single cell necrosis) |
| PF-06463922 Non-GLP Dog/1M and 1F | 25, 50, 100 Oral gavage      | mg/kg                            | MTD: 100 mg/kg/day                                   | 100 mg/kg : reduced body weight, emesis, watery faeces, Increased WBC, Increased neutrophil, Increased monocyte   |

## Repeat dose toxicity

Lorlatinib was administered to rats and dogs in toxicity studies up to 13 weeks in duration with BID dosing. Moribundity preceded by clinical signs of intolerance was observed in repeat-dose toxicity studies at ≥30 mg/kg/day in rats and ≥25 mg/kg/day in dogs where systemic exposure exceeded exposure at clinically relevant doses.

The main target organs:

- Inflammation was observed in the skin and cervix of rats and the lung, trachea, skin, lymph nodes and/or the oral cavity including mandibular bone of dogs in repeat-dose studies of ≥4 weeks in duration and was associated with moribundity in dogs during the 13-week repeat-dose toxicity study. Inflammation in multiple tissues was associated higher WBC counts, fibrinogen, and/or globulin and lower albumin in rats and dogs. The inflammatory response in tissues and associated changes in clinical pathology parameters were partially to completely reversible following a 4-week non-dosing period in both rats and dogs.
- -Pancreas: acinar atrophy with decreased zymogen granules and occasional single cell necrosis, and/or islet angiectasis. The incidence and severity of the pancreatic findings were dose-related and often correlated with elevations of amylase and lipase.
- -Hepatobiliary system: Bile duct hyperplasia associated with elevations in liver enzymes (ALT, AST, ALP, GLDH, and/or GGT) was observed in rats and dogs. Increases in sinusoidal Kupffer cell pigmentation and mild haemorrhage in the mucosa of the gallbladder was also observed after 13 weeks of dosing in dogs. Findings in the liver included higher liver weights in rats with microscopic observations of hepatocellular hypertrophy and/or increased sinusoidal cellularity; higher liver weights with no microscopic correlates was observed in dogs. The bile duct hyperplasia was considered adverse when associated with increased bilirubin or presence of icterus in rats and when at moderate severity in dogs.
- -Male reproductive organs: seminiferous tubule degeneration with associated secondary effects and/or glandular atrophy of the prostate were observed in rats and dogs in repeat-dose toxicity studies ≥2 weeks in duration. Partial or complete reversibility of the effects was demonstrated.
- -Cardiovascular system: changes in blood pressure and heart rate and associated secondary effects on cardiac parameters of lorlatinib were identified in telemetered rats and dogs in single- and/or repeatdose studies. Higher heart weights with no microscopic correlates were observed in rats after 4 weeks of dosing; higher heart weights associated with minimally increased cellularity of Anichkov cells was identified after 13 weeks of dosing. These changes likely reflect a compensatory response to hemodynamic changes and not a direct effect on cardiac tissue. Lorlatinib administration to dogs

<div style=\"page-break-after: always\"></div>

resulted in ECG changes with increases in PR intervals considered to be a direct effect of lorlatinib; other changes were considered secondary to increased heart rate.

-Gastrointestinal tract: Clinical signs of gastrointestinal effects (emesis and/or abnormal faeces), stomach (erosions and/or ulceration), and intestinal macroscopic/microscopic findings (non-adverse single cell necrosis, villous atrophy, crypt hyperplasia, epithelial degeneration, and/or subacute inflammation) were observed in rats and/or dogs. Partial or complete reversibility of the effects was demonstrated.

-Peripheral nerves: Axonal degeneration was observed in rats at ≥4 weeks of dosing. Dysregulation of BDNF-TrkB signalling through TrkB inhibition might be a potential mechanism of the observed axon degeneration. Complete reversibility of axon degeneration in rats.

-CNS: No functional observational effects were identified in the pivotal toxicity studies following 4 and 13 weeks of dosing. Functional observational battery effects after 14 days of lorlatinib administration to rats included abnormal behaviour (i.e. teeth chattering), involuntary movements (i.e. retropulsion and trembling), reduced handling reactivity, decreased arousal, abnormal gait, and reduced reflex responses (i.e. uncoordinated air righting-reflex, and reduced extensor thrust response) at 60 mg/kg/day. No functional observational effects were identified in the pivotal toxicity studies following 4 and 13 weeks of dosing at doses up to 30 mg/kg/day, despite achieving comparable systemic exposures as the 60 mg/kg/day in the 14-day study. There were no microscopic findings observed in the CNS in any of the studies conducted in rats or dogs, although non-adverse lower brain weights were observed in rats after 13 weeks of lorlatinib administration. The potential for an effect on cognitive function was suggested from an ex vivo hippocampal brain slice assay and an exploratory in vivo contextual renewal model in rats.

-Kidney: Renal changes including glomerulopathy, arterial degeneration/necrosis, increased incidence and/or severity of tubular basophilia and pigmentation, and hyaline casts were observed in rats following 13 weeks of dosing, and correlated with urinalysis changes. Alterations in renal biomarkers without microscopic correlates were observed in rats at 4 weeks. The renal changes in rats were partially or completely reversible.

-Haematolymphopoietic system: Alterations in the cellularity of the spleen, lymph nodes, and/or thymus with associated haematological changes were identified in rats and dogs following ≥2 and ≥4 weeks of lorlatinib administration, respectively. The haematolymphopoietic findings were not considered adverse due to limited severity and/or adaptive nature of the changes. Partial or complete reversibility was demonstrated.

-Body weight changes: Lorlatinib administration caused dose-related non-adverse higher body weight and body weight gain that correlated with higher food consumption in rats after ≤13 weeks of lorlatinib administration. Similar lorlatinib-related effects did not occur in dogs.

-Hyperlipidaemia (cholesterol and triglycerides) was observed in rats and dogs following ≥2 weeks lorlatinib administration. The finding of increased food consumption, body weight gain, and cholesterol after lorlatinib administration were likely due to off-target inhibition of TrkB.

Other non-adverse findings observed inconsistently in rats and/or dogs after ≥4 weeks of lorlatinib administration included minimal to moderate mammary gland atrophy (male rats), minimal secretory depletion in the salivary (rats), and changes in adrenal gland weight (decreased in rats and increased in dogs), minimal electrolyte imbalances (rats and dogs), uterine atrophy (rats), and minimal decreases in brain weight (rats).

The NOAELs were identified as 8/4 (M/F) mg/kg/day in rats and 7 mg/kg/day in dogs, with associated unbound AUC24 exposures of 6240/7820 ng·h/ml and 2980 ng·h/ml, respectively, following 13 weeks

<div style=\"page-break-after: always\"></div>

of lorlatinib administration. The NOAELs in rats and dogs provide margins of 3.3x (male)/4.1x (female) and 1.6x, respectively, the unbound human steady-state AUC exposure of 1920 ng·h/mL at the recommended dose of 100 mg QD. However, it seems that the NOAELs following 13 weeks of BID dosing in rats and dogs were not well established given the toxicities observed at those doses.

The exposure of the main metabolite of lorlatinib (PF-06895751, M8) were obtained from 13-week repeat-dose toxicity studies in rats and dogs. However, the unbound plasma area under the concentration-time curve (AUC) of PF-06895751 in rat and dog plasma following oral administration of repeat doses of lorlatinib was &lt;4% of that observed in humans after oral administration of multiple doses of lorlatinib (100 mg once daily [QD]).

## Genotoxicity

Lorlatinib was tested in a conventional genotoxicity battery. It was identified as an aneugen, but not a mutagen or clastogen following genetic toxicity assessments. Significant increases in micronucleus formation were detected in vitro in TK6 cells following 4 hours of lorlatinib treatment at concentrations ≥293 µg/mL with or without metabolic activation. Lorlatinib induced significant increases in micronucleus formation at 100 mg/kg/day but not at ≤30 mg/kg/day following 2 days of administration in rats. Centromere analysis in the in vitro micronucleus assay determined that positive micronucleus results ( in vitro and in vivo ) were due to an aneugenic mechanism. As it is widely accepted that aneugens induce their effects by a threshold mechanism, a NOEL was established for micronucleus formation in vivo at 30 mg/kg/day in male and female rats, with associated unbound AUC24 values of 17,700 (males) and 45,500 ng·h/ml (females) providing margins of 9.2x (males) and 24x (females) the unbound human steady-state AUC exposure of 1920 ng·h/ml, at the clinical dose of 100 mg QD.

PF-06895751, the major human metabolite of lorlatinib was not mutagenic in the bacterial reverse mutation assay when tested up to 5000 µg/plate and did not cause micronucleus formation in an in vitro micronucleus assay.

## Carcinogenicity

No carcinogenicity studies with lorlatinib were submitted (see non-clinical discussion).

## Reproduction Toxicity

No fertility studies were performed. Effects on male reproductive organs (testes, epididymis, and/or prostate) were observed in rats and dogs in repeat-dose toxicity studies after ≥2 weeks of lorlatinib administration. Seminiferous tubular degeneration and/or atrophy in the testes, and epididymal changes (inflammation and/or vacuolation) were observed in the rat and dog. In the prostate, minimal to mild glandular atrophy was observed at 25 mg/kg/day in dogs. These changes correlated with lower testes, epididymis and prostate weights in dogs. Partial or complete reversibility of the effects on male reproductive system was demonstrated following a 4-week non-dosing recovery period after 4 or 13 weeks of lorlatinib administration to rats and dogs.

Preliminary GLP embryo-foetal development studies were conducted in rats and rabbits. Because embryo-foetal toxicity and developmental abnormalities were observed in the preliminary studies, pivotal studies were not conducted.

Lorlatinib-related maternal toxicity and developmental toxicities including lower embryo-foetal viability, lower embryo-foetal viability, lower mean foetal body weights, and/or foetal malformations (including

<div style=\"page-break-after: always\"></div>

rotated limbs, supernumerary digits, gastroschisis, malformed kidneys, domed head, high arched palate, and dilation of ventricles of the brain) were observed in rats and rabbits. There were no animal to human exposure margins for lorlatinib at the developmental lowest-observed-adverse-effect level (LOAEL) in the rat (1 mg/kg/day) and the developmental NOAEL in the rabbit (1 mg/kg/day). No preand postnatal studies were performed.

## Toxicokinetic data

Toxicokinetic  data  have  been  obtained  from  repeat-dose  toxicity  of  Lorlatinib  in  rats  and  dogs. Likewise, the exposure of the main metabolite of lorlatinib (PF-06895751, M8) has been obtained from 13-week repeat-dose toxicity studies in rats and dogs.

Table 7: Animal exposure in the pivotal repeat-dose toxicity studies with Lorlatinib

a  Doses are for males/females

| Study ID                                           | Daily Dose (mg/kg)    | Unbound AUC (ng.h/mL)   | Unbound AUC (ng.h/mL)   | Unbound C max (ng/mL)   | Unbound C max (ng/mL)   | Unbound Exposure Margin b   | Unbound Exposure Margin b   |
|----------------------------------------------------|-----------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|
|                                                    |                       | ♂                       | ♀                       | ♂                       | ♀                       | ♂                           | ♀                           |
| Wistar Rats 4-week with 4-week recovery 12GR341    | 2/1 a (1/0.5)         | 1120                    | 1740                    | 92.7                    | 110                     | 0.6                         | 0.9                         |
| Wistar Rats 4-week with 4-week recovery 12GR341    | 8/4 a (4/2 BID)       | 4850                    | 5700                    | 382                     | 292                     | 2.5                         | 3.0                         |
| Wistar Rats 4-week with 4-week recovery 12GR341    | 30/15 a (15/7.5 BID)  | 25200                   | 20800                   | 1940                    | 1440                    | 13                          | 11                          |
| Wistar Rats 13-week with 4 week recovery (8001588) | 2/1 a (1/0.5)         | 1190                    | 1750                    | 97.6                    | 118                     | 0.6                         | 0.9                         |
| Wistar Rats 13-week with 4 week recovery (8001588) | 8/4 a (4/2 BID)       | 6240                    | 7820                    | 442                     | 451                     | 3.3                         | 4.1                         |
| Wistar Rats 13-week with 4 week recovery (8001588) | 15/15 a (7.5/7.5 BID) | 13600                   | 39700                   | 915                     | 2000                    | 7.1                         | 21                          |
| Dogs 4-week with 4-week recovery 12GR342           | 2 (1BID)              | 1160                    | 1160                    | 101                     | 101                     | 0.6                         | 0.6                         |
| Dogs 4-week with 4-week recovery 12GR342           | 7 (3.5 BID)           | 3130                    | 3130                    | 278                     | 278                     | 1.6                         | 1.6                         |
| Dogs 4-week with 4-week recovery 12GR342           | 25 (12.5 BID)         | 11500                   | 11500                   | 1110                    | 1110                    | 6.0                         | 6.0                         |
| Dogs 13-week (8001589)                             | 2 (1BID)              | 809                     | 809                     | 91.3                    | 91.3                    | 0.4                         | 0.4                         |
|                                                    | 7 (3.5 BID)           | 2980                    | 2980                    | 330                     | 330                     | 1.6                         | 1.6                         |
|                                                    | 25 (12.5 BID)         | 8900                    | 8900                    | 1030                    | 1030                    | 4.6                         | 4.6                         |

b  The unbound human steady-state AUC exposure of 1920 ngh/mL at the recommended dose of 100mg QD. NOAEL in bold

Table 8: Mean Plasma TK Parameters of PF-06895751 (M8) in Rats and Dogs Given Oral Repeat Doses of Lorlatinib

| Week                                      | Dose (mg/kg/day)                          | N/Sex                                     | T max (h)                                 | C max (ng/mL)                             | C max (ng/mL)                             | AUC 24 (ng•h/mL)                          | AUC 24 (ng•h/mL)                          |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                                           |                                           |                                           |                                           | Total                                     | Unbound b                                 | Total                                     | Unbound a                                 |
| 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) | 13-Week Study in Rats (8001588 [16LJ022]) |
| 4                                         | 2                                         | 3/M                                       | NR                                        | NR                                        | NC                                        | NR                                        | NC                                        |
|                                           | 8                                         | 3/M                                       | 6.7                                       | 3.57                                      | 0.750                                     | 47.0                                      | 9.87                                      |
|                                           | 15                                        | 3/M                                       | 6.7                                       | 8.75                                      | 1.84                                      | 153                                       | 32.1                                      |
|                                           | 1                                         | 3/F                                       | NR                                        | NR                                        | NC                                        | NR                                        | NC                                        |
|                                           | 4                                         | 3/F                                       | 7.0                                       | 3.08                                      | 0.647                                     | NR                                        | NC                                        |
|                                           | 15                                        | 3/F                                       | 5.7                                       | 4.01                                      | 0.842                                     | 44.4                                      | 9.32                                      |
| 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) | 13-Week Study in Dogs (8001589 [16LJ023]) |
| 4                                         | 2                                         | 3/M + 3/F                                 | NR                                        | NR                                        | NC                                        | NR                                        | NC                                        |
|                                           | 7                                         | 3/M + 3/F                                 | 4.5                                       | 4.31                                      | 0.496                                     | 63.7                                      | 7.33                                      |
|                                           | 25                                        | 3/M + 3/F                                 | 4.2                                       | 10.9                                      | 1.25                                      | 175                                       | 20.1                                      |

AUC24 = Area under the concentration-time curve from 0 to 24 hours after dosing; BLQ = Below the limit of quantitation; Cmax = Maximum observed plasma concentration; F = Female; fu = Fraction unbound; GD = Gestation day; M = Male; N = Number of animals; NC = Not calculated; NR = Not reported; Tmax = Time to reach Cmax.

a. Cmax or AUC unbound = Cmax or AUC (total) × 0.210/0.115 (mean fu in rat/dog plasma, respectively; Study YDP067/136).

<div style=\"page-break-after: always\"></div>

## Local Tolerance

Administration of lorlatinib was not associated with vascular or perivascular irritation at the doses tested and was not considered to cause local irritation.

## Other toxicity studies

## Immunotoxicity

A dedicated immunotoxicity study has not been performed. Potential immunotoxic effects of lorlatinib were addressed in the repeat-dose toxicity studies.

## Mechanistic studies

## Metabolic and Lipid Profile Studies

Lorlatinib administration was associated with increases in body weight and body weight gain with correlated increases in food consumption in rats and elevations in cholesterol and/or triglycerides in rats and dogs at ≥2 weeks in duration.

Mechanistic studies 7 days to 4 weeks in duration were conducted in rats to further evaluate the time course of effects on fractionated lipid profiles and the potential mechanism associated with the body weight and food consumption changes.

## CNS Toxicity

The potential for CNS effects and impairment of cognitive function was suggested from the ex vivo hippocampal brain slice model, the rat contextual renewal model, and FOB assessments in repeat-dose toxicity studies. Clinical signs of CNS effects were observed and animals with higher exposure to lorlatinib were more likely to exhibit a higher incidence of CNS effects.

## Phototoxicity

The NOEL for phototoxicity in rats provided a margin of 17x, the unbound human steady-state AUC exposure of 1920 ng·h/ml at the recommended dose of 100 mg once daily (QD).

## Metabolites

No separate non-clinical evaluation of metabolites has been conducted.

In vitro bacterial reverse mutation and micronucleus assays were conducted with the major human circulating metabolite (PF-06895751) of lorlatinib (see Genotoxicity).

## Impurities

Four impurities (PF-06752166, PF-06876367, PF-06744689 and PF-06856050) are specified above 0.15%, the level of qualification in the drug substance. These impurities were tested in a 4-week repeat-dose toxicity study in rats. The adverse effects in this impurity qualification study were consistent with those observed in the other repeat-dose toxicity studies.

According to the guideline ICH Q3A, genotoxicity studies have to be conducted. An in vitro bacterial reverse mutation assay that demonstrates that PF-06744689 impurities is not mutagenic, clastogenic or aneugenic with a lower NOAEL than lorlatinib has been submitted. PF-06752166, PF-06876367 and PF-06856050 have been assessed in 2 validated and complimentary in silico systems with additional expert analysis in accordance with ICH M7 guidance and are predicted to be not mutagenic (Class 4).

<div style=\"page-break-after: always\"></div>

PF-06856050 and PF-06752166 share structural features and SARAH hypothesis with the parent and were thus qualified by Ames negative test of the parent. PF-06752166 is qualified by Ames negative tests of PF-06668559, PF-06841215, and parent which share the same structural features and Sarah hypotheses as this impurity.

## 2.3.4. Ecotoxicity/environmental risk assessment

In the Phase 1 screening environmental risk assessment, the PECsurfacewater for lorlatinib was calculated as 0.005 µg/L, using a refined Fpen for the target patient population.

Lorlatinib PECsurfacewater value is below the action limit of 0.01 µg/L and is not a PBT substance as log Kow does not exceed 4.5. Therefore, lorlatinib is not expected to pose a risk to the environment.

Table 9: Summary of main study results

| Substance (INN/Invented Name): Lorlatinib   | Substance (INN/Invented Name): Lorlatinib      | Substance (INN/Invented Name): Lorlatinib      | Substance (INN/Invented Name): Lorlatinib      |
|---------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| CAS-number (if available):                  | CAS-number (if available):                     | CAS-number (if available):                     | CAS-number (if available):                     |
| PBT screening                               |                                                | Result                                         | Conclusion                                     |
| Bioaccumulation potential- log K ow         | OECD107 or … ? (Other Concern)                 | 2.23 (pH=5) 2.47 (pH=7) 2.45 (pH=9)            | Potential PBT (N)                              |
| PBT-assessment                              | PBT-assessment                                 | PBT-assessment                                 | PBT-assessment                                 |
| Parameter                                   | Result relevant for conclusion                 |                                                | Conclusion                                     |
| Bioaccumulation                             | log K ow                                       |                                                | B/not B                                        |
|                                             | BCF                                            |                                                | B/not B                                        |
| Persistence                                 | DT50 or ready biodegradability                 |                                                | P/not P                                        |
| Toxicity                                    | NOEC or CMR                                    |                                                | T/not T                                        |
| PBT-statement :                             | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB |
| Phase 1                                     | Phase 1                                        | Phase 1                                        | Phase 1                                        |
| Calculation                                 | Value                                          | Unit                                           | Conclusion                                     |
| PEC surfacewater refined (e.g. prevalence)  | 0.005                                          |  g/L                                          | <0.01 threshold                                |

## 2.3.5. Discussion on non-clinical aspects

In vitro and in vivo pharmacodynamics evaluation of lorlatinib demonstrated that lorlatinib is a potent inhibitor  of  wild-type  ALK,  wild-type  ROS1,  and  several  ALK  mutant  kinase  activity.  Comparing  to crizotinib,  lorlatinib  had  significantly  enhanced  potency  against  ALK  mutations.  Primary in  vivo pharmacodynamics of lorlatinib were evaluated in human xenograft tumour models in athymic mice. Subcutaneous xenograft models tested for ALK and ROS fusions including secondary ALK mutations. An  orthotopic  brain  metastasis  model  was  also  used.  The in  vivo pharmacodynamics  studies  with lorlatinib  showed  significant  and  dose  dependent  antitumor  activity  against  a  broad  range  of mutations. The safety pharmacology studies conducted revealed a cardiovascular safety signal in in vitro , ex vivo and in in vivo studies. Furthermore, lorlatinib appears to affect memory recall in the rat at clinically relevant exposure levels.

Single dose pharmacokinetics and bioavailability of lorlatinib were evaluated in rats and beagle dogs after administration of a single oral dose. Lorlatinib appears to be readily absorbed with a very high bioavailability in both rats and dogs. Repeated dose pharmacokinetics of lorlatinib were evaluated  in rats, dogs and rabbits. Repeated dose studies in male and female rats showed dose proportionality. However, a sex-related difference in exposure was seen. Neither dogs nor rabbits showed these sexrelated differences.

Lorlatinib appears to be distributed in all tissues, which is consistent with the Vss being higher than total body water and thereby reflecting distribution to tissue including distribution to CNS.

<div style=\"page-break-after: always\"></div>

The rat and dog were selected as the rodent and non-rodent species, respectively, for general toxicity studies  because  they  demonstrated  the  ability  to  assess  potential  toxicities  from  both  primary  and secondary pharmacological targets, exposure profiles were sufficient, and there was representation of major metabolism pathways observed in humans.

The single dose toxicity studies in rats and dogs were not GLP compliant. This is accepted, as there are GLP compliant repeated dose toxicity studies that cover this part of the toxicity evaluation.

The main toxicities observed were inflammation across multiple tissues (skin and cervix of rats and lung, trachea, skin, lymph nodes and/or the oral cavity including mandibular bone of dogs; associated with increases in white blood cells, fibrinogen, and/or globulin and decreases in albumin) and changes in  the  pancreas (with increases in amylase and lipase), hepatobiliary system (with increases in liver enzymes),  male  reproductive  system,  cardiovascular  system,  kidneys  and  gastrointestinal  tract, peripheral nerves and the CNS (potential for cognitive functional impairment) (at dose equivalent to human clinical exposure at the recommended posology. Changes in blood pressure and heart rate, and QRS  complex  and  PR  interval  were  also  observed  in  animals  after  acute  dosing  (approximately 2.6 times the human clinical exposure at 100 mg after a single dose based on Cmax). All target organ findings  with  the  exception  of  hepatic  bile  duct  hyperplasia  were  partially  to  fully  reversible  (see Section 5.3 of the SmPC).

Lorlatinib  is  not  mutagenic  but  is  aneugenic in  vitro and in  vivo with  a  no  observed  effect  level  for aneugenicity  approximately  16.5  times  human  clinical  exposure  at  100  mg  based  on  AUC.  No carcinogenicity studies were conducted with lorlatinib which is acceptable in line with ICH S9 guideline.

Seminiferous tubular degeneration and/or atrophy in the testes, and epididymal changes (inflammation and/or  vacuolation)  were  observed  in  the  rat  and  dog.  In  the  prostate,  minimal  to  mild  glandular atrophy  was  observed  in  dogs  at  dose  equivalent  to  human  clinical  exposure  at  the  recommended posology). The effects on male reproductive organs were partially to fully reversible.

In embryo foetal toxicity studies, conducted in rats and rabbits, respectively, increased embryolethality and  lower  foetal  body  weights  and  malformations  were  observed.  Foetal  morphologic  abnormalities included  rotated  limbs,  supernumerary  digits,  gastroschisis,  malformed  kidneys,  domed  head,  high arched palate, and dilation of ventricles of the brain. The exposure at the lowest doses with embryo foetal effects in animals was equivalent to the human clinical exposure at 100 mg, based on AUC (see Section 5.3 of the SmPC).

Lorlatinib is not expected to result in phototoxicity in the eyes or skin upon UV radiation exposure after repeat dosing.

The Environmental Risk Assessment of the medicinal product lorlatinib, was realised according to the 'Guideline on the Environmental Risk Assessment of medicinal products for human use (EMA/CHMP/SWP/4447/00 corr1, 2006) and considering the Questions and Answers document on it (EMEA 2011).

In the Phase 1 screening environmental risk assessment, the PECsurfacewater for lorlatinib was calculated as 0.005 µg/L, using a refined Fpen for the target patient population. The refined PECsurfacewater is lower than the 0.01 µg/L action limit for continuing to a Phase 2 Tier A assessment.

The octanol-water partition coefficient (Kow) was estimated using a validated and recognised method 'Shake Flask Method' according to the OECD 107. The log Pow values for lorlatinib are 2.23, 2.47 and 2.45 at pHs 5, 7 and 9, respectively, which are below the trigger value of 4.5 for conducting a PBT assessment.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Conclusion on the non-clinical aspects

The non-clinical data submitted are considered acceptable and support the use of lorlatinib in the intended indication.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The clinical trials were performed in accordance with Good Clinical Practice (GCP) as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

-  Tabular overview of clinical studies

## Overview of Clinical Studies Including Subjects Who Received Lorlatinib and Were Evaluable for

Pharmacokinetics

| Protoco l No. Study Status                 | Study Design                                                                                             | Treatment Groups (Formulation)                                                                                                                                                                                                                                                                                                                       | Number of subjects                         | Sampli ng                                  | PK Analy sis                               | Demograp hics                                                                | Study start (FSFV)/ Study end (LSLV)       |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------|
| HEALTHY SUBJECT STUDIES                    | HEALTHY SUBJECT STUDIES                                                                                  | HEALTHY SUBJECT STUDIES                                                                                                                                                                                                                                                                                                                              | HEALTHY SUBJECT STUDIES                    | HEALTHY SUBJECT STUDIES                    | HEALTHY SUBJECT STUDIES                    | HEALTHY SUBJECT STUDIES                                                      | HEALTHY SUBJECT STUDIES                    |
| Mass Balance Study                         | Mass Balance Study                                                                                       | Mass Balance Study                                                                                                                                                                                                                                                                                                                                   | Mass Balance Study                         | Mass Balance Study                         | Mass Balance Study                         | Mass Balance Study                                                           | Mass Balance Study                         |
| B74610 04 Complet ed                       | Phase 1, open- label, single-dose, single-center study to evaluate the mass balance and PK of lorlatinib | 100 mg lorlatinib containing approximately 100  Ci of [ 14 C]lorlatinib, fasted (Bulk powder for preparation of an oral solution at the clinic)                                                                                                                                                                                                     | 6 healthy subjects                         | Full PK profile                            | NCA and popPK analysi s                    | Sex: 6 M Age range: 27-44 years Race: 6 W                                    | 30 Septembe r 2015/ 04 Novem ber 2015      |
| Bioavailability and Bioequivalence Studies | Bioavailability and Bioequivalence Studies                                                               | Bioavailability and Bioequivalence Studies                                                                                                                                                                                                                                                                                                           | Bioavailability and Bioequivalence Studies | Bioavailability and Bioequivalence Studies | Bioavailability and Bioequivalence Studies | Bioavailability and Bioequivalence Studies                                   | Bioavailability and Bioequivalence Studies |
| B74610 05 Complet ed                       | Phase 1, randomized, open-label, 3- period, 6-sequence, crossover Relative BA study                      | Treatment A (Reference): 1 × 100 mg lorlatinib tablet, fasted (Acetic acid solvate immediate-release tablet) Treatment B (test): 1 × 100 mg lorlatinib tablet, fasted (Anhydrous free-base extemporaneous immediate- release tablet) Treatment C (test): 1 × 100 mg lorlatinib tablet, fasted (Maleate salt extemporaneous immediate-release tablet) | 20 healthy subjects                        | Full PK profile                            | NCA and popPK analysi s                    | Sex: 20 M Mean age (SD): 39.4 (9.0) Age range: 25-55 years Race: 4 W/9 B/7 O | 05 March 2015/ 13 May 2015                 |

<div style=\"page-break-after: always\"></div>

## Overview of Clinical Studies Including Subjects Who Received Lorlatinib and Were Evaluable for Pharmacokinetics

| Protoco l No. Study Status   | Study Design                                                                                                                | Treatment Groups (Formulation)                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number of subjects   | Sampli ng       | PK Analy sis            | Demograp hics                                                                  | Study start (FSFV)/ Study end (LSLV)   |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----------------|-------------------------|--------------------------------------------------------------------------------|----------------------------------------|
| B74610 07 Complet ed         | Phase 1, open label, single-dose, randomized, 2-period, 2- treatment, 2-sequence, crossover Absolute BA study               | Treatment A (Reference): 50 mg lorlatinib, fasted (IV solution for injection) Treatment B (Test): 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base immediate-release tablet)                                                                                                                                                                                                                                                                      | 11 healthy subjects  | Full PK profile | NCA and popPK analysi s | Sex: 11 M Mean age (SD): 37.6 (10.3) Range: 24- 52 Race: 1 W/4 B/ 1 A/5 O      | 13 June 2016/ 02 Septembe r 2016       |
| B74610 08 Complet ed         | Phase 1, randomized, open-label, 4- period, 4 treatment, 4- sequence, crossover food- effect, antacid- effect, and BA study | Treatment A: 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base immediate-release tablets) Treatment B: 100 mg lorlatinib (4 × 25 mg tablets), fed (Anhydrous free-base immediate-release tablets) Treatment C: 20 mg QD rabeprazole from D1-D5 100 mg lorlatinib (4 × 25 mg lorlatinib tablets) on D6, fasted (Anhydrous free-base immediate-release tablets) Treatment D: 100 mg lorlatinib, fasted (Oral solution, 100 mL of a 1 mg/mL solution) | 27 healthy subjects  | Full PK profile | NCA and popPK analysi s | Sex: 1 F/26 M Mean age (SD): 35.9 (10.3) Age range: 20-55 years Race: 21 W/6 B | 01 December 2015/ 11 April 2016        |

<div style=\"page-break-after: always\"></div>

## Overview of Clinical Studies Including Subjects Who Received Lorlatinib and Were Evaluable for Pharmacokinetics

| Protoco l No. Study Status   | Study Design                                                                                                                                                               | Treatment Groups (Formulation)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Number of subjects       | Sampli ng                | PK Analy sis             | Demograp hics                                                                     | Study start (FSFV)/ Study end (LSLV)   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|-----------------------------------------------------------------------------------|----------------------------------------|
| B74610 16 Complet ed         | Phase 1, randomized, single-dose, open label, 4-period, 4- treatment, 4- sequence, crossover BE study                                                                      | Treatment A (Reference): 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base [Form 7] immediate-release tablets) Treatment B (Test Formulation 1): 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base [Form 7] commercial immediate-release tablets) Treatment C (Test Formulation 2): 100 mg lorlatinib (2 × 50 mg tablets), fasted (Anhydrous free-base [Form 7] commercial immediate-release tablets) Treatment D (Test Formulation 3): 100 mg lorlatinib (1 × 100 mg tablet), fasted (Anhydrous free-base [Form 7] commercial | 20 healthy subjects      | Full PK profile          | NCA and popPK analysi s  | Sex: 20 M Mean age (SD): 42.2 (9.46) years Age range: 25-54 years Race: 19 W/1 B  | 08 November 2016/ 06 Februa ry 2017    |
| Drug-interaction Studies     | Drug-interaction Studies                                                                                                                                                   | Drug-interaction Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Drug-interaction Studies | Drug-interaction Studies | Drug-interaction Studies | Drug-interaction Studies                                                          | Drug-interaction Studies               |
| B74610 11 Complet ed         | Phase 1, open- label, 2-period, 2- treatment, fixed- sequence, crossover study to estimate the effect of multiple dose rifampin on the single dose PK of lorlatinib in HVs | Treatment A (Reference): Day 1 of Period 1: single dose of 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base immediate-release tablets) Treatment B (Test): Day 1 to Day 12 of Period 2: Rifampin 600 mg QD Day 8 of Period 2: 100 mg lorlatinib (4 × 25 mg tablets), fasted (Anhydrous free-base immediate-release tablets)                                                                                                                                                                                                                    | 12 healthy subjects      | Full PK profile          | NCA and popPK analysi s  | Sex: 1 F/11 M Mean age (SD): 36.5 (11.1) Age range: 21-55 years Race: 6 B/2 W/4 O | 06 July 2016/ 06 Octobe r 2016         |
| B74610 12 Complet ed         | Phase 1, open- label, fixed sequence, 2- period study to investigate the effect of multiple doses of itraconazole on the PK of single dose lorlatinib                      | Period 1 (Reference): Day 1: 50, 75 or 100 mg lorlatinib, fasted (Anhydrous free-base immediate-release 25 mg tablets) Period 2 (Test): Days 1-11: Itraconazole 200 mg QD; Day 5: 50, 75 or 100 mg lorlatinib, fasted (Anhydrous free-base immediate-release 25-mg tablets)                                                                                                                                                                                                                                                                                      | 16 healthy subjects      | Full PK profiles         | NCA                      | Sex: 16 M Mean age (SD): 34.1 (10.6) Age range: 20-54 years Race: 1 B/12 W/3 O    | 16 August 2016/03 May 2017             |

<div style=\"page-break-after: always\"></div>

## Overview of Clinical Studies Including Subjects Who Received Lorlatinib and Were Evaluable for

Pharmacokinetics

| Protoco l No. Study Status   | Study Design                                                                                                                                                                                                                                                                                                                                                          | Treatment Groups (Formulation)                                                                                                                                                                        | Number of subjects                                                                                 | Sampli ng                      | PK Analy sis            | Demograp hics                                                                                                                                                                     | Study start (FSFV)/ Study end (LSLV)                                                                                          |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--------------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Patient Study                | Patient Study                                                                                                                                                                                                                                                                                                                                                         | Patient Study                                                                                                                                                                                         | Patient Study                                                                                      | Patient Study                  | Patient Study           | Patient Study                                                                                                                                                                     | Patient Study                                                                                                                 |
| B74610 01 Ongoing            | Phase 1 portion: To assess safety and tolerability of lorlatinib as a single agent at increasing dose levels in patients with ALK-positive or ROS1-positive advanced NSCLC in order to estimate the MTD and select RP2D.                                                                                                                                              | Phase 1 : Escalating doses of 10, 25, 50, 75, 100, 150, 200 mg QD and 35, 75 and 100 mg BID, fed or fasted (Acetic acid solvate 5-mg, 25 mg and 100-mg tablets)                                       | Phase 1 : 55 b ALK- positive or ROS1- positive advanced NSCLC                                      | Full PK and sparse PK profiles | NCA and popPK analysi s | Phase 1 Sex: 32 F/22 M Mean age (SD): 51.9 (12.8) Age range: 27-82 years Race: 3 B/37 W/7 A/1 O/6 unspecified                                                                     | 08 January 2014 Ongoing, enrollment complete as of 15 March 2017, the data cutoff date for the interim clinical study report) |
| B74610 01 Ongoing            | Phase 2 portion: To evaluate overall (intra- and extracranial) and intracranial antitumor activity of single-agent lorlatinib at RP2D in patients with ALK-positive advanced NSCLC or ROS1-positive advanced NSCLC. Japan LIC a : To evaluate the safety and PK of lorlatinib in Japanese patients treated at a previously tested dose in Phase 1 (Japan Sites only). | Phase 2 : 100 mg QD, regardless of food (Anhydrous free-base immediate-release 4 x 25 mg tablets) Japan LIC : 100 mg QD, regardless of food (Anhydrous free-base immediate-release 4 x 25 mg tablets) | Phase 2 : 276 c (patients with ALK- positive NSCLC or ROS1- positive advanced NSCLC) Japan LIC : 3 | Full PK and sparse PK profiles | NCA and popPK analysi s | Phase 2 Sex: 157 F /118 M Mean age (SD): 53.6 (12.1) Age range: 19-85 years Race: 132 W/3 B/103 A/12 O/25 unspecified Japan LIC : Sex: 2 F/1 M Age range: 39-51 years Race: Asian | 08 January 2014 Ongoing, enrollment complete as of 15 March 2017, the data cutoff date for the interim clinical study report) |

a. Japan LIC was considered separate from Phase 1 and Phase 2 in terms of efficacy and safety evaluations; however PK data for the LIC patients and Phase 2 patients were summarized together.

b. Study B7461001 enrolled 55 patients in Phase 1, however only 54 patients received the treatment. Therefore, all other numbers reported in this table are based on total 54 patients.

c. Study B7461001 enrolled 276 patients in Phase 2, however only 275 patients received the treatment. Therefore, all other numbers reported in this table are based on total 275 patients.

## 2.4.2. Pharmacokinetics

The majority of clinical studies conducted with lorlatinib enrolled healthy volunteers. Study B7461001 (Phase 1/2) was conducted in patients.

## Methods

Bioanalytical methods using LC-MS/MS for the quantitative determination of lorlatinib in plasma, urine and CSF, for cortisol and 6β-hydroxycortisol in urine and for rifampin, desacetyl rifampin, midazolam, cholesterol and 4β-hydroxycholesterol in plasma were developed and validated at contract laboratories. LC-MS/MS methods for quantification of PF-06895751 (major human metabolite of lorlatinib) in plasma was developed and validated at Pfizer PDM (Groton, USA). Validations were conducted in compliance with current guidelines on bioanalytical method validation.

<div style=\"page-break-after: always\"></div>

PK parameters for lorlatinib and its metabolite PF-06895751 (M8) were derived from concentration vs time data, and estimated by non-compartmental methods. Plasma concentrations vs time data were modelled  using  a  nonlinear  mixed  effects  population  analysis  approach  in  NONlinear  Mixed  Effects Modeling (NONMEM).

## Evaluation and qualification of models

The Pop PK population included data from 425 subjects (healthy volunteers and patients). Out of this data pool, 27 data points were excluded with a stated reason.

Table 10: Covariates considered in the population PK analysis

| PK Parameter's   | Covariates                                                                                  |
|------------------|---------------------------------------------------------------------------------------------|
| CL               | AGE,SEX,PTST,CYP2C19,CYP3A5,CYP2C9,TDOSE,RACE,BALB,BALK, BBIL,BTG,BHGRADE,BRGRADE,WNCL,BALT |
| V2               | AGE,SEX,BRGRADE,BTG,RACE,WNCL                                                               |
| ka               | FOOD,PSCI,PPI                                                                               |
| Relative F       | FOOD,PSCI,PPI,TDOSE,BHGRADE,BRGRADE,WNCL,BALT,CYP2C19, CYP3A5,CYP2C9                        |

Source:Module5,Section5.3.3.5,PMAR-681,Table4.

CL=clearance,which is comprisedof aninitial clearance aftersingledose and a timedependent induced clearance:V2=volume ofdistributionofcentralcompartment;k=Rateconstant of absorption; F=absolutebioavailability;BWT=baselinebodyweight;BALT=baseline alanine aminotransferase; BALB=baseline albumin;BBIL=baselinetotalbilirubin;BTG=baselinetriglycerides;BALK=baseline alkalinephosphatase;BHGRADE=baselinehepaticimpairmentasassessedbyNCIcriteriamethod (normal[A],mild[B1],mild[B2],and moderate[C]);BRGRADE=baselinerenalimpairment as assessed by K/DOQI staging (normal [A], mild [B], moderate [C], severe [D]); CYP2C19=CYP2C19 phenotype (poor,intermediate,extensive,orultrametabolizer);CYP3A5=CYP3A5phenotype(poor,intermediate, extensive,or ultra metabolizer);PK=pharmacokinetic;PPI=rabeprazole or norabeprazole coadministration;PSCI=formulation(acetic acidsolvate,freebase,orIVsolution);FOOD=fasted orfed; PTST=healthy volunteer or patient;RACE=Race(White,Black,Asian,or Other);TDOSE=total daily dose:WNCL=baselinestandardizedcreatinineclearance.

Covariate data from triglycerides and CYP phenotype had &gt;10% missing. Covariate data collected in the 7 studies with healthy subjects for triglycerides had 29.4% missing data and phenotype CYP2C19, CYP2C9  and  CYP3A5  data  had  35%  missing  data.  The  category  for  ultra-rapid  metabolisers  was represented for CYP2C19 (n=7). All other categories were represented by at least 5 subjects.

<div style=\"page-break-after: always\"></div>

<!-- image -->

ePharmacologyartifactIDsareshowninsubfigurelabels.

TAFDwasresetonPeriod1Day1andthusthefirst120hoursrepresents apoolingofDay-7andPeriod1Day 1.Shaded areasrepresent asimulation based90%predictioninterval of the5th,50h,and95thpercentileof the simulated dataRed lines represent the 5th,5oth,and 95thpercentile of the observed dataFigure 9a AllPatient Data,Figure9bAllhealthyvolunteerdata,Figure9cFirst600hours（patientsonly），Figure9dFirst120hours (bothpatients and healthyvolunteers).andFigure9eDay15of Cycle1(patientsonly).

DV=dependentvariableorobservedconcentrations;hr=hour;PTST=patientstatus,Oforhealthyvolunteer,1for patients;TAFD=timeafterfirstdose.

Figure 3: Prediction- and variability-corrected visual predictive check of final model

The final model was a 2-compartment model, with mixed first order and, zero-order absorption and a time-dependent induction of clearance. The VPCs for the final model were acceptable. The shrinkage on final parameters was high (&gt;30%) for almost all PK parameters, which could have profound impact on the sequential PK/PD analyses. Sensitivity analysis of PPI-use on ka showed impact of PPI-use on exposure expressed as Cmax, but not AUC. This is in line with the results from study 1008 indicating a 30% reduction on Cmax after PPI-use with no impact on AUC.

<div style=\"page-break-after: always\"></div>

Table 11: Final model final parameter estimates

| Parameter         | Value     | Model Results RSE(%)   | Shrinkage(%)   | Mean      | BootstrapResults 95%ConfidenceInterval   |
|-------------------|-----------|------------------------|----------------|-----------|------------------------------------------|
| DCLI(L/h)         | 9.035     | 6.860                  |                | 9.088     | (8.0115-10.0609)                         |
| θV(L)             | 120.511   | 10.764                 |                | 120.618   | (103.3633-137.6947)                      |
| Oka(h-)           | 3.113     | 12.063                 |                | 3.128     | (2.3125-3.9145)                          |
| BQ (/h)           | 22.002    | 8.515                  |                | 22.491    | (17.6495-26.3563)                        |
| θv;(L)            | 154.905   | 5.314                  |                | 156.640   | (134.2215-175.6205)                      |
| θIND              | 0.020     | 10.787                 |                | 0.027     | (-0.2136-0.2535)                         |
| 0D1 (h)           | 1.148     | 5.200                  |                | 1.149     | (1.0344-1.2611)                          |
| 0F                | 0.759     | 7.169                  |                | 0.764     | (0.6728 -0.8462)                         |
| 0CLMX (L/h)       | 14.472    | 6.860                  |                | 14.584    | (12.7286-16.2186)                        |
| ORes Eror for IV  | 0.115     | 14.929                 |                | 0.110     | (0.0811-0.1487)                          |
| ORes. Eror for PO | 0.438     | 3.485                  |                | 0.437     | (0.4090-0.4670)                          |
| OBALB on CL       | 0.067     | 37.112                 |                | 0.069     | (0.0214-0.1122)                          |
| OIDOSE on CL      | 0.001     | 55.719                 |                | 0.001     | (0.0004-0.0023)                          |
| OwNCL on CL.      | 0.235     | 20.164                 |                | 0.240     | (0.1457-0.3238)                          |
| OpPI on ka        | -0.675    | -11.020                |                | -0.664    | (-0.8508--0.4986)                        |
| IIV               | Value     | CV(%)                  | Shrinkage(%)   | Mean      | CI                                       |
|                   | 0.030     | 17.201                 | 23.212         | 0.030     | (0.0159-0.0433)                          |
| @p@CLMX (L/h)     | -0.006    | 7.460                  |                | -0.005    | (-0.0173-0.0061)                         |
|                   | 0.022     | 14.964                 | 40.174         | 0.023     | (0.0027-0.0420)                          |
|                   | 0.086     | 29.268                 | 52.835         | 0.085     | (0.0430-0.1284)                          |
| @V,OV3            | -0.017    | 12.881                 |                | -0.017    | (-0.0492-0.0160)                         |
|                   | 0.101     | 31.742                 | 53.123         | 0.099     | (0.0513-0.1502)                          |
|                   | 2.329     | 152.626                | 45.113         | 2.345     | (1.5982-3.0608)                          |
| OFV               | -2588.508 |                        |                | -2640.454 | (-3277.2723 --1899.7429                  |

ePharmacology artifact IDRA13523032.Line1 substituted.

Themean and95%ConfidenceIntervals aregeneratedfrom abootsraprunof1000resampleddatasets BALB=baseline albumin; CV=Coefficient of Variation; CI=Confidence Interval; Res Err=Residual Error; CLI=initial clearance; D1=zero order duration of absorption; F=bioavailability; h=hour;IIV=inter-individual variability;IND=rate constant of induction;ka=rate constant of absorption;L=liter;OFV=objectivefunction value; PO=oral; PPI=proton pump inhibitor use; RSE=Relative Standard Error; TDOSE=total daily dose (mg); V2=central volume of distribution; V3=peripheral volume of distribution; WNCL=baseline standardized creatinine clearance.

The sensitivity  analysis  of  various  covariate  effects  on  CL  showed  impact  from  body  weight  (BWT), TDOSE and WNCL, but within the extended boundary range of 70-142.9%. This boundary range was chosen as the area of no effect, based on results of the DDI study with itraconazole which resulted in a lorlatinib exposure increase of 42%.

The sensitivity analysis of BWT influence on CL showed a clear effect where clearance increased with body  weight.  Body  weights  in  the  studied  Pop  PK  population  ranged  from  31.8  to  155.5  kg  and exceeded the 10 th  and 90 th percentiles interval.

<div style=\"page-break-after: always\"></div>

<!-- image -->

BALB=basline albumin;BWT=baselinebodyweight;CrCL=baselinestandardizedcreatinineclearance.

Figure 4: Sensitivity analysis with lorlatinib clearance

The  final  popPK  model  was  used  in  sequential  PK/PD  analyses,  to  evaluate  E-R  relationships  for efficacy and safety endpoints.

## Statistical methods

Results were presented using descriptive statistics. Data were analysed after log-transformation using linear mixed effect statistical methods and the ratio of adjusted mean differences (test/reference) and associated 90% CIs were calculated for evaluation of effect.

## Absorption

Lorlatinib is categorised as a BCS Class IV drug substance with pH-dependent solubility (10 mg/ml at pH &lt;2 and 0.1 mg/ml at pH 7.7).

<div style=\"page-break-after: always\"></div>

Median time to peak concentration, Tmax, was 1.2 hours following a single 100 mg dose and 2.0 hours following multiple daily doses of 100 mg lorlatinib in cancer patients. (Study 1001, Phase 2 and Japan LIC).

Co-administration of agents that can affect gastric pH may potentially alter drug absorption, hence 100 mg lorlatinib with concomitant treatment of rabeprazole was investigated in healthy subjects (study 1008).  PK  results  are  presented  in  Table  12  showed  a  30%  decrease  in  Cmax  with  no  impact  on lorlatinib AUC.

The potential for efflux transporters P-gp and BCRP to transport lorlatinib was investigated in vitro in transfected MDCKII cells with positive controls and the results indicated lorlatinib was not a substrate.

## Bioavailability

Bioavailability of lorlatinib was studied in healthy volunteers in study 1005, 1007 and 1008.

Comparison  of  IV  versus  oral  tablets  in  study  1007,  showed  the  mean  absolute  bioavailability  for lorlatinib is 80.8% (Table 12). There was no difference in the exposure of the major metabolite PF06895751 after oral administration of lorlatinib compared to IV.

Table 12: Statistical summary of treatment comparison for lorlatinib pharmacokinetic parameters; Study 1007

|                      | AdjustedGeometricMeans               | AdjustedGeometricMeans                 |                                          |               |
|----------------------|--------------------------------------|----------------------------------------|------------------------------------------|---------------|
| Parameter(Units)     | Reference Lorlatinib50mg Intravenous | Test Lorlatinib 4 x 25 mg Oral Tablets | Ratio (Test/Reference) ofAdjusted Means\" | 0%06 Ratio    |
| AUCinr(dn)(ng·hr/mL) | 5189                                 | 41916                                  | 80.78                                    | (75.73.86.16) |
| AUCa(dn)(nghr/mL)    | 5028                                 | 4106b                                  | 81.65                                    | (76.56.87.08) |

Source:Module5.Section5.3.1.1.Study1007CSRIn-textTable14

Valueshadbeenback-transformedfromthelogscale.

The mixed effects model included sequence.period and treatment as fixed effects and subject within sequenceasarandomeffect.

AUCnareaundertheplasmaconcentration-timeprofilefromtimeOextrapolatedtoinfinitetime:

AUCiast=areaundertheplasmaconcentration-timeprofilefromtimeOtothetimeofthelastquantifiable

concentration: CI=confidence interval: CSR=clinical study report: dn=dose normalized; hr=hour(s).

The ratios(and 90%CIs)were expressed aspercentages.

Valueswerenormalizedto50mgintravenousdose.

At 100 mg once daily, the geometric mean (% coefficient of variation [CV]) peak plasma concentration was 577 (42) ng/ml and the AUC24 was 5,650 (39) ng·h/ml in patients with cancer. The geometric mean (% CV) oral clearance was 17.7 (39) L/h (Study 1001, Phase 2 and Japan LIC).

Table 13: Pharmacokinetic parameters of lorlatinib at steady state in patients with ALKpositive or ROS-1 positive NSCLC (study 1001) following administration of lorlatinib multiple oral doses (100 mg QD)

| Cohort                   | Visit   | N, n', n   | AUCtau (nghr/mL)   | Cmar (ng/mL)   | Tmax (hr)      | CL/F (/h)   | Rac         | R            |
|--------------------------|---------|------------|--------------------|----------------|----------------|-------------|-------------|--------------|
| 100lPhase1               | CID15   | 16, 15, 14 | 5121 (30)          | 550 (32)       | 1.1 (1.0-4.0)  | 19.5 (30)   | 1.07± 0.31  | 0.660 ±0.186 |
| 100lPhase2 and Japan LIC | C1D15   | 22,20,14   | 5650 (39)          | 577 (42)       | 2.0 (0.5-22.7) | 17.7 (39)   | 1.08 ± 0.43 | 0.658± 0.286 |

Source:Module5,Section5.3.5.2,Study1001,Table14.4.4.1.1.1,Table14.4.4.1.2.1.

PharmacokineticparametersaredefinedinTable3.

%CV=percent coefficient of variation; C=Cycle; D=Day; Japan LIC=Japanese patient only Lead-in Cohort; N=number of subjects in the treatment group;

n=number of subjects for whom Rcould be determined,n=number of subjects for whom R,could be determined;NSCLC=non-small-cell lung cancer,

QD=oncedaily;SD=standarddeviation.

Different  oral  formulations  of  lorlatinib  were  used  throughout  the  development  programme:  Form 1 maleate salt formulation, Form 3 acetic acid solvate formulation and Form 7 anhydrous free base that was selected as commercial form of the drug substance.

<div style=\"page-break-after: always\"></div>

Formulations  used  in  healthy  subjects  and  in  the  main  efficacy  study  in  patients  were  compared  in studies 1005 and 1016. Results indicated no clinically relevant exposure differences. For study 1005, it is of note, the geometric mean ratio of free base formulation compared to acetic acid solvate for Cmax was 85.13% with a 90%CI: 78.22-92.65, slightly below BE acceptance criteria of 80-125%.

Table 14: Overview of biopharmaceutics studies of lorlatinib

Source:SBSTable1andSBSTable2.

|   Study Nunber | StudyDesign/Objective                               | StudyPopulationa   | Formulation                                                                                                                                         |
|----------------|-----------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|           1005 | Relativebioavailability study                       | 20healthysubjects  | 1)Acetatesolvateimmediate-release Phaselclinicalimagetablet 2)Anhydrousfree-base extemporaneousimmediate-release tablet 3)Maleatesaltextemporaneous |
|           1007 | Absolutebioavailability study                       | 11healthy subjects | 1)IVsolutionforinjection 2)PO:Anhydrousfree-base immediate-release clinicalimage tablet                                                             |
|           1008 | Food-effect,antacid effect,and bioavailabilitystudy | 27healthy subjects | 1)Anhydrousfree-baseimmediate- release clinicalimage tablet 2)Oral solution                                                                         |
|           1016 | Bioequivalence study                                | 20healthy subjects | 1)Anhydrousfree-baseimmediate- releaseclinicalimage tablet 2)Anhydrousfree-baseimmediate- releasecommercialimagetablet                              |

Abbreviations:IV=intravenous;PO=per os(orally):SBS=Summary of Biopharmaceutics andAssociatedAnalytical Methods

a.Numberofsubjectswhoreceived lorlatinib.

Bioequivalence was shown between the free base clinical reference formulation and different strengths of the commercial image tablet in study 1016 (Figure 5).

<!-- image -->

Source: SBS, Appendix 2.

B7461005:Thereference（treatmentA)isthe aceticacidsolvatereferenceformulation,Test1(treatmentB)is theanhydrousfreebaseclinicalimageformulation,andTest2（TreatmentC)isthemaleateformulation. B7461016:Referenceistheanhydrousfreebaseclinicalformulation,Test1refersto4x25mgofthe commercialimagetablets,Test2is2×50mgofthecommercialimagetablets,andTest3is1x100mgofthe commercialimage tablets.

AUCin=area under theconcentrationtime curvefromtimeOtoinfinity,Cmax=maximum-observed plasma concentration;90%CI=90%confidenceinterval;ID=identification;PK=pharmacokinetic(s);SBS=summaryof biopharmaceutics;vs.=versus.

Figure 5: Bridging of lorlatinib clinical trial formulations with relative bioavailability and bioequivalence studies 1005 and 1016

Influence of food

The influence of food was investigated in 6 patients in study 1001 and in 24 healthy subjects in study 1008 (results presented in  Table  15).  Results  indicated  Tmax  was  slightly  prolonged in  the  fed  state compared to the fasted in both study groups.

<div style=\"page-break-after: always\"></div>

Table 15: Summary of plasma PF-06463922 PK parameter values following single oral doses

|                   | ParameterSummaryStatisticsbyTreatinent   | ParameterSummaryStatisticsbyTreatinent   | ParameterSummaryStatisticsbyTreatinent    | ParameterSummaryStatisticsbyTreatinent   |
|-------------------|------------------------------------------|------------------------------------------|-------------------------------------------|------------------------------------------|
| Parameter (units) | PF-06463922 100mg tablets                | PF-06463922100mg tabletswithHighFat Meal | PF-06463922100mg tablets+Rabeprazole 20mg | PF-06463922 100mgOral Solution           |
| u'N               | 24,24                                    | 23,23                                    | 23,23                                     | 24,24                                    |
| AUC (ng·hr/mL)    | 8712 (24)                                | 8779 (24)                                | 8629 (24)                                 | 9359 (24)                                |
| AUCu (ng·hr/mL)   | 8191 (21)                                | 8262(22)                                 | 8011(21)                                  | 8789(21)                                 |
| Cx (ng/mL)        | 547.8 (20)                               | 488.5 (26)                               | 383.0 (28)                                | 704.7 (22)                               |
| Tm(hr)            | 1.50(0.500-2.02)                         | 2.00 (1.00-6.00)                         | 2.00 (1.50-6.00)                          | 1.00(0.500-1.50)                         |
| t(hr)             | 24.2±5.22                                | 23.7±6.04                                | 25.6±6.42                                 | 24.1±5.36                                |
| CL/F(L/hr)        | 11.48(24)                                | 11.40 (24)                               | 11.58(24)                                 | 10.69 (24)                               |
| V/F(L)            | 390.6 (20)                               | 378.2(22)                                | 414.5(21)                                 | 361.1 (19)                               |

Source:Table14.4.3.1

PKParametersaredefinedinTable7

Abbreviations:%CV=percent coefficient of variation;N=Numberof subjects in the treatment group;n=

Number of subjectsconmibuting to thesummary statistics(seeTable 16.2.5.5.1.2 supportingdata forkand t); PK=phammacokinetics.

a Geometricmean(geometric%CV)for allexcept:median(range)forTmax:arithmeticmean(±SD)for t

## Distribution

The apparent volume of distribution of lorlatinib (Vz/F) was large and indicated extensive distribution into  tissues  (Table  15).  The  volume  of  distribution  of  the  major  metabolite  PF-06895751  was  not given.

In vitro binding to human plasma proteins was 66% (fu of 0.340). For human serum albumin (HSA) and for α1-acid glycoprotein (AAG), fu was 0.474, and 0.620 respectively. Concentration dependency was not studied. The concentration investigated was &gt;Cmax after multiple doses of lorlatinib 100 mg QD and within the dose proportional exposure range after QD 10 mg - 200 mg lorlatinib. Protein binding of PF-06895751  was  moderate  with  a  fu  of  0.207  in  human  plasma.  With  a  Cb/Cp  of  0.99,  lorlatinib distributes equally to whole blood and plasma. The blood-plasma ratio of the major metabolite was not determined.

The ability of lorlatinib to cross the BBB was evaluated in Study 1001. CSF concentrations and timematched plasma concentrations of lorlatinib were available for 4 patients from Phase 1 and 1 patient from Phase 2 and Japan LIC. Mean CSF/free plasma ratios were 0.7481 and 0.6791, respectively, for Phase  1  (n=4)  and  Phase  2  and  Japan  LIC  (n=1)  patients.  Therefore,  lorlatinib  can  cross  the  BBB following oral administration. CSF samples from treated patients were not analysed for PF-06895751.

## Elimination

## Excretion

In cancer patients the plasma half-life of lorlatinib after a single 100 mg dose was 23.6 hours (Study 1001, Phase 2 and Japan LIC). The plasma half-life of lorlatinib ranged from 20.9 to 25.5 hr across studies  and  was  close  to  tau  (QD  dosing).  Despite  the  long  half-life,  no  accumulation  of  lorlatinib occurred after multiple doses of the planned intended daily dose of 100 mg.

In the human mass balance study (Study 1004) following oral administration of a 100 mg radiolabelled dose  of  lorlatinib,  the  urinary  excretion  of  unchanged  lorlatinib  was  found  to  be  a  minor  route  of elimination  with  less  than  1%  of  the  administered  parent  drug.  In  plasma  and  faeces,  lorlatinib accounted for 44.4% and 9.1% of total radioactivity respectively.

Metabolism

<div style=\"page-break-after: always\"></div>

In the mass balance study, a mean 47.7% of the radioactivity was recovered in urine and 40.9% of the radioactivity  was  recovered  in  faeces,  with  an  overall  recovery  of  radioactivity  in  excreta  of  88.6%. Radioactivity  corresponding  to  64%  of  the  dose  was  identified  (estimated  including  metabolites observed  in  single  subjects).  In  plasma,  a  benzoic  acid  metabolite  of  lorlatinib  resulting  from  the oxidative  cleavage  of  the  amide  and  aromatic  ether  bonds  of  lorlatinib  was  observed  as  a  major metabolite  (PF-06895751),  accounting  for  21%  of  the  circulating  radioactivity.  A  follow-up  study (B7461017) with a different site of radiolabelling has been completed.

The  major  human  metabolite  PF-06895751  was  not  detected  in  the  rat  or  dog  ADME  study.  PF06895751 was detected in plasma after repeat-dose administration of lorlatinib in the 13-week rat and dog toxicity studies, at levels 30-40 fold below the mean steady-state exposure in humans achieved after 100 mg QD lorlatinib. The observed exposure of PF-06895751 in humans is not covered by nonclinical safety studies.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Figure 6: Proposed biotransformation pathways of lorlatinib in human excreta

## Inter-conversion

Results from Study 1001 (n=6) indicated that no considerable chiral inversion of lorlatinib occurred in plasma.

## Pharmacokinetics of metabolites

The metabolite  PF-06895751 was considered pharmacological inactive  after  CEREP  screening.  There was inhibition of binding to GABAA1 of 30.9% at 10 µM, which is considered to be a weak to moderate effect.  The  tested  concentration  was  above  the  maximum  observed  plasma  concentration  of  PF06895751 in a patient (761 ng/mL at Cycle 10).

Table 16: PK parameters of lorlatinib metabolite, PF-06895751, in healthy subjects (studies 1007, 1011 and 1012) by study and treatment arm following administration of a single oral dose (100 mg) of lorlatinib

|                   |                                                      |                  | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   | LorlatinibPKParaimeterSuninaryStatisticsfora100-mgSingleOral Dose   |
|-------------------|------------------------------------------------------|------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| StudyNo! Data Set | LorlatinibFormulation; Fasted/Fed Condition          | N,n              | AUCr (ng·hr/mL)                                                     | (ng/mL)                                                             | (hr)                                                                | t (hr)                                                              | MRRatio AUCat                                                       | AIR RatioCmr                                                        |
| Healthv Subjects  | Healthv Subjects                                     | Healthv Subjects | Healthv Subjects                                                    | Healthv Subjects                                                    | Healthv Subjects                                                    | Healthv Subjects                                                    | Healthv Subjects                                                    | Healthv Subjects                                                    |
| 1007              | Anhydrousfree-base immediate-release tablets; Fasted | 01'11            | 4399(23)                                                            | 47.0(38)                                                            | 24.0(12.1-48.0)                                                     | 32.8±6.1                                                            | 1.19(38)                                                            | 0.207(34)                                                           |
| 1011              | Anhydrousfree-base immediate-release tablets; Fasted | 12,10            | 4453(38)                                                            | 59.0(29)                                                            | 30.1 (24.0-36.1)                                                    | 29.1±7.5                                                            | 1.17 (25)                                                           | 0.209 (29)                                                          |
| 1012              | Anhydrousfree-base immediate-release tablets; Fasted |                  | 3721(34)                                                            | 51.7(38)                                                            | 24.0 (12.0-48.0)                                                    | 29.6±6.7                                                            | 1.12 (54)                                                           | 0.276(49)                                                           |

Souce:Module5,Section5.3.1.1,Study1007CSR,In-textTable15;Module5,Section5.3.3.4,Study1011CSR,In-textTable16;Module5,Section 5.3.1.4,Study1012CSR,In-textTable15

PharmacokineticparametersaredefinedinTable3.

Geometricmean（geometric%CV)for allexcept:median(range)forTm andarithmeticmean±SDfor ty

%CV=percent coefficientof variation;hr=hour(s);JapanLIC=Japanese patient only Lead-in Cohort;N=number of subjects in the treatment group and contributing to the summaries;n=numberof subjects with reportableAUCmstand MR Ratio AUCmvalues;PK-pharmacokinetic(s);SD=standard deviation.

<!-- image -->

Source: ePhamm Artifact IDs 13307219 and 13307745.

Figure 7: Linear and semi-log plots of median plasma concentration-time profiles of lorlatinib following administration of multiple oral 100 mg doses of lorlatinib in patients with non-small cell lung cancer (study 1001)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: ePharm Artifact IDs 13307218 and 13307743.

Figure 8: Linear and semi-log plots of median plasma concentration-time profiles of PF-06895751 following administration of multiple oral 100 mg doses of lorlatinib in patients with non-small cell lung cancer (study 1001)

The  exposure  profile  of  lorlatinib  100  mg  QD  displayed  in  Figure  7  indicates  that  steady-state  was reached  at  Cycle  1,  Day  15  in  contrast  to  the  plasma  profile  for  PF-06895751  which  indicates  that steady-state was not reached (Figure 8)  at Cycle 1, Day 15. After a single 100 mg dose of lorlatinib, Tmax for PF-06895751 was ≥24 hours and the elimination seemed effective from 40 hours post-dose.

## Consequences of possible genetic polymorphism

The Pop PK model indicated that polymorphisms of the phenotypes for CYP3A5, CYP2C9 and CYP2C19 evaluated  as  poor,  intermediate,  extensive  or  ultra  metabolisers  (data  from  the  7  healthy  subject studies) did not have  significant  impact  on  lorlatinib  exposure.  Ultra-rapid  metabolisers  were represented for CYP2C19. No data were collected from ultra-rapid metabolisers of CYP2C9. None of the investigated phenotypes represented major routes of elimination.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Figure 9: Log-Log plots of individual and geometric mean Cmax and AUCtau values of lorlatinib as a function of dose following administration of multiple QD doses of lorlatinib (Cycle 1 Day 15) (study 1001)

<!-- image -->

Data indicate a dose proportional increase in lorlatinib exposure expressed as Cmax and AUCtau over the investigated dose range of 10-200 mg QD, after single and multiple doses. Lorlatinib AUCtau seemed to increase less than dose-proportionally after 15 doses.

The accumulation ratio for lorlatinib at steady-state was &lt;1 even though the half-life was close to tau and indicated auto-induction of metabolising enzymes. This is in line with the increased metabolic ratio (AUCtau) of PF-06895751 to lorlatinib of 1.8 observed on Cycle 1, Day 15 after 100 mg QD.

## Intra- and inter-individual variability

The  inter-individual  variability  (CV%)  after  a  single  oral  dose  of  100  mg  QD  lorlatinib  in  healthy subjects across studies 1004, 1005, 1007, 1008, 1011, 1012 and 1016 ranged from 18-38% and 1837%,  for  Cmax  and  AUCinf  respectively.  Intra-individual  variability  between  first  and  last  dose evaluated in Study 1001, Phase 2 in patients, (N=19/22) was based on geometric mean after 100 mg QD and the %CV ranged from 36-39% and 40-42% for AUCtau and Cmax, respectively. Inter- and intraindividual  variability  of  lorlatinib  PK  appear  to  be  moderate.  The  variability  was  slightly  higher  in patients after multiple doses compared to healthy subjects.

## Pharmacokinetics in target population

<div style=\"page-break-after: always\"></div>

PK was evaluated in patients after single and multiple doses of lorlatinib after dose escalation and after long-term administration of 100 mg QD (4x25 mg). The PK profile of lorlatinib after single dose was comparable in both healthy subject and patients. Steady-state was reached after 15 days of dosing, which was longer than expected from t½, but in line with the lack of accumulation and increased CL/F after  multiple  doses.  This  effect  caused  by  auto-induction  was  also  indicated  by  ratios  of  4βhydroxycholesterol/cholesterol and 6β-hydroxycortisol/cortisol that reached a maximum within 8 days.

Table 17: PK parameters of lorlatinib at steady state in patients with ALK-positive or ROS1positive NSCLC (study 1001) following administration of multiple oral doses of lorlatinib (100 mg QD)

| Cohort                   | Visit   | N,n,n    | AUCau (ng.hr/mL)   | Cmax (ng/mL)   | Tmax (hr)      | CL/F (m/D)   | R         | R..         |
|--------------------------|---------|----------|--------------------|----------------|----------------|--------------|-----------|-------------|
| 100lPhasel               | CIDIS   | 16,15,14 | 5121(30)           | 550 (32)       | 1.1 (1.0-4.0)  | 19.5 (30)    | 1.07±0.31 | 0.660±0.186 |
| 1001Phase2 and Japan LIC | CIDI5   | 22,20,14 | 5650(39)           | 577(42)        | 2.0 (0.5-22.7) | 17.7(39)     | 1.08±0.43 | 0.658±0.286 |

Souuce:Module5.Section5.3.5.2.Study1001.Table14.4.4.1.1.1,Table14.4.4.1.2.1.

Pharmacokineticparameters are definedinTable3.

Geometicmean（geometric%CV)forAUCCm,and CL/F;arithmeticmean±SDforRand Rmedian(range)forTx

n=numberof subjectsforwhomRxcould be determined,n=numberof subjectsfor whomRcould be determined;NSCLC=non-small-cell lumgcancer,

%CV=percent coefficient of variation;C=Cycle;D=Day;JapanLIC=Japanese patient only Lead-in Cohort,N=number of subjectsim the teatment group;

QD=oncedaily;SD=standard deviation

## Special populations

## Renal impairment

Clearance was notably reduced in one patient with severe renal impairment. Renal function assessed as baseline creatinine clearance (WNCL), was found to be a statistically significant covariate affecting lorlatinib clearance in Pop PK analysis.

Table 18: Lorlatinib initial clearance summarized by baseline K/DOQI renal impairment stage for healthy volunteers and patients dosed at 100 mg

| Basline Renal Impaimment   |   n | Baseline CrCL (ml/min)Median (Range)   | Baseline CrCL (ml/min)Mean± SD   | Baseline Standardized CrCL（mL/min） Median(Range)   | Baseline Standardized CICLMean±SD   | LorlatinibSingle Dose Clearance (L/hr)Median (Range)   | Lorlatinib Single Dose Clearance (L/hr)Mean±SD   |
|----------------------------|-----|----------------------------------------|----------------------------------|----------------------------------------------------|-------------------------------------|--------------------------------------------------------|--------------------------------------------------|
| A (Normal)                 | 226 | 115.78 (90.23-235.39)                  | 120.12±23.36                     | 111.78 (64.40-458.06)                              | 116.27±33.87                        | 9.80 (6.35-17.09)                                      | 9.84±1.63                                        |
| B(Mild)                    | 120 | 76.11 (60.53-89.98)                    | 76.59±8.58                       | 88.02 (53.50-156.48)                               | 90.45±21.13                         | 8.04 (5.84-11.42)                                      | 8.17±1.17                                        |
| C(Moderate)                |  45 | 53.59 (31.58-59.93)                    | 52.04±6.61                       | 68.00 (46.40-107.58)                               | 69.50±13.68                         | 7.22(5.38-9.87)                                        | 7.16±1.01                                        |
| D(Severe)                  |   1 | 24.54                                  | 24.54                            | 36.82                                              | 36.82                               | 4.81                                                   | 4.81                                             |
| All                        | 392 | 96.96 (24.54-235.39)                   | 98.74±31.95                      | 101.03 (36.82-458.06)                              | 102.79±33.28                        | 8.88(4.81-17.09)                                       | 9.01±1.77                                        |

ePharmacologyartifactIDRA13519111.

CrCL=Cockcroft-Gaultcalculated creatinine clearance;hr=hour,L=liter;mg=milligram;n=numberofpatients;K/DOQI=KidneyDisease Outcome Quality Initiative;Stdev=standard deviation.

<div style=\"page-break-after: always\"></div>

Table 19: Lorlatinib single-dose and steady state clearance summarized by baseline renal function with K/DOQI classification at 100 mg QD

| Baseline Renal              | Single-Dose Clearance (L/hr)   | Single-Dose Clearance (L/hr)   | Single-Dose Clearance (L/hr)   | Steady-State Clearance* (L/hr)   | Steady-State Clearance* (L/hr)   | Steady-State Clearance* (L/hr)   |
|-----------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Function Stage (CrCL range) |                                | Median (Range)                 | Mean±SD                        | I                                | Median (Range)                   | Mean±SD                          |
| Nomal (290)                 | 226                            | 9.80(6.35-17.09)               | 9.84.1.63                      | 133                              | 15.17(10.15-23.09)               | 15.21 ± 2.52                     |
| Mild impaiment (60-89)      | 120                            | 8.04(5.84-11.42)               | 8.17 ± 1.17                    | 103                              | 12.70 (9.33-18.25)               | 12.90 ±1.80                      |
| Moderate impainment (30-59) | 45                             | 7.22 (5.38-9.87)               | 7.16 ± 1.01                    | 41                               | 11.61 (8.60-15.77)               | 11.50 ± 1.66                     |
| Severe impainment (15-29)   | 1                              | 4.81                           | 4.81                           |                                  | 7.68                             | 7.68                             |

Source:Module 5,Section 5.3.3.5,PMAR-681,Table 15 and Table 16

CrCL=Cockcroft-Gault calculated creatinine clearance; hr=hour; n=nuumber ofpatients; K/DOQI=Kidney

Disease Outcome Quality Imitiative; QD=onrce daily, SD=standard deviation.

a. The lorlatimib steady state clearance reported are the individual clearance estimates for each patient in Study 1001 at Cycle 1 Day 15, after multiple dosing.

## Hepatic impairment

Impact of hepatic impairment on lorlatinib exposure has not been formally studied. Results from the patient study (Study 1001) and the human mass-balance study (Study 1004) indicate that lorlatinib elimination primarily occurred via hepatobiliary elimination.

Table 20: Lorlatinib steady state clearance summarized by baseline NCI hepatic impairment stage for B7461001 patients dosed at 100 mg QD

| BaslineHepatic Impairment   |   n | LorlatinibSteadyState Clearance(L/hr)Median(Range)   | LorlatinibSteadyState Clearance(L/hr)Mean±SD   |
|-----------------------------|-----|------------------------------------------------------|------------------------------------------------|
| A(Normal)                   | 236 | 13.39 (7.68-23.09)                                   | 13.78±2.55                                     |
| B1(Mild)                    |  36 | 13.15(8.79-20.15)                                    | 13.71±2.98                                     |
| B2(Mild)                    |   6 | 12.56(11.56-19.05)                                   | 14.08±3.16                                     |
| AlI                         | 278 | 13.31 (7.68-23.09)                                   | 13.78±2.61                                     |

ePharmacologyartifactIDRA13519110.

Thelorlatinibsteadystateclearancereportedaretheindividualclearanceestimatesforeachindividualat Cycle 1Day15,aftermultipledosing.

hr=hour;L=liter;mg=milligram;n=numberofpatients;NCl=National CancerInstitute;Stdev=standard deviation.

## Gender

In  the  Pop  PK  analysis,  gender  did  not  affect  lorlatinib  PK,  in  contrast  to pre-clinical  findings  where gender  had  marked  effect  on  exposure.  Both  genders  were  represented  in  the  clinical  PK  studies. Women represented 57% of the studied patient Pop PK population. The studies in healthy subjects were predominantly performed in males.

## Race

Race was evaluated as Asian vs non-Asian in selected patients from Study 1001. No clinically relevant differences were observed. Race was also tested as a covariate in Pop PK analysis and did not have significant effect on PK parameters. Half of the subjects in the clinical studies were white.

<div style=\"page-break-after: always\"></div>

Table 21: Statistical summary of treatment comparison for lorlatinib PK parameters in Asian vs. non-Asians patients by visit (Phase 2 and Japan LIC)

|                  | AdjustedGeometricMeans                                | AdjustedGeometricMeans                                |                                                       |                 |
|------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------|
| Parameter(units) | Test                                                  | Reference                                             | Ratio (Test/Reference) ofAdjustedMeans                | I%06 forRatio   |
|                  | Asian （Test)vs.Non-Asian(Reference)(Lead InDay-7)     | Asian （Test)vs.Non-Asian(Reference)(Lead InDay-7)     | Asian （Test)vs.Non-Asian(Reference)(Lead InDay-7)     |                 |
| AUC(ng·hr/mL)    | 9590                                                  | 8717                                                  | 110.02                                                | (80.48,150.40)  |
| Cmax(ng/mL)      | 907.2                                                 | 595.2                                                 | 152.40                                                | (116.21,199.86) |
|                  | Asian (Test)vs.Non-Asian(Reference)(Cycle1Day15) 5946 | Asian (Test)vs.Non-Asian(Reference)(Cycle1Day15) 5946 | Asian (Test)vs.Non-Asian(Reference)(Cycle1Day15) 5946 |                 |
| AUCau(ng·hr/mL)  |                                                       | 5369                                                  | 110.74                                                | (83.71,146.49)  |
| Cmax (ng/mL)     | 644.8                                                 | 515.5                                                 | 125.07                                                | (93.71,166.93)  |

Source:Table14.4.4.1.2.3.1and14.4.4.1.2.3.2

Abbreviation:CI=confidenceinterval.

PharmacokineticparametersaredefinedinTable4.

a.Theratios(and90%CIs)areexpressedaspercentages.

b.AsiansubjectsincludedJapanesepatients

## Weight

Sensitivity analysis of body weight influence on clearance showed that clearance increased with body weight. The sensitivity analysis simulating the concentrations following 100 mg QD administration with body weights at the 10 th  and 90 th  percentile extremes (corresponding to 50 and 91.3 kg) indicated no clinically relevant effect on exposure. Body weights in the studied Pop PK population ranged from 31.8 to 155.5 kg.

<!-- image -->

Source:Module5,Section5.3.3.5.PMAR-681,Figure13.

Theshadedgrayribbonrepresentsthe95%predictionintervalforatypical70kgWhitemalewithnoPPIuse,a baselinealbuminof4mg/dL,anddosedat100mg.50and91.3kgarethe10thand90thpercentilebody weights,ofpooledhealthysubjectsandsubjects.All covariatesotherthanweightaresetatthetypicalvalues.

hur=hour;PPI=proton-pumpinhibitor,QD=oncedaily.

Figure 10: Simulated body weight effect on lorlatinib PK

<div style=\"page-break-after: always\"></div>

## Elderly

In the studied Pop PK population (age 19 to 85), age did not seem to affect lorlatinib PK. Elderly ≥65 years were all cancer patients from Study 1001, and represented approximately 14% of the studied Pop PK population.

## Age distribution of patients with PK data in Study B7461001

|                          | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|--------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| PK data - Study B7461001 | 45/334                                            | 16/334                                            | 1/334                                           |

## Children

Lorlatinib PK was not studied in children. Lorlatinib is currently proposed indicated in adults only.

## Pharmacokinetic interaction studies

## In vitro

The potential for lorlatinib to cause DDI was investigated in vitro . The results indicated lorlatinib could induce  CYP3A4,  CYP2B6,  activate  hPXR  and  hCAR1  and  inhibit  CYP3A4/5,  CYP2C9,  UGT1A1,  P-gp, BCRP (GI tract), OATP1B1, OATP1B3, OCT1, OAT3 and MATE1 at clinically relevant concentrations.

The DDI effects identified in the in-vitro studies with possible clinical impact were further investigated in-vivo or in relevant cell lines (transporter studies). DDI caused by the major metabolite PF-06895751 was tested in-vitro over a large range of concentrations. Interactions were found to be unlikely at the clinically relevant concentrations achieved after 100 mg QD Lorlatinib in patients.

## Interaction study with CYP3A4/5 inhibitor (Study 1012)

The effect of a single oral  dose of lorlatinib (50 mg, 75 mg, and 100 mg) with and without 200 mg once daily itraconazole was evaluated in a 2-way crossover study in 16 healthy volunteers. Lorlatinib AUCinf increased by 42% and Cmax by 24%.

Table 22: Statistical summary of treatment comparison for PF-06463922 (100 mg) PK parameters with and without itraconazole

| Parameters(tnits)   | Aeljusted GeometricMleans                                      | Aeljusted GeometricMleans               | Ratio (Tesu/Reference) ofAdjusted leans   | 1%06            |
|---------------------|----------------------------------------------------------------|-----------------------------------------|-------------------------------------------|-----------------|
|                     | PF-06463922100mg SingleDose + Itraconazole2o0 mg Multiple Dose | Reference PF-06463922 100mg Single Dote |                                           | forRatio        |
| AUC(ngh/mL)         | 10400                                                          | 7338                                    | 141.79                                    | (128.71,156.21) |
| AUC(ngh/mL)         | 10180                                                          | 7119                                    | 142.94                                    | (130.02.157.15) |
| C(ngmL)             | 514.4                                                          | 413.6                                   | 124.39                                    | (110.20,140.41) |

Source:Table14.4.3.3

Parameters are definediTable5

Abbreviations:Cl=confidence interval

The ratios （and90% CIs）are expressed as percentages

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure10.MIedianPlasmaLorlatinibConcentration-TimeProfilesFollowingaSingle Oral100mgDoseofLorlatinibAloneandinCombinationwithMultiple Oral200mgQDDosesofItraconazole,Study1012

<!-- image -->

Source:Module5,Section5.3.3.4,Study1012CSR,In-textFigue1 Upperdlweranelsrliarandsemilgarithmicscalesepectivly. Corresponding mean plotsFigures 14.4.2.2.1.3 and14.4.2.2.1.4. HR=hour(s);MD=multiple dose;PF-06463922=lorlatinib;QD=once daily;SD=single dose.

Interaction study with CYP3A4/5 inducer (Study 1011)

Co-administration of 600 mg QD rifampin decreased lorlatinib exposure expressed as AUCinf and Cmax by  85%  and  76%,  respectively  and  led  to  elevated  aspartate  aminotransferase  (AST)  and  alanine aminotransferase (ALT) levels in all subjects, hence concomitant use of strong CYP3A4/5 inducers with lorlatinib are contraindicated. The Applicant advices concomitant use of moderate CYP3A4/5 inducers with lorlatinib  should  be  avoided.  The  metabolic ratio of PF-06895751 increased from 1.2 to 5.5 for AUCinf and from 0.21 to 1.1 for Cmax, following co-administration of lorlatinib and rifampin.

Table15.StatisticalSummaryofTreatmentComparisonforPF-06463922 PharmacokineticParameters

| Parameter (units)   | Adjusted GeometricMleans                 | Adjusted GeometricMleans      | Ratio (Test/Reference) ofAdjusted   | I%06          |
|---------------------|------------------------------------------|-------------------------------|-------------------------------------|---------------|
|                     | Test Rifampin600mgQD+ PF-06463922100mgSD | Reference PF-06463922 100mgSD | Means'                              | forRatio      |
| AUCr(nghr/mL)       | 1292                                     | 8766                          | 14.74                               | (12.78.17.01) |
| AUC(nghr/mL)        | 1200                                     | 8597                          | 13.96                               | (12.09.16.12) |
| C(ng/mL)            | 148.4                                    | 621.4                         | 23.88                               | (21.58.26.43) |

Source:Table 14.4.3.3

Rifampin was only given fromDay1 toDay 9 inPenod 2 to all subjects(versusprotocol specifiedrifampin dosingfromDay1toDay 12).Addstionally.Subject10011007discontimuedfrom study duringPeriod2and did not take rifampin dose onDay 9onwards.Values had been back-transformed from the log scale Pharmacokineticparameters are defined inTable7.

Abbreviations:CI=confidence interval:hr=hour（s）:QD=once a day,SD=single dose

Theratios(and90%6Cls)areexpressed aspercentages.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Interaction study with CYP3A4/5 substrate (Study 1001, Phase 1)

The  effect  on  midazolam  exposure  after  co-administration  with  lorlatinib,  was  estimated  to  be decreases of AUCinf of 61% and 62% after 25 and 150 mg QD lorlatinib dosing and decreases in Cmax of 40% and 50% after 25 mg and 150 mg QD lorlatinib dosing, respectively, compared to midazolam dosed alone. Co-administration with CYP3A4/5 substrates should be avoided. The study demonstrated that  lorlatinib  induced  a  reduction  in  oral  midazolam  exposure  (AUC)  which  classifies  lorlatinib  as  a moderate CYP3A inducer.

Time-dependent CYP3A4/5 inhibition towards midazolam was demonstrated in vitro .

<div style=\"page-break-after: always\"></div>

Table 23: Descriptive summary of plasma midazolam PK parameters following a single oral 2 mg dose alone and in presence of lorlatinib (25 mg QD or 150 mg QD)

|                   | ParameterSummaryStatistics?byTreatment   | ParameterSummaryStatistics?byTreatment   | ParameterSummaryStatistics?byTreatment   | ParameterSummaryStatistics?byTreatment   |
|-------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                   | Day-7 Lead In (Alone)                    | Day-7 Lead In (Alone)                    | Cycle1 Day15(WithLorlatinib)             | Cycle1 Day15(WithLorlatinib)             |
| Parameter [Units] | 25 mg QD PF-06463922                     | 150 mg QD PF-06463922                    | 25 mgQD PF-06463922                      | 150 mg QD PF-06463922                    |
| N, n              | 3,3                                      | 3.2                                      | 3.3                                      | 3.3                                      |
| AUCnr[nghr/mL]    | 54.53 (43)                               | (42.2,46.8)                              | 21.32 (18)                               | 16.09 (29)                               |
| AUCst [nghr/mL]   | 51.30 (47)                               | 36.49 (20)                               | 20.43 (18)                               | 14.44 (25)                               |
| Cmax [ng/mL]      | 16.06 (42)                               | 11.56 (48)                               | 9.697 (40)                               | 5.734 (43)                               |
| Tmax [hr]         | 0.500 (0.500-1.00)                       | 0.500 (0.500-0.500)                      | 0.500 (0.500-1.00)                       | 0.500 (0.500-0.533)                      |
| t,[hr]            | 4.620±1.933                              | (2.35, 7.89)                             | 3.343±2.036                              | 5.257 ± 5.064                            |
| CL/F [L/hr]       | 36.68 (43)                               | (42.7, 47.4)                             | 93.86 (18)                               | 124.2 (29)                               |
| VzF[L]            | 229.0 (7)                                | (161,486)                                | 404.4 (51)                               | 702.2 (100)                              |

Source:Table 14.4.4.3.1.1

On Lead-in Day-7, the treatment was a 2 mg dose of midazolam and the exposure parameters were reported for midazolam alone before any doses of lorlatinib were given.OnCycle1 Day15, the exposures reported were of 2 mg dose of midazolam after 15 days of continuous lorlatinib dosing at the respectivedoselevels.

Abbreviations: N=number of patients contributing to the summary statistics; n = Number of patients where t, AUCinf, CL/F and Vz/F could be determined. Parameters are defined in Table 4.

a. Geometric mean (geometric %CV) for all parameters except: median (range) for Tmax; arithmetic mean (±Std Dev) for ty. Individual values were reported when n=2.

## Interaction study with a PPI (Study 1008)

Please refer to Table 15 in section 'Absorption, Influence of food' for PK results.

The effect of PPI use was evaluated in healthy subjects in Study 1008 and showed a 30% decrease in Cmax with no effect on AUC. 20 mg QD rabeprazole was used for evaluation of gastric effect. The effect of PPI use on lorlatinib exposure was statistically significant in Pop PK analyses. Bootstrap analysis of 1000 simulated individuals showed some effect of PPI-use compared to without PPI-use.

## Ongoing

In-vitro  studies  have  indicated  lorlatinib  has  potential  for  inhibition  of  CYP2C9,  UGT1A1,  P-gp  and induction  of  CYP2B6.  In-vivo  studies  with  specific  probe  substrates  are  ongoing  to  investigate  this further: a DDI study with the CYP2C9 substrate tolbutamide; a DDI study with the CYP2B6 substrate bupropion; a DDI study with a UGT substrate acetaminophen and a DDI study with the P-gp substrate fexofenadine. Lorlatinib  may  have  the  potential  for DDI  by  inhibiting  hepatic transporters  OATP1B1, OATP1B3, OCT1, and renal transporters OAT3 and MATE1 at clinically relevant concentrations. No in vivo studies are planned to investigate this further.

## Exposure relevant for safety evaluation

The PK for lorlatinib was comparable between patients and healthy subjects with no apparent gender differences.  The  exposure  increased  linearly  with  dose,  however  multiple  dosing  resulted  in  an accumulation ratio close to 1 due to a time-dependent auto-induction of metabolising enzymes. Pop PK analysis indicated clearance increased with increasing weight. Simulation of weight extremes impact on plasma exposure did not describe the range of weight extremes observed in the study population.

The majority of mean Ctrough (pre-dose) values for lorlatinib ranged from 70-125 ng/ml (%CV high), throughout EXP-1 to EXP-6 in the PK concentration population up to Cycle 20, Day 1.

Peripheral neuropathy was observed in patients who received lorlatinib 100 mg QD.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Mechanism of action

No dedicated mechanism of action studies have been submitted (see Section 2.3).

## Primary and Secondary pharmacology

## Primary pharmacology

<!-- image -->

Source: Appendix 3,Figure 3.1

Car=efficacious concentration of lorlatinib; hr=hour

The solidblack linerepresents a typical median concentrationvs time profile following administration of lorlatinib100 mg QD at steady state(Cycle 1 Day 15),based on the popPK model simulation.The shaded gray ribbon represents the 95% prediction interval, based on popPK model-estimated inter-patient variability. The dashed lines represent the Cefr values for each of the mutations based on the Shaw et al.

Figure 11: Predicted steady-state plasma lorlatinib concentration-time profile following oral administration of lorlatinib 100 mg QD

Dose rationale

In  study  1001,  a  patient  treated  at  200  mg  QD  met  the  criteria  for  dose  limiting  toxicity  and  the majority  of  patients  had  treatment  emergent  adverse  effects  at  the  150  and  200  mg  QD  cohorts. Simulations  showed  that  100  mg  QD  dose  was  the  lowest  dose  that  would  exceed  the  effective concentration (Ceff) of 150 ng/ml to inhibit ALK G1202, for at least 8 hours, at steady-state.

## Secondary pharmacology

The effect of lorlatinib on cardiac conduction was analysed in a non-clinical and in a clinical setting. A prolongation  of  PR  interval  was  observed  in  the  guinea  pig  heart  model  and  in  dog  at  a  dose  of 15 mg/kg/day. These data were confirmed in the analysis conducted by iCardiac on data from clinical Study 1012 (Holter monitoring) in which a prolongation of PR interval was observed in lorlatinib alone (12.7 msec at 1 hour post-dose) and in lorlatinib+itraconazole (16.6 msec at 1.5 hour post-dose). No subjects showed a PR interval &gt;200 msec. A shortening in QTcF interval was observed 1 hour post lorlatinib dose and this effect was slightly more evident with itraconazole administration.

<div style=\"page-break-after: always\"></div>

<!-- image -->

ePharmacologyartifactIDRA13727264.

ScatteplotsorthechangefrombaslinePerod1Day1）forPRRRQT,QTFandQTSrelative tothe loriatinibplasmaconcentrationsareresentedfromPeriod1,Day1andPeriod2,Day5.Theredpoints correspondtothePeriod1Day1doseof lorlatinib100mgandthebluepointscorrespondtothePeriod2Day5 doseof lorlatinib100mgwhichfollowed5daysofitraconaz.ole200mg. ml=milliliter;msec=millisecond;ng=nanogram;PR=time between thePwave and the Rwave;QT=the distancebetween theTwaveand theQwave:QTcF=QTeF;QTeS=QTeS;RR=timebetweenthesuccessiveR waves.

Figure 12: Change from baseline versus lorlatinib concentration

PKPD analysis showed no relationship of lorlatinib concentration on heart rate or QTc prolongation but confirmed the shortening of QTcS or QTcF due to lorlatinib concentration.

Increase in lorlatinib concentration was associated with PR prolongation and the baseline PR value was a predictor of PR prolongation. Simulations indicate the probability for PR intervals &gt;200 msec is low.

Study  1001,  Phase  2  further  evaluated  the  effects  of  lorlatinib  on  the  PR  interval  conducted  via continuous  Holter  telemetry  in  a  sub-group  of  patients.  Of  292  patients  in  the  100-mg  QD  pooled group, 29 patients with baseline PR &lt;200 ms had PR prolongation 200-&lt;220 ms while 11 patients with baseline PR &lt;200 ms had prolonged PR &gt;220 ms after treatment. Seven (7) patients with PR 200&lt;220 ms at baseline had prolonged PR &gt;220 ms after treatment and 1 patient with baseline PR &gt;220 ms  had  PR  prolongation  ≥260  ms.  There  was  treatment-related  AV  block  (Grade  1)  reported  in  2 patients  and  1  temporary  treatment discontinuation.  The  sub-study  confirmed  lorlatinib  100  mg  QD treatment could cause PR-prolongation.

Table 24: Estimated mean change from baseline in the study-specific QTc interval

| Dosing               | Cmax Average   |   Change in QTc(msec) | 95%CI           |
|----------------------|----------------|-----------------------|-----------------|
| SingleDosePatients   | 695 ng/mL Cmax |                -26.68 | (-31.32.-22.49) |
| Steady-StatePatients | 576ng/mLCmax   |                -22.11 | (-25.96.-18.64) |

ePharmacologyartifact IDRA13729974.Line1substituted.

ThetableprovidesthesimulatedmeanQTeSchangefrombaselineatthesingledoseCmaxandthesteady-state Cmaxalongwithrespective95%confidence intervals.Theconcentrationswere takenfromPhase2patient descriptivesummariesfromthesource:Module5,3.5.1,B7461001CSR,Table14.4.4.1.2.1.

Cl=confidenceinterval:ml=milliliter,msec=millisecond;ng=nanogram;QTe=corected QT interval;

QTeS=study-specificcomectedQTinterval.

<div style=\"page-break-after: always\"></div>

Table 25: Estimated mean change from baseline in the Fridericia QTc interval

| Dosing               | Cmax Average   |   Change in QTc (msec) | 95%CI           |
|----------------------|----------------|------------------------|-----------------|
| SingleDosePatients   | 695ng/mLCmax   |                 -25.85 | (-30.08.-21.32) |
| Steady-StatePatients | 576ng/mLCmax   |                 -21.42 | (-24.93.-17.67) |

ePharmacologyartifactIDRA13729973.LineIsubstituted.

ThetableprovidesthesimulatedmeanQTcFchangefrombaselineatthesingkedoseCmaxandthesteady-state

Cmax alongwithrespective95%confidence intervals.Theconcentrationswere takenfromPhase2patient descriptivesummariesfromthesource:Module5.3.5.1,B7461001 CSR.Table14.4.4.1.2.1.

Cl=confidence interval;ml=milliliter,msec=millisecond;ng=nanogram;QTe=corrected QT interval;

QTcF=FridericiacorrectedQTinterval.

Table 26: Simulated probability of a PR interval length over 200 milliseconds

|          | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   | BaselinePRInterval   |
|----------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Cmax     | 151 (msec)           | 170 (msec)           | 175 (msec)           | 180 (msec)           | 185 (msec)           | 190 (msec)           | 195 (msec)           | 200 (msec)           |
| 576ng/mL | <0.001               | 0.050                | 0.128                | 0.268                | 0.458                | 0.658                | 0.821                | 0.924                |
| 695ng/mL | <0.001               | 0.078                | 0.187                | 0.360                | 0.569                | 0.760                | 0.892                | 0.962                |

ePharmacologyartifactIDRA13733719.Line1substituted.

ThesimulatedprobabilitiesofexperiencingaPRintervalover200msecfora48yearoldsubject(48wasthe

medianage)atagivenbaselinePRintervalvalueforboththesingledoseandsteady-stateconcentrations

observedinPatientsareprovidedinthetable.

mL=milliliter;msec=millisecond;ng=nanogram;PR=timebetween thePwave andtheRwave.

## PD interactions with other medicinal products or substances

Predicted  effect  of  increasing  plasma  concentrations  of  lorlatinib  on  the  development  of  the  most frequently  occurring  AEs  have  been  investigated  appropriately  (see  below).  From  a  PD  perspective, clinical  management  in  the  event  of  lorlatinib-induced  AEs  belonging  to  the  SOCs  of  metabolic disorders,  CNS  disorders,  cardiac  disorders  and  other  AEs  has  been  appropriately  described  in  the SmPC. It is noteworthy that all-causality AEs of hypercholesterolemia and hypertriglyceridemia were reported at a frequency of 82.4% and 60.7%. The current SmPC proposal contains a warning with a recommendation  to  monitor  plasma  cholesterol  and  triglycerides.  In  the  event  that  concomitant medication  which  independently  increases  plasma  cholesterol  and  triglycerides  is  administered, synergistic  increases  may  be  expected.  However,  these  are  expected  to  be captured  given  that the current warnings and recommendations are followed.

## Genetic differences in PD response

Analysis  of  ALK  kinase  domain  mutation  was  performed  in  plasma  and  in  tumour  tissue  in  cancer patients from Phase 2 of Study 1001 to investigate the impact of genetic differences with regard to tyrosine  kinase  inhibition  (data  not  shown).  Results  did  not  indicate  any  impact  of  the  ALK  kinase domain  mutation  or  of  the  G1202R  mutation  on  number  of  responders  or  duration  of  response compared to patients without detectable mutations in plasma and tumour tissue. Analysis for the ROS1 kinase domain mutation had not been performed at the time of data cut off.

## Relationship between plasma concentration and effect

No exposure-response relationship of efficacy could be demonstrated by PK/PD modelling, using the efficacy endpoints: objective response rate (ORR) and intracranial objective response rate (IC-ORR) in patient data from Study 1001. The effective concentration Ceff was determined to be 150 ng/ml. The majority  of  patients  included  were  probably  exposed  well-above  this  cutoff.  90%  of  the  study population received 100 mg QD.

In  Phase  1,  maximum  hypercholesterolemia  adverse  event  Grade  ≥2  (CHLGR)  was  found  to  be predictive of response. The Applicant suggested sensitivity to lorlatinib was a driver for response more than  exposure.  Asian  race  was  somehow  predictive  of  response  correlated  with  higher  baseline amylases (BAMY). Odds for achieving ORR or IC-ORR was found to be correlated with higher BAMY in

<div style=\"page-break-after: always\"></div>

different patient groups. Odds of achieving ORR was lower for patients with 1 and 2+ prior systemic therapies.  Odds  of  achieving  IC-ORR  were  lower  for  patients  with  prior  CNS  radiation  and  higher baseline alkaline phosphatase (BAP).

## Relationship between plasma concentration and safety endpoints

Baseline cholesterol, time on treatment and lorlatinib exposure were statistically significant predictors of  hypercholesterolemia  Grade  ≥3.  With  each  unit  increase  in  log(Cmax  event),  patients  were  5.256 times  more  likely  to  experience  Hypercholesterolemia  Grade  ≥3.  Baseline  bodyweight  and  time  on treatment were significant predictors of Weight Gain Grade ≥2. Asian ethnicity, baseline triglycerides and time of treatment were significant predictors of Hypertriglyceridemia Grade ≥3. Age, concomitant use or narcotics and steroids, time on treatment and lorlatinib exposure were statistically significant predictors of TEAEs Grade ≥3.

The frequency of the CNS endpoints in the investigated population were too low to allow for a robust analysis, however it seemed lorlatinib exposure was not predictive of CNS effects when the majority of the studied population received 100 mg QD.

## 2.4.4. Discussion on clinical pharmacology

Overall, the bioanalytical method validations and PK analysis are considered thorough and acceptable according to guidelines. The Pop PK population included data from 425 subjects (healthy volunteers and patients). Although the model underestimates the exposure around Cmax after a single dose, model performance at steady state in cancer patients is in general considered acceptable.

Peak  lorlatinib  concentrations  in  plasma  are  rapidly  reached  with  the  median  Tmax  of  1.2 hours following a single 100 mg dose and 2.0 hours following multiple dosing of 100 mg once daily.

After  oral  administration  of  lorlatinib  tablets,  the  mean  absolute  bioavailability  is  80.8%  (90%  CI: 75.7, 86.2) compared to intravenous administration.

Administration of lorlatinib with a high fat, high calorie meal resulted in 5% higher exposure compared to fasted conditions. Lorlatinib may be administered with or without food.

At 100 mg once daily, the geometric mean (%CV) peak plasma concentration was 577 (42) ng/ml and the AUC24 was 5,650 (39) ng·h/ml in patients with cancer. The geometric mean (% CV) oral clearance was 17.7 (39) L/h.

In vitro binding of lorlatinib to human plasma proteins is 66% with moderate binding to albumin or to α1-acid glycoprotein.

In  humans,  lorlatinib  undergoes  oxidation  and  glucuronidation  as  the  primary  metabolic  pathways . In vitro data  indicate  that  lorlatinib  is  metabolised  primarily  by  CYP3A4  and  UGT1A4,  with  minor contribution from CYP2C8, CYP2C19, CYP3A5 and UGT1A3.

In plasma, a benzoic acid metabolite of lorlatinib resulting from  the oxidative cleavage of the amide and aromatic ether bonds of lorlatinib was observed as a major metabolite, accounting for 21% of the circulating radioactivity. This oxidative cleavage metabolite is pharmacologically inactive.

The  plasma  half-life of lorlatinib after  a  single  100 mg  dose  was  23.6 hours.  Following  oral administration  of  a  100 mg  radiolabelled  dose  of  lorlatinib,  a  mean  47.7%  of  the  radioactivity  was recovered in  urine  and  40.9%  of  the  radioactivity  was  recovered  in  faeces,  with  overall  mean  total recovery of 88.6%.

<div style=\"page-break-after: always\"></div>

Unchanged lorlatinib was the major component of human plasma and faeces, accounting for 44% and 9.1% of total radioactivity, respectively. Less than 1% of unchanged lorlatinib was detected in urine.

At single dose, lorlatinib systemic exposure (AUCinf and Cmax) increased in a dose-related manner over the 10 to 200 mg dose range. Few data are available over the 10 to 200 mg dose range; however, no deviation from linearity was observed for AUCinf and Cmax after single dose.

At  steady-state,  the  systemic  exposure  (AUC24)  increased  less  than  proportionally  over  the  10  to 200 mg dose range.

Also,  at  steady-state  lorlatinib  plasma  exposures  are  lower  than  those  expected  from  single  dose pharmacokinetics, indicative of a net time-dependent auto-induction effect.

As  lorlatinib  is  metabolised  in  the  liver,  hepatic  impairment  is  likely  to  increase  lorlatinib  plasma concentrations. Clinical studies that were conducted excluded patients with AST or ALT &gt; 2.5 × ULN, or if due  to underlying malignancy,  &gt; 5.0 × ULN  or  with  total  bilirubin  &gt; 1.5 × ULN.  Population pharmacokinetic analyses have shown that lorlatinib exposure was not clinically meaningfully altered in patients with mild hepatic impairment (n = 50). No dose adjustments are recommended for patients with mild hepatic impairment. No information is available for patients with moderate or severe hepatic impairment.

Less  than  1%  of  the  administered  dose  is  detected  as  unchanged  lorlatinib  in  urine.  Population pharmacokinetic analyses have shown that lorlatinib exposure was not clinically meaningfully altered in patients with mild (n = 103) or moderate (n = 41) renal impairment (CLcr &gt; 30 ml/min). No starting dose adjustments are recommended for patients with mild or moderate renal impairment. Information for lorlatinib use in patients with severe renal impairment (CLcr &lt; 30 ml/min) is limited (n = 1).

The  applicant  will  submit  the  results  of  studies  investigating  the  use  of  lorlatinib  in  patients  with hepatic (Study B7461009) and renal (Study B7461010) impairments (see RMP).

Population pharmacokinetic analyses in patients with advanced NSCLC and healthy volunteers indicate that  there  are  no  clinically  relevant  effects  of  age,  gender,  race,  body  weight,  and  phenotypes  for CYP3A5 and CYP2C19.

The  in-vitro  interaction  studies  indicated  that  lorlatinib  could  induce  CYP3A4,  CYP2B6  mediated  by hPXR  and  hCAR1.  Until  final  results  of  DDI  studies  with  CYP2C9,  CYP2B6,  UGT1A1,  and  P-gp  are available,  substrates of  CYP2C9,  CYP2B6,  UGT1A1, and P-gp should be avoided. This information is mentioned  in  the  SmPC  Section 4.5  with  an  amended  list  of  medicinal  products  with  a  narrow therapeutic index.

The in-vitro results also indicated that lorlatinib could inhibit CYP3A4/5, CYP2C9, UGT1A1, P-gp, BCRP (GI tract), OATP1B1, OATP1B3, OCT1, OAT3, and MATE1 at clinically relevant concentrations. In-vivo studies  with  specific  probe  substrates  for  CYP2C9,  CYP2B6,  UGT1A1  and  P-gp  are  ongoing  to investigate  this  further.  No in  vivo DDI  studies  with  inhibition  of  OATP1B1-3,  OCT1  or  OAT3  are planned. Potential interactions with substrates of OATP1B1-3, OCT1 or OAT3 are not expected to be clinically relevant.

Itraconazole,  a  strong  inhibitor  of  CYP3A4/5,  administered  at  oral  doses  of  200 mg  once  daily  for 5 days, increased the mean area under the curve (AUC) 42% and Cmax 24% of a single 100 mg oral dose of lorlatinib in healthy volunteers. Concomitant administration of lorlatinib with strong CYP3A4/5 inhibitors  (e.g.  boceprevir,  cobicistat,  itraconazole,  ketoconazole,  posaconazole,  troleandomycin, voriconazole, ritonavir, paritaprevir in combination with ritonavir and ombitasvir and/or dasabuvir, and ritonavir  in  combination  with  either  elvitegravir,  indinavir,  lopinavir  or  tipranavir)  may  increase lorlatinib plasma concentrations.   Grapefruit products may also increase lorlatinib plasma concentrations and  should  be  avoided.  An  alternative  concomitant  medicinal  product  with  less  potential  to  inhibit

<div style=\"page-break-after: always\"></div>

CYP3A4/5 should be considered. If a strong CYP3A4/5 inhibitor must be concomitantly administered, a dose reduction of lorlatinib is recommended (see Sections 4.2 and 4.5 of the SmPC).

Rifampin, a strong inducer of CYP3A4/5, administered at oral doses of 600 mg once daily for 12 days, reduced the mean lorlatinib AUC by 85% and Cmax by 76% of a single 100 mg oral dose of lorlatinib in healthy  volunteers;  increases  in  AST  and  ALT  were  also  observed.  Concomitant  administration  of lorlatinib  with  strong  CYP3A4/5  inducers  (e.g.  rifampicin,  carbamazepine,  enzalutamide,  mitotane, phenytoin  and  St.  John's  wort)  may  decrease  lorlatinib  plasma  concentrations.  The  use  of  a  strong CYP3A4/5 inducer with lorlatinib is contraindicated. Concomitant use with moderate CYP3A4/5 inducers should  be  avoided,  if  possible,  as  they  may  also  reduce  lorlatinib  plasma  concentrations  (see Sections 4.3, 4.4 and 4.5 of the SmPC).

In vitro studies indicated that lorlatinib is a time-dependent inhibitor as well as an inducer of CYP3A4/5 and it  activates  the  human  pregnane-X-receptor  (PXR),  with  the  net  effect in  vivo being  induction. Concurrent  administration  of  lorlatinib  in  patients  resulted  in  decreased  oral  midazolam  AUC  when midazolam  was  administered  alone,  suggesting  that  lorlatinib  is  an  inducer  of  CYP3A4/5.  Lorlatinib 150 mg  orally  once  daily  for  15 days  decreased  AUCinf  and  Cmax  of  a  single  oral  2 mg  dose  of midazolam (a sensitive CYP3A substrate) by 61% by 50%, respectively; hence, lorlatinib is a moderate CYP3A  inducer.  Thus,  concurrent  administration  of  lorlatinib  with  CYP3A4/5  substrates  with  narrow therapeutic indices, including but not limited to alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl,  hormonal  contraceptives,  pimozide,  quinidine,  sirolimus  and  tacrolimus,  should  be  avoided since the concentration of these medicinal products may be reduced by lorlatinib (see Sections 4.4 and 4.5 of the SmPC).

The ongoing DDI studies (sub-study of B7461001) with CYP2C9, P-gp, CYP2B6 and UGT1A1 substrates are  performed  following  15  days  of  lorlatinib  100  mg  QD  dosing,  i.e.  at  steady-state,  which  is considered  a  sufficiently  long  period  to  cover  the  full  induction  potential.  Results  from  the  ongoing interactions  studies  will  be  included  in  the  final  CSR.  The  applicant  is  recommended  to  provide  a summary of the PK data from the DDI sub-study in patients.

The rationale behind the daily dosing interval of 100 mg QD lorlatinib is adequately described.

In the clinical Study 1012 a prolongation of the PR interval was observed via Holter monitoring. PKPD simulations  indicated  the  probability  for  PR  intervals  &gt;200  msec  is  low.  Study  B7461001,  Phase  2 evaluated the effects of lorlatinib on the PR interval conducted via continuous Holter telemetry in a sub-group  of  patients.  The  sub-study  confirmed  lorlatinib  100  mg  QD  treatment  could  cause  PRprolongation.  The  prolongation  of  PR  interval  occurred  in  a  concentration  dependent  manner.  There was  treatment-related  AV  block  (Grade  1)  reported  in  2  patients  and  1  temporary  treatment discontinuation. Adequate guidance is provided in Sections 4.2, 4.4 and 5.2 of the SmPC.

ALK kinase domain mutation analysis was performed in plasma and in tumour tissue in cancer patients from Phase 2 of Study 1001 to investigate the impact of genetic differences with regard to tyrosine kinase inhibition. Results indicated no impact of ALK kinase domain mutation or G1202R mutation on number of responders or duration of response compared to patients without detectable mutations in plasma and tumour tissue.

The  exposure-response  relationship  was  analysed  for  efficacy  and  safety  endpoints.  No  exposureresponse relationship was identified between any lorlatinib exposure metric (Cmax,P1, Ctrough,P1, Cavg,P1, as such or as its logarithmic value) and ORR or IC-ORR. Lorlatinib exposure was a statistically significant predictor of hypercholesterolemia Grade ≥3 and of TEAEs Grade ≥3. Age, concomitant use or narcotics and  steroids,  time  on  treatment  and  lorlatinib  exposure  were  statistically  significant  predictors  of TEAEs Grade ≥3. Adequate guidance for adverse reactions is provided in SmPC Section 4.2 and 4.4. The rate of CNS endpoints in the investigated population were too low to allow for a robust analysis.

<div style=\"page-break-after: always\"></div>

No  statistically  significant  exposure-safety  relationship  was  found  for  any  of  the  CNS-related  safety endpoints.

## 2.4.5. Conclusions on clinical pharmacology

Overall, bioanalytical methods and the PK analysis were acceptable. The PK of lorlatinib is adequately described and the in vitro and in vivo interaction studies in healthy subjects and patients are considered acceptable.

The applicant will submit the following measures post authorisation to address remaining uncertainties in relation to pharmacology:

- In order to further investigate the effect of lorlatinib on patients with renal and hepatic impairment, the applicant should submit the results of studies B7461010 and B7461009 (see RMP)

- In order to further characterise the full induction potential of lorlatinib on CYP2C9, P-gp, CYP2B6 and UGT1A1 substrates, the applicant is recommended to provide a summary of the PK data from the DDI sub-study in patients

## 2.5. Clinical efficacy

The clinical study that provides the basis for the efficacy evaluations of lorlatinib consists of 2 portions, Phase 1 and Phase 2. Data from this study were initially based on the data cutoff date of 15 March 2017, at which time the study was ongoing, but enrollment in both Phases was complete. During the procedure, updated efficacy results were provided with data cutoff date of 02 February 2018, allowing for a median follow-up of 9.9 months of the pooled cohorts EXP-4 and 5. Efficacy results are presented for 41 patients with advanced ALK-positive NSCLC from the Phase 1 portion of Study 1001 and for 197 patients  with  advanced  ALK-positive  NSCLC  from  the  Phase  2  portion  of  Study  1001,  as  well  as  2 Japanese patients in the Japan LIC.

Table 27: Efficacy Cohorts of ALK-Positive NSCLC Patients Assessed by ICR (Phase 1 and

Phase 2)

| Study Portion   | Cohort Name   | Cohort Description                                      |   Total Number of Patients N |   Patients with Brain Metastases at Baseline n |
|-----------------|---------------|---------------------------------------------------------|------------------------------|------------------------------------------------|
| Phase 1         | N/A           | Treatment-naïve or pre-treated with 1 or more ALK-TKI a |                           41 |                                             34 |
| Phase 2         | EXP-3B        | 1 prior non-crizotinib ALK-TKI  chemotherapy           |                           27 |                                             12 |
| Phase 2         | EXP-4:EXP-5   | 2 or more prior ALK-TKI  chemotherapy                  |                          111 |                                             83 |
| Phase 2         | EXP-2:3A      | Prior crizotinib only  prior chemotherapy              |                           59 |                                             37 |

Source: SCE Tables 14.1.2.5.2.2.1 and 14.1.2.5.2.2.2, Study 1001 Phase 1 Table 14.1.1.1.1, and CO Table 14.1.1.1.2.co.

Abbreviations: ALK=anaplastic lymphoma kinase; EXP=expansion; ICR=independent central review; N/n=number of patients; N/A=not applicable; NSCLC=non-small cell lung cancer; QD=once daily; SCE=summary of clinical efficacy; TKI=tyrosine kinase inhibitor.

a. Patients in the dose-escalation part of Phase 1 were treated across all doses tested (10 to 200 mg QD).

<div style=\"page-break-after: always\"></div>

Phase 1:

AdvancedALK/ROS1-posNSCLC: Treatment-naive or PD after prior ALK TKI; any prior chemo

## Phase 2:

Lorlatinib once daily orBID*

Dose escalation: DL1=10 mg CRM design: 25 mg-400 mg

<!-- image -->

Asymptomatic brain metastases are allowed in all cohorts.

If the same TKI were given twice, that would be considered 2 prior lines of ALK TKIs

ALK=anaplastic lymphoma kinase; BID=twice a day; Chemo=Chemotherapy; CRM=continual reassessment method; crizo=crizotinib; DL1=dose level 1; EXP=expansion (cohort); NSCLC=non-small cell lung cancer; PD=progressive disease; pos=positive, QD=once daily; TKI=tyrosine kinase inhibitor.

Figure 13: Study 1001 Schema

## 2.5.1. Dose-response study(ies)

<!-- image -->

Source: Tables 14.1.1.1.1 and 14.1.1.3.1.

Abbreviations: AE=adverse event; ALK-positive=anaplastic lymphoma kinase-positive; ITT=intention to treat; N/n=number of patients.

Figure 14: Study flow chart (Phase 1)

<div style=\"page-break-after: always\"></div>

In  the  dose-escalation  Phase  1  portion  of  the  1001  study,  the  optimal  dosing  of  lorlatinib  was established. The MTD was not reached as only 1 patient met the dose-limiting criteria. This patient was treated with lorlatinib at 200 mg QD and did not receive 16 of the planned 21 doses of lorlatinib during Cycle  1  due  to  toxicities  attributed  to  study  drug,  which  met  the  protocol  definition  of  a  DLT.  This patient experienced Grade 1 and Grade 2 CNS effects during Cycle 1, including Grade 2 aphasia and cognitive disorder, and Grade 1 visual impairment and abnormal dreams, so lorlatinib was temporarily discontinued for the remainder of the cycle. Additionally, in the 150 mg QD and 200 mg QD cohorts, the majority of patients experienced AEs resulting in temporary discontinuation and/or dose reduction. At 150 mg QD, these included temporary discontinuations for Hallucination (in 2 patients  Grade 2), Confusional  state  (1  patient  Grade  2),  Mental  status  changes  (1  patient  Grade  3),  and  Seizure  (1 patient Grade 2). At 200 mg QD, in addition to the patient with the DLT, temporary discontinuation included  1  additional  patient  who  experienced  Formication  and  Irritability  (Grade  1  and  Grade  2, respectively). As a result, it was agreed upon by the Sponsor and the Phase 1 Investigators to evaluate doses  lower  than  200  mg  QD  and  consider  an  alternative  dosing  regimen.  BID  dosing  was subsequently evaluated to assess whether reducing the Cmax would lessen the CNS effects. Patients did not tolerate 75 mg or 100 mg BID dosing. Thus, while the MTD was not formally reached, lorlatinib was considered tolerable at the 100 mg QD dose level, which was declared the recommended Phase 2 dose (RP2D) in patients with ALK-positive or ROS1-positive NSCLC.

## 2.5.2. Main study

## Study of PF-06463922 (an ALK Tyrosine Kinase Inhibitor) in Patients With Advanced Non-Small Cell Lung Cancer Harbouring Specific Molecular Alterations (study B7461001) - Phase 2 part

## Methods

## Study Participants

## Inclusion criteria:

1. Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, American Joint Committee on Cancer [AJCC] version 7.0) that carried an ALK rearrangement, as determined by the Food and Drug Administration (FDA)-approved fluorescence in situ hybridisation (FISH) assay (Abbott Molecular Inc) or by Immunohistochemistry (IHC) (Ventana Inc). All patients had to have archival tissue sample available and collected prior to enrollment.

## 2. Disease status requirements:

ALK-positive NSCLC patients were to either have or have had:

-  Treatment naïve (i.e., no prior chemotherapy in the metastatic disease setting and no prior ALK inhibitor therapy allowed). [EXP-1];
-  Disease progression after crizotinib only. No prior chemotherapy was allowed in the metastatic disease setting. [EXP-2];
-  Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the metastatic disease setting. [EXP-3A];

<div style=\"page-break-after: always\"></div>

-  Disease progression after 1 prior ALK inhibitor therapy other than crizotinib. Patients were allowed to have any number of prior chemotherapy regimens in any disease setting. [EXP3B];
-  Disease progression after 2 prior ALK inhibitor therapies. Patients were allowed to have any number of prior chemotherapy regimens in any disease setting. [EXP-4];
-  Disease progression after 3 prior ALK inhibitor therapies. Patients were allowed to have any number of prior chemotherapy regimens in any disease setting. [EXP-5].

## 3. Tumour Requirements:

All patients had at least 1 measurable target extracranial lesion according to RECIST version 1.1. In addition patients with asymptomatic CNS metastases (including patients controlled with stable or decreasing steroid use within the last 2 weeks prior to study entry) were eligible. The brain metastases were either diagnosed or have been presented as progressive disease after surgery, whole brain radiotherapy or stereotactic radiosurgery (see Exclusion Criterion #3 for the lapsed time period required between the end of radiotherapy and study entry). Patients who had leptomeningeal disease (LM) or carcinomatous meningitis (CM) were eligible if the LM/CM was visualised on MRI or if documented baseline CSF positive cytology was available.

4. Age ≥18 years (or ≥20 years of age if required by local regulation).
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, or 2.
6. Adequate bone marrow function, including:
4.  ANC ≥1.5 × 109/L;
5.  Platelets ≥100 × 109/L;
6.  Haemoglobin ≥9 g/dL.
7. Adequate pancreatic function, including:
8.  Serum total amylase ≤1.5 upper limit of normal (ULN);
9.  Serum lipase ≤1.5 ULN.
8. Adequate renal function, including:
11.  Serum creatinine ≤1.5 × ULN or estimated creatinine clearance ≥60 mL/min as calculated using the method standard for the institution.
9. Adequate liver function, including:
13.  Total serum bilirubin ≤1.5 × ULN;
14.  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 × ULN; ≤5.0 × ULN if there were liver metastases involvement.

10. Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade ≤1 except for AEs that in the investigator' judgment did not constitute a safety risk for the patient.

11. Serum pregnancy test (for females of childbearing potential) negative at Screening (before the patient was allowed to receive the investigational product [IP]). A patient was of childbearing potential if, in the opinion of the investigator, she was biologically capable of having children and was sexually active.

<div style=\"page-break-after: always\"></div>

12. Evidence of a personally signed and dated informed consent document indicating that the patient had been informed of all pertinent aspects of the study.

13. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

14. Male and female patients of childbearing potential and at risk for pregnancy were required to agree to use 2 highly effective methods of contraception from the time of the first negative pregnancy test at Screening, throughout the study and for 90 days after the last dose of assigned treatment. A patient was of childbearing potential if, in the opinion of the investigator, he/she was biologically capable of having children and was sexually active.

## Exclusion Criteria

Patients were ineligible to participate in this study if any of the following criteria were met:

1. Spinal cord compression was excluded unless the patient demonstrated good pain control attained through therapy and there was stabilisation or recovery of neurological function for the 4 weeks prior to study entry.

2. Major surgery within 4 weeks of study entry. Minor surgical procedures (e.g., port insertion) were not excluded, but sufficient time (e.g., up to 2 weeks) should have passed for wound healing.

3. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) had to be completed at least 48 hours prior to study entry. Stereotactic or small field brain irradiation had to be completed at least 2 weeks prior to study entry. Whole brain radiation had to be completed at least 4 weeks prior to study entry.

4. Systemic anti-cancer therapy completed within a minimum of 5 half-lives of study entry (unless clinically meaningful tumour flare per discretion of the investigator, in which discussion with the Sponsor was warranted).

5. Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti- programmed cell death receptor-1 (PD-1), anti-PD-ligand 1 (PD-L1), anti-PD ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody.

6. Previous high-dose chemotherapy requiring stem cell rescue.

7. Prior irradiation to &gt;25% of the bone marrow.

8. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.

9. Clinically significant cardiovascular disease (that was, active or &lt;3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), second-degree or third-degree atrioventricular (AV) block (unless paced) or any AV block with pulse rate &gt;220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as &lt;50 bpm (unless patient was otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc &gt;470 msec, or congenital long QT syndrome.

10. Patients with predisposing characteristics for acute pancreatitis according to investigator judgment.

11. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial

<div style=\"page-break-after: always\"></div>

pneumonia, interstitial lung disease (ILD), obliterative bronchiolitis and pulmonary fibrosis. Patients with history of prior radiation pneumonitis were not excluded.

12. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behaviour, or laboratory abnormality that could have increased the risk associated with study participation or IP administration or could have interfered with the interpretation of study results and, in the judgment of the investigator, would have made the patient inappropriate for entry into this study.
13. Patients who were investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the investigator, or patients who were Pfizer employees directly involved in the conduct of the trial.
14. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ (DCIS) of the breast or localised and presumed cured prostate cancer) within the last 3 years.
15. Active inflammatory gastrointestinal disease, chronic diarrhoea, symptomatic diverticular disease or previous gastric resection or lap band.
16. Current use or anticipated need for food or drugs that were known strong or moderate CYP3A4 inhibitors, including their administration within 10 days prior to the first lorlatinib dose.
17. Current use or anticipated need for drugs that are known strong CYP3A4 inducers, including their administration within 12 days prior to the first lorlatinib dose.
18. Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.
19. Concurrent use of drugs that are CYP2C9 substrates with narrow therapeutic indices.
20. Concurrent use of drugs that are sensitive CYP2B6 substrates.
21. Current use or anticipated need for drugs that are known strong CYP2C19 inhibitors, including their administration within 12 days prior to study entry.
22. Current use or anticipated need for drugs that are known strong CYP2C8 inhibitors, including their administration within 12 days prior to study entry.
23. Current use or anticipated need for drugs that are known P-gp substrates with a narrow therapeutic index, including their administration within 12 days prior to study entry.
24. Patients presenting with abnormal LVEF by echocardiogram or MUGA according to institutional lower limits.
25. Breastfeeding female patients (including patients who intended to interrupt breastfeeding).

## Treatments

In all study parts, lorlatinib was administered orally QD continuously in 21-day cycles. Patients selfadministered lorlatinib in the outpatient setting.

In  the  event  of  toxicities,  dose  reductions  were  contemplated  by  the  protocol  according  to  the following:

| CurrentDoseLevel   | DoseLevel-1   | DoseLevel-2   | DoseLevel-3   |
|--------------------|---------------|---------------|---------------|
| 100 mg QD          | 75mg QD       | 50mg gQD      | 25 mg QD      |

<div style=\"page-break-after: always\"></div>

## Objectives

## Primary Objective:

The primary objective of the Phase 2 portion of the study was to evaluate overall (intra- and extracranial) and intracranial anti-tumour activity of single-agent lorlatinib at RP2D in patients with advanced ALK-positive NSCLC.

Secondary Objectives:

-  To confirm the safety and tolerability of single-agent lorlatinib at the RP2D.
-  To confirm single- and multiple-dose PK profiles of single-agent lorlatinib at the RP2D.
-  To assess secondary measures of clinical efficacy.
-  To detect early signs of changes in mood, cognitive function, or suicidal ideation and behaviour (SIB).
-  To evaluate PRO of global QoL, functioning and the impact of lorlatinib on disease/treatmentrelated symptoms of lung cancer at the RP2D.
-  To further evaluate the effects of single-agent lorlatinib at the RP2D on the QTc interval.
-  To further evaluate tumour and blood-based molecular markers of response and resistance to single-agent lorlatinib at the RP2D.
-  To evaluate the safety and efficacy of single-agent crizotinib following lorlatinib in treatmentnaïve patients with advanced ALK-positive NSCLC.
-  To evaluate response to prior systemic therapies.

## Exploratory Objective

The exploratory objective of the Phase 2 portion of the study was to explore the brain penetration of single-agent lorlatinib at the RP2D.

## Outcomes/endpoints

Primary endpoints:

-  ORR was defined as the percent of patients with Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR) according to RECIST version 1.1. Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.
-  Intracranial ORR (IC ORR) was defined as the percent of patients with CNS metastases at study entry with Best Overall Intracranial Response of confirmed CR or confirmed PR (considering only the lesions having brain as the disease site).

Secondary endpoints:

-  TTR (IC TTR) was defined as the time from Cycle 1 Day 1 (C1D1) to first documentation of objective (intracranial) tumour response (CR or PR) that is subsequently confirmed.
-  DOR (IC DOR) was defined as the time from the first documentation of objective (intracranial) tumour response, CR or PR, to the first documentation of disease progression or death associated with any cause, whichever occurs first.

<div style=\"page-break-after: always\"></div>

-  Progression-Free-Survival (PFS) was defined as the time from C1D1 to first documentation of objective disease progression or to death on study due to any cause, whichever came first. If tumour progression data include more than 1 date, the first date will be used.
-  Overall Survival (OS) was defined as the time from C1D1 to the date of death due to any cause.
-  Probabilities of survival at 1 year and 18 months were defined as the probabilities of survival at 1 year and 18 months, respectively, after the date of first dose.

Other analyses conducted in Phase 2 included Disagreement in Response assessment, PROs based on EORTC QLQ C30 (Version 3.0) and its lung cancer module, QLQ LC13, and Biomarker analyses.

## Sample size

The  Phase  2  study  was  initially  designed  to  recruit  240  patients  with  40  patients  in  each  of  the  6 cohorts. There was no sample size definition based on either expected desirable outcomes or a prespecified precision of the estimates for the hypothesised ORR, as demonstrated by the large width of the 95% CI listed in the table below, showing possible estimated ORR and 95% CIs for different level of responses in populations of 30, 40 patients, 70 and 80 patients.

| Responses/Cohort Sample Size   | ORR (Estimated 95% C1)   |
|--------------------------------|--------------------------|
| 21/30                          | 70% (50.6-85.3)          |
| 23/30                          | 77% (57.7-0.90)          |
| 25/30                          | 83% (65.3-94.4)          |
| 16/40                          | 40% (24.9-56.7)          |
| 20/40                          | 50% (33.8-66.2)          |
| 24/40                          | 60% (43.3-75.1)          |
| 24/70                          | 34% (23.3-46.6)          |
| 28/70                          | 40% (28.5-52.4)          |
| 32/70                          | 45% (33.7-58.1)          |
| 32/80                          | 40% (29.2-51.6)          |
| 40/80                          | 50% (38.6-61.4)          |
| 48/80                          | 60% (48.4-70.8)          |

Therefore, data only allow for descriptive statistics of results to be made.

## Randomisation

The study was not randomised.

## Blinding (masking)

The study was not blinded.

## Statistical methods

## Analysis Sets

The intention-to-treat (ITT) analysis set included all enrolled patients with documented ALK gene rearrangement who were treated with at least 1 dose of lorlatinib. The ITT Analysis Set is the primary efficacy analysis set and is the focus of the efficacy presentations in this SCE.

<div style=\"page-break-after: always\"></div>

With the goal of increasing the precision of efficacy endpoints estimation, an additional analysis set (100mg QD pooled group), that was not pre-specified in the Statistical Analysis Plan (SAP), comprised all 215 previously treated patients with purported ALK-positive NSCLC who received the RP2D of lorlatinib 100 mg QD as a starting dose in the study (Phase 2, n=198).

The safety analysis set included all enrolled patients treated with at least 1 dose of lorlatinib (including the Day -7 lorlatinib dose).

PRO-evaluable analysis set is defined as all patients in the safety analysis set who completed a baseline and at least 1 post-baseline PRO assessment. The PRO-evaluable analysis set is the primary population for the analysis of change from baseline for PRO assessments (EORTC QLQ-C30 and QLQLC13).

The following biomarker analysis sets were defined:

- a) CNA Peripheral Blood Analysis Set: defined as all patients of the ITT analysis set who had at least 1 molecular biomarker (analyte mutation) assayed,
- b) Paired CNA Peripheral Blood Set: defined as all patients in the ITT analysis set who had valid paired results from at least 1 molecular biomarker (analyte mutation) assayed at Screening and posttreatment (i.e., EOT for Phase 2),
- c) Tumour Tissue Analysis Set: defined as all patients in the ITT analysis set who had at least 1 molecular tumour biomarker assayed from either the screening archival or screening de novo tumour biopsy sample (or both),

d) Paired Tumour De Novo Analysis Set: defined as all patients in the ITT analysis set who had both 1) either archival tumour tissue or de novo biopsy at Screening, and 2) an EOT de novo biopsy with at least 1 molecular tumour biomarker assayed.

## Statistical and Analytical Plans

## Table 28: Summary of Endpoints and Statistical Methodology - Study 1001

| Endpoint                                                           | Statistical Method                                                                                                                               |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| ORR a                                                              | Percentage (2-sided 95% CI*)                                                                                                                     |
| IC ORR a                                                           | Percentage (2-sided 95% CI*)                                                                                                                     |
| TTR a , IC TTR                                                     | Descriptive statistics; n (%)                                                                                                                    |
| DOR a , IC DOR                                                     | K-M method (median and 2-sided 95% CI)*** Descriptive statistics; n (%)                                                                          |
| PFS a , OS                                                         | K-M method (median and 2-sided 95% CI)***                                                                                                        |
| Probabilities of being event free/survival at 1 year and 18 months | K-M method (2-sided 95% CI**)                                                                                                                    |
| PROs                                                               | Descriptive statistics for absolute scores and change from baseline of the EORTC QLQ-C30 and QLQ-LC13 multiple-item and single-item scale scores |
| Biomarker related endpoints                                        | Outlined in Study 1001 SAP Section 6.3.4                                                                                                         |

Source: Study 1001 Statistical Analysis Plan Version 5.

*Using exact method based on binomial distribution.

**Using the normal approximation to the log-transformed cumulative hazard function.

*** Confidence intervals for the median and quartiles using the method of Brookmeyer and Crowley.

a. Based on ICR and Investigator assessment.

Abbreviations: CI=confidence interval; CNS=central nervous system; DOR=duration of response; K-M=Kaplan-Meier; IC=intracranial; ICR=Independent Central Review; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PRO=patient-reported outcome; EORTC QLQ-C30=European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; QLQ-LC13=Quality of Life Questionnaire Lung Cancer 13; SAP=Statistical Analysis Plan; TTR=time to tumour response.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

Source: Tables 14.1.1.1.2, 14.1.1.2.2 and 14.1.1.3.2

Abbreviations: AE=adverse event; ALK-positive=anaplastic lymphoma kinase-positive; ITT=intention to treat; N/n=number of patients.

Figure 15: Study Flow Chart (Phase 2)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 16: Study Flow Chart for EXP3B:EXP5, data cutoff date 2 February 2018 (Phase 2)

## Recruitment

The Phase 2 study was conducted at 47 centres in 14 countries, including Australia, Belgium, Canada, France, Germany, Hong Kong, Italy, Japan, Korea, Singapore, Spain, Switzerland, Taiwan, and United States (US).

## Conduct of the study

The protocol of study 1001 was amended in consideration of safety aspects, selection of RP2D and for sample size adjustment in due course.

## Protocol deviations

Table 29: Important protocol deviations in Phase 2 (Full analysis set)

| ProtocolDeviationCategory   | ProtocolDeviationSubcategory                                            | Total (N=276) n (%)   |
|-----------------------------|-------------------------------------------------------------------------|-----------------------|
| Inclusioncriteria           | No archival tissue available or no de novo biopsy performed             | 8 (2.9)               |
|                             | ALK/ROS1statusnotconfirmed                                              | 1 (0.4)               |
|                             | ALK/ROS1testingmethodnotperprotocol                                     | 14 (5.1)              |
|                             | Didnotmeetallotherinclusioncriteria                                     | 31 (11.2)             |
| Concomitanttreatment        | Anti-cancertherapy administeredpriortodocumentedPD                      | 1 (0.4)               |
| Safety reporting            | SAEdelayedornotreportedtosponsor                                        | 12 (4.3)              |
| Informedconsent             | Requiredinformedconsentnotobtainedontime                                | 6 (2.2)               |
| Other                       | Special safety concern letter not relayed to patient in a timely manner | 2 (0.7)               |

Source:Table14.1.1.4.2.

Abbreviations:ALK=anaplasticlymphomakinase:N/n=number ofpatients;SAE=serious adverseevent

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 30: Demographic characteristics (Phase 2) - safety analysis set

|                    | EXP-1 (N=30)   | EXP-2 (N=27)   | EXP-3 (N=60)   | EXP-4 (N=65)   | EXP-5 (N=46)   | EXP-6 (N=47)   | Total (N=275)   |
|--------------------|----------------|----------------|----------------|----------------|----------------|----------------|-----------------|
| Gender, n (%)      |                |                |                |                |                |                |                 |
| Female             | 13             | 17             | 38             | 37             | 25             | 27             | 157             |
| Male               | 17             | 10             | 22             | 28             | 21             | 20             | 118             |
| Age (years), n (%) |                |                |                |                |                |                |                 |
| <18                | 0              | 0              | 0              | 0              | 0              | 0              | 0               |
| 18 - 44            | 4 (13.3)       | 5 (18.5)       | 14 (23.3)      | 19 (29.2)      | 13 (28.3)      | 12 (25.5)      | 67 (24.4)       |
| 45 - 64            | 18 (60.0)      | 13 (48.1)      | 34 (56.7)      | 37 (56.9)      | 26 (56.5)      | 27 (57.4)      | 155 (56.4)      |
| ≥65                | 8 (26.7)       | 9 (33.3)       | 12 (20.0)      | 9 (13.8)       | 7 (15.2)       | 8 (17.0)       | 53 (19.3)       |
| Mean               | 57.4           | 57.1           | 54.0           | 52.2           | 51.5           | 52.8           | 53.6            |
| SD                 | 12.1           | 12.7           | 11.9           | 11.8           | 11.2           | 12.9           | 12.1            |
| Range              | 27-75          | 35-85          | 30-77          | 29-83          | 32-78          | 19-77          | 19-85           |
| Race, n (%)        |                |                |                |                |                |                |                 |
| White              | 10 (33.3)      | 13 (48.1)      | 25 (41.7)      | 32 (49.2)      | 27 (58.7)      | 25 (53.2)      | 132 (48.0)      |
| Black              | 1 (3.3)        | 0              | 1 (1.7)        | 0              | 0              | 1 (2.1)        | 3 (1.1)         |
| Asian              | 17 (56.7)      | 10 (37.0)      | 23 (38.3)      | 23 (35.4)      | 14 (30.4)      | 16 (34.0)      | 103 (37.5)      |
| Other              | 1 (3.3)        | 2 (7.4)        | 1 (1.7)        | 3 (4.6)        | 2 (4.3)        | 3 (6.4)        | 12 (4.4)        |
| Unspecified        | 1 (3.3)        | 2 (7.4)        | 10 (16.7)      | 7 (10.8)       | 3 (6.5)        | 2 (4.3)        | 25 (9.1)        |
| Weight (kg)        |                |                |                |                |                |                |                 |
| Mean               | 68.1           | 69.7           | 66.3           | 66.4           | 69.0           | 68.8           | 67.7            |
| SD                 | 20.4           | 18.5           | 16.7           | 15.5           | 15.7           | 18.4           | 17.1            |
| Range              | 41.6-102.6     | 43.7-121.6     | 43.3-116.0     | 32.6-106.1     | 44.9-126.7     | 38.0-133.0     | 32.6-133.0      |
| BMI (kg/m)         |                |                |                |                |                |                |                 |
| Mean               | 24.7           | 25.6           | 24.1           | 23.9           | 24.3           | 24.6           | 24.4            |
| SD                 | 5.6            | 5.0            | 5.0            | 4.5            | 4.0            | 4.4            | 4.7             |
| Range              | 16.9-38.5      | 19.4-38.8      | 16.8-45.2      | 16.0-40.2      | 17.7-37.9      | 13.5-36.6      | 13.5-45.2       |

Source:Table 14.1.2.1.2

Abbreviation: BMI=body mass index; N/n=number of patients; SD=standard deviation.

Table 31: Baseline disease characteristics (Phase 2) - safety analysis set

|                                   | EXP-1 (N=30)   | EXP-2 (N=27)   | EXP-3 (N=60)   | EXP-4 (N=65)   | EXP-5 (N=46)   | EXP-6 (N=47)   | Total (N=275)   |
|-----------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|-----------------|
| Involved disease site             |                |                |                |                |                |                |                 |
| Bone                              | 12 (40.0)      | 7 (25.9)       | 27 (45.0)      | 31 (47.7)      | 19 (41.3)      | 18 (38.3)      | 114 (41.5)      |
| Brain                             | 6 (20.0)       | 17 (63.0)      | 32 (53.3)      | 42 (64.6)      | 32 (69.6)      | 23 (48.9)      | 152 (55.3)      |
| Liver                             | 5 (16.7)       | 7 (25.9)       | 12 (20.0)      | 17 (26.2)      | 15 (32.6)      | 11 (23.4)      | 67 (24.4)       |
| Lung                              | 29 (96.7)      | 25 (92.6)      | 48 (80.0)      | 56 (86.2)      | 41 (89.1)      | 41 (87.2)      | 240 (87.3)      |
| Lymph node                        | 25 (83.3)      | 12 (44.4)      | 26 (43.3)      | 28 (43.1)      | 21 (45.7)      | 28 (59.6)      | 140 (50.9)      |
| Other                             | 7 (23.3)       | 9 (33.3)       | 22 (36.7)      | 22 (33.8)      | 16 (34.8)      | 14 (29.8)      | 90 (32.7)       |
| Number of involved disease sitesa |                |                |                |                |                |                |                 |
| 1                                 | 4 (13.3)       | 2 (7.4)        | 4 (6.7)        | 4 (6.2)        | 5 (10.9)       | 4 (8.5)        | 23 (8.4)        |
| 2                                 | 7 (23.3)       | 9 (33.3)       | 22 (36.7)      | 16 (24.6)      | 7 (15.2)       | 17 (36.2)      | 78 (28.4)       |
| 3                                 | 11 (36.7)      | 7 (25.9)       | 15 (25.0)      | 23 (35.4)      | 16 (34.8)      | 9 (19.1)       | 81 (29.5)       |
| 4                                 | 5 (16.7)       | 6 (22.2)       | 14 (23.3)      | 12 (18.5)      | 11 (23.9)      | 9 (19.1)       | 57 (20.7)       |
| >4                                | 3 (10.0)       | 3 (11.1)       | 5 (8.3)        | 10 (15.4)      | 7 (15.2)       | 8 (17.0)       | 36 (13.1)       |

Source: Table 14.1.2.5.1.2.2

Abbreviations:EXP=expansion; N=number of patients.

Involved disease sites (per investigator assessment) included both target and non-target lesions. Disease sites with multiple lesions were counted once. Each 'Other' disease site was counted as separate disease site.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 32: Data Sets Analysed (Phase 2)

| Number (%) of Patients   | EXP-1    | EXP-2     | EXP-3     | EXP-4     | EXP-5     | EXP-6     | Total      |
|--------------------------|----------|-----------|-----------|-----------|-----------|-----------|------------|
| Full analysis set        | 30       | 27        | 60        | 66        | 46        | 47        | 276        |
| Analyzed for safety      |          |           |           |           |           |           |            |
| Safety analysis set      | 30 (100) | 27 (100)  | 60 (100)  | 65 (100)  | 46 (100)  | 47 (100)  | 275 (100)  |
| Analyzed for efficacy    |          |           |           |           |           |           |            |
| ITT                      | 30 (100) | 27 (100)  | 59 (98.3) | 65 (100)  | 46 (100)  | 47 (100)  | 274 (99.6) |
| ITT (a)                  | 6 (20.0) | 17 (63.0) | 32 (53.3) | 42 (64.6) | 32 (69.6) | 23 (48.9) | 152 (55.3) |
| ITT (b)b                 | 8 (26.7) | 17 (63.0) | 32 (53.3) | 45 (69.2) | 38 (82.6) | 25 (53.2) | 165 (60.0) |

Source: Table 14.1.1.1.2.

Abbreviations: CNS=central nervous system; EXP=expansion; ITT=intention-to-treat.

- a. ITT (a): Patients with CNS metastases in ITT by Investigator assessment.
- b. ITT (b): Patients with CNS metastases in ITT by Independent Central Review.

## Outcomes and estimation

Primary endpoint- ORR and Intra-cranial-ORR - UPDATED

- ORR

In Phase 2, the primary endpoint was ORR based on ICR assessment in the ITT population.

Table 33: Summary of Best Overall Response Based on Independent Central Review (Phase 2) - ITT Population, in EXP-1:EXP-6.

|                                    | EXP-1 (N=30) n (%)   | EXP-2 (N=27) n (%)   | EXP-3A (N=32) n (%)   | EXP-3B (N=27) n (%)   | EXP-4 (N=65) n (%)   | EXP-5 (N=46) n (%)   | EXP-6 (N=47) n (%)   | Total (N=274) n (%)   |
|------------------------------------|----------------------|----------------------|-----------------------|-----------------------|----------------------|----------------------|----------------------|-----------------------|
| Complete response [CR]             | 1 (3.3)              | 1 (3.7)              | 0                     | 1 (3.7)               | 2 (3.1)              | 0                    | 2 (4.3)              | 7 (2.6)               |
| Partial response [PR]              | 26 (86.7)            | 19 (70.4)            | 21 (65.6)             | 8 (29.6)              | 25 (38.5)            | 16 (34.8)            | 15 (31.9)            | 130 (47.4)            |
| Stable diseasea                    | 2 (6.7)              | 4 (14.8)             | 6 (18.8)              | 10 (37.0)             | 22 (33.8)            | 16 (34.8)            | 22 (46.8)            | 82 (29.9)             |
| Objective progression              | 1 (3.3)              | 3 (11.1)             | 3 (9.4)               | 6 (22.2)              | 10 (15.4)            | 10 (21.7)            | 2 (4.3)              | 35 (12.8)             |
| Indeterminate                      | 0                    | 0                    | 2 (6.3)               | 2 (7.4)               | 6 (9.2)              | 4(8.7)               | 6 (12.8)             | 20 (7.3)              |
| Objective response rate: [CR + PR] | 27 (90.0)            | 20 (74.1)            | 21 (65.6)             | 9 (33.3)              | 27 (41.5)            | 16 (34.8)            | 17 (36.2)            | 137 (50.0)            |
| 95% exact Crb                      | 73.5,97.9            | 53.7,88.9            | 46.8, 81.4            | 16.5,54.0             | 29.4, 54.4           | 21.4, 50.2           | 22.7, 51.5           | 43.9, 56.1            |

Source: Tables 14.2.2.1.1.1.1.2.1 and 14.2.2.1.2.1.1.2.1.

Stable disease at day &lt;42 were rated as indeterminate.

Abbreviations: BOR=best overall response; CI = confidence interval; CR=complete response; EXP=expansion; ITT = intention-to-treat; N/n = number of patients; PD=progressive disease; PR=partial response.

a.For a patient to be called having a BOR of SD, he/she must have maintained the status of SD for at least 6 weeks after treatment start. Patients with only non-measurable disease atbaseline and aBORofnon-CR/non-PDwere counted aspatients withSD.

b.Using exact method based on binomial distribution.

Table 34: Best overall response based on ICR in patients with ALK-positive NSCLC - ITT population in EXP cohorts (Phase 2) Data cutoff date: 15 March 2017

| Variable                                 | EXP-3B (N=27)                | EXP-4:EXP-5 (N=111)          | EXP-2:EXP-3A (N=59)          |
|------------------------------------------|------------------------------|------------------------------|------------------------------|
| Objective response rate [CR + PR], n (%) | 9 (33.3)                     | 43 (38.7)                    | 41 (69.5)                    |
| 95% exact CIa                            | (16.5, 54.0)                 | (29.6, 48.5)                 | (56.1, 80.8)                 |
| Best overall response, n (%)             | Best overall response, n (%) | Best overall response, n (%) | Best overall response, n (%) |
| Complete response (CR)                   | 1 (3.7)                      | 2 (1.8)                      | 1 (1.7)                      |
| Partial response (PR)                    | 8 (29.6)                     | 41 (36.9)                    | 40 (67.8)                    |
| Stable/no response                       | 10 (37.0)                    | 38 (34.2)                    | 10 (16.9)                    |
| Objective progression                    | 6 (22.2)                     | 20 (18.0)                    | 6 (10.2)                     |

<div style=\"page-break-after: always\"></div>

Source:Study1001CSRTable14.2.2.1.2.1.1.2.1

Stable disease at Day&lt;42were rated as indeterminate EXP 2: patients relapsing after only crizotinib therapy.

Abbreviations:ALK=anaplasticIymphomakinase;CI=confidenceinterval;CR=completeresponse;EXP=expansion;

ICR=independentcentralreview;ITT=intention-to-treat;N/n=numberofpatients;NSCLC=non-smallcelllungcancer;

PR=partialresponse.

a. Usingexactmethodbasedonbinomialdistribution.

Table 35: Best overall response based on ICR assessment in patients with ALK-positive NSCLC-ITT population in EXP cohorts (Phase 2) - Data cutoff date: 02 February 2018

| Data cutoff: 02 Feb 2018   | EXP-3B (N=28)   | EXP-4 (N=65)   | EXP-5 (N=46)   | (N=111)      | EXP-4:EXP-5EXP-3B:EXP-5 (N=139)   |
|----------------------------|-----------------|----------------|----------------|--------------|-----------------------------------|
| ORR [CR+PR]                | 12 (42.9)       | 27 (41.5)      | 17 (37.0)      | 44 (39.6)    | 56 (40.3)                         |
| 95% exact CIa              | (24.5, 62.8)    | (29.4, 54.4)   | (23.2, 52.5)   | (30.5, 49.4) | (32.1, 48.9)                      |
| Best overall response      |                 |                |                |              |                                   |
| CR                         | 1 (3.6)         | 2 (3.1)        | 0              | 2 (1.8)      | 3 (2.2)                           |
| PR                         | 11 (39.3)       | 25 (38.5)      | 17 (37.0)      | 42 (37.8)    | 53 (38.1)                         |
| Stable/no response         | 8 (28.6)        | 22 (33.8)      | 15 (32.6)      | 37 (33.3)    | 45 (32.4)                         |
| Objective progression      | 6 (21.4)        | 10 (15.4)      | 10 (21.7)      | 20 (18.0)    | 26 (18.7)                         |
| Indeterminate              | 2 (7.1)         | 6 (9.2)        | 4 (8.7)        | 10 (9.0)     | 12 (8.6)                          |

<!-- image -->

Source:Study 1001 CSRFigure14.2.2.1.2.1.2.2.2.

Figure 17: Waterfall plot of best percentage change in tumour size based on ICR in patients with ALKpositive NSCLC - ITT population in Cohort EXP-3B (Phase 2)

<!-- image -->

Source: Study 1001 CSR Figure 14.2.2.1.2.1.2.2.2.

Figure 18: Waterfall plot of best percentage change in tumour size based on ICR in patients with ALKpositive NSCLC - ITT population in pooled Cohort EXP-4:EXP-5 (Phase 2)

<div style=\"page-break-after: always\"></div>

## - IC-ORR

Table 36: Best overall intracranial response based on ICR by ALK-positive NSCLC and brain metastases - ITT population in EXP cohorts (Phase 2)

| Variable                          | EXP-3B (N=12)   | EXP-4:EXP-5 (N=83)   | EXP-2:EXP-3A (N=37)   |
|-----------------------------------|-----------------|----------------------|-----------------------|
| Objective response rate (CR + PR) | 5 (41.7)        | 40 (48.2)            | 25 (67.6)             |
| 95% exact CIa                     | (15.2, 72.3)    | (37.1, 59.4)         | (50.2, 82.0)          |
| Best Overall Response             |                 |                      |                       |
| Complete response (CR)            | 1 (8.3)         | 24 (28.9)            | 10 (27.0)             |
| Partial response (PR)             | 4 (33.3)        | 16 (19.3)            | 15 (40.5)             |
| Stable/no response                | 3 (25.0)        | 28 (33.7)            | 9 (24.3)              |
| Objective progression             | 3 (25.0)        | 6 (7.2)              | 2 (5.4)               |
| Indeterminate                     | 1 (8.3)         | 9 (10.8)             | 1 (2.7)               |

Source: Study 1001 CSR Table 14.2.2.1.2.2.1.2.1.

Stable disease at Day&lt;42 were rated as indeterminate.

Abbreviations:ALK=anaplastic lymphoma kinase;CI=confidence interval;CR=completeresponse;CSR=clinical study report; EXP=Expansion; ITT=intention-to-treat; N=number of patients; NSCLC=non-small cell lung cancer; PR=partial response.

- a.Using exact method based on binomial distribution.

<!-- image -->

Source:Study1001CSRFigure14.2.2.1.2.2.2.2.2

Figure 19: Waterfall plot of best percentage change from baseline in intracranial tumour size based on ICR assessment - ITT population in patients with brain metastases in pooled Cohort EXP-4:EXP-5 (Phase 2)

<div style=\"page-break-after: always\"></div>

Table 37: Best overall intracranial response based on ICR assessment in patients with ALKpositive NSCLC and brain metastases with at least 1 measurable lesion - ITT population in EXP cohorts (Phase 2)

| Data cutoff: 02Feb2018      | EXP-3B (6=N)   | EXP-4 (N=24)   | EXP-5 (N=24)   | EXP-4:EXP-5 (N=48)   | EXP-3B:EXP-5 (N=57)   |
|-----------------------------|----------------|----------------|----------------|----------------------|-----------------------|
| ORR (CR + PR) n (%)         | 6 (66.7)       | 14 (58.3)      | 11 (45.8)      | 25 (52.1)            | 31 (54.4)             |
| 95% exact CIa               | (29.9, 92.5)   | (36.6, 77.9)   | (25.6, 67.2)   | (37.2, 66.7)         | (40.7, 67.6)          |
| Best Overall Response n (%) |                |                |                |                      |                       |
| CR                          | 2 (22.2)       | 6 (25.0)       | 4 (16.7)       | 10 (20.8)            | 12 (21.1)             |
| PR                          | 4 (44.4)       | 8 (33.3)       | 7 (29.2)       | 15 (31.3)            | 19 (33.3)             |
| Stable/no response          | 0              | 8 (33.3)       | 9 (37.5)       | 17 (35.4)            | 17 (29.8)             |
| Objective progression       | 2 (22.2)       | 2 (8.3)        | 2 (8.3)        | 4 (8.3)              | 6 (10.5)              |
| Indeterminate               | 1 (11.1)       | 0              | 2 (8.3)        | 2 (4.2)              | 3 (5.3)               |
| Data cutoff: 15Mar2017      | EXP-3B (N=9)   | EXP-4 (N=25)   | EXP-5 (N=24)   | EXP-4:EXP-5 (N=49)   | EXP-3B:EXP-5b         |
| ORR (CR + PR) n (%)         | 5 (55.6)       | 16 (64.0)      | 10 (41.7)      | 26 (53.1)            |                       |
| 95% exact CIa               | (21.2, 86.3)   | (42.5, 82.0)   | (22.1, 63.4)   | (38.3, 67.5)         |                       |
| Best Overall Response n (%) |                |                |                |                      |                       |
| CR                          | 1 (11.1)       | 6 (24.0)       | 4 (16.7)       | 10 (20.4)            |                       |
| PR                          | 4 (44.4)       | 10 (40.0)      | 6 (25.0)       | 16 (32.7)            |                       |
| Stable/no response          | 0              | 7 (28.0)       | 10 (41.7)      | 17 (34.7)            |                       |
| Objective progression       | 3 (33.3)       | 2 (8.0)        | 2 (8.3)        | 4 (8.2)              |                       |
| Indeterminate               | 1 (11.1)       | 0              | 2 (8.3)        | 2 (4.1)              |                       |

15 Mar 2017: Module 5.3.5.3 D120 Supporting Table 14.2.2.1.1.2.1.2.1.t; Table 14.2.2.1.2.2.1.2.1.t.

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Table 14.2.2.1.2.3.1.2.1.ema

Abbreviations: ALK=anaplastic lymphoma kinase; CI=confidence interval; CR=complete response;

EXP=expansion; ICR=Independent Central Review; ITT=intention-to-treat; N/n=number of patients;

NSCLC=non-small cell lung cancer; ORR=objective response rate; PR=partial response; SCE=Summary of Clinical Efficacy.

a. Using exact method based on binomial distribution.

b. Data (15 March 2017 data cutoff) were not provided before.

## ORR by investigator

Table 38: Summary of best overall response based on derived investigator assessment (Phase 2) - ITT population by EXP-1:EXP-6 - Data cutoff date: 15 March 2017

|                               | EXP-1 (N=30)   | EXP-2   |             | EXP-3        | EXP-4 EXP-5 (N=46)   |    |             |
|-------------------------------|----------------|---------|-------------|--------------|----------------------|----|-------------|
|                               |                | (N=27)  |             | (N=59)       | (N=65)               |    |             |
|                               | n (%)          | n       | (%)         | n (%)        | n (8)                | n  | (%)         |
| Complete response             | 1 (3.3)        | 0       |             | 0            | 1 (1.5)              | 0  |             |
| Partial response              | 23 (76.7)      | 19      | (70.4)      | 29 (49.2)    | 19 (29.2)            | 16 | (34.8)      |
| Stable/Noresponse             | 5 (16.7)       | 8       | (29.6)      | 21 (35.6)    | 32 (49.2)            | 16 | (34.8)      |
| objectiveprogression          | 0              | 0       |             | 6 (10.2)     | 7 (10.8)             | 9  | (19.6)      |
| Indeterminate                 | 1 (3.3)        | 0       |             | 3 (5.1)      | 6 (9.2)              | 5  | (10.9)      |
| objectiveResponseRate (CR+PR) | 24 (80.0)      | 19      | (70.4)      | 29 (49.2)    | 20 (30.8)            | 16 | (34.8)      |
| 95$ Exact CI [1]              | [61.4, 92.3]   |         | [49.8,86.2] | [35.9, 62.5] | [19.9,43.4]          |    | [21.4,50.2] |

[1]Usingexact methodbasedonbinomialdistribution

UnconfirmedCR/PRaredowngradedtoSD，SDatday&lt;42 areratedasIndeterminate. PFIZERCONFIDENTIALSourCeData:Table16.2.6.4.2.1.1 Dateof ReportingDatasetCreation:10MAY2017

Date of Table Generation:29JuN2017（03:53)

<div style=\"page-break-after: always\"></div>

The summary of response disagreement in ORR and in the different cohorts is reported below:

Table 39: Summary of Response Disagreement Rate (Phase 2) - ITT Population based on either Derived Investigator Assessment or Independent Central Review, by EXP-1:EXP-6

EXP-1

(N=30)

n

(+)

3 (10.0)

EXP-2

(N=27)

n

(2)

3 (11.1)

EXP-3

(N=59)

n

(±)

11 (18.6)

EXP-4

(N=65)

(2)

15 (23.1)

EXP-5

(N=46)

n

(+)

6 (13.0)

EXP-6

(N=47)

n

(+)

(14.9)

Response Disagreement Rate (c+d)/N

1= c+d is the number of disagreement cases.

C: Derived Investigator Assessment indicates response; Independent Central Review assessment indicates no response or no scan available.

d: Independent Central Review assessment indicates response; Derived Investigator Assesument indicates no response or no scan available. Unconfirmed CR/PR are downgraded to SD, SD at day  42 are rated as Indeterminate. PFIZER CONPIDENTIAL Source Data:Table 16.2.6.6.3.1.2 Date of Reportinq Dataset Creation: 10MAY2017 Date of Table Generation:29JUN2017 (04:27)

Table 40: Summary of Intra-Cranial Response Disagreement Rate (Phase 2) - ITT Population in Patients with CNS Metastases based on either Derived Investigator Assessment or Independent Central Review, by EXP-1:EXP-6

<!-- image -->

PFIZER CONFIDENTIALSource Data:Table 16.2.6.6.3.2.2

C: Derived Investigator Assessment indicates response; Independent Central Review assessment indicates no response or no scan available. d: Independent Central Review assessment indicates reuponse; Derived Investigator Assessment indicates no response or no scan available. Unconfirmed CR/PR are downgraded to SD, SD at day &lt; 42 are rated as Indeterminate.

Date of Reporting Datanet Creation:23MAY2017

Date of Table Generation:

29JUN2017(10:26)

The ORR by IRC in the Phase 2 part was 42.9% (95%CI: 24.5-62.8) in EXP-3B and 39.6% (95%CI: 30.5-49.4)  in  EXP-4:EXP-5,  although  the  CI's  are  wide.  In  addition,  approximately  a  third  of  the patients in both cohorts had stable disease.

A summary of the best IC-ORR across the different cohorts are reported below:

Table 41: Summary of Best Intra-Cranial Overall Response Based on ICR (Phase 2) - ITT Population in Patients with CNS Metastases, in EXP-1: EXP-6

|                                    | EXP-1 (N=8) n (%)   | EXP-2 (N=17) n (%)   | EXP-3A (N=20) n (%)   | EXP-3B (N=12) n (%)   | EXP-4 (N=45) n (%)   | EXP-5 (N=38) n (%)   | EXP-6 (N=25) n (%)   | Total (N=165) n (%)   |
|------------------------------------|---------------------|----------------------|-----------------------|-----------------------|----------------------|----------------------|----------------------|-----------------------|
| Complete response [CR]             | 4 (50.0)            | 6 (35.3)             | 4 (20.0)              | 1 (8.3)               | 15 (33.3)            | 9 (23.7)             | 9 (36.0)             | 48 (29.1)             |
| Partial response [PR]              | 2 (25.0)            | 4 (23.5)             | 11 (55.0)             | 4 (33.3)              | 10 (22.2)            | 6 (15.8)             | 5 (20.0)             | 42 (25.5)             |
| Stable diseasea                    | 2 (25.0)            | 6 (35.3)             | 3 (15.0)              | 3 (25.0)              | 13 (28.9)            | 15 (39.5)            | 7 (28.0)             | 49 (29.7)             |
| Objective progression              | 0                   | 1 (5.9)              | 1 (5.0)               | 3 (25.0)              | 4 (8.9)              | 2 (5.3)              | 0                    | 11 (6.7)              |
| Indeterminate                      | 0                   | 0                    | 1 (5.0)               | 1 (8.3)               | 3 (6.7)              | 6 (15.8)             | 4 (16.0)             | 15 (9.1)              |
| Objective response rate: [CR + PR] | 6 (75.0)            | 10 (58.8)            | 15 (75.0)             | 5 (41.7)              | 25 (55.6)            | 15 (39.5)            | 14 (56.0)            | 90 (54.5)             |
| 95% exact CIb                      | 34.9, 96.8          | 32.9,81.6            | 50.9, 91.3            | 15.2,72.3             | 40.0, 70.4           | 24.0, 56.6           | 34.9, 75.6           | 46.6, 62.3            |

Source: Tables 14.2.2.1.1.2.1.2.1 and 14.2.2.1.2.2.1.2.1.

Stablediseaseat day&lt;42wererated asindeterminate.

Abbreviations:BOR=best overall response; CI = confidence interval; CNS=cerebrospinal;CR=complete response; EXP=expansion; ITT = intention-to-treat; N/n= number of patients; PD=progressive disease; SD=stable disease.

Patientswith onlynon-measurableCNSmetastasis atbaseline and an intracranialBORofnon-CR/non-PDwerecounted aspatientswith SD.

b.Using exact method based on binomial distribution.

Total

(N=274)

n

(+)

45 (16.4)

<div style=\"page-break-after: always\"></div>

Time to tumour response (TTR):

Table 42: Time to tumour response in EXP cohorts - ITT population (Phase 2)

| Data cutoff: 02 Feb 2018       | EXP-3B         | EXP-4          | EXP-5          | EXP-4:EXP-5    | EXP-3B:EXP-5   |
|--------------------------------|----------------|----------------|----------------|----------------|----------------|
| Overall Response, N            | 12             | 27             | 17             | 44             | 56             |
| Median TTR, months (range)     | 1.4 (1.2-16.6) | 2.6 (1.2-16.4) | 1.4 (1.2-9.3)  | 1.4 (1.2-16.4) | 1.4 (1.2-16.6) |
| IC response,* N                | 6              | 14             | 11             | 25             | 31             |
| Median IC TTR?, months (range) | 1.4 (1.2-3.0)  | 1.5 (1.2-16.2) | 1.4 (1.2-10.6) | 1.4 (1.2-16.2) | 1.4 (1.2-16.2) |
| Data cutoff: 15 Mar 2017       | EXP-3B         | EXP-4          | EXP-5          | EXP-4:EXP-5    | EXP-3B:EXP-5b  |
| Overall Response, N            | 9              | 27             | 16             | 43             |                |
| Median TTR, months (range)     | 1.4 (1.3-3.0)  | 2.6 (1.2-9.9)  | 1.4 (1.2-4.0)  | 1.4 (1.2-9.9)  |                |
| IC response,* N                | 5              | 16             | 10             | 26             |                |
| Median IC TTR?, months (range) | 1.4 (1.3-3.0)  | 1.5 (1.2-6.2)  | 1.4 (1.2-3.3)  | 1.4 (1.2-6.2)  |                |

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Table mo.171.2: Module 5.3.5.3 D120 Supporting Tables ema.233.feb.7; ema.233.feb.7.1.

15 Mar 2017: Module 5.3.5.2 Study 1001 CSR Supporting Tables 14.2.2.3.1.1.3.2.1; 14.2.2.3.2.1.3.2.1; Module 5.3.5.3 D120 Supporting Tables 14.2.2.3.2.2.3.2.1.t; 14.2.2.3.1.2.3.2.1.t.

Abbreviations: CSR=clinical study report; EXP=expansion; IC=intracranial; ITT=intention-to-treat;

N=number of patients; TTR=time to tumor response.

a. In patients with at least 1 measurable CNS lesion.

b. Data(15March datacutoff)werenotprovidedbefore.

## Disease Control Rate:

The overall DCRs at 12 and 24 weeks in cohorts EXP-1:EXP-6 based on ICR assessment in the ITT population are summarised in the table below:

Table 43: Summary of Disease Control Rate Based on ICR (Phase 2) - ITT Population, by EXP-1:EXP-6

<!-- image -->

The intracranial DCRs at 12 and 24 weeks in cohorts EXP-1:EXP-6 based on ICR  assessment in the ITT population are summarised in the table below:

Table 44: Summary of Intra-Cranial Disease Control Rate Based on ICR (Phase 2) - ITT Population in Patients with CNS Metastases, by EXP-1:EXP-6

<!-- image -->

<div style=\"page-break-after: always\"></div>

Duration of response

Table 45: ICR-assessed duration of response (objective responders only) - ITT population in EXP cohorts (Phase 2)

| Data cutoff: 15Mar2017                                              | EXP-3B (N=27)   | EXP-4 (N=65)   | EXP-5 (N=46)   | (N=111)   | EXP-4:EXP-5 EXP-3B:EXP-5b   |
|---------------------------------------------------------------------|-----------------|----------------|----------------|-----------|-----------------------------|
| Patients with confirmed objective response (CR or PR), n            | 9               | 27             | 16             | 43        |                             |
| Median DOR (in months)                                              | NR              | 6.9            | NR             | NR        |                             |
| 95% CI                                                              | (4.1, NR)       | (5.2, NR)      | (4.2, NR)      | (5.5, NR) |                             |
| N (%) of patients with events (PD or death) among the responders, n | 4 (44.4)        | 11 (40.7)      | 6 (37.5)       | 17 (39.5) |                             |
| (%)                                                                 |                 |                |                |           |                             |
| <3 months                                                           | 0               | 4 (14.8)       | 4 (25.0)       | 8 (18.6)  |                             |
| 3 to<6 months                                                       | 4 (44.4)        | 5 (18.5)       | 1 (6.3)        | 6 (14.0)  |                             |
| 6 to <9 months                                                      | 0               | 2 (7.4)        | 1 (6.3)        | 3 (7.0)   |                             |
| 9 to<12 months                                                      | 0               | 0              | 0              | 0         |                             |
| 12 <15 months                                                       | 0               | 0              | 0              | 0         |                             |
| 18 <21 months                                                       | 0               | 0              | 0              | 0         |                             |
| 21 <24 months                                                       | 0               | 0              | 0              | 0         |                             |
| ≥24 months                                                          | 0               | 0              | 0              | 0         |                             |
| Number (%) of patients censored                                     | 5 (55.6)        | 16 (59.3)      | 10 (62.5)      | 26 (60.5) |                             |
| among the responders                                                |                 |                |                |           |                             |
| <3months                                                            | 0               | 5 (18.5)       | 0              | 5 (11.6)  |                             |
| 3 to<6 months                                                       | 2 (22.2)        | 0              | 4 (25.0)       | 4 (9.3)   |                             |
| 6to<9months                                                         | 2 (22.2)        | 5 (18.5)       | 5 (31.3)       | 10 (23.3) |                             |
| 9 to<12 months                                                      | 0               | 5 (18.5)       | 0              | 5 (11.6)  |                             |
| 12 to<15months                                                      | 1 (11.1)        | 1 (3.7)        | 1 (6.3)        | 2 (4.7)   |                             |
| 15 to<18months                                                      | 0               | 0              | 0              | 0         |                             |
| 18 <21 months                                                       | 0               | 0              | 0              | 0         |                             |
| 21 <24 months                                                       | 0               | 0              | 0              | 0         |                             |
| ≥24 months                                                          | 0               | 0              | 0              | 0         |                             |

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Table 14.2.2.8.2.1.3.2.1.ema; Table 14.2.2.7.2.1.3.2.1.ema

151Mar2017:Module2.7.3SCETable12;Module5.3.5.2Study1001CSRTable35;Study1001CSR Supporting Table 14.2.2.7.1.1.3.2.1; Supporting Table 14.2.2.7.2.1.3.2.1.

Abbreviations: CSR=clinical study report; CI=confidence interval; CR=complete response; DOR=duration of response; EXP=expansion cohort; ICR=Independent Central Review; ITT=intention-to-treat; N/n=number of patients; NR=not reached, PR=partial response; PD=progressive disease; SCE=Summary of Clinical Efficacy.

- a. Using Brookmeyer Crowley method.
- b. Data (15 March 2017 data cutoff) were not provided before.

Figure 20: Kaplan-Meier Plot of Duration of Objective Response Based on ICR (Phase 2) - in Patients with a Confirmed Response, by EXP-1:EXP-6

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 46: Duration of Intracranial response (objective responders with a confirmed response only) based on ICR assessment in patients with at least 1 measurable CNS lesion ITT population in EXP cohorts (Phase 2)

| Data cutoff: 02 Feb 2018                                         | EXP-3B (N=9)   | EXP-4 (N=24)   | EXP-5 (N=24)   | (N=48)                           | EXP-4:EXP-5EXP-3B:EXP-5 (N=57)   |
|------------------------------------------------------------------|----------------|----------------|----------------|----------------------------------|----------------------------------|
| Patients with confirmed objective response (CR or PR), n         | 6              | 14             | 11             | 25                               | 31                               |
| Median DOR (in months)                                           | NR             | 11.1           | 12.4           | 12.4                             | 12.4                             |
| 95% CIa                                                          | (4.1, NR)      | (5.8, NR)      | (5.6, NR)      | (6.0, NR)                        | (5.8, NR)                        |
| N (%) of patients with events (PD or death) among the responders | 3 (50.0)       | 7 (50.0)       | 7 (63.6)       | 14 (56.0)                        | 17 (54.8)                        |
| <3 months                                                        | 0              | 2 (14.3)       | 1 (9.1)        | 3 (12.0)                         | 3 (9.7)                          |
| 3 to <6 months                                                   | 3 (50.0)       | 2 (14.3)       | 2 (18.2)       | 4 (16.0)                         | 7 (22.6)                         |
| 6 to<9months                                                     | 0              | 1 (7.1)        | 2 (18.2)       | 3 (12.0)                         | 3 (9.7)                          |
| 9 to<12 months                                                   | 0              | 1 (7.1)        | 0              | 1 (4.0)                          | 1 (3.2)                          |
| 12 to<15 months                                                  | 0              | 1 (7.1)        | 2 (18.2)       | 3 (12.0)                         | 3 (9.7)                          |
| N (%) of patients censored among                                 | 3 (50.0)       | 7 (50.0)       | 4 (36.4)       | 11 (44.0)                        | 14 (45.2)                        |
| the responders                                                   |                |                |                |                                  |                                  |
| <3months                                                         | 0              | 1 (7.1)        | 0              | 1 (4.0)                          | 1 (3.2)                          |
| 3 to<6months                                                     | 0              | 0              | 0              | 0                                | 0                                |
| 6to<9months                                                      | 0              | 1 (7.1)        | 1 (9.1)        | 2 (8.0)                          | 2 (6.5)                          |
| 9 to<12months                                                    | 1 (16.7)       | 2 (14.3)       | 1 (9.1)        | 3 (12.0)                         | 4 (12.9)                         |
| 12 to<15months                                                   | 1 (16.7)       | 1 (7.1)        | 0              | 1 (4.0)                          | 2 (6.5)                          |
| 15to<18months                                                    | 0              | 2 (14.3)       | 0              | 2 (8.0)                          | 2 (6.5)                          |
| 18 to<21 months                                                  | 0              | 0              | 1 (9.1)        | 1 (4.0)                          | 1 (3.2)                          |
| 21 to<24 months                                                  | 1 (16.7)       | 0              | 0              | 0                                | 1 (3.2)                          |
| ≥24 months                                                       | 0              | 0              | 1 (9.1)        | 1 (4.0)                          | 1 (3.2)                          |
| Data cutoff: 15 Mar 2017                                         | EXP-3B (N=9)   | EXP-4 (N=25)   | EXP-5 (N=24)   | EXP-4:EXP-5 EXP-3B:EXP-5b (N=49) |                                  |
| Patients with confirmed objective response (CR or PR), n         | 5              | 16             | 10             | 26                               |                                  |
| Median DOR (in months)                                           | NR (4.1, NR)   | 14.5           | NR             | 14.5 (6.9, 14.5)                 |                                  |
| 95% CIa                                                          |                | (6.0, 14.5)    | (6.9, NR)      |                                  |                                  |
| N (%) of patients with events (PD or death) among the responders | 2 (40.0)       | 5 (31.3)       | 4 (40.0)       | 9 (34.6)                         |                                  |
| <3months                                                         | 0              | 2 (12.5)       | 1 (10.0)       | 3 (11.5)                         |                                  |
| 3 to<6months                                                     | 2 (40.0)       | 1 (6.3)        | 1 (10.0)       | 2 (7.7)                          |                                  |
| 6to<9months                                                      | 0              | 1 (6.3)        | 2 (20.0)       | 3 (11.5)                         |                                  |
| 9 to<12 months 12to<15months                                     | 0 0            | 0 1 (6.3)      | 0 0            | 0 1 (3.8)                        |                                  |
| N (%) of patients censored among                                 |                |                | 6 (60.0)       |                                  |                                  |
| the responders                                                   | 3 (60.0)       | 11 (68.8)      |                | 17 (65.4)                        |                                  |
| <3months                                                         | 0              | 2 (12.5)       | 0              | 2 (7.7)                          |                                  |
| 3 to<6months                                                     | 2 (40.0)       | 2 (12.5)       | 1 (10.0)       | 3 (11.5)                         |                                  |
| 6to<9months                                                      | 0              | 4 (25.0)       | 4 (40.0)       | 8 (30.8)                         |                                  |
| 9to<12months                                                     | 0              | 2 (12.5)       | 0              | 2 (7.7)                          |                                  |
| 12 to<15 months                                                  | 1 (20.0)       | 1 (6.3)        | 1 (10.0)       | 2 (7.7)                          |                                  |
| 15 to<18months                                                   | 0              | 0              | 0              | 0                                |                                  |

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Table 14.2.2.8.3.2.4.2.1.ema; Table

14.2.2.7.3.2.4.2.1.ema.

15 MIar 2017: Module 5.3.5.3 D120 Supporting Tables 14.2.2.8.1.2.3.2.1.t; 14.2.2.8.2.2.3.2.1.t;

14.2.2.7.1.2.3.2.1.t; 14.2.2.7.2.2.3.2.1.t

Abbreviations: ALK=anaplastic lymphoma kinase; CI=confidence interval; CR=complete response;

DOR=duration ofresponse; EXP=expansion; ICR=Independent Central Review; ITT=intention-to-treat;

N/n=number of patients; NSCLC=non-small cell lung cancer; PD=progressive disease. PR=partial response.

a. UsingBrookmeyer Crowley method.

b. Data (15 March 2017 data cutoff) were not provided before.

<div style=\"page-break-after: always\"></div>

Progression Free Survival (PFS)

Table 47: PFS based on ICR (Phase 2) - ITT population, by EXP-1:EXP-6

|                | EXP-1 N=30   | EXP-2 N=27   | EXP-3A N=32   | EXP-3B N=27   | EXP-4 N=65   | EXP-5 N=46   | EXP-6 N=47   | Total N=274   |
|----------------|--------------|--------------|---------------|---------------|--------------|--------------|--------------|---------------|
| % Censored     | 76.7         | 70.4         | 59.4          | 37.0          | 44.6         | 43.5         | 55.3         | 53.3          |
| Median(months) | NR           | NR           | 12.5          | 5.5           | 7.3          | 5.6          | 9.6          | 9.6           |
| (95% CI)a      | (11.4, NR)   | (NR, NR)     | (6.9, NR)     | (2.9, 9.0)    | (5.4, 11.0)  | (4.0, 12.5)  | (4.7, NR)    | (7.1, 12.5)   |

Source: Table 14.2.2.5.1.1.1.2.1 and 14.2.2.5.2.1.1.2.1.

Abbreviations: CI=confidence interval;EXP=expansion;ITT=intention to treat; N/n=number of patients; NR=not reached.

a. UsingBrookmeyerCrowley method

<!-- image -->

Source: Figure 14.2.2.5.1.1.1.2.2.

Abbreviations:EXP=expansion;ITT=intention-to-treat.

Figure 21: Kaplan-Meier plot of PFS based on ICR (Phase 2) - ITT population, in EXP1:EXP-6

<div style=\"page-break-after: always\"></div>

Table 48: PFS in patients with ALK-positive NSCLC - ITT population in EXP cohorts (Phase 2)

| Data cutoff: 02 Feb 2018                                  | EXP-3B (N=28)     | EXP-4 (N=65)      | EXP-5 (N=46)      | EXP-4:EXP-5 (N=111)   | EXP-3B:EXP-5 (N=139)   |
|-----------------------------------------------------------|-------------------|-------------------|-------------------|-----------------------|------------------------|
| Median Time to Event (months)                             | 5.5               | 7.4               | 5.6               | 6.9                   | 6.9                    |
| 95% CIa                                                   | (2.9, 8.2)        | (5.4, 11.1)       | (4.0, 8.3)        | (5.4, 9.5)            | (5.4, 8.2)             |
| Number with event, n (%)                                  | 20 (71.4)         | 44 (67.7)         | 33 (71.7)         | 77 (69.4)             | 97 (69.8)              |
| Number censored, n (%)                                    | 8 (28.6)          | 21 (32.3)         | 13 (28.3)         | 34 (30.6)             | 42 (30.2)              |
| % Probability of being. event free at Month 12b (95% CI)c | 27.3 (12.2,45.0)  | 36.7 (24.6, 48.7) | 28.3 (15.2,42.9]  | 33.3 (24.2, 42.6)     | 32.1 (24.0, 40.3)      |
| % Probability of being. event free at Month 18b (IO %S6)  | 21.9 (8.1, 39.9)  | 27.1 (16.3, 39.0) | 17.0 (7.1, 30.6)  | 23.1 (15.2, 32.0)     | 22.6 (15.5, 30.6)      |
| Data cutoff: 15 Mar 2017                                  | EXP-3B (N=27)     | EXP-4 (N=65)      | EXP-5 (N=46)      | EXP-4:EXP-5 (N=111)   | EXP-3B:EXP-5b          |
| Median Time to Event (months)                             | 5.5               | 7.3               | 5.6               | 6.9                   |                        |
| 95% CI                                                    | (2.9, 9.0)        | (5.4, 11.0)       | (4.0, 12.5)       | (5.4, 9.5)            |                        |
| Number with event, n (%)                                  | 17 (63.0)         | 36 (55.4)         | 26 (56.5)         | 62 (55.9)             |                        |
| Number censored, n (%)                                    | 10 (37.0)         | 29 (44.6)         | 20 (43.5)         | 49 (44.1)             |                        |
| % Probability of being event free at Month 12c (95% CI)d  | 29.3 (11.9, 49.3) | 32.4 (19.3, 46.3) | 36.0 (20.6, 51.6) | 31.9 (21.2, 43.1)     |                        |
| % Probability of being event free at Month 18° (95% CI)d  |                   |                   |                   |                       |                        |

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Table 14.2.2.5.2.1.1.2.1.ema.

15 Mar 2017: Module 5.3.5.2 Study 1001 CSR Supporting Tables 14.2.2.5.2.1.1.2.1; 14.2.2.5.1.1.1.2.1.

Abbreviations: ALK=anaplastic lymphoma kinase; CI=confidence interval; CSR=clinical study report; EXP=expansion;ITT=intention to treat;N/n=number of patients;NSCLC=non-small-cell lung cancer. Note: The difference in number of patients in EXP-3B across the 2 data cutoffs was due to the positive ALK status confirmationforPatient10022026asof the 02February 2018datacutoff.

a. BasedontheBrookmeyerCrowleyMethod.

b. Data (15 March 2017 data cutoff) were not provided before.

C. Estimated from the Kaplan-Meier curve.

d. Calculated using the normal approximation to the log transformed cumulative hazard rate.

## Overall Survival

In  Phase 2, the updated median duration of follow-up for OS was approximately 20 months for the cohorts EXP-3B:EXP-5.

In cohort EXP-3B , the median OS was 21.1 months (95% CI: 12.3, NR) and 60.7% patients were still censored for OS. Most patients 14 (50.0%) were alive and in follow up at the data cutoff date. The survival probability for EXP-3B at 12 months was 69.8% (95% CI: 48.5, 83.6) and at 18 months was 61.6% (95% CI: 40.2, 77.2).

In  pooled  cohort EXP-4:EXP-5 ,  the  median  OS  for  the  111  ALK-positive  NSCLC  patients  was  19.2 months (95% CI: 15.4, NR). A total of 55 (49.5%) patients were censored for OS. Most patients were censored 47 (42.3%) because they were alive at the data cutoff date. The survival probability for EXP4:EXP-5 at 12 months was 67.3% (95% CI: 57.6, 75.4) and at 18 months was 54.2% (95% CI: 44.0, 63.2).

<div style=\"page-break-after: always\"></div>

## Time to Tumour Progression

The median TTP based on independent assessment was 11 months (95%CI: 8.2, 13.7) overall, 9.0 months for cohort EXP-3 (95%CI: 5.5, NR), 8.4 months for cohort EXP-4 (95%CI: 5.6, 13.7), and 7.1 months (95%CI: 4.1, 12.5) for cohort EXP-5.

## Comparison between TTP on lorlatinib and the TTP on last treatment prior to lorlatinib

For  patients  who  had  received  ALK-inhibitor  treatment  prior  to  lorlatinib,  the  median  TTP  was  12.9 months (95%CI: 11.2, 18.1) for cohort EXP-3, 12.1 months (95%CI: 7.9, 16.4) for cohort EXP-4, and 3.7  months  (95%CI:  2.1,  6.6)  for  cohort  EXP-5.  The  corresponding  hazard  ratios  (lorlatinib  versus prior therapy) were 0.572 (95%CI: 0.324, 1.010) for EXP-3, 0.757 (95%CI: 0.489, 1.173) for EXP-4, and 0.628 (95%CI: 0.382, 1.034) for EXP-5.

For patients who had received systemic therapy other than ALK-TKI treatment prior to lorlatinib, the median TTP was 8.5 months (95%CI: 5.0, 12.6) for EXP-3, 5.0 months (95%CI: 3.1, 10.8) for cohort EXP-4,  and  5.6  months  (95%CI:  4.7,  11.2)  for  cohort  EXP-5.  The  corresponding  hazard  ratios (lorlatinib versus prior therapy) were 0.314 (95%CI: 0.086, 1.148) for EXP-3, 0.745 (95%CI: 0.357, 1.552) for EXP-4, and 0.886 (95%CI: 0.398, 1.972) for EXP-5.

Data were not provided specifically for cohort EXP-3B.

During the procedure, the applicant was requested to provide information on TTP on last treatment prior  to  lorlatinib  as  grouped  by  first  and  second-generation  ALK  inhibitors  in  cohorts  EXP-3:EXP-5, with data provided by both individual cohorts (including EXP-3B) and pooled analysis (data not shown). No significant differences were observed in terms of TTP between lorlatinib and prior ALK-TKI.

## Intracranial Time to Tumour Progression

The median IC-TTP based on independent assessment was not reached (95% CI: 6.9, NR) for cohort EXP-3, 15.7 months (95%CI: 11.0, 15.7) for cohort EXP-4, and NR (95% CI: 8.3, NR) for cohort EXP5.

Probability of First Event Being a CNS Progression, non-CNS Progression, or Death

- Overall efficacy population

Figure 22: Plot of cumulative incidence function based on ICR (pooled EXP-3B: EXP-5) - ITT population excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib Data cutoff date: 02 February 2018

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 23: Plot of cumulative incidence function based on ICR (EXP-3B) - ITT population excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib - Data cutoff date: 02 February 2018

<!-- image -->

- Patients with brain metastases at baseline

Figure 24: Plot of cumulative incidence function based on ICR (pooled EXP-3B: EXP-5) - ITT population in patients with CNS metastases at baseline, excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib - Data cutoff date: 02 February 2018

<!-- image -->

Figure 25: Plot of cumulative incidence function based on ICR (EXP-3B) - ITT population in patients with CNS metastases at baseline, excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib - Data cutoff date: 02 February 2018- Patients without brain metastases at baseline

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 26: Plot of cumulative incidence function based on ICR (pooled EXP-3B: EXP-5) - ITT population in patients without CNS metastases at baseline, excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib - Data cutoff date: 02 February 2018

<!-- image -->

Figure 27: Plot of cumulative incidence function based on ICR (EXP-3B) - ITT population in patients without CNS metastases at baseline, excluding patients receiving radiotherapy for brain metastases up to 8 weeks before starting lorlatinib - Data cutoff date: 02 February 2018

<!-- image -->

## Efficacy by ALK mutation status

The BOR based on independent central review and median duration of treatment by expansion cohort and according to either presence or absence of ALK mutations measured in blood or tumour samples are summarised in the following tables:

<div style=\"page-break-after: always\"></div>

Table 49: Summary of Subjects with None vs. ≥1 Plasma CNA Mutation at Baseline (Phase 2) - CNA Peripheral Blood Analysis Set, by EXP-1:EXP-5

|                          |                                             | EXP-1                              | EXP-2                              | EXP-3                              | EXP-4                              | EXP-5                              |
|--------------------------|---------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                          |                                             | (N=30) (N=26) (N=58) (N=61) (N=45) | (N=30) (N=26) (N=58) (N=61) (N=45) | (N=30) (N=26) (N=58) (N=61) (N=45) | (N=30) (N=26) (N=58) (N=61) (N=45) | (N=30) (N=26) (N=58) (N=61) (N=45) |
| No ALK Mutation Detected | n(*)                                        | 28 (93.3)                          | 19 (73.1)                          | 48 (82.8)                          | 42 (68.9)                          | 30 (66.7)                          |
|                          | Responders n ($)                            | 25 (83.3)                          | 14 (53.8)                          | 23 (39.7)                          | 14 (23.0)                          | 7 (15.6)                           |
|                          | Best Overal1 Response ($)                   | 1 (3.3)                            | 1 (3.8)                            | 1 (1.7)                            | 2 (3.3)                            | 0                                  |
|                          | Completeresponse Partial response           | 24 (80.0)                          | 13 (50.0)                          | 22 (37.9)                          | 12 (19.7)                          | 7 (15.6)                           |
|                          | Stable/No response                          | 2 (6.7)                            | 4 (15.4)                           | 16 (27.6)                          | 18 (29.5)                          | 12 (26.7)                          |
|                          | Objective progression                       | 1 (3.3)                            | (3.8)                              | 7 (12.1)                           | 7 (11.5)                           | 8 (17.8)                           |
|                          | Indeterminate                               | 0                                  | 0                                  | 2 (3.4)                            | 3 (4.9)                            | E (6.7)                            |
|                          | Median Treatment Duration (Months)          | 9.1                                | 8.8                                | 7.8                                | 8.0                                | 7.7                                |
|                          | Treatment Duration Range (Months)           | 1.68, 17.08)                       | (0.36, 15.83)                      | (0.26， 17.77)                      | (0.23,17.48)                       | (0.39,17.28)                       |
| >=1 CNA ALK Mutation     | n()                                         | 1 (3.3)                            | 6 (23.1)                           | 8 (13.8)                           | 17 (27.9)                          | 14 (31.1)                          |
|                          | Responders n()                              | (3.3)                              | 5 (19.2)                           | 4 (6.9)                            | 12 (19.7)                          | 8 (17.8)                           |
|                          | Best Overal1 Response ($) Complete response | 0                                  | 0                                  | 0                                  | 0                                  | 0                                  |
|                          | Partial response                            | 1 (3.3)                            | 5 (19.2)                           | 4 6.9)                             | 12 (19.7)                          | 8 (17.8)                           |
|                          | Stable/No response                          | 0                                  | 0                                  | 0                                  | 2 (3.3)                            | 3 (6.7)                            |
|                          | Objective progression                       | 0                                  | 1 ( 3.8)                           | 2 (3.4)                            | 1 (1.6)                            | 2 (4.4)                            |
|                          | Indeterminate                               | 0                                  | 0                                  | 2 (3.4)                            | 2 (3.3)                            | (2.2)                              |
|                          | Median Treatment Duration (Months)          |                                    | 7.8                                | 8.0                                | 7.6                                | 7.7                                |
|                          | Treatment Duration Range (Months)           | 9.9 (9.86,9.86)                    | (4.11, 13.63)                      | (1.38, 15.11)                      | (0.46,15.70)                       | (1.22,11.96)                       |
| other                    | n (3)                                       | 1 (3.3)                            | ( 3.8)                             | (3.4)                              | 2 (3.3)                            | ( 2.2)                             |
|                          | Responders n ()                             | 1 (3.3)                            | (3.8)                              | 2 (3.4)                            | 1 (1.6)                            | 1 (2.2)                            |
|                          | Best Overal1 Response () Complete response  | 0                                  | 0                                  | 0                                  | 0                                  | 0                                  |
|                          | Partial response                            | 1 (3.3)                            | 1 ( 3.8)                           | 2 3.4)                             | 1 (1.6)                            | 1 (2.2)                            |
|                          | Stable/No response                          | 0                                  | 0                                  |                                    | 1 (1.6)                            | 0                                  |
|                          | Objective progression                       | 0                                  | 0                                  | 0                                  | 。                                  | 0                                  |
|                          | Indeterminate                               | D                                  | 0                                  | 0                                  | 0                                  | 0                                  |
|                          | Median Treatment Duration (Months)          |                                    |                                    |                                    |                                    |                                    |
|                          | Treatment Duration Range (Months)           | 16.3                               | 10.6                               | 8.7                                | 10.2                               | 6.1                                |
|                          |                                             | (16.33, 16.331                     | (10.58, 10.58)                     | (8.25, 9.17)                       | (8.51, 11.83)                      | (6.08, 6.08)                       |

Source Data: Tab1e 16.2.8.5.1.1.1.2, Tab1e 16.2.8.5.1.1.2.2 and Tab1e 16.2.6.4.2.1.2

Other: Sample failed analysis;Uninformative; Or not analyzed.

Responder 1s based on Independent Central Review.

The duration of treatment is defined as the total number of months =(Last Dose Date-Cycle 1 Day 1+ 1)/30.44.

Only AlK results for AlK+ patients are included.

PPIZER CONFIDENTIAL Date of Reportinq Dataset Creation:19MAY2017

Date of Table Generation: 02JUL2017 (06:17)

Table 50: Summary of Subjects with None vs. ≥1 DNA Mutation at Baseline (Phase 2) Tumour Tissue Analysis Set, by EXP-1:EXP-5

|                          |                                    | EXP-1 (N=28)   | BXP-2         |               | BXP-3 (N=57)   | BXP-4 (N=62)   | BXP-5 (N=43)   |
|--------------------------|------------------------------------|----------------|---------------|---------------|----------------|----------------|----------------|
|                          |                                    |                | (N=26)        |               |                |                |                |
| No ALK Mutation Detected | n ($)                              | 26 (92.9)      | 19 (73.1)     | 44            | (77.2)         | 37 (59.7)      | 20 (46.5)      |
|                          | Responders n ($)                   | 23 (82.1)      | 13 (50.0)     | 23            | (40.4)         | 12 (19.4)      | 4 (9.3)        |
|                          | Best Overal1 Response ()           |                |               |               |                |                |                |
|                          | Complete response                  | 1 (3.6)        | 1 ( 3.8)      | 0             | 1 ( 1.6)       |                | 0              |
|                          | Partialresponse                    | 22 (78.6)      | 12 (46.2)     | 23            | 11             | (17.7)         | 4 (9.3)        |
|                          | Stable/No response                 | 2 (7.1)        | 4 (15.4)      | 12            | (40.4) (21.1)  | 12 (19.4)      | 7 (16.3)       |
|                          | Objective progression              | 1 (3.6)        | 2 (7.7)       | 6 (10.5)      | 9              | (14.5)         | (11.6)         |
|                          | Indeterminate                      | 0              | 0             | 3 ( 5.3)      | 4              | (6.5)          | (9.3)          |
|                          | Median Treatment Duration (Months) | 9.7            | 9.2           | 7.9           | 6.4            |                | 3.0            |
|                          | Treatment Duration Range (Months)  | 1.68, 17.08)   | (0.36, 15.83) | (0.26， 17.77) | (0.23,17.48)   |                | 0.39,10.78)    |
| >=1 DNA ALK Mutation     | n($)                               | 0              | 7 (26.9)      | 8 (14.0)      | 11             | (17.7)         | 13 (30.2)      |
|                          | Responders n ()                    | 0              | 6 (23.1)      | 5 (8.8)       | 7              | (11.3)         | 7 (16.3)       |
|                          | Best Overal1 Response ($)          |                |               |               |                |                |                |
|                          | Complete response                  | 0              | 0             | 1 (1.8)       | 0              | 0              |                |
|                          | Partial response                   | 0              | 6 (23.1)      | 4 (7.0)       | 7 (11.3)       | 7              | (16.3)         |
|                          | Stable/No response                 | 0              | 0             | 0             | 3 (4.8)        | 5              | (11.6)         |
|                          | Objective progression              | 0              | 1 (3.8)       | 2 (3.5)       | 1 (1.6)        | 1              | (2.3)          |
|                          | Indeterminate                      | 0              |               | 1 (1.8)       | 0              |                | 0              |
|                          | Median Treatment Duration (Months) |                | 7.6           | 8.0           | 9.0            |                | 8.8            |
|                          | Treatment Duration Range (Months)  |                | 4.11, 13.63)  | (2.56, 9.661  | (3.71,         | 15.701         | 1.41, 17.28)   |
| Not Analyzable           | n()                                | 2 (7.1)        | 0             | 5 (8.8)       | 14 (22.6)      | 10             | (23.3)         |
|                          | Responders n ()                    | 2 (7.1)        | 0             | 1 (1.8)       | 5 (8.1)        | 4              | (9.3)          |
|                          | Best Overal1 Response ($)          |                |               |               |                |                |                |
|                          | Complete response                  | 0              | 0             | 0             | 0              | 0              |                |
|                          | Partial response                   | 2 (7.1)        | 0             | 1 1.8)        | 5 (8.1)        | 4              | (9.3)          |
|                          | Stable/No response                 | 0              | 0             | 3 5.3)        | 7 (11.3)       |                | 3 (7.0)        |
|                          | objectiveprogression               | 0              | 0             | 1 1.8)        | 0              | 3              | 7.0)           |
|                          | Indeterminate                      | 0              |               | D             | 2 (3.2)        |                | D              |
|                          | Median Treatment Duration (Months) | 6.5            |               | 8.3           | 8.5            |                | 8.9            |
|                          | Treatment Duration Range (Months)  | 6.24, 6.77)    |               | (2.27， 10.22) | (1.68, 16.16)  |                | (4.40,16.82)   |

Source Data: Tab1e 16.2.8.5.2.1.2 and Tab1e 16.2.6.4.2.1.2

Responder 1s based on Independent Central Review.

Only ALKresults for ALK+ patients are included.

PFIZER CONPIDENTIALDate of Reporting Dataset Creation:19MAY2017

Date of Table Generation:

02JUL2017 (07:29)

In order to investigate the impact of the last therapy used prior to lorlatinib (either ALK-targeted or untargeted systemic therapy) the MAH submitted results of clinical outcomes based on last therapy prior to lorlatinib.

<div style=\"page-break-after: always\"></div>

Table 51: Summary of clinical outcomes based on ICR (pooled EXP-3B: EXP-5) by last prior therapy immediately prior to lorlatinib - CAN peripheral analysis set

| Last Prior Therapy   | N   | Mutational Status       | N1(%0)                      | ClinicalOutcomes   | ClinicalOutcomes             | ClinicalOutcomes            | ClinicalOutcomes   | ClinicalOutcomes   | ClinicalOutcomes                    | ClinicalOutcomes          | ClinicalOutcomes              |
|----------------------|-----|-------------------------|-----------------------------|--------------------|------------------------------|-----------------------------|--------------------|--------------------|-------------------------------------|---------------------------|-------------------------------|
|                      |     |                         |                             | CR                 | PR                           | SD                          | PD                 | IND                | ORR (95%6 C1)                       | mDOR\" (95%6 C1)           | mPFS\" (95% CT)                |
| Alectinib            | 49  | 21 Mutation Other       | 33 (67.3) 15 (30.6) 1 (2.0) | 2 (6.1)            | 6 (18.2) 11 (73.3)           | 14(42.4) 3 (20.0) 1 (100.0) | 9 (27.3) 1 (6.7)   | 2 (6.1)            | 24.2 (11.1, 42.3) 73.3 (44.9, 92.2) | 8.3 (4.2) 5.2 (2.8, 24.4) | 4.2 (2.9,5.6) 8.2 (4.1, 25.6) |
| Brigatinib           |     | None 21 Mutation Otherb | 3 (42.9) 4 (57.1)           |                    | 1 (33.3) 2 (50.0)            | 1 (25.0)                    | 1 (33.3) 1 (25.0)  | 1 (33.3)           | 50.0 (6.8, 93.2)                    | NE                        | 4.8 (1.4)                     |
| Cerilinib            | 39  | None 21 Mutation Otherb | 32 (82.1) 4 (10.3) 3 (7.7)  |                    | 13 (40.6) 2 (50.0) 3 (100.0) | 13 (40.0) 1 (25.0)          | 4 (12.5) 1 (25.0)  | 2 (6.3)            | 40.6 (23.7, 59.4) 50.0 (6.8. 93.2)  | 6.1 (4.2, 12.5) NE        | 6.9 (4.0, 11.1) 8.4 (1.4)     |
| Crizotinib           | 17  | None 21 Mutation Otherb | 13 (76.5) 4 (23.5)          |                    | 4 (30.8) 3 (75.0)            | 4 (30.8)                    | 4 (30.8) 1 (25.0)  | 1 (7.7)            | 30.8 (9.1. 61.4) 75.0 (19.4, 99.4)  | 12.6 (5.2) 9.9 (7.0)      | 8.3 (2.6) 11.1 (1.2)          |
| Other TKT            |     | None 21 Mutation Other  | 1(33.3) 2 (66.7)            |                    |                              | 1(100.0)                    |                    | 2 (100.0)          |                                     |                           |                               |
| Chemotherapy         | 17  | None 21 Mutation Otherb | 12 (70.6) 5 (29.4)          | 1 (8.3)            | 3(25.0) 3 (60.0)             | 5 (41.7)                    | 2 (16.7)           | 1 (8.3) 2 (40.0)   | 33.3 (9.9, 65.1) 60.0 (14.7. 94.7)  | NE NE                     | 9.9(2.7) 4.1(1.5)             |

Response based on Independent Central Review.

Source: Module 5.3.5.3 D120 Supporting Table ema.225.2.1; ema.225.2.2; ema.225.2.3

N=CNA Periphenl Blood Analysis Set population for the associated last prior therapy: Percentages in the Nlcolumn (by mutational status) are calculated using N as the

CI=confidence interval; CR=complete response; DOR=duation of response; IND=indeterminate; KM=Kaplan-Meier, mDR=median duation of response; mPFS=median progression free survival; NE=not estimated; PR=partial response; PD=progressive disense.

denominator. Percentages in subsequent columns are calculated using Nl as the denominator.

When N124, ORR. (95% CI) and KM estimate of DOR/PFS median (95% CI) in months are presented in the table.

a. Using Brookmeyer Crowley method.

C. Other ALK TKIs included Ensartinib and Entrectinib.

b. Sample failed analysis; Sample not analyzed; Or result uminfommative.

The incidence of ALK-mutations varied across the different groups according  to the previously used ALK-inhibitor. The efficacy of lorlatinib was overall reduced in the absence of ALK-mutations.

## Patient-reported outcome

Figure 28: Mean change from baseline in patient-reported global QoL (PRO-evaluable population)

<!-- image -->

The majority of patients had either improved (42.7%) or stable (39.6%) scores in global QoL during treatment (including all cycles).

<div style=\"page-break-after: always\"></div>

Table 52: Change in EORTC (QLQ-C30 and QLQ-LC13) scales (PRO-evaluable population)

| EORIC (QLQ-C30 and QLQ-LC13) Scales   | EORIC (QLQ-C30 and QLQ-LC13) Scales   | No.(%) of Patients N=255   | No.(%) of Patients N=255   | No.(%) of Patients N=255   |
|---------------------------------------|---------------------------------------|----------------------------|----------------------------|----------------------------|
|                                       |                                       | Improved                   | Stable                     | Worsening                  |
| Global QoL (QLQ-C30)                  | Global QoL                            | 109 (42.7)                 | 101 (39.6)                 | 44 (17.3)                  |
| Functional ScalesQLQ-C30              | Physical functioning                  | 73 (28.6)                  | 146 (57.3)                 | 35 (13.7)                  |
| Functional ScalesQLQ-C30              | Role functioning                      | 96 (37.6)                  | 111 (43.5)                 | 46 (18.0)                  |
| Functional ScalesQLQ-C30              | Emotional functioning                 | 98 (38.4)                  | 129 (50.6)                 | 27 (10.6)                  |
| Functional ScalesQLQ-C30              | Cognitive functioning                 | 62 (24.3)                  | 131 (51.4)                 | 61 (23.9)                  |
| Functional ScalesQLQ-C30              | Social functioning                    | 86 (33.7)                  | 135 (52.9)                 | 33 (12.9)                  |
| SymptomScales/Items QLQ-C30           | Fatigue                               | 125 (49.0)                 | 97 (38.0)                  | 32 (12.5)                  |
| SymptomScales/Items QLQ-C30           | Nausea and vomiting                   | 63 (24.7)                  | 181 (71.0)                 | 10 (3.9)                   |
| SymptomScales/Items QLQ-C30           | Pain                                  | 104 (40.8)                 | 111 (43.5)                 | 39 (15.3)                  |
| SymptomScales/Items QLQ-C30           | Dyspnoea                              | 82 (32.2)                  | 121 (47.5)                 | 51 (20.0)                  |
| SymptomScales/Items QLQ-C30           | Insomnia                              | 115 (45.1)                 | 107 (42.0)                 | 32 (12.5)                  |
| SymptomScales/Items QLQ-C30           | Appetite loss                         | 106 (41.6)                 | 142 (55.7)                 | 6 (2.4)                    |
| SymptomScales/Items QLQ-C30           | Constipation                          | 64 (25.1)                  | 151 (59.2)                 | 39 (15.3)                  |
| SymptomScales/Items QLQ-C30           | Diarrhoea                             | 44 (17.3)                  | 177 (69.4)                 | 33 (12.9)                  |
| SymptomScales/Items QLQ-C30           | Financial difficulties                | 61 (23.9)                  | 155 (60.8)                 | 38 (14.9)                  |
| Symptom Scales/Items QLQ-LC13         | Dyspnoea                              | 72 (28.2)                  | 141 (55.3)                 | 41 (16.1)                  |
| Symptom Scales/Items QLQ-LC13         | Coughing                              | 111 (43.5)                 | 108 (42.4)                 | 35 (13.7)                  |
| Symptom Scales/Items QLQ-LC13         | Haemoptysis                           | 25 (9.8)                   | 220 (86.3)                 | 9 (3.5)                    |
| Symptom Scales/Items QLQ-LC13         | Sore mouth                            | 23 (9.0)                   | 189 (74.1)                 | 42 (16.5)                  |
| Symptom Scales/Items QLQ-LC13         | Dysphagia                             | 25 (9.8)                   | 203 (79.6)                 | 26 (10.2)                  |
| Symptom Scales/Items QLQ-LC13         | Peripheral neuropathy                 | 34 (13.3)                  | 122 (47.8)                 | 98 (38.4)                  |
|                                       | Alopecia                              | 31 (12.2)                  | 173 (67.8)                 | 50 (19.6)                  |
|                                       | Pain in chest                         | 76 (29.8)                  | 150 (58.8)                 | 27 (10.6)                  |
|                                       | Pain in arm or shoulder               | 64 (25.1)                  | 146 (57.3)                 | 44 (17.3)                  |
|                                       | Pain in other parts                   | 83 (32.5)                  | 102 (40.0)                 | 68 (26.7)                  |

Source:Tables 14.5.1.8.1.2 and 14.5.1.9.1.2.

For functioning and Global QoL, \"improved\" was defined as ≥10-point increase from Baseline and \"worsening\"\" was defined as ≥10-point decrease from Baseline. \"Stable\" was defined as a patient who was

neither improved nor worsened.

For symptoms, \"improved\" was defined as ≥10-point decrease from Baseline and \"worsening\"\" was defined as ≥10-point increase fromBaseline.\"Stable\"was defined as a patient who was neither improved nor worsened.

Abbreviations: EORTC QLQ-C30= European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Questionnaire;N=number of patients;No.=number; PRO = patient-reported outcome; QoL = quality of life; QLQ-LC13=modular supplement to QLQ-C30.

## Ancillary analyses

## Prior treatment

- The sixty-five (65) patients treated with lorlatinib in the subgroup of patients with 2 prior ALKinhibitor (ALKi) therapy (EXP-4) received the following prior treatments:

<div style=\"page-break-after: always\"></div>

| First-Line             | Second-Line            |   N |
|------------------------|------------------------|-----|
| Crizotinib             | second-generation ALKi |  61 |
| Second-generation ALKi | second-generation ALKi |   3 |
| Second-generation ALKi | crizotinib             |   1 |

In the group of patients receiving crizotinib in first-line and a second-generation ALK-inhibitor in second-line, the ORR and IC-ORR in patients with Intra Cranial lesion at baseline were as follows:

ORR = 27/61=44.3% (95% CI 31.5%-57.6%)

IC-ORR= 23/42=54.8% (95% CI 38.7%-70.2%)

- The 46 patients treated with lorlatinib in cohort EXP-5 received the following prior treatments:

| First-Line             | Second-Line            | Third Line             |   N |
|------------------------|------------------------|------------------------|-----|
| crizotinib             | crizotinib             | second-generation ALKi |   4 |
| crizotinib             | second-generation ALKi | second-generation ALKi |  23 |
| crizotinib             | second-generation ALKi | crizotinib             |  16 |
| second-generation ALKi | crizotinib             | second-generation ALKi |   2 |
| second-generation ALKi | second-generation ALKi | crizotinib             |   1 |

Five (5) patients, who received also a fourth line ALK inhibitor have been categorised to the corresponding line of therapy group based on the first 3 lines received.

| Prior Lines of ALKi in EXP-5                                                 | ORR                              | IC-ORR                           |
|------------------------------------------------------------------------------|----------------------------------|----------------------------------|
| crizotinib (1L and 2L) and second generation ALKi (3L)                       | 2/4=50.0% (95% CI 6.8%-93.2%)    | 1/2=50.0% (95% CI 1.3%-98.7%)    |
| crizotinib (1L) and second generation ALKi (2L and 3L)                       | 7/23=30.4% (95% CI 13.2%-52.9%)  | 6/20=30.0% (95% CI 11.9%-54.3%)  |
| crizotinib (1L), second generation ALKi (2L) and crizotinib (3L)             | 7/16=43.8% (95% CI 19.8%-70.1%)  | 8/13=61.5% (95% CI 31.6%-86.1%)  |
| second generation ALKi (1L), crizotinib (2L) and second generation ALKi (3L) | 1/2=50.0% (95% CI 1.3%-98.7%)    | 1/2=50.0% (95% CI 1.3%-98.7%)    |
| second generation ALKi (1L and 2L) and crizotinib (3L)                       | 0/1= 0.0% (95% CI 0.0%-97.5%)    | NA                               |
| TOTAL                                                                        | 17/46=37.0% (95% CI 23.2%-52.5%) | 16/37=43.2% (95% CI 27.1%-60.5%) |

NA: the patient receiving second generation ALKi in 1L and 2L and crizotinib in 3L had No Intra-cranial lesions at baseline

Moreover, information was provided regarding the time lapse between last tumour irradiation and first dose of lorlatinib, particularly in the population of patients with CNS involvement.

Table 53: Summary of prior radiation therapy (pooled EXP-3B:EXP-5)

|                          | PooledEXP-3B:EXP-5 (N =139) n (%)   |
|--------------------------|-------------------------------------|
| PriorRTSite(s)ofPriorRT* | 95 (68.3)                           |
| Abdominal                | 1 (1.1)                             |
| AdrenalGland             | 1 (1.1)                             |
| Bone                     | 7 (7.4)                             |
| Brain                    | 67 (70.5)                           |

<div style=\"page-break-after: always\"></div>

| Eye         | 1 (1.1)   |
|-------------|-----------|
| Face        | 1 (1.1)   |
| Liver       | 1 (1.1)   |
| Lung        | 20 (21.1) |
| Mediastinum | 9 (9.5)   |
| Neck        | 1 (1.1)   |
| Pelvis      | 3 (3.2)   |
| Spine       | 14 (14.7) |
| Thorax      | 6 (6.3)   |
| Unknown     | 1 (1.1)   |

Source:Module5.3.5.3D120SupportingTable ema.114.2

Dateof DataCutoff:02Feb2018andDateof DataSnapshot:17Apr2018

The denominator of PriorRTis N.The denominator of site(s)of prior RTis thenumber of subjectswith prior RT.One prior RT may be classifiedinto multiple sites of RT.The patient with this RTis counted in

eachcorrespondingsite.

RT=radiationtherapy

* Patients could have more than one prior RT.

Table 54: Summary of time from prior brain radiation therapies to the start of lorlatinib in patients with CNS metastases at baseline based on ICR (pooled EXP-3B: EXP-5)

|                                                                | PooledEXP-3B:EXP-5 (N=139)   |
|----------------------------------------------------------------|------------------------------|
| Time from Radiation Therapy to the Start of Lorlatinib (Weeks) |                              |
| n                                                              | 59                           |
| Mean                                                           | 71.6                         |
| STD                                                            | 61.49                        |
| Median                                                         | 52.3                         |
| Min                                                            | 2.1                          |
| Max                                                            | 199.0                        |

Source:Module5.3.5.3D120SupportingTable ema.114.4

Date ofData Cutoff: 02Feb 2018and Date of Data Snapshot: 17Apr 2018

N is the number of patients of EXP-3B: EXP-5.

nisthenumberofpatientswithCNSMetastasesatbaselineaccordingtoICRandwhoreceivedpriorbrain radiationtherapy.

For a subject with multiple prior radiation therapy, the one closest to the start of lorlatinib (but still prior) is usedin the analysis.

Time from Radiation Therapy to the Start of Lorlatinib = Start of Lorlatinib - Start of Radiation Therapy

## Biomarker assessments

Plasma  biospecimens  were  available  from  at  least  93%  of  the  patients  in  each  of  the  ALK-positive expansion cohorts (EXP-2:EXP-5), for a total of 190 (96.4%).

Plasma CNA samples were analysed for ALK gene rearrangements and kinase domain mutations by NGS. Patients in EXP-3B were not analysed separately. The ALK gene rearrangement and ALK kinase domain mutation data and sample disposition are summarised in Table 55.

Of  note,  lorlatinib  exhibited  antitumor  activity  across  a  variety  of  ALK  kinase  domain  resistance mutations, including the well characterised L1196M and G1269A crizotinib resistance mutations as well as the difficult-to-treat G1202R/G1202del mutations, but also in rarer, newly identified mutations such as P1329S.

Table 55: Sample Disposition and Summary Results for Patients with ALK-Positive NSCLC CNA Peripheral Blood Analysis Set by EXP Cohort (Phase 2)

|                                  | Total (N=190) n (%)   | EXP-2 (N=26) n (%)   | EXP-3 (N=58) n (%)   | EXP-4 (N=61) n (%)   | EXP-5 (N=45) n (%)   |
|----------------------------------|-----------------------|----------------------|----------------------|----------------------|----------------------|
| No ALK                           | 49 (25.8)             | 8 (30.8)             | 16 (27.6)            | 16 (26.2)            | 9 (20.0)             |
| Alteration Detected              |                       |                      |                      |                      |                      |
| ALK Gene                         | 79 (41.6)             | 13 (50.0)            | 24 (41.4)            | 17 (27.9)            | 25 (55.6)            |
| ALK Mutation (w/o Rearrangement) | 13 (6.8)              | 1 (3.8)              | 1 (1.7)              | 7 (11.5)             | 4 (8.9)              |
| ALK Mutation (w/                 | 31 (16.3)             | 5 (19.2)             | 7 (12.1)             | 9 (14.8)             | 10 (22.2)            |
| No cfDNA detected                | 38 (20.0)             | 3 (11.5)             | 13 (22.4)            | 17 (27.9)            | 5 (11.1)             |
| Not analyzable                   | 6 (3.2)               | 1 (3.8)              | 2 (3.4)              | 2 (3.3)              | 1 (2.2)              |
| Missing                          | 5 (2.6)               | 0 (0)                | 2 (3.4)              | 2 (3.3)              | 1 (2.2)              |

<div style=\"page-break-after: always\"></div>

Source: Study 1001 CSR Table 14.3.4.5.1.6.1.2

Abbreviations: ALK=anaplastic lymphoma kinase; CNA=circulating nucleic acid; cfDNA=circulating free deoxyribonucleic acid; EXP=expansion; N=number of patients; NSCLC=non-small cell lung cancer; w/=with; w/o=without. Missing: result missing at the time of the data cutoff.

Tumour tissue biospecimens (archival tumour and/or de novo tumour biopsy) were available in total for 188 patients with ALK-positive NSCLC.

|                          |   Total (N= 188) |   EXP-2 (N=26) |   EXP-3 (N=57) |   EXP-4 (N=62) |   EXP-5 (N=43) |
|--------------------------|------------------|----------------|----------------|----------------|----------------|
| No ALK mutation detected |              120 |             19 |             44 |             37 |             20 |
| ALK mutation detected    |               39 |              7 |              8 |             11 |             13 |
| Not analyzable           |               29 |              0 |              5 |             14 |             10 |

Source: Study 1001 CSR Table 14.3.4.5.2.9.1.2

Abbreviations: ALK=anaplastic lymphoma kinase; EXP=expansion; N=number of patients; NSCLC=non-small cell lung cancer.

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table 57: Summary of Efficacy for study B7461001 (study 1001)

| Title: Phase 1/2 study on patient safety and efficacy   | Title: Phase 1/2 study on patient safety and efficacy                                                     | Title: Phase 1/2 study on patient safety and efficacy                                                     | Title: Phase 1/2 study on patient safety and efficacy                                                     | Title: Phase 1/2 study on patient safety and efficacy                                                     | Title: Phase 1/2 study on patient safety and efficacy                                                     | Title: Phase 1/2 study on patient safety and efficacy                                                     |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Study identifier                                        | B7461001 (1001)                                                                                           | B7461001 (1001)                                                                                           | B7461001 (1001)                                                                                           | B7461001 (1001)                                                                                           | B7461001 (1001)                                                                                           | B7461001 (1001)                                                                                           |
| Design                                                  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  | Multicenter, multiple-dose, dose-escalation, safety, PK, Pharmacodynamics, and antitumor activity study.  |
|                                                         | Duration of main phase:                                                                                   | Duration of main phase:                                                                                   | Phase 2                                                                                                   | Phase 2                                                                                                   | Phase 2                                                                                                   | Phase 2                                                                                                   |
|                                                         | Duration of Run-in phase:                                                                                 | Duration of Run-in phase:                                                                                 | not applicable                                                                                            | not applicable                                                                                            | not applicable                                                                                            | not applicable                                                                                            |
|                                                         | Duration of Extension phase: not applicable                                                               | Duration of Extension phase: not applicable                                                               | Duration of Extension phase: not applicable                                                               | Duration of Extension phase: not applicable                                                               | Duration of Extension phase: not applicable                                                               | Duration of Extension phase: not applicable                                                               |
| Hypothesis                                              | Exploratory: Non-comparative Phase 1 Lorlatinib toxicity,                                                 | Exploratory: Non-comparative Phase 1 Lorlatinib toxicity,                                                 | study                                                                                                     | study                                                                                                     | study                                                                                                     | study                                                                                                     |
|                                                         | EXP-3B                                                                                                    | EXP-3B                                                                                                    | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 27 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 27 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 27 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 27 patients                                      |
|                                                         | EXP-4-5                                                                                                   | EXP-4-5                                                                                                   | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 111 patients                                     | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 111 patients                                     | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 111 patients                                     | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 111 patients                                     |
|                                                         | EXP-2-3A                                                                                                  | EXP-2-3A                                                                                                  | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 59 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 59 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 59 patients                                      | Lorlatinib 100 mg QD. Until PD or unacceptable toxicity, 59 patients                                      |
| Endpoints and definitions                               | Primary endpoint (Phase 2)                                                                                | ORR                                                                                                       | IRC according to RECIST 1.1                                                                               | IRC according to RECIST 1.1                                                                               | IRC according to RECIST 1.1                                                                               | IRC according to RECIST 1.1                                                                               |
|                                                         | Secondary endpoints                                                                                       | Efficacy                                                                                                  | IC ORR, TTR, IC TTR, PFS, 1 year survival                                                                 | IC ORR, TTR, IC TTR, PFS, 1 year survival                                                                 | IC ORR, TTR, IC TTR, PFS, 1 year survival                                                                 | IC ORR, TTR, IC TTR, PFS, 1 year survival                                                                 |
|                                                         | Secondary endpoints                                                                                       | Other analyses                                                                                            | PROs and biomarker-related endpoint                                                                       | PROs and biomarker-related endpoint                                                                       | PROs and biomarker-related endpoint                                                                       | PROs and biomarker-related endpoint                                                                       |
| Database lock                                           | 02 February 2018                                                                                          | 02 February 2018                                                                                          | 02 February 2018                                                                                          | 02 February 2018                                                                                          | 02 February 2018                                                                                          | 02 February 2018                                                                                          |
| Results and Analysis                                    | Results and Analysis                                                                                      | Results and Analysis                                                                                      | Results and Analysis                                                                                      | Results and Analysis                                                                                      | Results and Analysis                                                                                      | Results and Analysis                                                                                      |
| Analysis description                                    | Primary Analysis                                                                                          | Primary Analysis                                                                                          | Primary Analysis                                                                                          | Primary Analysis                                                                                          | Primary Analysis                                                                                          | Primary Analysis                                                                                          |
| Analysis population and time point description          | Intent to treat population at primary analysis                                                            | Intent to treat population at primary analysis                                                            | Intent to treat population at primary analysis                                                            | Intent to treat population at primary analysis                                                            | Intent to treat population at primary analysis                                                            | Intent to treat population at primary analysis                                                            |
| Descriptive statistics and estimate variability         | Treatment group                                                                                           |                                                                                                           |                                                                                                           | EXP-4:EXP-5                                                                                               |                                                                                                           |                                                                                                           |
|                                                         | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] | Number of subject N=28 N=111 N=59 ORR (%) 42.9 % 38.7 % 69.5% 95%CI [24.5; 62.8] [29.6; 48.5] [56.1;80.8] |
|                                                         | CR (%) 3.6 1.8 1.7                                                                                        | CR (%) 3.6 1.8 1.7                                                                                        | CR (%) 3.6 1.8 1.7                                                                                        | CR (%) 3.6 1.8 1.7                                                                                        | CR (%) 3.6 1.8 1.7                                                                                        | CR (%) 3.6 1.8 1.7                                                                                        |
|                                                         | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    | PR (%) 39.3 36.9 67.8 IC-ORR (%) 66.7 % 52.1 % N/A 95%CI [29.9; 92.5] [37.2; 66.7] N/A                    |
| Effect estimate per comparison                          | Disease control rate DCR (%) 71.4 73.0 86.0                                                               | Disease control rate DCR (%) 71.4 73.0 86.0                                                               | Disease control rate DCR (%) 71.4 73.0 86.0                                                               | Disease control rate DCR (%) 71.4 73.0 86.0                                                               | Disease control rate DCR (%) 71.4 73.0 86.0                                                               | Disease control rate DCR (%) 71.4 73.0 86.0                                                               |
|                                                         | Time to response (TTR) (months) 1.4 1.4 1.4                                                               | Time to response (TTR) (months) 1.4 1.4 1.4                                                               | Time to response (TTR) (months) 1.4 1.4 1.4                                                               | Time to response (TTR) (months) 1.4 1.4 1.4                                                               | Time to response (TTR) (months) 1.4 1.4 1.4                                                               | Time to response (TTR) (months) 1.4 1.4 1.4                                                               |
|                                                         | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    | Range 1.2-16.6 1.2-16.4 1.1-11.0 Duration of response (DOR) 5.6 9.9 NR                                    |
|                                                         | (months)                                                                                                  | (months)                                                                                                  | (months)                                                                                                  | (months)                                                                                                  | (months)                                                                                                  | (months)                                                                                                  |
|                                                         | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           | Range 4.17-NR 5.65-24.44 11.1-NR PFS (months) 5.5 months 6.9 NR                                           |
|                                                         | 95%CI                                                                                                     |                                                                                                           |                                                                                                           | 5.4, 9.5                                                                                                  | 12.5, NR                                                                                                  | 12.5, NR                                                                                                  |
|                                                         | OS (months)                                                                                               | 2.9, 8.2                                                                                                  | 2.9, 8.2                                                                                                  | 20.2                                                                                                      | NR                                                                                                        | NR                                                                                                        |
|                                                         |                                                                                                           | 21.9                                                                                                      | 21.9                                                                                                      |                                                                                                           |                                                                                                           |                                                                                                           |
| Notes                                                   | 95%CI                                                                                                     |                                                                                                           |                                                                                                           | 19.4,                                                                                                     | NA                                                                                                        | NA                                                                                                        |
|                                                         |                                                                                                           |                                                                                                           |                                                                                                           | 21.4                                                                                                      |                                                                                                           |                                                                                                           |
|                                                         | 19.2, 23.5                                                                                                | 19.2, 23.5                                                                                                | 19.2, 23.5                                                                                                |                                                                                                           |                                                                                                           |                                                                                                           |
| Analysis description                                    |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                         | IC= Intracranial                                                                                          | IC= Intracranial                                                                                          | IC= Intracranial                                                                                          |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                         | N/A                                                                                                       |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
|                                                         | Secondary analysis:                                                                                       | Secondary analysis:                                                                                       | Secondary analysis:                                                                                       | Secondary analysis:                                                                                       |                                                                                                           |                                                                                                           |

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Table 58: Number of elderly patients (by age group) included in efficacy and safety analyses

|                | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|----------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Study B7461001 | 45/334                                            | 16/334                                            | 1/334                                           |

Subgroup analyses of the ORR according to sex, age, race group, and performance status did not show any significant differences.

Table 59: ORR and IC-ORR outcomes by age group, gender, race and baseline ECOG performance status

| Baseline Characteristic   | N 215   | ORR 100-mg QD Pooled Group n (%) [C1]   | N 149   | IC ORR 100-mg QD Pooled Group [10] (%) u   |
|---------------------------|---------|-----------------------------------------|---------|--------------------------------------------|
| Sex                       |         |                                         |         |                                            |
| Male                      | 88      | 39 (44.3) [33.7, 55.3]                  | 60      | 29 (48.3) [35.2, 61.6]                     |
| Female                    | 127     | 60 (47.2) [38.3, 56.3]                  | 89      | 50 (56.2) [45.3, 66.7]                     |
| Age                       |         |                                         |         |                                            |
| <65 years                 | 177     | 83 (46.9) [39.4, 54.5]                  | 130     | 68 (52.3) [43.4, 61.1]                     |
| ≥65 years                 | 38      | 16 (42.1) [26.3, 59.2]                  | 19      | 11 (57.9) [33.5, 79.7]                     |
| Race group                |         |                                         |         |                                            |
| Asian                     | 74      | 39 (52.7) [40.7, 64.4]                  | 44      | 25 (56.8) [41.0, 71.7]                     |
| Non-Asian                 | 118     | 44 (37.3) [28.6, 46.7]                  | 89      | 40 (44.9) [34.4, 55.9]                     |
| Unspecified               | 23      | 16 (69.6) [47.1, 86.8]                  | 16      | 14 (87.5) [61.7, 98.4]                     |
| ECOG performance status   |         |                                         |         |                                            |
| 0                         | 95      | 43 (45.3) [35.0, 55.8]                  | 68      | 32 (47.1) [34.8, 59.6]                     |
| 1                         | 112     | 53 (47.3) [37.8, 57.0]                  | 75      | 44 (58.7) [46.7, 69.9]                     |
| 2                         | 8       | 3 (37.5) [8.5, 75.5]                    | 6       | 3 (50.0) [11.8, 88.2]                      |

Source:Study 1001 Table 14.2.2.1.1.1.2.1.s3,Table 14.2.2.1.1.2.2.1.s3,Table 14.2.2.1.2.1.2.1.s3,Table 14.2.2.1.2.2.2.1.s3,Table 14.2.2.1.3.1.2.1.s3,Table 14.2.2.1.3.2.2.1.s3,Table 14.2.2.1.4.1.2.1.s3,Table 14.2.2.1.4.2.2.1.s3, and Table 14.2.2.11.2.s3

Abbreviations: ALK=anaplastic lymphoma kinase; CI=confidence interval, ECOG=Eastern Cooperative Oncology Group; IC=intracranial; N/n=number; NSCLC=non-small-cell lung cancer; ORR=objective response rate; QD=once daily.

A  trend  towards  an  increased  number  of  responders  in  the  groups  of  Asians  (ORR  54.3%)  and Unspecified  ethnicity  (68.2%)  compared  with  Non-Asians  (38.1%)  is  observed.  The  efficacy  data reported in the cohorts of interest (EXP-3B, EXP-4 and EXP-5) were requested.

<div style=\"page-break-after: always\"></div>

Table 60: ORR and IC-ORR by baseline characteristics in patients with ALK-positive NSCLCITT population in cohort EXP-3B:EXP-5 (Phase 2)

| Baseline Characteristic   | N   | ORR n (%) [C1]*        | N   | IC ORRb n (%) [C1]*    |
|---------------------------|-----|------------------------|-----|------------------------|
| 02 Feb 2018               |     |                        |     |                        |
| Race                      |     |                        |     |                        |
| Asians                    | 53  | 26 (49.1) [35.1, 63.2] | 22  | 12 (54.5) [32.2, 75.6] |
| NonAsians                 | 73  | 23 (31.5) [21.1, 43.4] | 28  | 13 (46.4) [27.5, 66.1] |
| Unspecifiedc              | 13  | 7 (53.8) [25.1, 80.8]  | 7   | 6 (85.7) [42.1, 99.6]  |
| Age                       |     |                        |     |                        |
| <65 years                 | 117 | 46 (39.3) [30.4, 48.8] | 51  | 29 (56.9) [42.2, 70.7] |
| ≥65 years                 | 22  | 10 (45.5) [24.4, 67.8] | 6   | 2 (33.3) [4.3, 77.7]   |
| 15 Mar 2017               |     |                        |     |                        |
| Race                      |     |                        |     |                        |
| Asians                    | 53  | 24 (45.3) [31.6, 59.6] | 22  | 11 (50.0) [28.2, 71.8] |
| NonAsians                 | 72  | 20 (27.8) [17.9, 39.6] | 28  | 13 (46.4) [27.5, 66.1] |
| Unspecifiedc              | 13  | 8 (61.5) [31.6, 86.1]  | 8   | 7 (87.5) [47.3, 99.7]  |
| Aged                      |     |                        |     |                        |
| <65 years                 |     |                        |     |                        |
| ≥65 years                 |     |                        |     |                        |

Source: 02 Feb 2018: Module 5.3.5.3 D120 Supporting Tables ema.125.feb.1.1; ema.125.feb.1.3; Module

5.3.5.3 D120 Supporting Tables mo.171.3; mo.171.5.

15 Mar 2017: Module 5.3.5.3 D120 Supporting Tables ema.125.csr.1.1; ema.125.csr.1.3.

Abbreviations: ALK=anaplastic lymphoma kinase; CI=confidence interval; IC=intracranial; ITT=intention to treat; EXP=expansion (cohort); N/n=number of patients; NSCLC=non-small-cell lung cancer;

ORR=objective response rate.

- a. Using exact method based on binomial distribution.
- b. Patientswithatleast1measureablebrainlesion atbaseline.
- C. Race data were not collected, as per local regulations.

d. Data (15 March 2017 data cutoff) were not provided before.

## Supportive study

## Phase 1 part of study B7461001

Patients  included  in  the  Phase  1  part  had  advanced  ALK/ROS1-positive  NSCLC  and  were  either treatment-naïve or experienced disease progression after prior ALK-TKI and any prior chemotherapy.

Thirty-two (32; 59.3%) female patients and 22 (40.7%) male patients were enrolled in Phase 1, and the  mean  age  was  51.9  years  old.  Most  patients  enrolled  were  White  (68.5%).  Only  17  patients received  the  relevant  dose  (100  mg  QD).  Fifty-two  (52;96.3%)  Phase  1  patients  received  prior systemic therapy in any treatment setting and 2 patients (3.7%) were treatment naïve (i.e. no prior chemotherapy in the metastatic disease setting and no prior ALK or ROS1 inhibitor therapy). Of those patients who received prior systemic therapy, 48/52 patients received at least 1 prior ALK or ROS1 TKI. Thirty-five (35;64.8%) patients had prior surgery and 35 (64.8%) had radiation therapy.

<div style=\"page-break-after: always\"></div>

Table 61: Baseline Disease Characteristics based on Investigator Assessment (Phase 1) Safety Analysis Set

|                                  | Total (N=54)   | 100 mg QD (N=17)   |
|----------------------------------|----------------|--------------------|
| Involved disease site            |                |                    |
| Bone                             | 26 (48.1)      | 10 (58.8)          |
| Brain                            | 39 (72.2)      | 13 (76.5)          |
| Liver                            | 21 (38.9)      | 8 (47.1)           |
| Lung                             | 44 (81.5)      | 13 (76.5)          |
| Lymph node                       | 33 (61.1)      | 12 (70.6)          |
| Other                            | 15 (27.8)      | 5 (29.4)           |
| Number of involved disease sites |                |                    |
| 1                                | 5 (9.3)        | 1 (5.9)            |
| 2                                | 12 (22.2)      | 2 (11.8)           |
| 3                                | 13 (24.1)      | 6 (35.3)           |
| 4                                | 11 (20.4)      | 3 (17.6)           |
| >4                               | 13 (24.1)      | 5 (29.4)           |

Source: Table 14.1.2.5.1.2.1.

Abbreviations: N/n=number of patients; QD=once daily.

Involved disease sites (per investigator assessment) included both target and non-target lesions. Disease sites with multiple lesions were counted once. Each 'Other' disease site was counted as separate disease site.

The ORR was 39% (95%CI: 24.2-55.5) in the 41 patients with ALK-positive NSCLC, and furthermore 22% of these patients had  stable  disease.  In  the  CNS,  the  ORR  by  IRC  was  also  clinically  relevant 41.2% (95%CI: 24.6-53.3) in this setting.

Table 62: Summary of best overall response based on ICR by ALK-positive/ROS-1 positive status (Phase 1)-ITT population

|                                    | ALK- Positive NSCLC (N=41)   | ROSl-Positive NSCLC (N=12)   | Total (N=53)   |
|------------------------------------|------------------------------|------------------------------|----------------|
| Complete response [CR]             | 1 (2.4)                      | 0                            | 1 (1.9)        |
| Partial response [PR]              | 15 (36.6)                    | 6 (50.0)                     | 21 (39.6)      |
| Stable dieasea                     | 9 (22.0)                     | 2 (16.7)                     | 11 (20.8)      |
| Objective progression              | 14 (34.1)                    | 3 (25.0)                     | 17 (32.1)      |
| Indeterminate                      | 2 (4.9)                      | 1 (8.3)                      | 3 (5.7)        |
| Objective response rate: [CR + PR] | 16 (39.0)                    | 6 (50.0)                     | 22 (41.5)      |
| 95% exact CIb                      | (24.2, 55.5)                 | (21.1, 78.9)                 | (28.1, 55.9)   |

Source: Table 14.2.1.1.1.1.1.2.1.

Abbreviations: ALK-positive = anaplastic lymphoma kinase positive; BOR=best overall response; CI = confidence interval; CR=complete response; ITT = intention-to-treat; N/n = number of patients;

NSCLC=non small cell lung cancer; PD=progressive disease; SD=stable disease.

a.For a patient to be called having a BOR of stable disease, he/she must have maintained the status of stable disease for at least 6 weeks after treatment start. Patients with only non-measurable disease at baseline and a BOR of non-CR/non-PD were counted as patients with SD.

b.  Using exact method based on binomial distribution.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Source: Figure 14.2.1.1.1.1.2.2.2

Abbreviations: ALK-positive = anaplastic lymphomakinase positive;ITT=intention-to-treat; PD=progressive disease.

Figure 29: Waterfall plot of best percentage change in tumour size based on ICR (Phase 1) - ITT population

Table 63: Summary of best overall intracranial response based on ICR by ALK-positive or ROS1-positive status (Phase 1) - ITT population in patients with CNS metastases at baseline

|                                   | ALK- Positive NSCLC (N=34) n (%)   | ROSl-positive NSCLC (N=8)   | Total (N=42)    |
|-----------------------------------|------------------------------------|-----------------------------|-----------------|
| Complete response [CR]            | 10 (29.4)                          | n (%) 3 (37.5)              | n (%) 13 (31.0) |
| Partial response [PR]             | 4 (11.8)                           | 1 (12.5)                    | 5 (11.9)        |
| Stable dieasea                    | 8 (23.5)                           | 0                           | 8 (19.0)        |
| Objective progression             | 7 (20.6)                           | 3 (37.5)                    | 10 (23.8)       |
| Indeterminate                     | 5 (14.7)                           | 1 (12.5)                    | 6 (14.3)        |
| Objective response rate [CR + PR] | 14 (41.2)                          | 4 (50.0)                    | 18 (42.9)       |
| 95% exact CIb                     | (24.6, 59.3)                       | (15.7, 84.3)                | (27.7, 59.0)    |

Source: Table 14.2.1.1.1.2.1.2.1.

Abbreviations: ALK-positive = anaplastic lymphoma kinase positive; BOR=best overall response;

CI = confidence interval; CR=complete response; ITT = intention-to-treat; N/n = number of patients;

NSCLC=non small cell lung cancer; PD=progressive disease; PR=partial response; SD=stable disease.

a.ForapatienttobecalledhavingaBORof SD,he/shemusthavemaintainedthestatusofSDforatleast 6 weeks after treatment start.Patients with only non-measurable CNS disease at baseline and a BOR of non-CR/non-PDwerecounted aspatientswithSD.

hUsinoexactmethod hasedonbinomial distrihntion

Time to tumour response

Among  the  16  patients  with  ALK-positive  NSCLC  with  a  confirmed  objective  tumour  response  by independent assessment, the median TTR was 1.4 months (range: 1.2 to 15.2). Among the 6 patients with ROS1-positive NSCLC with a confirmed objective tumour response by independent assessment, the median TTR was 1.4 months (range: 1.2 to 2.8). The median TTR by investigator assessment was similar to independent assessment for patients with ALK-positive NSCLC and the same for patients with ROS1-positive NSCLC.

For  patients  with  baseline  CNS  metastases  and  a  confirmed  objective  response  by  independent assessment, the median IC-TTR was 1.4 months (range: 1.2 to 20.1) among the 14 patients with ALKpositive NSCLC and 1.4 months (range: 1.1 to 2.8) among the 4 patients with ROS1-positive NSCLC. The analysis included both measurable and non-measurable disease.

## DOR

The median follow-up time for DOR by IRC was 27.8 months (95%CI: 20.4, 31.8) for patients with ALK-positive NSCLC.

The duration of response in the CNS for Phase 1 patients with ALK-positive NSCLC was 14.1 months (95%CI:  4.17,  NR)  with  50%  of  patients  censored.  The  median  intracranial  DOR  could  not  be

<div style=\"page-break-after: always\"></div>

estimated (78.6% of patients censored), however, the lower boundary of the 95%CI was 14.1 months as well.

PFS

Table 64: PFS based on ICR (Phase 1) - ITT population

|                 | ALK-positive NSCLC (N=41)   | ROSl-positive NSCLC   | Total       |
|-----------------|-----------------------------|-----------------------|-------------|
|                 |                             | (N=12)                | (N=53)      |
| % Censored      | 29.3                        | 41.7                  | 32.1        |
| Median (months) | 5.3                         | 10.1                  | 5.4         |
| (95% CI)a       | (2.5, 11.8)                 | (1.6, NR)             | (2.7, 11.1) |

Source:Table 14.2.1.5.1.1.1.2.1

Abbreviations: ALK-positive = anaplastic lymphoma kinase positive; CI=confidence interval; ITT=intention to treat;NR=not reached.

a.Using Brookmeyer Crowley method

<!-- image -->

Source:Figure 14.2.1.5.1.1.1.2.2.

Abbreviations: ALK-positive = anaplastic lymphoma kinase positive; ITT = intention-to-treat.

Figure 30:Kaplan-Meier plot of PFS by ALK-positive status based on ICR (Phase 1) - ITT population OS

A total of 26 patients (49.1%) died during Phase 1. The survival probability, for the total population, at 12 and 18 months was 62.7% (95%CI: 47.9, 74.4) and 56.6% (95%CI: 41.9, 69.0).

## 2.5.3. Discussion on clinical efficacy

The proposed therapeutic dose was identified in Phase 1, based on a combination of toxicity parameters, mechanism-based PK/PD modelling and also taking into account the pre-clinical antitumour activity of lorlatinib against the ALK mutation G1202, which is known to confer resistance to both crizotinib and the second generation ALK-inhibitors alectinib and ceritinib. The approach used for RP2D selection is endorsed. However, other relevant ALK-resistance mutations have been identified for ceritinib (L1152R and F1174C/V) or alectinib (I1171N/T/S) [Muller et al. Onco Targets Ther. 2017; 10: 4535-4541] against which lorlatinib has not been tested in vitro using a PK/PD modelling-based approach.

## Design and conduct of clinical studies

The efficacy  assessment  is  based  on  the  ongoing  Phase  1/2  Study  1001.  In  the  Phase  2  part,  228 patients with ALK-positive NSCLC were included in various cohorts according to prior treatment.

<div style=\"page-break-after: always\"></div>

The amendments and protocol violations in the study are deemed unlikely to have had relevant impact on the integrity of study.

The design of the dose escalation study is considered acceptable and standard for a Phase 1 oncology study. The recommended dose of lorlatinib is 100 mg QD orally, and the rationale behind the clinical dose setting and dosing interval has been adequately described and justified. The aims of the Phase 2 part were both efficacy (ORR) and safety, including Patient-related Outcomes (PROs).

Patient demographics were representative of an ALK-positive NSCLC patient population. Most of the patients  enrolled  in  the  Phase  2  part  were  white  (48%)  or  Asian  (37.5%)  and  the  age  and  gender distribution was as could be expected, i.e. a mean age of 53.6 years and 57.1% were female patients. Only 45/334 (13.5%) of patients recruited, were aged &gt;65 years, reflecting that the targeted patient population  is  generally  younger  due  to  the  demographics  of  ALK-positive  NSCLC  and  the  study population are considered to be reflective of the patient population regarding age.

Data was not collected regarding smoking history and response. Other studies with ALK-inhibitors have shown some relationship between baseline smoking status and ORR, and although the efficacy was not absent, it seemed to be diminished in patients who were current smokers. The Applicant did not collect data  on  smoking  in  the  pivotal  study,  but  are  doing  so  in  the  ongoing  Phase  3  study  and  this  is acceptable. The ECOG performance status at baseline was 0-1 in 96.2% of the cases in the Phase 1 part and 96.4% of the cases in the Phase 2 part. This is considered to be expected in the early clinical trial setting, however, more patients with PS 2 are expected in the target population.

The pre-treatment varied a lot between the cohorts and this is now reflected in the final wording of the indication.  For  example,  newly  presented  data  from  the  EXP-4  and  EXP-5  cohorts  show  that  the majority of patients had received prior crizotinib. For the applied indication, results from the EXP-3B to EXP-5 cohort  are  considered  relevant  and  comprises  139  patients.  It  is  noted  that  the  cohort  EXP4:EXP-5 enrolled a high number of patients with brain metastases at baseline (75%), which is both considered representative of the possible target population and endorsed because efficacy in the CNS can be demonstrated. Overall, the study population is representative of a heavily pre-treated group of NSCLC patients, who became unresponsive to currently available ALK-inhibitors and, therefore, reflects an unmet medical need that can be recognised in clinical practice.

## Efficacy data and additional analyses

The  primary  endpoint  of  the  Phase  2  part  was  ORR  by  IRC  (RECIST  1.1),  while  this  endpoint  was exploratory for the Phase 1 part. However, it is noted that the ORR was 39% (95%CI: 24.2-55.5) in the 41 patients with ALK-positive NSCLC in the Phase 1 study, and furthermore 22% of these patients had stable disease. In the CNS, a similar ORR was observed, which is considered clinically relevant in this setting. The ORR by IRC in the Phase 2 part was 42.9% (95%CI: 24.5-62.8) in EXP-3B and 39.6% (95%CI: 30.5-49.4) in EXP-4:EXP-5. In addition, approximately a third of the patients in both cohorts had stable disease. These results are not outstanding but within an expectable range, considering that the  ORRs  for  other  ALK  inhibitors  are  around  50%  in  the  second-line  setting  and  that  the  ORR generally drops down through the lines of therapy. The magnitude of this effect is difficult to interpret in the absence of a comparator; however, the ability to induce complete remission, although in a very small fraction of subjects, is noted.

Regarding concordance rates, the response disagreement between ICR and Investigator assessments is  around  20%  for  some  EXP-groups.  Differences  are  observed  in  most  of  the  response  categories, which compromise the robustness of data and seem larger in the assessment of CNS metastases.

<div style=\"page-break-after: always\"></div>

In the CNS, the ORR by IRC was also showing clinically relevant efficacy, even in the later lines of ALKinhibition  therapy.  It  is  noted  that  only  few  patients  progressed  in  the  CNS  on  lorlatinib  and  a stabilisation of CNS disease is also considered highly clinically relevant in this patient population. In the Phase 1 part, the overall discordance rate for objective overall response was 20.8% and 23.8% for intracranial  responses.  In  the  Phase  2  part,  the  overall  discordance  rate  was  16.4%  and  29.6%  for intracranial responses. These discordance rates are surprisingly high, especially for the assessment of intracranial response in the Phase 2 part of the study, and the applicant suggests that differences may be  related  to  different  approaches  between  local  radiologists  and  ICR  to  the  imaging  assessment; rather than providing a reassuring explanation.

Another  source  of  uncertainty  in  evaluating  IC  ORR  results  is  prior  radiotherapy,  since  the  lapsed period required between the end of radiotherapy and study entry was only 2 weeks for stereotactic or small field brain irradiation and 4 weeks for whole brain radiation. However, data submitted comparing IC-ORR  in  the  efficacy  population  (pooled  EXP-3B,  EXP-4,  EXP-5)  for  all  patients,  and  excluding patients with an interval from the end of radiation and the start of lorlatinib treatment &lt;8 weeks and &lt;12 weeks, respectively excluded this bias (data not shown).

Plots of the cumulative incidence function of CNS progression, non-CNS progression, and death have been  provided.  In  all  analyses,  patients  receiving  RT  for  brain  metastases  up  to  8  weeks  before lorlatinib  were  excluded.  In  the  pooled  EXP-3B:EXP-5  population,  incidence  of  non-CNS  progression was  more  frequently  observed  than  CNS  progression  when  considering  all  patient  groups  (overall efficacy population, patients with brain metastases at baseline, patients without brain metastases at baseline). On the contrary, in the EXP-3B cohort, CNS progression had a higher incidence than nonCNS progression. The interpretation of these data in the context of a single arm trial is intrinsically limited, and need confirmation in a larger cohort, as planned.

The initial data cutoff was 15 March 2017 and results from an updated data cutoff (02 February 2018) have been provided during the procedure with a median duration of follow-up for OS of approximately 20 months in the relevant cohorts. Median PFS with matured data was similar to the prior data cutoff and  still  considered  clinically  meaningful.  A  confirmatory  randomised  Phase  3  study  is  ongoing, comparing the efficacy and safety of lorlatinib to crizotinib in the first-line setting and from updated timelines, it is evident that the CSR is at the earliest expected by Q4 2021. The applicant is planning to randomise  280  patients  in  total  and  so  far  approximately  240  of  the  planned  patients  have  been randomised, hence, full enrollment will be expected and final CSR should be available by the end of 2021.

The proposed confirmatory study is considered acceptable to complete a comprehensive evidence base in respect of safety and confirm the overall efficacy of lorlatinib. In addition, the applicant will conduct a single-arm efficacy study assessing lorlatinib in the second-line setting after disease progression on alectinib  or  ceritinib,  as  the  CHMP  considers  that  there  are  no  standard  of  care  in  this  setting.  This single-arm efficacy study will confirm the efficacy of lorlatinib in the proposed second-line setting post second generation ALK inhibitors and this study is added to the already proposed confirmatory study of efficacy of lorlatinib in the first-line setting as a special obligation.

Overall,  it  is  considered  that  mechanisms  of  on-target  resistance  to  second-generation  ALK-i  as conferred by ALK-mutations subsequent to treatment are expected to develop regardless of lines of therapy, making the EXP-4:EXP-5 cohorts supportive of the EXP-3B data. The applicant has showed a similar therapeutic activity of lorlatinib in 2L post 2 nd generation ALKi and 3L post crizotinib in the first line and a 2 nd  generation ALKi as 2L in terms of ORR and DOR, as well as a comparable response rate across  the  different  cohorts,  when  data  were  analysed  by  ALK-mutational  status,  demonstrating benefit of lorlatinib and it's potential to satisfy the requirement for fulfilment of the unmet clinical need in both settings. Considering that the main limitation of the data supporting the 2L currently resides in

<div style=\"page-break-after: always\"></div>

the limited sample size of EXP-3B (n=28 vs the 111 patients in EXP-4:EXP-5) the proposed PAES with consequent enlargement of the population of EXP-3B is regarded as confirmatory of the preliminary efficacy data in this population.

Among the secondary endpoints was time to response (TTP), which was approximately 1.4 months and similar in both the Phase 1 and 2 parts of the study. The responses were equally rapid in the CNS, demonstrating  clinically  relevant  efficacy  in  this  patient  population  with  a  high  frequency  of  brain metastases. Median DOR in Phase 1 was 14.1 months, and 12.5 months and 7.0 months in the EXP-4 and  EXP-5  cohorts  respectively.  In  the  CNS,  DOR  results  from  the  EXP  4:EXP-5  cohort  show encouraging results with a median DOR of 12.4 months. Median PFS in the Phase 1 was 5.3 months, but the CIs are wide. PFS data from Phase 2 have matured, and show clinically relevant results for the EXP-4:EXP-5 cohorts (6.9 months (95%CI: 5.4, 9.5). In addition,  OS  data  from  Phase  2  have  also matured and a median OS of ~20 months in the relevant cohorts are also considered clinically relevant and no obvious selection bias of the results were observed.

The PRO results from the Phase 1 part were generally in line with the Phase 2 results. It is noted that many  common  cancer  symptoms  were  significantly  reduced  on  treatment  but  also  that  peripheral neuropathy  at  the  following  time  points:  Cycles  3  to  14,  16,  and  33  was  worsened  clinically significantly. PRO results from the Phase 2 part showed similar improvements in the general cancer symptoms  fatigue,  pain,  insomnia,  and  appetite  loss.  Approximately  a  third  of  the  patients  had worsening  of  peripheral  neuropathy.  Overall,  PRO  results  is  considered  to  reflect  clinical  benefit  of lorlatinib and no obvious detrimental effect on QoL was observed.

A  trend  for  lower  activity  in  non-Asian  patients  was  reported,  however  available  data,  including  PK data, are too limited to draw any definitive conclusion (see Section 5.1 of the SmPC). The applicant will further  investigate  this  observation  in  the  B7461006  Clinical  Study  Report  (see  Annex  II),  in  which ethnic origin (Asian vs non-Asian) constitutes a randomisation factor.

## Additional efficacy data needed in the context of a conditional MA

Although a positive benefit-risk profile can be concluded, the data have limitations inherent to the noncomparative nature of the pivotal studies supporting the recommendation for a conditional MA. The applicant will submit the results of a Phase 3 study investigating lorlatinib versus crizotinib in the first line setting (CROWN study) which will further confirm the overall efficacy and safety of lorlatinib in ALK-positive NSCLC. Only 28 patients were included in the cohort EXP-3B including patients who have progressed after a second generation ALK inhibitors used as a first line treatment. As a consequence further data are needed to confirm the efficacy of lorlatinib in that setting and the applicant agreed to conduct a prospective observational single arm study to confirm the observed results from EXP-3B.

## 2.5.4. Conclusions on the clinical efficacy

The data from the pivotal 1001 study show clinically relevant efficacy of lorlatinib in a variation of cohorts according to prior treatments and this has been reflected in the final wording of the indication. The preliminary but clinically relevant efficacy of lorlatinib in the proposed second-line setting can be confirmed by a post-authorisation efficacy study.

The CHMP considers the following measures necessary to address the missing efficacy data in the context of a conditional MA:

- In order to further confirm the overall efficacy of lorlatinib in the treatment of patients with ALKpositive NSCLC, the MAH should submit the clinical study report of the Phase 3 study CROWN (1006) comparing lorlatinib versus crizotinib for the first-line treatment of advanced ALK-positive NSCLC. The clinical study report will be submitted by 31 December 2021.

<div style=\"page-break-after: always\"></div>

- In order to further confirm the efficacy of lorlatinib in patients who progressed after alectinib or ceritinib as the first ALK-TKI therapy, the MAH should conduct a prospective single arm study investigating patients in that same setting. The clinical study report will be submitted by 30 June 2024.

## 2.6. Clinical safety

One  clinical  ongoing  Phase  1/2  study  with  lorlatinib  100  mg  orally  once  daily  (QD)  including  adult patients with ALK-positive or ROS1-positive NSCLC was conducted and forms the basis of the safety evaluation. This clinical study consists of 2 portions, Phase 1 and Phase 2:

· The Phase 1 portion of the study was designed to estimate the maximum tolerated dose (MTD) for single-agent lorlatinib and to identify the recommended Phase 2 dose (RP2D). All treated patients (N=54) were included in the safety analysis set. The median duration of lorlatinib treatment in Phase 1 was 10.2 months.

· The Phase 2 portion of the study was designed to evaluate the anticancer activity of singleagent lorlatinib at the identified RP2D from Phase 1 in multiple subpopulations of patients based on ALK/ROS1 status and  number of prior therapies.  All  treated  patients  (N=275)  were  included  in  the safety analysis set. The updated median duration of treatment in Phase 2 was 16.33 months.

Table 65: Summary of Clinical Studies and Datasets Supporting the Registration of Lorlatinib for the Treatment of ALK-Positive NSCLC

| Study Title or Dataset Status                                                                                                                                                         | Study Design or Dataset Description                                                                                                               | Treatment                                                                                                      | Safety Population (n) †                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Studies in Patients with Advanced Cancer                                                                                                                                              | Studies in Patients with Advanced Cancer                                                                                                          | Studies in Patients with Advanced Cancer                                                                       | Studies in Patients with Advanced Cancer |
| B7461001 Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations Ongoing | Phase 1/2, open-label, multicenter, multiple- dose, dose-escalation, safety, PK, pharmacodynamics (PD) and anti-cancer efficacy exploration study | Dose escalation cohorts in 21-day cycles: Phase 1: QD: 10, 25, 50, 75, 100, 150, 200 mg Or BID: 35, 75, 100 mg | 54                                       |
|                                                                                                                                                                                       |                                                                                                                                                   | Phase 2 cohorts: 100 mg QD in 21-day cycles                                                                    | 275                                      |
|                                                                                                                                                                                       |                                                                                                                                                   | LIC (Japan only): 100 mg QD in 21-day cycles                                                                   | 3                                        |
|                                                                                                                                                                                       |                                                                                                                                                   | 100-mg QD pooled group: 100 mg QD in 21-day cycles                                                             | 295                                      |

The relevant dose of lorlatinib is 100 mg orally once daily  (QD) and the safety of this dosing is the main focus of the safety assessment.

## Patient exposure

The median duration of treatment was 10.18 months in Phase 1 patients and 17.41 months for the 100 mg QD cohort.

<div style=\"page-break-after: always\"></div>

Table 66: Duration of treatment (Phase 1) - safety population

|                                | Total N=54    | 100 mg QD N=17   |
|--------------------------------|---------------|------------------|
| Duration category, n (%)       |               |                  |
| <3 months                      | 15 (27.8)     | 5 (29.4)         |
| 3 -<6 months                   | 4 (7.4)       | 0                |
| 6 -<9 months                   | 4 (7.4)       | 1 (5.9)          |
| 9 -<12 months                  | 5 (9.3)       | 2 (11.8)         |
| 12 -<15 months                 | 1 (1.9)       | 0                |
| 15 -<18 months                 | 2 (3.7)       | 1 (5.9)          |
| 18 -<21 months                 | 4 (7.4)       | 2 (11.8)         |
| 21 -<24 months                 | 9 (16.7)      | 3 (17.6)         |
| ≥24 months                     | 10 (18.5)     | 3 (17.6)         |
| Duration of treatment (months) |               |                  |
| Mean                           | 13.84         | 14.16            |
| Median                         | 10.18         | 17.41            |
| Range                          | (0.07, 35.68) | (0.07, 29.07)    |

Source: Table 14.4.1.1.1

This table is based on descriptive statistics.

The duration of treatment was calculated as (Last dose date - Cycle 1 Day 1 + 1) / 30.44.

Abbreviations: n/N=number of patients; QD=once daily

Table 67: Drug administration (Phase 1) - safety population

|                              | Total N=54        | 100 mg QD N=17   |
|------------------------------|-------------------|------------------|
| Relative Dose Intensitya (%) |                   |                  |
| Median                       | 99.18             | 98.77            |
| Range                        | (14.29 - 483.10)d | (70.67 - 100.00) |
| Dose reductionsb, n (%)      | 14 (25.9)         | 0                |
| Dose delays , n (%)          | 44 (81.5)         | 13 (76.5)        |

Source: Tables 14.4.1.3.1 and Table 14.4.1.4.1

Abbreviations: n/N=number of patients

a. Relative dose intensity (%) = 100 x (overall actual total dose) / (intended total dose per day x number of days from Cycle 1 Day 1 to last dose of study drug).

b. Dose reduction: Prescribed dose is less than previously prescribed dose

c. Dose delay: Any O mg dose administered for any duration of time or dose missed on unknown dates

- d. Dose increases occurred due to intra-patient dose escalation beyond the initial assigned dose resulting in more than 100% overall relative dose intensity (Table 16.2.5.1.2.1).

The median duration of treatment was 16.33 months in Phase 2 patients. The number of patients still receiving study treatment is 130 (44.1%).

Table 68: Duration of treatment (Phase 2) - safety population

|                               | EXP-1 (N=30)   | EXP-2 (N=27)   | EXP-3 (N=60)   | EXP-4 (N=65)   | EXP-5 (N=46)   | EXP-6 (N=47)   | Total (N=275)   |
|-------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|-----------------|
| Duration category, n (%)      |                |                |                |                |                |                |                 |
| <3 months                     | 1 (3.3)        | 2 (7.4)        | 13 (21.7)      | 12 (18.5)      | 12 (26.1)      | 11 (23.4)      | 51 (18.5)       |
| 3 -<6 months                  | 2 (6.7)        | 4 (14.8)       | 3 (5.0)        | 10 (15.4)      | 5 (10.9)       | 9 (19.1)       | 33 (12.0)       |
| 6 -<9 months                  | 10 (33.3)      | 9 (33.3)       | 23 (38.3)      | 16 (24.6)      | 16 (34.8)      | 9 (19.1)       | 83 (30.2)       |
| 9 -<12 months                 | 9 (30.0)       | 6 (22.2)       | 11 (18.3)      | 9 (13.8)       | 8 (17.4)       | 6 (12.8)       | 49 (17.8)       |
| 12-<15 months                 | 2 (6.7)        | 3 (11.1)       | 4 (6.7)        | 10 (15.4)      | 2 (4.3)        | 5 (10.6)       | 26 (9.5)        |
| 15 -<18 months                | 6 (20.0)       | 3 (11.1)       | 6 (10.0)       | 8 (12.3)       | 3 (6.5)        | 7 (14.9)       | 33 (12.0)       |
| Duration of treatment(months) |                |                |                |                |                |                |                 |
| Mean                          | 10.17          | 8.75           | 7.77           | 8.15           | 7.06           | 7.92           | 8.13            |
| Median                        | 9.38           | 8.71           | 7.98           | 7.62           | 7.69           | 8.74           | 8.31            |
| Range                         | (1.68,         | (0.36,         | (0.26,         | (0.23,         | (0.39,         | (0.03,         | (0.03,          |
|                               | 17.08)         | 15.83)         | 17.77)         | 17.48)         | 17.28)         | 17.51)         | 17.77)          |

Source: Table 14.4.1.1.2

This table is based on descriptive statistics.

The duration of treatment was calculated as (Last dose date - Cycle 1 Day 1 + 1) / 30.44.

Abbreviations: n/N=number of patients.

<div style=\"page-break-after: always\"></div>

Table 69: Drug administration (Phase 2) - safety population

|                              | EXP-1 (N=30)    | EXP-2 (N=27)    | EXP-3 (N=60)     | EXP-4 (N=65)     | EXP-5 (N=46)    | EXP-6 (N=47)     | Total (N=275)    |
|------------------------------|-----------------|-----------------|------------------|------------------|-----------------|------------------|------------------|
| Relative Dose Intensitya (%) |                 |                 |                  |                  |                 |                  |                  |
| Median                       | 99.73           | 98.96           | 99.22            | 96.05            | 97.33           | 99.61            | 98.47            |
| Range                        | 63.94 -         | 23.38 -         | 48.92 -          | 30.95-           | 37.83 -         | 51.43 -          | 23.38 -          |
| Dose reductions,             | 100.00 8 (26.7) | 100.36 7 (25.9) | 104.17 15 (25.0) | 109.68 14 (21.5) | 100.00 8 (17.4) | 100.43 12 (25.5) | 109.68 64 (23.3) |
| n (%) Dose delays, n (%)     | 16 (53.3)       | 16 (59.3)       | 36 (60.0)        | 51 (78.5)        | 39 (84.8)       | 30 (63.8)        | 188 (68.4)       |

Source: Tables 14.4.1.3.2 and Table 14.4.1.4.2

Abbreviation: n/N=number of patients.

- a. Relative dose intensity (%) = 1o0 × (overall actual total dose) / (intended total dose per day x number of days from Cycle 1 Day 1 to last dose of study drug).
- b. Dose reduction: Prescribed dose is less than previously prescribed dose
- c. Dose delay: Any O mg dose administered for any duration of time or dose missed on unknown dates

In the Phase 1 part, only 17 of 41 patients were exposed to the proposed dose (100mg QD), but of these 12 patients were treated for more than 6 months at a high dose intensity 98.77% (range 70.67100.00).

Table 70: Duration of treatment (subjects starting lorlatinib 100 mg QD*) - Safety analysis set

|                                             | 100 mg QD (N=295)   | 100 mg QD (N=295)   |
|---------------------------------------------|---------------------|---------------------|
|                                             | n                   | (%)                 |
| Duration of Treatment (Months)-Category [1] |                     |                     |
| <3 Months                                   |                     | 56 (19.0)           |
| 3 Months <6Months                           |                     | 29 (9.8)            |
| 6 Months 9 Months                           | 25                  | (8.5)               |
| 9 Months <12 Months                         |                     | 19 ( 6.4)           |
| 12 Months <15 Months                        | 12                  | (4.1)               |
| 15 Months <18 Months                        |                     | 34 (11.5)           |
| 18 Months < 21 Months                       |                     | 62 (21.0)           |
| 21 Months <24 Months                        |                     | 13 (4.4)            |
| >=24 Months                                 |                     | 45  (15.3)          |
| Duration of Treatment (Months) [1]          |                     |                     |
| Mean                                        |                     | 13.78               |
| Median                                      |                     | 16.33               |
|                                             | (0.03,39.72)        |                     |
| Days on Drug (Months）-Category [2]          |                     |                     |
| <3 Months                                   | 58                  | (19.7)              |
| 3 Months <6 Months                          |                     | (11.2)              |
| 6 Months < 9Months                          | 22                  | (7.5)               |
| 9 Months 12 Months                          | 20                  | 6.8)                |
| 12 Months 15 Months                         | 16                  | (5.4)               |
| 15 Months < 18 Months                       | 42                  | (14.2)              |
| 18 Months 21 Months                         | 54                  | (18.3)              |
| 21 Months <24 Months                        | 10                  | (3.4)               |
| >= 24 Months                                | 40                  | (13.6)              |
| Days on Drug (Months）[2]                    |                     |                     |
| Mean                                        |                     | 13.21               |
| Median                                      |                     | 14.68               |
|                                             |                     | (0.03,39.65)        |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 71: Adverse Events (100-mg QD Pooled Group) - Safety Population

|                                                    | All-causality   | Treatment-Related   |
|----------------------------------------------------|-----------------|---------------------|
|                                                    | (N=295) n (%)   | (N=295) n (%)       |
| Patients evaluable for AEs                         | 295             | 295                 |
| Number of AEs                                      | 3392            | 1835                |
| Patients with AEs                                  | 294 (99.7)      | 280 (94.9)          |
| Patients with SAEs                                 | 98 (33.2)       | 20 (6.8)            |
| Patients with Grade 3 or 4 AEs                     | 184 (62.4)      | 121 (41.0)          |
| Patients with Grade 5 AEs                          | 33 (11.2)       | 0                   |
| Patients discontinued due to AEs                   | 21 (7.1) a      | 7 (2.4)             |
| Patients with dose reduction due to AEs            | 65 (22.0)       | 62 (21.0)           |
| Patients with temporary discontinuation due to AEs | 132 (44.7)      | 89 (30.2)           |

Source: Study 1001 Table 14.3.1.2.1.2.f1 and Table 14.3.1.3.1.2.f1

Abbreviation: AE=adverse event; n=number of patients; SAE=serious adverse event; N/n=number.

a. One (1) patient discontinued treatment due to progressive disease with fatigue being reported as an AE, which was mistakenly indicated as primary reason of discontinuation.

Table 72: All-Causality and Treatment-Related Adverse Events With Clustering by MedDRA Preferred Terms and Maximum CTCAE Grades (All Grades and Grades 3 and 4 by Decreasing Order of Frequency (&gt; 10%), All Cycles (100-mg QD Pooled Group) - Safety Population 100-mg QD pooled group (N=295)

|                                      | All-Causality   | All-Causality   | All-Causality   | Treatment-Related   | Treatment-Related   | Treatment-Related   |
|--------------------------------------|-----------------|-----------------|-----------------|---------------------|---------------------|---------------------|
| Preferred Term                       | All Grades      | Grade 3         | Grade 4         | All Grades          | Grade 3             | Grade 4             |
| Any AEs a                            | 294 (99.7)      | 131 (44.4)      | 24 (8.1)        | 280 (94.9)          | 107 (36.3)          | 14 (4.7)            |
| **HYPERCHOLESTEROLEMIA               | 243 (82.4)      | 41 (13.9)       | 5 (1.7)         | 241 (81.7)          | 40 (13.6)           | 5 (1.7)             |
| **HYPERTRIGLYCERIDEMIA               | 179 (60.7)      | 39 (13.2)       | 7 (2.4)         | 178 (60.3)          | 39 (13.2)           | 7 (2.4)             |
| **EDEMA                              | 151 (51.2)      | 7 (2.4)         | 0               | 129 (43.7)          | 6 (2.0)             | 0                   |
| **PERIPHERAL NEUROPATHY              | 129 (43.7)      | 7 (2.4)         | 0               | 88 (29.8)           | 5 (1.7)             | 0                   |
| Dyspnoea                             | 69 (23.4)       | 11 (3.7)        | 3 (1.0)         | 9 (3.1)             | 1 (0.3)             | 0                   |
| **COGNITIVE EFFECTS                  | 68 (23.1)       | 5 (1.7)         | 0               | 53 (18.0)           | 4 (1.4)             | 0                   |
| **FATIGUE                            | 68 (23.1)       | 1 (0.3)         | 0               | 39 (13.2)           | 1 (0.3)             | 0                   |
| **MOOD EFFECTS                       | 62 (21.0)       | 4 (1.4)         | 0               | 43 (14.6)           | 2 (0.7)             | 0                   |
| Weight increased                     | 61 (20.7)       | 7 (2.4)         | 0               | 54 (18.3)           | 6 (2.0)             | 0                   |
| Arthralgia                           | 58 (19.7)       | 0               | 0               | 30 (10.2)           | 0                   | 0                   |
| Diarrhoea                            | 52 (17.6)       | 2 (0.7)         | 0               | 30 (10.2)           | 1 (0.3)             | 0                   |
| Cough                                | 48 (16.3)       | 0               | 0               | 3 (1.0)             | 0                   | 0                   |
| Dizziness                            | 44 (14.9)       | 2 (0.7)         | 0               | 25 (8.5)            | 2 (0.7)             | 0                   |
| Headache                             | 44 (14.9)       | 2 (0.7)         | 0               | 16 (5.4)            | 0                   | 0                   |
| Nausea                               | 43 (14.6)       | 1 (0.3)         | 1 (0.3)         | 23 (7.8)            | 0                   | 0                   |
| Constipation                         | 42 (14.2)       | 0               | 0               | 24 (8.1)            | 0                   | 0                   |
| **VISION DISORDER                    | 39 (13.2)       | 1 (0.3)         | 0               | 21 (7.1)            | 0                   | 0                   |
| Anaemia                              | 37 (12.5)       | 9 (3.1)         | 0               | 18 (6.1)            | 2 (0.7)             | 0                   |
| Aspartate aminotransferase increased | 35 (11.9)       | 2 (0.7)         | 1 (0.3)         | 31 (10.5)           | 1 (0.3)             | 0                   |
| Back pain                            | 35 (11.9)       | 2 (0.7)         | 0               | 5 (1.7)             | 0                   | 0                   |
| Alanine aminotransferase increased   | 33 (11.2)       | 2 (0.7)         | 1 (0.3)         | 28 (9.5)            | 2 (0.7)             | 0                   |
| Pain in extremity                    | 33 (11.2)       | 0               | 0               | 12 (4.1)            | 0                   | 0                   |
| Lipase increased                     | 32 (10.8)       | 15 (5.1)        | 4 (1.4)         | 22 (7.5)            | 10 (3.4)            | 1 (0.3)             |
| Myalgia                              | 31 (10.5)       | 0               | 0               | 18 (6.1)            | 0                   | 0                   |

Source: Study Table 14.3.1.2.9.1.2.2.2.f1 and Table 14.3.1.3.9.1.2.2.2.f1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities; N/n=number of patients.

Most (25/33) patients who had a Grade 5 event in Phase 2 were due to Disease Progression. Details on remaining patients can be found in Section 2.7.4.2.1.2

* =Cluster terms as indicated (see Table 84)

a= Total number independent of frequency cutoff used in the title

Additional all-causality  Grade 3 /4 events (&gt;2 patients) not listed in the table were:  Vomiting (3 patients Grade 3), Hyperglycaemia (7 patients Grade 3), Hypertension (10 patients,  Grade 3), Pleural effusion (8 patients Grade 3), Pneumonia (7 patients Grade 3), Abdominal pain (3 patients, Grade 3), Hypophosphatemia (6 patients, Grade 3), Fall (3 patients, Grade 3), Hypoxia (4 patients, Grade 3, 1 patient Grade 4), Pericardial effusion 3 patients, Grade 3), Mental status change (4 patients, Grade 3), Pulmonary embolism (4 patients, Grade 3), Respiratory failure (3 patients Grade 3, 2 patients, Grade 4), Superior vena cava syndrome (3 patients, Grade 3), Sepsis (3 patients Grade 4), Amylase increased (7 patients Grade 3 and 1 patient Grade 4), Acute respiratory failure (2 patients Grade 3 and 2 patients Grade 4).

<div style=\"page-break-after: always\"></div>

## Adverse drug reactions (ADRs)

ADRs were identified based on internal clinical and safety review of available safety data and included AEs and cluster terms of Study 1001 considered as associated to lorlatinib (as listed in the table below)

Table 73: Adverse Drug Reactions in 295 Patients with ALK-positive or ROS1-positive Advanced NSCLC who Received Lorlatinib 100 mg QD in Study B7461001 - Safety Update

| System organ class and adverse reaction              | Frequency category   | All Grades   | Grades 3-4   |
|------------------------------------------------------|----------------------|--------------|--------------|
| Blood and lymphatic system disorders Anaemia         | Very common          | 15.9         | 5.1          |
| Metabolism and nutrition disorders                   |                      |              |              |
| Hypercholesterolaemia a                              | Very common          | 84.4         | 16.6         |
| Hypertriglyceridaemia b                              | Very common          | 67.1         | 16.6         |
| Psychiatric disorders                                |                      |              |              |
| Mood effects c                                       | Very common          | 22.7         | 1.7          |
| Hallucinations d                                     | Common               | 7.8          | 1.0          |
| Nervous system disorders                             |                      |              |              |
| Cognitive effects e                                  | Very common          | 28.8         | 2.0          |
| Peripheral neuropathy f                              | Very common          | 47.8         | 2.7          |
| Headache                                             | Very common          | 18.0         | 0.7          |
| Speech effects g                                     | Common               | 9.8          | 0.3          |
| Eye disorders                                        |                      |              |              |
| Vision disorder h                                    | Very common          | 15.3         | 0.3          |
| Gastrointestinal disorders                           |                      |              |              |
| Diarrhoea                                            | Very common          | 22.7         | 1.0          |
| Nausea                                               | Very common          | 18.3         | 0.7          |
| Constipation                                         | Very common          | 15.9         | 0            |
| Musculoskeletal and connective tissue                |                      |              |              |
| disorders Arthralgia                                 | Very common          | 24.7         | 0.7          |
| Myalgia i                                            | Very common          | 19.3         | 0            |
| General disorders and administration site conditions |                      |              |              |
| Oedema j                                             | Very common          | 54.6         | 2.4          |
| Fatigue k                                            | Very common          | 28.1         | 0.7          |
| Investigations                                       |                      |              |              |
| Weight increased                                     | Very common          | 26.4         | 5.4          |
| Lipase increased                                     | Very common          | 13.9         | 8.8          |
| Amylase increased                                    | Very common          | 10.2         | 3.1          |
| Electrocardiogram PR prolongation                    | Uncommon             | 0.7          | 0            |
| Respiratory, thoracic and mediastinal disorders      |                      |              |              |
| Pneumonitis l                                        | Common               | 1.4          | 1.0          |
| Skin and subcutaneous tissue disorders Rash m        | Very common          | 14.2         | 0.3          |

Adverse reactions that represent the same medical concept or condition were grouped together and reported as a single adverse reaction in the table above. Terms actually reported in the studies and contributing to the relevant adverse reaction are indicated in parentheses, as listed below.

- a Hypercholesterolaemia (including blood cholesterol increased, hypercholesterolaemia).

b Hypertriglyceridaemia (including blood triglycerides increased, hypertriglyceridaemia).

- c Mood effects (including affective disorder, affect lability, aggression, agitation, anxiety, depressed mood, depression, euphoric mood, irritability, mania, mood altered, mood swings, personality change, stress).
- d Hallucinations (including hallucination, auditory hallucination, visual hallucination)
- e Cognitive effects (including events from SOC Nervous system disorders: amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment; and also including events from SOC Psychiatric disorders: attention deficit/hyperactivity disorder, confusional state, delirium, disorientation,  reading disorder). Within these effects, terms from SOC Nervous system disorders were more frequently reported than terms from SOC Psychiatric disorder.
- f Peripheral neuropathy (including burning sensation, carpal tunnel syndrome, dysaesthesia, formication, gait disturbance, hypoaesthesia, muscular weakness, neuralgia, neuropathy peripheral, neurotoxicity, paraesthesia, peripheral sensory neuropathy, peroneal nerve palsy, sensory disturbance).
- g Speech effects (dysarthria, slow speech, speech disorder).
- h Vision disorder (including diplopia, photophobia, photopsia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters).
- i Myalgia (including musculoskeletal pain, myalgia)
- j Oedema (including generalised oedema, oedema, oedema peripheral, peripheral swelling, swelling).
- k Fatigue (including asthenia, fatigue).
- l Pneumonitis (including interstitial lung disease, pneumonitis).
- m Rash (including dermatitis acneiform, maculopapular rash, pruritic rash, rash).

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

Table 74: Prevalence of Treatment-Emergent Adverse Events for Individual MedDRA Preferred Terms and Cluster Terms of Special Interest by Preferred Term and Maximum CTCAE Grade (All-causality, by Cycle) (Phase 2) - Safety Population

|                                     | Cycle 1 N=274   | Cycle 2 N=263   | Cycle 3 N=250   | Cycle 4 N=238   | Cycle 5 N=225   | Cycle 6 N=218   | Cycle 7 N=210   | Cycle  8 N=208   |
|-------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------|
| HYPERCHOLESTEROLEMIA*               | 180 (65.7)      | 202 (76.8)      | 193 (77.2)      | 182 (76.5)      | 175 (77.8)      | 174 (79.8)      | 167 (79.5)      | 172 (82.7)        |
| HYPERTRIGLYCERIDEMIA*               | 115 (42.0)      | 131 (49.8)      | 133 (53.2)      | 131 (55.0)      | 123 (54.7)      | 126 (57.8)      | 119 (56.7)      | 130 (62.5)        |
| EDEMA*                              | 42 (15.3)       | 65 (24.7)       | 81 (32.4)       | 90 (37.8)       | 93 (41.3)       | 91 (41.7)       | 80 (38.1)       | 95 (45.7)         |
| PERIPHERAL NEUROPATHY*              | 15 (5.5)        | 26 (9.9)        | 36 (14.4)       | 57 (23.9)       | 64 (28.4)       | 64 (29.4)       | 74 (35.2)       | 98 (47.1)         |
| COGNITIVE EFFECTS*                  | 19 (6.9)        | 21 (8.0)        | 26 (10.4)       | 30 (12.6)       | 30 (13.3)       | 32 (14.7)       | 30 (14.3)       | 49 (23.6)         |
| MOOD EFFECTS*                       | 18 (6.6)        | 20 (7.6)        | 27 (10.8)       | 27 (11.3)       | 25 (11.1)       | 22 (10.1)       | 25 (11.9)       | 32 (15.4)         |
| SPEECH EFFECTS*                     | 8 (2.9)         | 7 (2.7)         | 9 (3.6)         | 12 (5.0)        | 14 (6.2)        | 11 (5.0)        | 8 (3.8)         | 12 (5.8)          |
| Weight increased                    | 11 (4.0)        | 15 (5.7)        | 23 (9.2)        | 31 (13.0)       | 33 (14.7)       | 36 (16.5)       | 39 (18.6)       | 48 (23.1)         |
| VISION DISORDER*                    | 12 (4.4)        | 10 (3.8)        | 9 (3.6)         | 12 (5.0)        | 12 (5.3)        | 13 (6.0)        | 13 (6.2)        | 23 (11.1)         |
| Hepatic enzyme increased            | 0               | 0               | 1 (0.4)         | 1 (0.4)         | 0               | 0               | 0               | 0                 |
| Electrocardiogram QT prolonged      | 10 (3.6)        | 12 (4.6)        | 16 (6.4)        | 11 (4.6)        | 9 (4.0)         | 8 (3.7)         | 8 (3.8)         | 8 (3.8)           |
| Interstitial lung disease           | 0               | 0               | 0               | 1 (0.4)         | 0               | 0               | 0               | 0                 |
| Pneumonitis                         | 0               | 1 (0.4)         | 0               | 1 (0.4)         | 0               | 1 (0.5)         | 0               | 0                 |
| Atrioventricular block first degree | 1 (0.4)         | 1 (0.4)         | 1 (0.4)         | 1 (0.4)         | 2 (0.9)         | 2 (0.9)         | 1 (0.5)         | 1 (0.5)           |
| Atrioventricular block complete     | 1 (0.4)         | 0               | 0               | 0               | 0               | 0               | 0               | 0                 |
| Pancreatitis                        | 0               | 0               | 1 (0.4)         | 0               | 0               | 0               | 0               | 0                 |

*=cluster terms as indicated

Abbreviation:  N=number, AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities

## Hyperlipidaemia

Table 75: Summary of Treatment-Emergent Hyperlipidaemia Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (Phase 1) - All-causality and Treatment-related - Safety Population

|                               | N = 54        | N = 54        | N = 54          | N = 54          | N = 54            | N = 54            | N = 54            | N = 54            |
|-------------------------------|---------------|---------------|-----------------|-----------------|-------------------|-------------------|-------------------|-------------------|
|                               | All-Causality | All-Causality | All-Causality   | All-Causality   | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related |
|                               | All Grades    | All Grades    | Grade 3 Grade 4 | Grade 3 Grade 4 | All Grades        | All Grades        | Grade 3 Grade 4   | Grade 3 Grade 4   |
| PT                            | n             | (%)           | n (%)           | n (%)           | n                 | (%)               | (%)               | n (%)             |
| Any AEs                       | 41            | (75.9)        | 7 (13.0)        | 4 (7.4)         | 40                | (74.1)            | (14.8)            | 3 (5.6)           |
| Hypercholesterolaemia         | 31            | (57.4)        | 3 (5.6)         | 3 (5.6)         | 30                | (55.6)            | (5.6)             | 3 (5.6)           |
| Hypertriglyceridaemia         | 17            | (31.5)        | 3 (5.6)         | 1 (1.9)         | 17                | (31.5)            | (3.7)             | 0 (0.0)           |
| Blood cholesterol increased   | 11            | (20.4)        | 1 (1.9)         | 0 (0.0)         | 11                | (20.4)            | (1.9)             | 0 (0.0)           |
| Blood triglycerides increased | 8             | (14.8)        | 2 (3.7)         | 0 (0.0)         | 8                 | (14.8)            | (3.7)             | 0 (0.0)           |

Source: Study 1001 CSR Table 14.3.1.2.9.1.2.4.1 and  Table 14.3.1.3.9.1.2.4.1

AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number

<div style=\"page-break-after: always\"></div>

Table 76: Summary of Treatment-Emergent Hyperlipidemia Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency(All Cycles) (Phase 2) - All-causality and Treatment-related - Safety Population

|                               | N = 275       | N = 275       | N = 275       | N = 275       | N = 275       | N = 275       | N = 275           | N = 275           | N = 275           | N = 275           | N = 275           | N = 275           |
|-------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                               | All-Causality | All-Causality | All-Causality | All-Causality | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related |
|                               | All Grades    | All Grades    | Grade 3       | Grade 3       | Grade 4       | Grade 4       | All Grades        | All Grades        | Grade 3           | Grade 3           | Grade 4           | Grade 4           |
| PT                            | n             | (%)           | n             | (%)           | n             | (%)           | n                 | (%)               | n                 | (%)               | n                 | (%)               |
| Any AEs                       | 236           | (85.8)        | 61            | (22.2)        | 10            | (3.6)         | 234               | (85.1)            | 60                | (21.8)            | 10                | (3.6)             |
| Hypertriglyceridaemia         | 155           | (56.4)        | 35            | (12.7)        | 7             | (2.5)         | 154               | (56.0)            | 35                | (12.7)            | 7                 | (2.5)             |
| Hypercholesterolaemia         | 145           | (52.7)        | 26            | (9.5)         | 1             | (0.4)         | 144               | (52.4)            | 25                | (9.1)             | 1                 | (0.4)             |
| Blood cholesterol increased   | 96            | (34.9)        | 16            | (5.8)         | 3             | (1.1)         | 96                | (34.9)            | 16                | (5.8)             | 3                 | (1.1)             |
| Blood triglycerides increased | 17            | (6.2)         | 2             | (0.7)         | 1             | (0.4)         | 17                | (6.2)             | 2                 | (0.7)             | 1                 | (0.4)             |

Source: Study 1001 CSR Table 14.3.1.2.9.1.2.4.2 and  Table 14.3.1.3.9.1.2.4.2

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs, MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number

Table 77: Descriptive Summary of Time to Medication to Lower Cholesterol and/ or Triglycerides (Phase 1 and Phase 2) - Safety Population Time to Start (in Days) n (%) Mean SD Median

| Time to Start (in Days)                              | n (%)      | Mean   | SD    | Median   | Min, Max   |
|------------------------------------------------------|------------|--------|-------|----------|------------|
| Phase 1 (N=54)                                       |            |        |       |          |            |
| Medication to Lower Cholesterol and/ or Triglyceride | 39 (72.2)  | 65.2   | 99.67 | 28       | (8, 580)   |
| Phase 2 (N=275)                                      |            |        |       |          |            |
| Medication to Lower Cholesterol and/ or Triglyceride | 222 (80.7) | 27.3   | 27.07 | 18       | (1, 190)   |
| 100-mg QD pooled group (N=295)                       |            |        |       |          |            |
| Medication to Lower Cholesterol and/ or Triglyceride | 239 (81.0) | 27.3   | 26.92 | 20       | (1, 190)   |

Source:  Study 1001 CSR Table 14.4.2.4.1 and Table 14.4.2.4.2

Medication used to lower cholesterol and/or triglycerides list: Atorvastatin, Atorvastatin Calcium, Bezafibrate, Ezetimibe, Fenofibrate, Fish Oil, Gemfibrozil, Inegy, Lovastatin, Nicotinic Acid, Omega-3 Triglycerides, Omega-3-Acid Ethyl Ester, Pitavastatin, Pitavastatin Calcium, Pravastatin, Pravastatin Sodium, Rosuvastatin, Rosuvastatin Calcium, Simvastatin, Tocopheryl Nicotinate.

Time to start of medication to lower cholesterol and/or triglycerides is calculated from Day -7 and/or C1D1 if this is the first dose, to the start of relevant medications.

Abbreviation: N/n=number; SD=standard deviation; min=minimum; max=maximum

Table 78: Summary of Treatment-Emergent Hyperlipidaemia* Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (100-mg QD Pooled Group) - All-causality and Treatment-related - Safety Population - Data cutoff date: 02 February 2018

|                               | N=295         | N=295         | N=295         | N=295             | N=295             | N=295             |
|-------------------------------|---------------|---------------|---------------|-------------------|-------------------|-------------------|
|                               | All-Causality | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
|                               | AllGrades     | Grade3        | Grade4        | AllGrades         | Grade3            | Grade 4           |
| PT                            | n (%)         | n (%)         | n (%)         | n (%)             | n (%)             | n (%)             |
| Any AEs                       | 259 (87.8)    | 67 (22.7)     | 13 (4.4)      | 256 (86.8)        | 67 (22.7)         | 12 (4.1)          |
| Hypertriglyceridaemia         | 183 (62.0)    | 39 (13.2)     | 8 (2.7)       | 181 (61.4)        | 39 (13.2)         | 8 (2.7)           |
| Hypercholesterolaemia         | 164 (55.6)    | 28 (9.5)      | 3 (1.0)       | 162 (54.9)        | 28 (9.5)          | 2 (0.7)           |
| Bloodcholesterolincreased     | 103 (34.9)    | 16 (5.4)      | 3 (1.0)       | 103 (34.9)        | 16 (5.4)          | 3 (1.0)           |
| Blood triglycerides increased | 21 (7.1)      | 3 (1.0)       | 1 (0.3)       | 21 (7.1)          | 3 (1.0)           | 1 (0.3)           |

Source:Table14.3.1.2.9.1.2.4.2.ema.1andTable14.3.1.3.9.1.2.4.2.ema.1

Abbreviations:AE=adverseevent;CTCAE=CommonTerminologyCriteriaforAEs,MedDRA=Medical

DictionaryforRegulatoryActivities,PT=preferred term,N/n=number,QD=oncedaily.

*Hyperlipidemia includes the cluster terms ofHYPERCHOLESTEROLEMIA and

HYPERTRIGLYCERIDEMIA

Overall in the 100-mg QD pooled group (n=295), 76.3% of patients were treated with lipid-lowering therapy only; however, in 19.0% and 38.4% of subjects with hypercholesterolemia or hypertriglyceridemia respectively, the AE did not resolve.

The  median  time  to  increased  levels  of  cholesterol  values  of  500  mg/dL  or  higher  and  blood triglycerides values of 1,000 mg/dl or higher was 201 days (range 42 - 518 days) and 127 days (range 15 - 358 days), respectively.

<div style=\"page-break-after: always\"></div>

## Oedema

Table 79: Summary of Treatment-Emergent OEDEMA Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (100-mg QD Pooled Group) - All-causality and Treatment-related -Safety Population

|                     | N = 295       | N = 295       | N = 295       | N = 295       | N = 295           | N = 295           | N = 295           | N = 295           | N = 295           |
|---------------------|---------------|---------------|---------------|---------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                     | All-Causality | All-Causality | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related | Treatment-Related |
|                     | All Grades    | All Grades    | Grade 3       | Grade 4       | All Grades        | All Grades        | Grade 3           | Grade 3           | Grade 4           |
| PT                  | n             | (%)           | n (%)         | n (%)         | n                 | (%)               | n                 | (%)               | n (%)             |
| Any AEs             | 151           | (51.2)        | 7 (2.4)       | 0 (0.0)       | 129               | (43.7)            | 6                 | (2.0)             | 0 (0.0)           |
| Oedema peripheral   | 123           | (41.7)        | 4 (1.4)       | 0 (0.0)       | 105               | (35.6)            | 4                 | (1.4)             | 0 (0.0)           |
| Oedema              | 22            | (7.5)         | 2 (0.7)       | 0 (0.0)       | 19                | (6.4)             | 2                 | (0.7)             | 0 (0.0)           |
| Peripheral swelling | 18            | (6.1)         | 1 (0.3)       | 0 (0.0)       | 13                | (4.4)             | 0                 | (0.0)             | 0 (0.0)           |
| Generalised oedema  | 2             | (0.7)         | 1 (0.3)       | 0 (0.0)       | 2                 | (0.7)             | 1                 | (0.3)             | 0 (0.0)           |
| Swelling            | 2             | (0.7)         | 0 (0.0)       | 0 (0.0)       | 0                 | 0                 | 0                 | 0                 | 0 0               |

Source: Study 1001 SCS Table 14.3.1.2.9.1.2.10.2.f1 and Table 14.3.1.3.9.1.2.10.2.f1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number

## Peripheral neuropathy

Table 80: Summary of Treatment-Emergent Peripheral Neuropathy Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles, all causality) (100-mg QD Pooled Group) - All-causality and Treatment-related Safety Population - Data cutoff date: 02 February 2018

|                               | (N = 295)        | (N = 295)     | (N = 295)     | (N = 295)         | (N = 295)         | (N = 295)         |
|-------------------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
|                               | All-Causality    | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
| PT                            | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | All Grades n (%)  | Grade 3 n (%)     | Grade 4 n (%)     |
| Any AEs                       | 141 (47.8)       | 8 (2.7)       | 0             | 99 (33.6)         | 6 (2.0)           | 0                 |
| Paraesthesia                  | 42 (14.2)        | 1 (0.3)       | 0             | 31 (10.5)         | 1 (0.3)           | 0                 |
| Neuropathy peripheral         | 39 (13.2)        | 3 (1.0)       | 0             | 34 (11.5)         | 3 (1.0)           | 0                 |
| Peripheral sensory neuropathy | 28 (9.5)         | 1 (0.3)       | 0             | 24 (8.1)          | 1 (0.3)           | 0                 |
| Muscular weakness             | 17 (5.8)         | 1 (0.3)       | 0             | 3 (1.0)           | 0                 | 0                 |
| Gait disturbance              | 14 (4.7)         | 1 (0.3)       | 0             | 2 (0.7)           | 0                 | 0                 |
| Carpal tunnel syndrome        | 10 (3.4)         | 1 (0.3)       | 0             | 4 (1.4)           | 1 (0.3)           | 0                 |
| Hypoaesthesia                 | 10 (3.4)         | 0             | 0             | 7 (2.4)           | 0                 | 0                 |
| Dysaesthesia                  | 6 (2.0)          | 0             | 0             | 4 (1.4)           | 0                 | 0                 |
| Neuralgia                     | 3 (1.0)          | 1 (0.3)       | 0             | 1 (0.3)           | 1 (0.3)           | 0                 |
| Neurotoxicity                 | 3 (1.0)          | 0             | 0             | 3 (1.0)           | 0                 | 0                 |
| Burning sensation             | 1 (0.3)          | 0             | 0             | 1 (0.3)           | 0                 | 0                 |
| Formication                   | 1 (0.3)          | 0             | 0             | 1 (0.3)           | 0                 | 0                 |
| Peroneal nervepalsy           | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |
| Sensory disturbance           | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |

Source:Table14.3.1.2.9.1.2.3.2.ema.1andTable14.3.1.3.9.1.2.3.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number, QD=once daily, SCS=summary of clinical safety, SU=safety update.

Events of neuropathy were frequent both in Phase 1 and 2, however, high-grade events were rare. Median time to PERIPHERAL NEUROPATHY was 85 days (range, 1-723) and the median duration was 258 days (range 1-1041) in the 100mg group. Updated data showed a small increase of treatmentrelated AEs.

## Central nervous system (CNS) effects

Events  of  cognitive  effects  were  frequent  in  all  grades  in  the  Phase  1  part  and  most  events  were considered  treatment-related.  Even  though  high-grade  events  were  rare,  a  quarter  of  the  patients were affected and many PTs were used.

An analysis of CNS effects was submitted identifying 4 defined patient populations:

- Group A Patients who reported any Grade (1-4) of Cognitive Effects AEs.

<div style=\"page-break-after: always\"></div>

- Subgroup A1  Patients who reported maximum Grade 1 or 2 of Cognitive Effects AEs.
- Subgroup A2  Patients who reported maximum Grade 3 or 4 of Cognitive Effects AEs.
- Group B Patients who reported no Cognitive Effects AEs (control group).

Patients for whom cognitive effect adverse events were reported were not systematically evaluated for radiological alterations, as the focus of the radiological evaluation was on changes in tumour growth. There were no spontaneous reports of radiological alterations in patients with cognitive effect adverse events.

<!-- image -->

BL*- Baseline is defined as the last PRO assessment prior to first dose, which could be day -7 or C1D1 window. The visit label and visit windows are applied for the analysis of the PRO endpoints. In the case of multiple records for a patient within a particular visit window, then use the assessment which is closest to the target day. Group A is defined as patients who reported any Grade(1-4) of Cognitive Effects AEs. Group B is defined as patients who reported no Cognitive Effects AEs. N1 and N2 are numbers of subjects at risk for Group A and B respectively. It is defined as the number of subjects who completed the scale at baseline and at the respective cycle. A questionnaire is considered complete if at least one question is answered regardless of whether DONE/NOT DONE is checked in the CRF page. Mean Change (+/-) SE was truncated to be in [-100,100]. Figures drawn on a scale of [-100,100] to show trends. In the unlikely event that both (or all) the records are equidistant from the target day the patient's last assessment within that visit window was used.

Source: Module 5.3.5.3 D120 Supporting Table ema.175.1

## Figure 31: Plot of Mean Change from Baseline (+/-) SE over time for EORTC QLQ-C30 Cognitive Function (Group A and B) - PRO Evaluable Population, Pooled EXP-1: EXP-6

Comparable degree of variation  in  emotional  functioning  can  be  observed  between  the  2  groups  of people who either suffered or not AEs within the category of mood effects.

<div style=\"page-break-after: always\"></div>

Table 81: Summary of EORTC QLQ-C30 Cognitive Function Scales Change (Group A, A1, A2 and B) - PRO Evaluable Population, Pooled EXP-1:EXP-6

|                       |         | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   | PooledEXP-1:EXP-6(N=255)   |
|-----------------------|---------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                       |         | Improved [1]               | Improved [1]               | Stable [2]                 | Stable [2]                 | Worsening [3]              | Worsening [3]              |                            |                            |
| Functionalscales      |         | n                          | （%)                        | n                          | （%)                        | n                          | （%)                        | n                          | Missing （%)                |
| Cognitive functioning | Group A | 19                         | 7.5)                       | 28                         | (11.0)                     | 28                         | (11.0)                     | 0                          | 0.0)                       |
|                       | GroupA1 | 17                         | (6.7)                      | 26                         | (10.2)                     | 27                         | (10.6)                     | 0                          | (0.0)                      |
|                       | GroupA2 | 2                          | (0.8)                      | 2                          | (0.8)                      | 1                          | (0.4)                      | 0                          | (0.0)                      |
|                       | Group B | 38                         | (14.9)                     | 107                        | (42.0)                     | 34                         | (13.3)                     | 1                          | 0.4)                       |

% = (n/N)*100. n is the number of distinct patients who met the scale change criterion. N is the number of subjects in PRO population with mean scale scores. A Questionnaire is considered complete if at least one question is answered regardless of whether DONE/NOT DONE is checked in the CRF page. In the case of multiple records for a patient within a particular visit window, use the assessment which is closest to the target day. In the unlikely event that both (or all) the records are equidistant from the target day, use the patient's last assessment within that visit window. [1]In the functioning scales improvement is defined as an increase of at least 10 points. [2]Not improved nor worsened will be considered 'stable'. [3]Worsening is defined as a decrease of at least 10 points. Group A is defined as patients who reported any Grade(1-4) of Cognitive Effects AEs. Group A1 is defined as patients who reported maximum Grade 1 or 2 of Cognitive Effects AEs. Group A2 is defined as patients who reported maximum Grade 3 or 4 of Cognitive Effects AEs. Group B is defined as patients who reported no Cognitive Effects AEs.

Source: Module 5.3.5.3 D120 Supporting Table ema.175.3

A  &gt;10-point  decline  in  patient-reported  cognitive  function  was  detected  in  37.3%  of  cases  among subjects with Cognitive Effect AEs (Group A), compared to 19.0% in Group B.

Table 82: Summary of Treatment-Emergent COGNITIVE EFFECTS Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (100-mg QD Pooled Group) - All-causality and Treatment-related - Safety Population - Data cutoff date: 02 February 2018

|                                           | (N = 295)        | (N = 295)     | (N = 295)     | (N = 295)         | (N = 295)         | (N = 295)         |
|-------------------------------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
|                                           | All-Causality    | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
| PT                                        | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | All Grades n (%)  | Grade 3 n (%)     | Grade 4 n (%)     |
| Any AEs                                   | 85 (28.8)        | 6 (2.0)       | 0             | 68 (23.1)         | 4 (1.4)           | 0                 |
| Memory impairment                         | 34 (11.5)        | 0             | 0             | 29 (9.8)          | 0                 | 0                 |
| Amnesia                                   | 25 (8.5)         | 0             | 0             | 21 (7.1)          | 0                 | 0                 |
| Cognitive disorder                        | 21 (7.1)         | 2 (0.7)       | 0             | 19 (6.4)          | 2 (0.7)           | 0                 |
| Confusional state                         | 13 (4.4)         | 2 (0.7)       | 0             | 5 (1.7)           | 1 (0.3)           | 0                 |
| Disturbance in attention                  | 10 (3.4)         | 0             | 0             | 10 (3.4)          | 0                 | 0                 |
| Delirium                                  | 3 (1.0)          | 1 (0.3)       | 0             | 1 (0.3)           | 1 (0.3)           | 0                 |
| Mental impairment                         | 3 (1.0)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |
| Attention deficit/ hyperactivity disorder | 2 (0.7)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |
| Dementia                                  | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |
| Disorientation                            | 1 (0.3)          | 1 (0.3)       | 0             | 0                 | 0                 | 0                 |
| Reading disorder                          | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |

Source: Table 14.3.1.2.9.1.2.7.2.ema.1 and Table 14.3.1.3.9.1.2.7.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number, QD=once daily, SCS=summary of clinical safety, SU=safety update.

<div style=\"page-break-after: always\"></div>

## Mood effects

Table 83: Summary of Treatment-Emergent MOOD EFFECTS Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (100-mg QD Pooled Group) - All-causality and Treatment-related - Safety Population - Data cutoff date: 02 February 2018

|                    | (N = 295)        | (N = 295)     | (N = 295)     | (N = 295)         | (N = 295)         | (N = 295)         |
|--------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
|                    | All-Causality    | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
| PT                 | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | All Grades n (%)  | Grade 3 n (%)     | Grade 4 n (%)     |
| Any AEs            | 67 (22.7)        | 5 (1.7)       | 0             | 46 (15.6)         | 3 (1.0)           | 0                 |
| Irritability       | 18 (6.1)         | 3 (1.0)       | 0             | 17 (5.8)          | 2 (0.7)           | 0                 |
| Anxiety            | 17 (5.8)         | 1 (0.3)       | 0             | 4 (1.4)           | 0                 | 0                 |
| Depression         | 16 (5.4)         | 2 (0.7)       | 0             | 11 (3.7)          | 2 (0.7)           | 0                 |
| Affect lability    | 7 (2.4)          | 0             | 0             | 6 (2.0)           | 0                 | 0                 |
| Affective disorder | 5 (1.7)          | 0             | 0             | 4 (1.4)           | 0                 | 0                 |
| Personality change | 5 (1.7)          | 0             | 0             | 4 (1.4)           | 0                 | 0                 |
| Mood altered       | 4 (1.4)          | 0             | 0             | 3 (1.0)           | 0                 | 0                 |
| Agitation          | 3 (1.0)          | 1 (0.3)       | 0             | 2 (0.7)           | 1 (0.3)           | 0                 |
| Mood swings        | 3 (1.0)          | 0             | 0             | 3 (1.0)           | 0                 | 0                 |
| Aggression         | 2 (0.7)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |
| Depressed mood     | 2 (0.7)          | 0             | 0             | 1 (0.3)           | 0                 | 0                 |
| Euphoric mood      | 1 (0.3)          | 0             | 0             | 1 (0.3)           | 0                 | 0                 |
| Mania              | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |
| Stress             | 1 (0.3)          | 0             | 0             | 0                 | 0                 | 0                 |

Source: Table 14.3.1.2.9.1.2.5.2.ema.1 and Table 14.3.1.3.9.1.2.5.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number, QD=once daily, SCS=summary of clinical safety, SU=safety update.

## Speech effects

Table 84: Summary of Treatment-Emergent SPEECH EFFECTS Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles) (100-mg QD Pooled Group) - All-causality and Treatment-related - Safety Population - Data cutoff date: 02 February 2018

|                  | (N = 295)        | (N = 295)     | (N = 295)     | (N = 295)         | (N = 295)         | (N = 295)         |
|------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
|                  | All-Causality    | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
| PT               | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | All Grades n (%)  | Grade 3 n (%)     | Grade 4 n (%)     |
| Any AEs          | 29 (9.8)         | 1 (0.3)       | 0             | 25 (8.5)          | 1 (0.3)           | 0                 |
| Dysarthria       | 12 (4.1)         | 0             | 0             | 9 (3.1)           | 0                 | 0                 |
| Slow speech      | 10 (3.4)         | 1 (0.3)       | 0             | 10 (3.4)          | 1 (0.3)           | 0                 |
| Speech dlisorder | 7 (2.4)          | 0             | 0             | 6 (2.0)           | 0                 | 0                 |

Source:Table14.3.1.2.9.1.2.6.2.ema.1andTab1e14.3.1.3.9.1.2.6.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number, QD=once daily, SCS=summary of clinical safety, SU=safety update.

The  median  time  to  onset  was  42  days  (range,  1-727).  No  patients  permanently  discontinued treatment  associated  with  this  event.  One  patient  required  a  dose  reduction  and  subsequently  a temporary treatment discontinuation for a second event of Dysarthria .

Cumulative lorlatinib exposure seems to increase the risk of COGNITIVE EFFECTS AEs, as revealed by the increasing AEs proportions over time.

## Weight gain

<div style=\"page-break-after: always\"></div>

## Phase 1

A total of 12/54 (22.2%) patients had all-causality Weight increased with a median time to first onset of 104 days (Range: 8-559). The median duration was 371 days, most events were Grade 1 (9.3%), Grade 2 (5.6%) or Grade 3 (7.4%) in severity and none required temporary discontinuation or dose reduction. No patients permanently discontinued treatment. Ten (10; 18.5%) patients had treatmentrelated  AEs,  none  were  Grade  4,  3  were  Grade  3 and  the  remainder  was  Grade  1  or  2 in  severity. There were 19 (35.2%) patients with a weight increase of 10 - 20%, and 9 (16.7%) patients with weight increase of  20%.

Phase 2

Table 85: Categorical Summary of Postbaseline Vital Sign and Body Weight Data, (100-mg QD Pooled Group) - Safety Population

|                                |          | 100-mg QD pooled group   | 100-mg QD pooled group   |
|--------------------------------|----------|--------------------------|--------------------------|
| Parameter                      | Criteria | N                        | n (%)                    |
| Sitting SBP (mmHg)             |          |                          |                          |
| Maximum increase from baseline |  40     | 290                      | 26 (9.0)                 |
|                                |  60     | 290                      | 1(0.3)                   |
| Maximum decrease from baseline |  40     | 290                      | 10 (3.4)                 |
|                                |  60     | 290                      | 0                        |
| Sitting DBP (mmHg)             |          |                          |                          |
| Maximum increase from baseline |  20     | 290                      | 76 (26.2)                |
|                                |  40     | 290                      | 3 (1.0)                  |
| Maximum decrease from baseline |  20     | 290                      | 42 (14.5)                |
|                                |  40     | 290                      | 0                        |
| Sitting pulse rate (bpm)       |          |                          |                          |
| Absolute value                 | <50      | 293                      | 6 (2.0)                  |
|                                | >120     | 293                      | 19 (6.5)                 |
| Maximum increase from baseline |  30     | 289                      | 56 (19.4)                |
| Maximum decrease from baseline |  30     | 289                      | 26 (9.0)                 |
| Body Weight (kg)               |          |                          |                          |
| Maximum increase from baseline | 10%-20%  | 282                      | 87 (30.9)                |
|                                |  20%    | 282                      | 38 (13.5)                |
| Maximum decrease from baseline |  10%    | 282                      | 13 (4.6)                 |

Source: Study 1001 SCS Table 14.3.4.2.3.1.2.f1,  14.3.4.2.3.2.2.f1 and Table 14.3.4.2.3.3.2.f1

Abbreviations: BP=blood pressure; DBP=diastolic BP; N=number of subjects evaluated against criteria. n=number of subjects that met criteria; SBP=systolic BP; bpm=beats per minute; mmHg=mm of mercury; kg=kilogram

The risk of increased body weight increased by cycle number i.e. with duration of treatment

<div style=\"page-break-after: always\"></div>

## Vision disorders

Table 86: Summary of Treatment-Emergent VISION DISORDER Adverse Events by MedDRA Preferred Term and Maximum CTCAE Grade by Decreasing Order of Frequency (All Cycles, all causality) (100-mg QD Pooled Group) - All-causality and Treatment-related - Safety Population - Data cutoff date: 02 February 2018

|                       | (N= 295)         | (N= 295)      | (N= 295)      | (N= 295)          | (N= 295)          | (N= 295)          |
|-----------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
|                       | All-Causality    | All-Causality | All-Causality | Treatment-Related | Treatment-Related | Treatment-Related |
| PT                    | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | All Grades n (%)  | Grade 3 n (%)     | Grade 4 n (%)     |
| Any AEs               | 45 (15.3)        | 1 (0.3)       | 0             | 22 (7.5)          | 0                 | 0                 |
| Vision blurred        | 15 (5.1)         | 0             | 0             | 7 (2.4)           | 0                 | 0                 |
| Visual impairment     | 14 (4.7)         | 0             | 0             | 8 (2.7)           | 0                 | 0                 |
| Diplopia              | 6 (2.0)          | 1 (0.3)       | 0             | 0                 | 0                 | 0                 |
| Photopsia             | 5 (1.7)          | 0             | 0             | 3 (1.0)           | 0                 | 0                 |
| Visual acuity reduced | 5 (1.7)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |
| Photophobia           | 2 (0.7)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |
| Vitreous floaters     | 2 (0.7)          | 0             | 0             | 2 (0.7)           | 0                 | 0                 |

Source:Table14.3.1.2.9.1.2.8.2.ema.1 andTable14.3.1.3.9.1.2.8.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities, PT=preferred term, N/n=number, QD=once daily, SCS=summary of clinical safety, SU=safety update.

Median  time  to  first  onset  was  71  days  (range:  1-731).  The  median  duration  was  100  days  and  1 patient  had  a  Grade  3  event.  No  SAEs  or  permanent  discontinuations  were  observed.  No  clinically relevant differences were observed with updated data.

## Liver tests increased

## 100-mg QD Pooled Group

A total of 43/295 (14.6%) patients had AST increased (Grade 3: 2[0.7%] patients, Grade 4: 2 [0.7%] patients),  40  (13.6%)  patients  had  ALT  increased  (Grade  3:  3[1.0%]  patients,  Grade  4:  2  [0.7%] patient),  5  (1.7%)  patients  had  Blood  alkaline  phosphatase  increased  (Grade  3:2  patients  [0.7%], Grade 4: none), 2 (0.7%) patients had Hepatic function abnormal. The majority of these events were Grade 1 or 2 in severity. None of these AEs resulted in permanent treatment discontinuation. Of note, 1 patient had a Grade 1 AE (treatment-related) of Hepatocellular injury. Some of the patients (&lt;2% in each  AE  category)  required  dose  reductions  or  temporary  discontinuations  due  to  AEs  of  liver  tests increased. The 2 patients who had liver test increased related SAEs are described above, the additional patients  in  this  pooled  group  did  not  result  in  further  SAEs.  No  clinically  relevant  differences  were observed with updated data.

Liver toxicity resulting in liver tests was considered within an acceptable range and the events do not seem dose-dependent.

<div style=\"page-break-after: always\"></div>

## QTc prolongation

Table 87: Shift Summary of Maximum Absolute QTcF or QTcB (100-mg QD Pooled Group) Safety Population - Data cutoff date: 02 February 2018

|                                 | Postbaseline Maximum Absolute QTc Results n (%)   | Postbaseline Maximum Absolute QTc Results n (%)   | Postbaseline Maximum Absolute QTc Results n (%)   | Postbaseline Maximum Absolute QTc Results n (%)   | Postbaseline Maximum Absolute QTc Results n (%)   |
|---------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Baseline results (msec) (N=295) | <450                                              | 450-<480                                          | 480-<500                                          | ≥500                                              | Total                                             |
| QTcF                            |                                                   |                                                   |                                                   |                                                   |                                                   |
| <450                            | 228 (77.3)                                        | 47 (15.9)                                         | 6 (2.0)                                           | 1 (0.3)                                           | 282 (95.6)                                        |
| 450 - <480                      | 1 (0.3)                                           | 10 (3.4)                                          | 1 (0.3)                                           | 0                                                 | 12 (4.1)                                          |
| 480 - <500                      | 0                                                 | 0                                                 | 0                                                 | 0                                                 | 0                                                 |
| ≥500                            | 0                                                 | 0                                                 | 0                                                 | 1 (0.3)                                           | 1 (0.3)                                           |
| Total                           | 229 (77.6)                                        | 57 (19.3)                                         | 7 (2.4)                                           | 2 (0.7)                                           | 295(100)                                          |
| QTcB                            |                                                   |                                                   |                                                   |                                                   |                                                   |
| <450                            | 141 (47.8)                                        | 92 (31.2)                                         | 10 (3.4)                                          | 4 (1.4)                                           | 247 (83.7)                                        |
| 450-<480                        | 2 (0.7)                                           | 18 (6.1)                                          | 19 (6.4)                                          | 5 (1.7)                                           | 44 (14.9)                                         |
| 480 -<500                       | 0                                                 | 0                                                 | 2 (0.7)                                           | 1 (0.3)                                           | 3 (1.0)                                           |
| ≥500                            | 0                                                 | 0                                                 | 0                                                 | 1 (0.3)                                           | 1 (0.3)                                           |
| Total                           | 143 (48.5)                                        | 110 (37.3)                                        | 31 (10.5)                                         | 11 (3.7)                                          | 295 (100)                                         |

Source: Tables 14.3.4.4.3.2.ema.1, 14.3.4.4.4.2.ema.1

Abbreviations:N/ n=number of patients meeting specified criterion; N=number of patients evaluated; QTcB=corrected QT interval using Bazett's correction formula; QTcF=corrected QT interval using Fridericia's correction formula, QD=once daily.

Five (5) patients (1.8%) had a change in QTcF from baseline &gt; 60 msec. It has been observed that lorlatinib  induced  QTc  prolongation  with  a  common  frequency  (5.4%  of  drug-related  events  in  the pooled 100 mg QD dataset; 1 patient (0.4%) with a shift from normal baseline QT interval to QTcF &gt;500 msec post-baseline (Grade 3 AE) whose causality cannot be ruled out).

## Interstitial lung disease or Pneumonitis

## 100-mg QD Pooled Group

Interstitial  lung  disease/pneumonitis  was  reported  in  4  patients.  The  AE  of  Interstitial  lung  disease (Grade 3) was  reported in 1 (0.3%)  patient  and the AE of Pneumonitis was  reported in 3 (1.0%) patients (1 each at Grade 2, 3 and 4). Lorlatinib was discontinued permanently due to the Grade 4  AE  of  Pneumonitis  (treatment-related)  for  1  patient.  The  1  patient  with  Grade  3  AE  of Interstitial  lung  disease  (treatment-related)  required  temporary  discontinuation  of  lorlatinib.  No patients required temporary discontinuations or dose reductions due to AE of Pneumonitis. Except the Grade 4 AE of Pneumonitis and Grade 3 AE of Interstitial lung disease, no other AEs of Interstitial lung disease or Pneumonitis were reported as treatment-related. SAEs were Grade 3 and 4 Pneumonitis and Grade 3 Interstitial lung disease. Updated data contains no new cases of ILD or pneumonitis.

Pneumonitis is a class effect of ALK-inhibitors but is not a frequent event with lorlatinib. No patients died due to this event, which was manageable with dose reductions or discontinuations.

## Atrioventricular block

In  healthy  volunteer  studies,  no  AEs  associated  with  AV  block  were  reported,  however  PR  interval prolongation was observed.

## 100-mg QD Pooled Group

In  295 patients who received lorlatinib at the recommended dose of 100 mg once daily and had an ECG  measurement  in  Study  1001,  the  maximum  mean  change  from  baseline  for  PR  interval  was 16.4 ms (2-sided 90% upper CI 19.4 ms). Of these, 7 patients had a baseline PR &gt; 200 ms. Among

<div style=\"page-break-after: always\"></div>

the 284 patients with PR interval &lt; 200 ms, 14% had PR interval prolongation ≥200 ms after starting lorlatinib.

Table 88: Shift Summary of Maximum Absolute PR Results (100-mg QD Pooled Group) Safety Population - Data cutoff date: 02 February 2018

|                         | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   | Maximum Absolute Post-baseline PR Interval n (%)   |
|-------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Baseline (msec) (N=292) | <160                                               | 160-<180                                           | 180- <200                                          | 200- <220                                          | 220- <240                                          | 240- <260                                          | ≥260                                               | Total                                              |
| <160                    | 102 (34.9)                                         | 78 (26.7)                                          | 18 (6.2)                                           | 4 (1.4)                                            | 1 (0.3)                                            | 3 (1.0)                                            | 0                                                  | 206 (70.5)                                         |
| 160-<180                | 0                                                  | 6 (2.1)                                            | 36 (12.3)                                          | 14 (4.8)                                           | 1 (0.3)                                            | 0                                                  | 0                                                  | 57 (19.5)                                          |
| 180-<200                | 0                                                  | 0                                                  | 4 (1.4)                                            | 11 (3.8)                                           | 3 (1.0)                                            | 2 (0.7)                                            | 1 (0.3)                                            | 21 (7.2)                                           |
| 200-<220                | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 3 (1.0)                                            | 1 (0.3)                                            | 3 (1.0)                                            | 7 (2.4)                                            |
| 220-<240                | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 1 (0.3)                                            | 1 (0.3)                                            |
| 240-<260                | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  |
| ≥260                    | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  | 0                                                  |
| Total                   | 102 (34.9)                                         | 84 (28.8)                                          | 58 (19.9)                                          | 29 (9.9)                                           | 8 (2.7)                                            | 6 (2.1)                                            | 5 (1.7)                                            | 292 (100)                                          |

Source:Table 14.3.4.4.2.ema.1

Abbreviations: N/n=number of patients meeting specified criterion; N/n=number of patients evaluated, QD=once daily, msec=millisecond.

AV block first degree was reported in 2 patients (both at Grade 1; treatment-related), and AV block complete was reported by 1 (0.3%) patient (Grade 3, not treatment-related). The median duration for AV block first degree was 141 days. The AV block complete occurred in 2 days. There was 1 temporary treatment  discontinuation  associated  with  the  Grade  3  event.  No  other  patients  required  a  dose reduction or temporary discontinuations, or permanent treatment discontinuations in association with atrioventricular block. No new case of AV block was observed with updated data.

Higher frequencies of 'PR prolonged AE' has been observed with increasing duration of baseline PR interval.

## Pancreatitis

## 100-mg QD Pooled Group

One  (1/295)  (0.3%)  patient  had  an  AE  of  Pancreatitis.  This  patient  had  a  treatment-related  SAE (Grade 3) from Cycle 3 Day 20, due to which the study treatment was temporarily discontinued. On Cycle 3 Day 21, the AE was considered resolved but another non-serious AE of pancreatic enzymes increased (Grade 1) was reported and while study treatment resumed, it was given at a reduced dose. Lipase increased was reported in 10.8% of patients and Amylase increased was reported in 8.5% of patients. There were no additional cases of pancreatitis with updated data.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Serious Adverse Events

Table 89: All-causality treatment-emergent (≥2 patients) and treatment-related SAEs (≥1 patient) by clustering and MedDRA preferred term (PT) and maximum CTCAE grade, All cycles (100-mg QD pooled group)- safety population- Data cutoff date: 02 February 2018

|                                        | 100-mg QD Pooled Group (N=295) All-Causality n (%)   | 100-mg QD Pooled Group (N=295) All-Causality n (%)   | 100-mg QD Pooled Group (N=295) All-Causality n (%)   |                 |                                 |           |
|----------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------|---------------------------------|-----------|
| PreferredTerm                          | All Grades                                           | Grade 3                                              | Grade 4                                              | All Grades      | Treatment-Related n (%) Grade 3 | Grade 4   |
| Any AEsa                               | 112 (38.0)                                           | 44 (14.9)                                            | 12 (4.1)                                             | 23 (7.8)        | 13 (4.4)                        | 5 (1.7)   |
| Disease progression                    | 27 (9.2)                                             | 0                                                    | 0                                                    | 0               | 0                               | 0         |
| Dyspnoea                               | 8 (2.7)                                              | 6 (2.0)                                              | 2 (0.7)                                              | 0               | 0                               | 0         |
| Pyrexia                                | 7 (2.4)                                              | 2 (0.7)                                              | 0                                                    | 0               | 0                               | 0         |
| Pneumonia                              | 6 (2.0)                                              | 5 (1.7)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Mental status changes                  | 5 (1.7)                                              | 4 (1.4)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Fall                                   | 4 (1.4)                                              | 4 (1.4)                                              | 0                                                    | 0               | 0                               | 0         |
| Pericardial effusion                   | 4 (1.4)                                              | 3 (1.0)                                              | 0                                                    | 0               | 0                               | 0         |
| *COGNITIVE EFFECTS                     | 3 (1.0)                                              | 3 (1.0)                                              | 0                                                    | 3 (1.0)         | 3 (1.0)                         | 0         |
| Pleural effusion                       | 3 (1.0)                                              | 3 (1.0)                                              | 0                                                    | 0               | 0                               | 0         |
| Pulmonary embolism                     | 3 (1.0)                                              | 3 (1.0)                                              | 0                                                    | 0               | 0                               | 0         |
| Respiratory failure                    | 3 (1.0)                                              | 3 (1.0)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Vomiting                               | 3 (1.0)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 0                               | 0         |
| *EDEMA                                 | 2 (0.7)                                              | 2 (0.7)                                              | 0                                                    | 0               | 0                               | 0         |
| *PERIPHERALNEUROPATHY                  | 2 (0.7)                                              | 0                                                    | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Acute respiratory failure              | 2 (0.7)                                              | 2 (0.7)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Alanine aminotransferase               | 2 (0.7)                                              | 1 (0.3)                                              | 1 (0.3)                                              | 1 (0.3)         | 1 (0.3)                         | 0         |
| increased                              |                                                      |                                                      |                                                      |                 |                                 |           |
| Aspartate aminotransferase             | 2 (0.7)                                              | 1 (0.3)                                              | 1 (0.3)                                              | 1 (0.3)         | 1 (0.3)                         | 0         |
| increased                              |                                                      |                                                      |                                                      |                 |                                 |           |
| Atrial fibrillation                    | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Chest pain                             | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Embolism                               | 2 (0.7)                                              | 0                                                    | 0                                                    | 0               | 0                               | 0         |
| Femoral neck fracture                  | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Headache                               | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 0                               | 0         |
| Lower respiratory tract infection      | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Lung disorder                          | 2 (0.7)                                              | 0                                                    | 0                                                    | 0               | 0                               | 0         |
| Lung infection                         | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Pain                                   | 2 (0.7)                                              | 2 (0.7)                                              | 0                                                    | 0               | 0                               | 0         |
| Pneumonitis                            | 2 (0.7)                                              | 1 (0.3)                                              | 1 (0.3)                                              | 1 (0.3)         | 0                               | 1 (0.3)   |
| Respiratory tract infection            | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Sepsis                                 | 2 (0.7)                                              | 0                                                    | 2 (0.7)                                              | 0               | 0                               | 0         |
| Superior vena cava syndrome            | 2 (0.7)                                              | 2 (0.7)                                              | 0                                                    | 0               | 0                               | 0         |
| Thrombosis                             | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Upper respiratory tract infection      | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Urinary tract infection                | 2 (0.7)                                              | 1 (0.3)                                              | 0                                                    | 0               | 0                               | 0         |
| Vertigo                                | 2 (0.7)                                              | 2 (0.7)                                              | 0                                                    | 0               | 0                               | 0         |
| Cerebral infarction                    | 1 (0.3)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Coronary artery disease                | 1 (0.3)                                              | 0                                                    | 1 (0.3)                                              | 1 (0.3)         | 0                               | 1 (0.3)   |
| Dyspnoea exertional                    | 1 (0.3)                                              | 0                                                    | 0                                                    | 1 (0.3)         | 0                               | 0         |
|                                        |                                                      |                                                      |                                                      |                 |                                 | 0         |
| Erysipelas                             | 1 (0.3)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 1 (0.3) 1 (0.3)                 |           |
| Gastritis                              | 1 (0.3)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         | 1 (0.3)                         | 0         |
| Glossitis                              | 1 (0.3)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3)         |                                 | 0         |
| Hallucination                          | 1 (0.3) 1 (0.3)                                      | 0 1 (0.3)                                            | 1 (0.3) 0                                            | 1 (0.3)         | 0                               | 1 (0.3) 0 |
| Interstitial lung disease Pancreatitis | 1 (0.3)                                              | 1 (0.3)                                              | 0                                                    | 1 (0.3) 1 (0.3) | 1 (0.3) 1 (0.3)                 | 0         |
|                                        |                                                      | 0                                                    |                                                      | 1 (0.3)         | 0                               |           |
| Presyncope                             | 1 (0.3)                                              |                                                      | 0                                                    |                 |                                 | 0         |
| Vagus nerve disorder                   | 1 (0.3)                                              | 0                                                    | 0                                                    | 1 (0.3)         | 0                               | 0         |
| *HYPERTRIGLYCERIDEMIA                  |                                                      | 0                                                    |                                                      | 1 (0.3)         |                                 |           |
|                                        | 1 (0.3)                                              |                                                      | 1 (0.3)                                              |                 | 0                               | 1 (0.3)   |

Source:Table 14.3.2.2.2.3.ema.1and Table 14.3.2.2.3.3.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical

Dictionary for RegulatoryActivities; N/n=number of patients; SAE=serious adverse event, QD=once daily.

*= Cluster terms as defined in Table 71

a=Total numberindependent of cutoff used in the table

## Deaths

Phase 1

<div style=\"page-break-after: always\"></div>

A  total  of  7  (13%)  of  54  patients  died  on  study  treatment  or  within  28  days  of  their  last  dose  of lorlatinib, and 20 (37.0%) patients died after 28 days of their last dose of lorlatinib; none of the deaths were treatment-related. Six (6) of 7 deaths, on study treatment or within 28 days, were due to disease progression and 1 death due to Hypoxia (supplemental oxygen dependency). Among the 27 deaths, the majority (24) died due to the disease progression, 1 patient died due to 'other' causes specified as hypertension, supplemental oxygen dependency, morbid obesity and diabetes, and 2 patients died due to an unknown cause.

## Phase 2

Out  of  275  patients,  26  (9.5%)  died  on  study  treatment  or  within  28  days  of  their  last  dose  of lorlatinib, and 38 (13.8%) patients died after 28 days of their last dose of lorlatinib; none of the deaths were  treatment-related.  The  most  frequent  reason  for  death  was  disease  progression  (59  patients (21.5%). Four (4) patients died due to 'other' causes, and specific reasons included pneumonia (2 patients) probable lung infection (1 patient), and suspected thrombus embolism (1 patient); none of which were considered treatment-related. One patient died due to an unknown cause.

Table 90: Summary of Deaths (Phase 1, Phase 2 and 100-mg QD Pooled Group) - Safety Population

| Deaths                                          | Phase 1 (N=54) n (%)   | Phase 2 (N=275) n (%)   | 100-mg QD Pooled Group (N=295) n (%)   |
|-------------------------------------------------|------------------------|-------------------------|----------------------------------------|
| Patients who died                               |                        |                         |                                        |
| Within 28 days after last dose of study drug    | 7 (13.0)               | 26 (9.5)                | 29 (9.8)                               |
| More than 28 days after last dose of study drug | 20 (37.0)              | 38 (13.8)               | 42 (14.2)                              |
| Cause of death                                  |                        |                         |                                        |
| Disease under study                             | 24 (44.4)              | 59 (21.5)               | 65 (22.0)                              |
| Unknown/not reported                            | 2 (3.7)                | 1 (0.4)                 | 2 (0.7)                                |
| Study treatment toxicity                        | 0                      | 0                       | 0                                      |
| Other                                           | 1 (1.9) a              | 4 (1.5) b               | 4 (1.4) b                              |

a. Specified as hypertension, supplemental oxygen dependency, morbid obesity and diabetes (Table 16.2.6.5.2.1).

b. Specified as pneumonia for 2 patients; Probable lung infection and suspected thrombus embolism for 1 patient each (Table 16.2.6.5.2.2).

The  following  fatal  AEs  occurred  in  1  patient  each:  pneumonia,  lung  infection,  acute  pulmonary oedema,  embolism,  general  physical  health  deterioration,  myocardial  infarction,  peripheral  artery occlusion, and respiratory distress.

| Table 91: Grade 5 AEs (Phase 1, Phase 2 and 100-mg QD Pooled Group) - Safety Population   | Table 91: Grade 5 AEs (Phase 1, Phase 2 and 100-mg QD Pooled Group) - Safety Population   | Table 91: Grade 5 AEs (Phase 1, Phase 2 and 100-mg QD Pooled Group) - Safety Population   | Table 91: Grade 5 AEs (Phase 1, Phase 2 and 100-mg QD Pooled Group) - Safety Population   |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Preferred Term n (%)                                                                      | Phase 1 Total AEs (N=54)                                                                  | Phase 2 Total AEs (N=275)                                                                 | 100-mg QD Pooled Group Total AEs (N=295)                                                  |
| Any AEs                                                                                   | 9 (16.7)                                                                                  | 30 (10.9)                                                                                 | 33 (11.2)                                                                                 |
| Disease progression                                                                       | 8 (14.8)                                                                                  | 22 (8.0)                                                                                  | 25 (8.5)                                                                                  |
| Hypoxia                                                                                   | 1 (1.9)                                                                                   | 0                                                                                         | 0                                                                                         |
| Pneumonia                                                                                 | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Lung Infection                                                                            | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Acute Pulmonary oedema                                                                    | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Embolism                                                                                  | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| General physical health deterioration                                                     | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Myocardial infarction                                                                     | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Peripheral artery occlusion                                                               | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |
| Respiratory distress                                                                      | 0                                                                                         | 1 (0.4)                                                                                   | 1 (0.3)                                                                                   |

Abbreviations:  AE=adverse event; N=number of patients evaluable for safety; n=number of patients with AEs

<div style=\"page-break-after: always\"></div>

Table 92: Summary of deaths (100 mg QD pooled group) - safety population

| Deaths                                          | SCS (cutoff 15 March 2017) 100-mg QD Pooled Group (N=295) n (%)   | SU(cutoff 02February 2018) 100-mg QD Pooled Group (N=295) n (%)   |
|-------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Patients who died                               |                                                                   |                                                                   |
| Within 28 days after last dose of study drug    | 29 (9.8)                                                          | 32 (10.8)                                                         |
| More than 28 days after last dose of study drug | 42 (14.2)                                                         | 69 (23.4)                                                         |
| Cause of death                                  |                                                                   |                                                                   |
| Disease under study                             | 65 (22.0)                                                         | 87 (29.5)                                                         |
| Unknown/notreported                             | 2 (0.7)                                                           | 6 (2.0)                                                           |
| Studytreatment toxicity                         | 0                                                                 | 0                                                                 |
| Other                                           | 4 (1.4)                                                           | 8 (2.7)                                                           |

Source:Table14.3.2.1.2.2.f1andTable14.3.2.1.2.2.ema.1

## Laboratory findings

Haematology

Table 93: Summary of haematology post-baseline laboratory results (SU) by maximum CTCAE grade (all cycles) (100 mg QD pooled group) - safety population - Data cutoff date: 02 February 2018

| Parameter                  |   N | Grade 1 n (%)   | Grade 2 n (%)   | Grade 3 n (%)   | Grade 4 (%) uI   | Total n (%)   |
|----------------------------|-----|-----------------|-----------------|-----------------|------------------|---------------|
| Anemia                     | 293 | 152 (51.9)      | 63 (21.5)       | 16 (5.5)        | 0                | 231 (78.8)    |
| Hemoglobin increased       | 293 | 7 (2.4)         | 0               | 0               | 0                | 7 (2.4)       |
| Lymphocyte count decreased | 292 | 52 (17.8)       | 59 (20.2)       | 14 (4.8)        | 0                | 125 (42.8)    |
| Lymphocyte count increased | 292 | 0               | 18 (6.2)        | 0               | 0                | 18 (6.2)      |
| Neutrophil count decreased | 292 | 21 (7.2)        | 12 (4.1)        | 1 (0.3)         | 2 (0.7)          | 36 (12.3)     |
| Platelet countdecreased    | 293 | 72 (24.6)       | 1 (0.3)         | 0               | 1 (0.3)          | 74 (25.3)     |
| White blood cell decreased | 293 | 41 (14.0)       | 7 (2.4)         | 2 (0.7)         | 0                | 50 (17.1)     |

Source: Table14.3.4.1.5.1.2.ema.1

Abbreviations: N=total number of patients; n=number of patients with Grade 1, 2, or 3 laboratory parameter, CTCAE=Common Terminology Criteria for AEs, QD=once daily.

<div style=\"page-break-after: always\"></div>

## Blood chemistry

Table 94: Summary of abnormal clinical chemistry laboratory test results by maximum CTCAE grade (All cycles) (100 mg QD pooled group) - safety population - Data cutoff date: 02 February 2018

|                         |     | Grade 1    | Grade 2   | Grade 3   | Grade 4   | Total      |
|-------------------------|-----|------------|-----------|-----------|-----------|------------|
| Parameter               | N   | n (%)      | n (%)     | n (%)     | n (%)     | n (%)      |
| ALTincreased            | 292 | 98 (33.6)  | 9 (3.1)   | 4 (1.4)   | 2 (0.7)   | 113 (38.7) |
| ALP increased           | 292 | 105 (36.0) | 10 (3.4)  | 3 (1.0)   | 0         | 118 (40.4) |
| AST increased           | 292 | 129 (44.2) | 7 (2.4)   | 4 (1.4)   | 2 (0.7)   | 142 (48.6) |
| BloodBilirubinincreased | 292 | 3 (1.0)    | 0         | 1 (0.3)   | 1 (0.3)   | 5 (1.7)    |
| Creatinineincreased     | 293 | 195 (66.6) | 26 (8.9)  | 1 (0.3)   | 0         | 222 (75.8) |
| Hypercalcemia           | 293 | 24 (8.2)   | 0         | 0         | 0         | 24 (8.2)   |
| Hyperglycemia           | 293 | 121 (41.3) | 50 (17.1) | 15 (5.1)  | 1 (0.3)   | 187 (63.8) |
| Hyperkalemia            | 293 | 60 (20.5)  | 7 (2.4)   | 2 (0.7)   | 1 (0.3)   | 70 (23.9)  |
| Hypermagnesemia         | 292 | 12 (4.1)   | 0         | 2 (0.7)   | 0         | 14 (4.8)   |
| Hypernatremia           | 293 | 31 (10.6)  | 1 (0.3)   | 0         | 0         | 32 (10.9)  |
| Hypoalbuminemia         | 291 | 135 (46.4) | 44 (15.1) | 3 (1.0)   | 0         | 182 (62.5) |
| Hypocalcemia            | 293 | 40 (13.7)  | 11 (3.8)  | 0         | 1 (0.3)   | 52 (17.7)  |
| Hypoglycemia            | 293 | 30 (10.2)  | 4 (1.4)   | 0         | 0         | 34 (11.6)  |
| Hypokalemia             | 293 | 53 (18.1)  | 0         | 3 (1.0)   | 1 (0.3)   | 57 (19.5)  |
| Hypomagnesemia          | 292 | 83 (28.4)  | 0         | 0         | 0         | 83 (28.4)  |
| Hyponatremia            | 293 | 68 (23.2)  | 0         | 7 (2.4)   | 0         | 75 (25.6)  |
| Hypophosphatemia        | 292 | 9 (3.1)    | 49 (16.8) | 20 (6.8)  | 0         | 78 (26.7)  |
| Lipase increased        | 290 | 38 (13.1)  | 15 (5.2)  | 24 (8.3)  | 7 (2.4)   | 84 (29.0)  |
| Serum amylase increased | 284 | 52 (18.3)  | 14 (4.9)  | 11 (3.9)  | 1 (0.4)   | 78 (27.5)  |

Source:Table14.3.4.1.6.1.2.ema.1

Abbreviations: N=total number of patients; n=number of patients with Grade 1-4 laboratory parameter; CTCAE=Common Terminology Criteria for Adverse Events; ALT=Alanine aminotransferase; ALP=alkaline phosphatase; AST=Aspartate aminotransferase, QD=once daily.

## Lipids

Table 95: Summary Results of Labs by Maximum CTCAE Grade (Others, All Cycles) (100-mg Pooled Group) - Safety Population

|                      | N=292      | N=292      | N=292     | N=292   | N=292      |
|----------------------|------------|------------|-----------|---------|------------|
| n (%)                | Grade 1    | Grade 2    | Grade 3   | Grade 4 | Total      |
| Cholesterol High     | 71 (24.3)  | 165 (56.5) | 43 (14.7) | 6 (2.1) | 285 (97.6) |
| Hypertriglyceridemia | 145 (49.7) | 82 (28.1)  | 42 (14.4) | 8 (2.7) | 277 (94.9) |

Source:  Study 1001 SCS Table 14.3.4.1.7.1.2.f1

Abbreviations: N is the number of patients who had at least one on-study assessment for the parameter of interest. n is the number of patients whose lab results had met the criteria of CTCAE Grade. CTCAE=Terminology Criteria for Adverse Events

The Grade 3 events of high cholesterol and hypertriglyceridemia were observed in around 15% of the patients. The observed changes in lipid parameters with updated data were of clinically insignificant.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic factors

## Age

Table 96: Safety in patients by age groups -100-mg QD pooled group - Safety Population

| MedDRA Terms                                                                        | Age<65 (N=241)   | Age<65 (N=241)   | Age 65-74 (N=41)   | Age 65-74 (N=41)   | Age 75-84 (N=12)   | Age 75-84 (N=12)   | Age 85+ (N=1)   | Age 85+ (N=1)   |
|-------------------------------------------------------------------------------------|------------------|------------------|--------------------|--------------------|--------------------|--------------------|-----------------|-----------------|
|                                                                                     | n1               | n2               | n1                 | n2                 | n1                 | n2                 | n1              | n2              |
| Total AEs                                                                           | 3357             | 13.9             | 627                | 15.3               | 165                | 13.8               | 6               | 6.0             |
| Serious AEs - Total                                                                 | 161              | 0.7              | 43                 | 1.0                | 21                 | 1.8                | 0               |                 |
| - Fatal                                                                             | 37               | 0.2              | 10                 | 0.2                | 6                  | 0.5                | 0               |                 |
| - Hospitalization/prolong existing hospitalization                                  | 125              | 0.5              | 32                 | 0.8                | 16                 | 1.3                | 0               |                 |
| - Life-threatening                                                                  | 5                | <0.1             | 0                  |                    | 0                  |                    | 0               |                 |
| - Disability/incapacity                                                             | 2                | <0.1             | 0                  |                    | 0                  |                    | 0               |                 |
| - Other (medically significant)                                                     | 4                | <0.1             | 3                  | <0.1               | 0                  |                    | 0               |                 |
| AE leading to drop-out                                                              | 25               | 0.1              | 5                  | 0.1                | 5                  | 0.4                | 0               |                 |
| Psychiatric disorders (SOC)                                                         | 140              | 0.6              | 29                 | 0.7                | 8                  | 0.7                | 2               | 2.0             |
| Nervous system disorders (SOC)                                                      | 390              | 1.6              | 66                 | 1.6                | 17                 | 1.4                | 0               |                 |
| Accidents and injuries [1]                                                          | 46               | 0.2              | 6                  | 0.1                | 10                 | 0.8                | 0               |                 |
| Cardiac disorders (SOC)                                                             | 45               | 0.2              | 15                 | 0.4                | 2                  | 0.2                | 0               |                 |
| Vascular disorders (SOC)                                                            | 55               | 0.2              | 10                 | 0.2                | 3                  | 0.3                | 0               |                 |
| Cerebrovascular disorders [2]                                                       | 1                | <0.1             | 1                  | <0.1               | 0                  |                    | 0               |                 |
| Infections and infestations (SOC)                                                   | 222              | 0.9              | 36                 | 0.9                | 10                 | 0.8                | 0               |                 |
| Anticholinergic syndrome (PT)                                                       | 0                |                  | 0                  |                    | 0                  |                    | 0               |                 |
| Quality of life decreased (PT)                                                      | 0                |                  | 0                  |                    | 0                  |                    | 0               |                 |
| Sum of postural hypotension,falls,black outs,syncope, dizziness, ataxia,fractures + | 72               | 0.3              | 13                 | 0.3                | 5                  | 0.4                | 0               |                 |
| <otherAE appearing more frequently in older patients>                               | 498              | 2.1              | 112                | 2.7                | 37                 | 3.1                | 1               | 1.0             |
| **EDEMA                                                                             | 144              | 0.6              | 31                 | 0.8                | 7                  | 0.6                | 1               | 1.0             |
| **COGNITIVE EFFECTS                                                                 | 86               | 0.4              | 22                 | 0.5                | 6                  | 0.5                | 0               |                 |
| **FATIGUE                                                                           | 65               | 0.3              | 16                 | 0.4                | 6                  | 0.5                | 0               |                 |
| Weight increased                                                                    | 70               | 0.3              | 6                  | 0.1                | 2                  | 0.2                | 0               |                 |
| Dyspnoea                                                                            | 62               | 0.3              | 14                 | 0.3                | 6                  | 0.5                | 0               |                 |
| Anaemia                                                                             | 33               | 0.1              | 9                  | 0.2                | 5                  | 0.4                | 0               |                 |
| Back pain                                                                           | 27               | 0.1              | 9                  | 0.2                | 4                  | 0.3                | 0               |                 |
| Dyspnoea exertional                                                                 | 11               | <0.1             | 5                  | 0.1                | 1                  | <0.1               | 0               |                 |

Abbreviations:AE=Adverseevent;N=number;MedDRA=MedicalDictionaryforRegulatoryActivities;PT= Preferred term; SOC= System organ class

MedDRA (v20.1) coding dictionary applied.

nl: The number of AEs.

n2: The average number of AEs per patient. n2 = n1/N

* Includes Phase 1, Phase 2 and Japan LIC

[1] PTs from Injury, Poisoning, and Procedural Complications System Organ Class (SOC)

** refers to AE cluster terms

[2] The following PTs were searched: Cerebrovascular accident, Cerebral haemorrhage, Cerebral infarction, Ischaemic cerebral infarction, Cerebral ischaemia, Cerebrovascular disorder, Cerebrovascular insufficiency, Haemorrhagicstroke,Ischaemicstroke,Thromboticstroke,Embolicstroke,Cerebralarteriosclerosis,Transient ischaemic attack, Cerebral vasoconstriction, Cerebrovascular stenosis, Haemorrhagic transformation stroke + The following Preferred Terms (PTs) were searched: Orthostatic hypotension, Dizziness, Dizziness postural, Loss of consciousness, Depressed level of consciousness, Altered state of consciousness, Syncope, Presyncope, Fall, Ataxia. In addition the HLT Fractures and dislocations (NEC) containing the following PTs was used: Atypical fracture, Avulsion fracture, Bone fissure, Bone fragmentation, Comminuted fracture, Complicated fracture, Compression fracture, Fracture, Fracture delayed union, Fracture displacement, Fracture nonunion, Impacted fracture, Joint dislocation, Joint dislocation pathological, Multiple fractures, Open fracture, Osteoporotic fracture, Pathological fracture, Stress fracture, Traumatic fracture, as well as the following reported PTs indicating a fracture: Spinal compression fracture, Ankle fracture, Foot fracture, Humerus fracture, Rib fracture, Femur fracture, Fractured sacrum, Lumbar vertebral fracture, Wrist fracture, Hip fracture,

Thoracic vertebral fracture, and Upper limb fracture

<div style=\"page-break-after: always\"></div>

Table 97: Most Common (&gt; 10% of Patients &lt;65 years and/ or  ≥65 years) All-Causality Adverse Events by Age Category - 100-mg QD pooled group - Safety Population Number (%) of Patients

| Preferred Term                       | < 65 years N= 241   | ≥ 65 years N= 54   |
|--------------------------------------|---------------------|--------------------|
| Any AEs                              | 240 (99.6)          | 54 (100.0)         |
| *HYPERCHOLESTEROLEMIA                | 200 (83.0)          | 43 (79.6)          |
| *HYPERTRIGLYCERIDEMIA                | 151 (62.7)          | 28 (51.9)          |
| *EDEMA                               | 116 (48.1)          | 35 (64.8)          |
| *PERIPHERAL NEUROPATHY               | 104 (43.2)          | 25 (46.3)          |
| Weight increased                     | 56 (23.2)           | 5 (9.3)            |
| *COGNITIVE EFFECTS                   | 54 (22.4)           | 14 (25.9)          |
| Dyspnoea                             | 54 (22.4)           | 15 (27.8)          |
| *FATIGUE                             | 52 (21.6)           | 16 (29.6)          |
| *MOOD EFFECTS                        | 52 (21.6)           | 10 (18.5)          |
| Arthralgia                           | 44 (18.3)           | 14 (25.9)          |
| Cough                                | 43 (17.8)           | 5 (9.3)            |
| Headache                             | 41 (17.0)           | 3 (5.6)            |
| Diarrhoea                            | 40 (16.6)           | 12 (22.2)          |
| Nausea                               | 40 (16.6)           | 3 (5.6)            |
| Dizziness                            | 36 (14.9)           | 8 (14.8)           |
| Constipation                         | 33 (13.7)           | 9 (16.7)           |
| *VISION DISORDER                     | 32 (13.3)           | 7 (13.0)           |
| Aspartate aminotransferase increased | 31 (12.9)           | 4 (7.4)            |
| Alanine aminotransferase increased   | 30 (12.4)           | 3 (5.6)            |
| Lipase increased                     | 29 (12.0)           | 3 (5.6)            |
| Pain in extremity                    | 29 (12.0)           | 4 (7.4)            |
| Anaemia                              | 28 (11.6)           | 9 (16.7)           |
| Myalgia                              | 26 (10.8)           | 5 (9.3)            |
| Pyrexia                              | 25 (10.4)           | 4 (7.4)            |
| Back pain                            | 23 (9.5)            | 12 (22.2)          |
| *SPEECH EFFECTS                      | 21 (8.7)            | 7 (13.0)           |
| Vomiting                             | 22 (9.1)            | 7 (13.0)           |
| Dyspnoea exertional                  | 11 (4.6)            | 6 (11.1)           |
| Hyperglycaemia                       | 15 (6.2)            | 6 (11.1)           |
| Insomnia                             | 16 (6.6)            | 6 (11.1)           |
| Rash                                 | 18 (7.5)            | 6 (11.1)           |

Source: Study 1001 SCS Table 14.3.1.2.9.1.2.2.3.1.s1

*=Cluster terms as indicated (Table 84)

Abbreviation:  N=number

There were more AEs of all causality in patients older than 65 years e.g. anaemia, oedema, dyspnoea, fatigue, arthralgia, and back pain. On the other hand, some incidences of AEs are lower in the elderly population however the number of patients aged  65 years was rather limited.

<div style=\"page-break-after: always\"></div>

## Gender

Table 98: Most Common (&gt; 10% of Patients in Any Category) All-Causality Adverse Events by Gender - 100-mg QD pooled group - Safety Population

|                                      | SCS (cutoff 15 March 2017)   | SCS (cutoff 15 March 2017)   | SU (cutoff 02 February   | SU (cutoff 02 February   |
|--------------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|
| PreferredTerm                        | Male N=125                   | Female N= 170                | 2018) Male N= 125        | Female N= 170            |
| Any AEs                              | 124 (99.2)                   | 170 (100)                    | 124 (99.2)               | 170 (100)                |
| *HYPERCHOLESTEROLEMIA                | 96 (76.8)                    | 147 (86.5)                   | 99 (79.2)                | 150 (88.2)               |
| *HYPERTRIGLYCERIDEMIA                | 83 (66.4)                    | 96 (56.5)                    | 88 (70.4)                | 110 (64.7)               |
| *EDEMA                               | 56 (44.8)                    | 95 (55.9)                    | 59 (47.2)                | 102 (60.0)               |
| *PERIPHERAL NEUROPATHY               | 56 (44.8)                    | 73 (42.9)                    | 60 (48.0)                | 81 (47.6)                |
| *COGNITIVE EFFECTS                   | 33 (26.4)                    | 35 (20.6)                    | 39 (31.2)                | 46 (27.1)                |
| *FATIGUE                             | 32 (25.6)                    | 36 (21.2)                    | 38 (30.4)                | 45 (26.5)                |
| Dyspnoea                             | 32 (25.6)                    | 37 (21.8)                    | 37 (29.6)                | 45 (26.5)                |
| Weight increased                     | 29 (23.2)                    | 32 (18.8)                    | 35 (28.0)                | 43 (25.3)                |
| *MOOD EFFECTS                        | 27 (21.6)                    | 35 (20.6)                    | 28 (22.4)                | 39 (22.9)                |
| Cough                                | 26 (20.8)                    | 22 (12.9)                    | 29 (23.2)                | 28 (16.5)                |
| Arthralgia                           | 21 (16.8)                    | 37 (21.8)                    | 30 (24.0)                | 43 (25.3)                |
| Diarrhoea                            | 18 (14.4)                    | 34 (20.0)                    | 23 (18.4)                | 44 (25.9)                |
| Headache                             | 18 (14.4)                    | 26 (15.3)                    | 18 (14.4)                | 35 (20.6)                |
| Aspartate aminotransferase increased | 16 (12.8)                    | 19 (11.2)                    | 19 (15.2)                | 24 (14.1)                |
| Dizziness                            | 16 (12.8)                    | 28 (16.5)                    | 19 (15.2)                | 30 (17.6)                |
| *VISION DISORDER                     | 15 (12.0)                    | 24 (14.1)                    | 20 (16.0)                | 25 (14.7)                |
| Constipation                         | 15 (12.0)                    | 27 (15.9)                    | 18 (14.4)                | 29 (17.1)                |
| Lipase increased                     | 15 (12.0)                    | 17 (10.0)                    | 20 (16.0)                | 21 (12.4)                |
| Myalgia                              | 15 (12.0)                    | 16 (9.4)                     | 16 (12.8)                | 20 (11.8)                |
| Pyrexia                              | 15 (12.0)                    | 14 (8.2)                     | 17 (13.6)                | 25 (14.7)                |
| Amylase increased                    | 14 (11.2)                    | 11 (6.5)                     | 17 (13.6)                | 13 (7.6)                 |
| Nausea                               | 14 (11.2)                    | 29 (17.1)                    | 20 (16.0)                | 34 (20.0)                |
| *SPEECH EFFECTS                      | 13 (10.4)                    | 15 (8.8)                     | 14 (11.2)                | 15 (8.8)                 |
| Alanine aminotransferase increased   | 13 (10.4)                    | 20 (11.8)                    | 16 (12.8)                | 24 (14.1)                |
| Pain in extremity                    | 12 (9.6)                     | 21 (12.4)                    | 13 (10.4)                | 27 (15.9)                |
| Vomiting                             | 11 (8.8)                     | 18 (10.6)                    | 15 (12.0)                | 21 (12.4)                |
| Anaemia                              | 9 (7.2)                      | 28 (16.5)                    | 12 (9.6)                 | 35 (20.6)                |
| Back pain                            | 9 (7.2)                      | 26 (15.3)                    | 13 (10.4)                | 27 (15.9)                |
| Upper respiratory tract infection    | 12 (9.6)                     | 12 (7.1)                     | 18 (14.4)                | 17 (10.0)                |
| Chest pain                           | 12 (9.6)                     | 7 (4.1)                      | 16 (12.8)                | 11 (6.5)                 |
| Hypertension                         | 12 (9.6)                     | 9 (5.3)                      | 15 (12.0)                | 14 (8.2)                 |
| Disease progression                  | 12 (9.6)                     | 13 (7.6)                     | 13 (10.4)                | 14 (8.2)                 |
| Rash                                 | 12 (9.6)                     | 12 (7.1)                     | 13 (10.4)                | 17 (10.0)                |
| Urinary tract infection              | 0                            | 11 (6.5)                     | 0                        | 20 (11.8)                |
| Tinnitus                             | 7 (5.6)                      | 15 (8.8)                     | 8 (6.4)                  | 18 (10.6)                |

Source:SCS Table 14.3.1.2.9.1.2.2.2.1.s1 and Table 14.3.1.2.9.1.2.2.2.2.ema.1 *=Cluster terms as indicated (Table 71) Abbreviation: N=number

All-causality AEs were generally balanced between genders.

<div style=\"page-break-after: always\"></div>

## Race

## Table 99: Most Common (&gt; 10% of Patients in Any Category) All-Causality Adverse Events by Race Category - 100-mg QD pooled group - Safety Population

|                                     | SCS (cutoff 15 March 2017)   | SCS (cutoff 15 March 2017)   | SU (cutoff 02 February   | SU (cutoff 02 February   |
|-------------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|
| PreferredTerm                       | Asian N=108                  | Non-Asian N= 161             | 2018) Asian N= 108       | Non-Asian N= 161         |
| Any AEs                             | 107 (99.1)                   | 161 (100)                    | 107 (99.1)               | 161 (100)                |
| *HYPERCHOLESTEROLEMIA               | 87 (80.6)                    | 133 (82.6)                   | 90 (83.3)                | 135 (83.9)               |
| *HYPERTRIGLYCERIDEMIA               | 73 (67.6)                    | 86 (53.4)                    | 82 (75.9)                | 92 (57.1)                |
| *EDEMA                              | 48 (44.4)                    | 94 (58.4)                    | 52 (48.1)                | 97 (60.2)                |
| *PERIPHERAL NEUROPATHY              | 37 (34.3)                    | 76 (47.2)                    | 41 (38.0)                | 82 (50.9)                |
| Constipation                        | 20 (18.5)                    | 20 (12.4)                    | 20 (18.5)                | 25 (15.5)                |
| Dizziness                           | 20 (18.5)                    | 23 (14.3)                    | 21 (19.4)                | 27 (16.8)                |
| Dyspnoea                            | 20 (18.5)                    | 43 (26.7)                    | 24 (22.2)                | 47 (29.2)                |
| Arthralgia                          | 19 (17.6)                    | 31 (19.3)                    | 21 (19.4)                | 43 (26.7)                |
| Nausea                              | 16 (14.8)                    | 23 (14.3)                    | 17 (15.7)                | 30 (18.6)                |
| Diarrhoea                           | 14 (13.0)                    | 30 (18.6)                    | 17 (15.7)                | 38 (23.6)                |
| Myalgia                             | 14 (13.0)                    | 14 (8.7)                     | 14 (13.0)                | 19 (11.8)                |
| *COGNITIVE EFFECTS                  | 13 (12.0)                    | 45 (28.0)                    | 18 (16.7)                | 53 (32.9)                |
| Alanine aminotransferase increased  | 13 (12.0)                    | 19 (11.8)                    | 14 (13.0)                | 25 (15.5)                |
| Back pain                           | 13 (12.0)                    | 17 (10.6)                    | 15 (13.9)                | 18 (11.2)                |
| Cough                               | 13 (12.0)                    | 27 (16.8)                    | 13 (12.0)                | 35 (21.7)                |
| Headache                            | 13 (12.0)                    | 23 (14.3)                    | 18 (16.7)                | 26 (16.1)                |
| Aspartate aminotransferaseincreased | 12 (11.1)                    | 22 (13.7)                    | 13 (12.0)                | 29 (18.0)                |
| *MOOD EFFECTS                       | 11 (10.2)                    | 44 (27.3)                    | 13 (12.0)                | 45 (28.0)                |
| Disease progression                 | 11 (10.2)                    | 14 (8.7)                     | 11 (10.2)                | 16 (9.9)                 |
| Vomiting                            | 11 (10.2)                    | 11 (6.8)                     | 13 (12.0)                | 15 (9.3)                 |
| Lipase increased                    | 10 (9.3)                     | 20 (12.4)                    | 11 (10.2)                | 24 (14.9)                |
| Pyrexia                             | 10 (9.3)                     | 17 (10.6)                    | 13 (12.0)                | 26 (16.1)                |
| Weight increased                    | 10 (9.3)                     | 36 (22.4)                    | 15 (13.9)                | 46 (28.6)                |
| *VISION DISORDER                    | 9 (8.3)                      | 24 (14.9)                    | 9 (8.3)                  | 29 (18.0)                |
| *FATIGUE                            | 5 (4.6)                      | 51 (31.7)                    | 8 (7.4)                  | 59 (36.6)                |
| Anaemia                             | 5 (4.6)                      | 31 (19.3)                    | 7 (6.5)                  | 35 (21.7)                |
| *SPEECH EFFECTS                     | 4 (3.7)                      | 17 (10.6)                    | 4 (3.7)                  | 17 (10.6)                |
| Pain in extremity                   | 5 (4.6)                      | 27 (16.8)                    | 7 (6.5)                  | 30 (18.6)                |
| Upper respiratory tract infection   | 8 (7.4)                      | 16 (9.9)                     | 15 (13.9)                | 20 (12.4)                |
| Rash                                | 9 (8.3)                      | 14 (8.7)                     | 11 (10.2)                | 17 (10.6)                |
| Tinnitus                            | 9 (8.3)                      | 9 (5.6)                      | 11 (10.2)                | 10 (6.2)                 |
| Hypertension                        | 5 (4.6)                      | 16 (9.9)                     | 9 (8.3)                  | 20 (12.4)                |
| Amylase increased                   | 9 (8.3)                      | 16 (9.9)                     | 9 (8.3)                  | 18 (11.2)                |

Source: SCS Table 14.3.1.2.9.1.2.2.1.1.s1 and Table 14.3.1.2.9.1.2.2.1.2.ema.1

*=Cluster terms as indicated (Table 71)

Abbreviation:, N=number

## Extrinsic factors

## Food effect

There was no clinically significant effect of food on lorlatinib exposure. Therefore, lorlatinib may be administered without regard to food.

## Safety related to drug-drug interactions and other interactions

See Section 2.4.2.

## Discontinuation due to adverse events

AEs leading to Permanent Discontinuation

<div style=\"page-break-after: always\"></div>

Table 100: Adverse Events leading to Permanent Discontinuation by MedDRA Preferred Terms (PT), All CTCAE Grades, All Cycles (100-mg QD Pooled Group) - Safety Population

Number (%) of Patients (N=295)

| PT                        | All-causality   | Treatment-Related   |
|---------------------------|-----------------|---------------------|
| Any AEs                   | 21 (7.1) a      | 7 (2.4)             |
| Acute respiratory failure | 2 (0.7)         | 0                   |
| Dyspnoea                  | 2 (0.7)         | 0                   |
| Respiratory failure       | 2 (0.7)         | 0                   |
| Affect lability           | 1 (0.3)         | 1 (0.3)             |
| Anxiety                   | 1 (0.3)         | 0                   |
| Brain compression         | 1 (0.3)         | 0                   |
| Cognitive disorder        | 1 (0.3)         | 1 (0.3)             |
| Confusional state         | 1 (0.3)         | 1 (0.3)             |
| Disease progression       | 1 (0.3)         | 0                   |
| Embolism                  | 1 (0.3)         | 0                   |
| Fatigue                   | 1 (0.3)         | 0                   |
| Hallucination, auditory   | 1 (0.3)         | 1 (0.3)             |
| Hallucination, visual     | 1 (0.3)         | 1 (0.3)             |
| Hydrocephalus             | 1 (0.3)         | 1 (0.3)             |
| Hypoxia                   | 1 (0.3)         | 0                   |
| Leukocytosis              | 1 (0.3)         | 1 (0.3)             |
| Loss of consciousness     | 1 (0.3)         | 0                   |
| Lung infection            | 1 (0.3)         | 0                   |
| Mental state changes      | 1 (0.3)         | 0                   |
| Myocardial infarction     | 1 (0.3)         | 0                   |
| Parkinsonian gait         | 1 (0.3)         | 0                   |
| Peripheral swelling       | 1 (0.3)         | 0                   |
| Pneumonitis               | 1 (0.3)         | 1 (0.3)             |
| Tinnitus                  | 1 (0.3)         | 1 (0.3)             |
| Vomiting                  | 1 (0.3)         | 0                   |

MedDRA (version 20.0) coding dictionary was applied.

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities; N=number of patients;

a. One (1) patient discontinued treatment due to progressive disease with fatigue being reported as an AE. The Fatigue AE was mistakenly used as the primary reason of discontinuation.

Table 101: Discontinuations from treatment (subjects starting lorlatinib 100 mg QD*) safety analysis set - Data cutoff date: 02 February 2018

| Number(&)of Subjects                      | 100mgQD 295   |        |
|-------------------------------------------|---------------|--------|
| Discontinuations from Treatment           |               |        |
| Subject Died                              | 9             | (3.1)  |
| Relation to StudyDrug not Defined         | 130           | (44.1) |
| Globaldeterioration of healthstatus       | 10            | (3.4)  |
| No longer willing to participate in study | 14            | (4.7)  |
| Objective progressionor relapse           | 103           | (34.9) |
| Other                                     | 2             | (0.7)  |
| Protocol violation                        | 1             | (0.3)  |
| Related to Study Drug                     | 9             | (3.1)  |
| Adverse event                             | 9             | (3.1)  |
| Not Related to Study Drug                 | 17            | (5.8)  |
| Adverse event                             | 17            | (5.8)  |
| Total                                     | 165           | (55.9) |

<div style=\"page-break-after: always\"></div>

Table 102: Adverse Events leading to Permanent Discontinuation by MedDRA PT in decreasing frequency, All CTCAE Grades, All Cycles (100-mg QD Pooled Group) - Safety Population - Data cutoff date: 02 February 2018

|                             | Number (%o) of Patients (N=295)   | Number (%o) of Patients (N=295)   |
|-----------------------------|-----------------------------------|-----------------------------------|
| PT                          | All-causality                     | Treatment-Related                 |
| Any AEs                     | 26 (8.8)                          | 9 (3.1)                           |
| Acute respiratoryfailure    | 2 (0.7)                           | 0                                 |
| Dyspnoea                    | 2 (0.7)                           | 0                                 |
| Respiratory failure         | 2 (0.7)                           | 0                                 |
| Acuteleukaemia              | 1 (0.3)                           | 0                                 |
| Acute myocardial infarction | 1 (0.3)                           | 0                                 |
| Affect lability             | 1 (0.3)                           | 1 (0.3)                           |
| Anxiety                     | 1 (0.3)                           | 0                                 |
| Asphyxia                    | 1 (0.3)                           | 0                                 |
| Brain compression           | 1 (0.3)                           | 0                                 |
| Cognitive disorder          | 1 (0.3)                           | 1 (0.3)                           |
| Confusional state           | 1 (0.3)                           | 1 (0.3)                           |
| Disease progression         | 1 (0.3)                           | 0                                 |
| Embolism                    | 1 (0.3)                           | 0                                 |
| Hallucination               | 1 (0.3)                           | 1 (0.3)                           |
| Hallucination, auditory     | 1 (0.3)                           | 1 (0.3)                           |
| Hallucination, visual       | 1 (0.3)                           | 1 (0.3)                           |
| Headache                    | 1 (0.3)                           | 1 (0.3)                           |
| Hydrocephalus               | 1 (0.3)                           | 1 (0.3)                           |
| Hypoxia                     | 1 (0.3)                           | 0                                 |
| Leukocytosis                | 1 (0.3)                           | 1 (0.3)                           |
| Loss of consciousness       | 1 (0.3)                           | 0                                 |
| Lung infection              | 1 (0.3)                           | 0                                 |
| Mental status changes       | 1 (0.3)                           | 0                                 |
| Myocardial infarction       | 1 (0.3)                           | 0                                 |
| Parkinsonian gait           | 1 (0.3)                           | 0                                 |
| Peripheral swelling         | 1 (0.3)                           | 0                                 |
| Pneumonitis                 | 1 (0.3)                           | 1 (0.3)                           |
| Renal cyst haemorrhage      | 1 (0.3)                           | 0                                 |
| Seizure                     | 1 (0.3)                           | 0                                 |
| Thrombocytopenia            | 1 (0.3)                           | 0                                 |
| Tinnitus                    | 1 (0.3)                           | 1 (0.3)                           |
| Vomiting                    | 1 (0.3)                           | 0                                 |

Source: Table 14.3.1.1.3.1.2.2.ema.1and Table 14.3.1.1.3.2.2.2.ema.1

Abbreviations: AE=adverse event; CTCAE=Common Terminology Criteria for AEs; MedDRA=Medical Dictionary for Regulatory Activities; N=number of patients, QD=once daily.

AEs leading to temporary discontinuations and dose reductions

Table 103: Most frequent (≥2% of patients) treatment-emergent all-causality and TRAEs associated with temporary discontinuation of lorlatinib (100 mg QD pooled group) safety population - Data cutoff date: 2 February 2018

|                       | 100-mg QD Pooled Group (N = 295) n (%)   | 100-mg QD Pooled Group (N = 295) n (%)   |
|-----------------------|------------------------------------------|------------------------------------------|
| PreferredTerm         | All-Causality n (%)                      | Treatment-Relatedn(%)                    |
| Any AEsa              | 147 (49.8)                               | 99 (33.6)                                |
| *HYPERTRIGLYCERIDEMIA | 19 (6.4)                                 | 19 (6.4)                                 |
| *EDEMA                | 18 (6.1)                                 | 17 (5.8)                                 |
| *PERIPHERALNEUROPATHY | 15 (5.1)                                 | 12 (4.1)                                 |
| *COGNITIVE EFFECTS    | 14 (4.7)                                 | 14 (4.7)                                 |
| Lipase increased      | 12 (4.1)                                 | 9 (3.1)                                  |
| *HYPERCHOLESTEROLEMIA | 11 (3.7)                                 | 11 (3.7)                                 |
| *MOOD EFFECTS         | 9 (3.1)                                  | 8 (2.7)                                  |

Source:Table14.3.1.1.2.1.3.2.ema.1 and Table14.3.1.1.2.2.3.2.ema.1

Abbreviation:N/n=number; AE=adverseEvent,QD=once daily.

*=Cluster terms as defined in Table 71

a=Total number independent of frequency cutoff usedin thetable

<div style=\"page-break-after: always\"></div>

Table 104: Most frequent (≥2% of patients) treatment-emergent all-causality and TRAEs associated with dose reductions (100 mg QD pooled group) safety population - Data cutoff date: 2 February 2018

|                       | 100-mg QD Pooled Group ( 295) n (%o)   | 100-mg QD Pooled Group ( 295) n (%o)   |
|-----------------------|----------------------------------------|----------------------------------------|
| PreferredTern         | All-Causality                          | Treatment-related                      |
| Any AEs               | 73 (24.7)                              | 69 (23.4)                              |
| *EDEMA                | 18 (6.1)                               | 18 (6.1)                               |
| *PERIPHERALNEUROPATHY | 14 (4.7)                               | 13 (4.4)                               |
| *COGNITIVE EFFECTS    | 13 (4.4)                               | 12 (4.1)                               |
| *MOOD EFFECTS         | 10 (3.4)                               | 10 (3.4)                               |

Source:Table14.3.1.1.2.1.3.2.ema.1andTable14.3.1.1.2.2.3.2.ema.1

Abbreviation: N/n=number; AE=adverse Event, QD=once daily.

*=Cluster terms as defined in Table 71.

a= Total number independent of frequency cutoff used in the table

Approximately half of the patients in the 100-mg group experienced temporary dose discontinuations, most frequently due to oedema, hypertriglyceridemia and neuropathy. Almost a quarter of the patients were dose reduced due to treatment-related AEs.

## Post marketing experience

Not applicable.

## 2.6.1. Discussion on clinical safety

The safety database comprises 332 patients, and of these, 295 patients received the proposed dose for marketing  (100mg  QD).  The  median  duration  of  treatment  was  10.2  months  in  Phase  1  and approximately 16 months in the Phase 2 patients. All patients experienced at least one AE, and most of these were treatment-related. The most common TEAEs were hypercholesteremia/hypertriglyceridemia,  oedema,  peripheral  neuropathy,  fatigue,  cognitive  and  mood effects, dyspnoea, and increased weight. The most common  Grade 3-4 events were also hypercholesterolemia/hypertriglyceridemia.

Adverse  events  of  special  interest  include  hyperlipidaemia,  oedema,  peripheral  neuropathy,  CNS effects, weight gain, vision disorders, etc.

The risk of increases in serum cholesterol and triglycerides is relatively high with lorlatinib and more than 80% of the patients in Phase 2/100-mg group were treated medically. Median time of occurrence of  severe  increase  in  serum  cholesterol  and  triglycerides  is  201 days  (range:  42  to  518 days)  and 127 days  (range:  15  to  358 days),  respectively.  Serum  cholesterol  and  triglycerides  should  be monitored  before  initiation  of  lorlatinib;  2, 4  and  8 weeks  after  initiating  lorlatinib;  and  regularly thereafter.  Lipid-lowering medicinal products should be initiated or their dose increased, if indicated (see Sections 4.2, 4.4 and 4.8 of the SmPC).

CNS effects have been observed in patients receiving lorlatinib, including changes in cognitive function, mood or speech (see Sections 4.4 and 4.8 of the SmPC). The risk of an event is less frequent in the Phase 2 part and these events may therefore be dose- and exposure related. Despite the relatively low rate of Grade 3 events, the impact of the reported cognitive disorders (neurological and psychiatric) may be important for the patient's  quality  of  life.  Such  events  included  confusion,  delirium,  mental impairment, amnesia, dementia, disturbance in attention, etc., which are considered clinically relevant also at a Grade 2 of severity. Their impact on patient's quality of life was discussed by the Applicant, however  as  CNS  effects  and  their  origin  are  very  complex  and  challenging  both  to  diagnose  and evaluate the degree of impact on patient functioning may be equally difficult to assess. CNS effects are an identified risk in the RMP and will be monitored via routine pharmacovigilance. Dose modification or

<div style=\"page-break-after: always\"></div>

discontinuation may be required for those patients who develop CNS effects (see Sections 4.2, 4.4 and 4.8).

Lorlatinib  was  studied  in  a  population  of  patients  that  excluded  those  with  second-degree  or third-degree  AV  block  (unless  paced)  or  any  AV  block  with  PR  interval  &gt; 220 msec.  PR  interval prolongation and AV block have been reported in patients receiving lorlatinib. ECG should be monitored prior to initiating lorlatinib and monthly thereafter, particularly in patients with predisposing conditions to the occurrence of clinically significant cardiac events. Dose modification may be required for those patients who develop PR prolongation or AV block (see Sections 4.2, 4.4 and 4.8 of the SmPC). AV block is identified as an important potential risk in the Risk Management Plan.

Left ventricular ejection fraction (LVEF) decrease has been reported in patients receiving lorlatinib who had baseline and at least one follow-up LVEF assessment. Based on the available clinical trial data, it is not possible to determine a causal relationship between effects on changes in cardiac contractility and lorlatinib. In patients with cardiac risk factors and those with conditions that can affect LVEF, cardiac monitoring,  including  LVEF  assessment  at  baseline  and  during  treatment,  should  be  considered.  In patients who develop relevant cardiac signs/symptoms during treatment, cardiac monitoring, including LVEF assessment should be considered.

Elevations  of  lipase  and/or  amylase  have  occurred  in  patients  receiving  lorlatinib.  Median  time  of occurrence of increase in serum lipase and amylase is 70 days (range: 7 to 696 days) and 41 days (range: 7 to 489 days), respectively. Risk of pancreatitis should be considered in patients receiving lorlatinib  due  to  concomitant  hypertriglyceridemia  and/or  a  potential  intrinsic  mechanism.  Patients should be monitored for lipase and amylase elevations prior to the start of lorlatinib treatment and regularly thereafter as clinically indicated (see Sections 4.2, 4.4 and 4.8 of the SmPC).

Severe or life-threatening pulmonary adverse reactions consistent with ILD/pneumonitis have occurred with  lorlatinib.  Any  patient  who  presents  with  worsening  of  respiratory  symptoms  indicative  of ILD/pneumonitis (e.g. dyspnoea, cough and fever) should be promptly evaluated for ILD/pneumonitis. Lorlatinib should be withheld and/or permanently discontinued based on severity (see Sections 4.2, 4.4 and 4.8 of the SmPC).

In Phase 1, 27 patients have died, and no deaths were considered treatment-related. In Phase 2, 30 patients died and although none of the deaths were considered treatment-related, after a clarification, 2  deaths  were  re-categorised  as  death  from  disease  progression  and  one  death  remains  due  to unknown causes.

Most  of  the  SAEs  are  cases  of  disease  progression,  or  due  to  other  known  risks  associated  with disseminated  cancer-disease  such  as  pulmonary  embolism  and  super  vena  cava  syndrome  that  are present in an expected number for this patient population.

There was generally more toxicity in non-Asian patients and clinically significant differences regarding hypertriglyceridemia,  oedema, peripheral neuropathy, cognitive and mood effects, increased weight, fatigue, and anaemia. This result correlates with other findings in clinical trials; however, although all causality  treatment-emergent  AEs  showed  a  similar  incidence  among  Asian  and  non-Asian  patients (99.1% versus 100%), the Grade 3-4 or Grade 5 adverse events were found respectively in 57.4% and 12.0% in the Asian group versus 48.4% and 14.9% in the non-Asian group. The greatest differences in incidence among the 2 race groups was found for: fatigue (Asian 7.4% versus non-Asian 36.6%), and anaemia  (Asian  6.5%  versus  non-Asian  21.7%).  Only  minor  differences  in  all  causality  AEs  were observed for Phase 1 and Phase 2 receiving RP2D after stratification by race and cumulating all cycles with regards to incidence or to severity.

<div style=\"page-break-after: always\"></div>

Less than 10% of the patients discontinued lorlatinib permanently, but it is noted that only a third of the discontinuations were assessed to be due to treatment-related AEs and these AEs were mostly related to cognitive effects, even at the 100 mg dose.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics

## Additional safety data needed in the context of a conditional MA

There are inherent limitations to the interpretation of the safety profile based on a single arm noncomparative trial. The safety data from the ongoing controlled Phase 3 CROWN study (1006) will be important to further characterise the safety profile of lorlatinib post authorisation (see Annex II).

## 2.6.2. Conclusions on the clinical safety

The  safety  profile  of  lorlatinib  is  in  line  with  what  could  be  expected  from  an  ALK-inhibitor.  Most toxicities were clinically manageable with dose modifications, and only few uncertainties regarding the safety  profile  remain  (see  SmPC  and  RMP).  The  ongoing  confirmatory  Phase  3  trial  is  expected  to provide  comprehensive  evidence  in  respect  to  safety,  in  particular,  regarding  the  CNS  effects.  The discontinuation rate was below 10% and is considered relatively low and acceptable in the palliative setting. Overall, the safety profile of lorlatinib is manageable and in line with other ALK-inhibitors.

The CHMP considers the following measures necessary to address the missing safety data in the context of a conditional MA:

- In order to further confirm the safety of lorlatinib in the treatment of patients with ALK-positive NSCLC, the MAH should submit the clinical study report of the Phase 3 study CROWN (1006) comparing lorlatinib versus crizotinib for the first-line treatment of advanced ALK-positive NSCLC. The clinical study report will be submitted by 31 December 2021.

## 2.7. Risk Management Plan

## Safety concerns

| Important Identified Risks   | CNS Effects                                         |
|------------------------------|-----------------------------------------------------|
|                              | Interstitial lung disease/pneumonitis               |
| Important Potential Risks    | Atrioventricular block                              |
|                              | Pancreatitis                                        |
|                              | Embryo-foetal toxicity                              |
| Missing Information          | Patients with moderate or severe hepatic impairment |
| Missing Information          | Patients with severe renal impairment               |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Lorlatinib Hepatic Impairment Trial (B7461009)                                                                                                                                                                             | To minimize toxicity in patients with hepatic impairment.                                                                                                                                                                  | Missing information on patients with moderate or severe hepatic impairment                                                                                                                                                 | Final Protocol Submission: Study/Trial Completion: Final Report Submission:                                                                                                                                                | 07/09/2018 03/31/2023 02/28/2024                                                                                                                                                                                           |
| Lorlatinib Renal Impairment Trial (B7461010)                                                                                                                                                                               | To determine an appropriate dose of lorlatinib to minimize toxicity in patients with renal impairment.                                                                                                                     | Missing information on patients with severe renal impairment                                                                                                                                                               | Final Protocol Submission: Study/Trial Completion: Final Report Submission:                                                                                                                                                | 04/12/2018 05/31/2020 01/31/2021                                                                                                                                                                                           |

## Risk minimisation measures

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                        | Risk Minimisation Measures                                                                                           | Pharmacovigilance Activities                                                                                                                                       |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks            | Important Identified Risks                                                                                           | Important Identified Risks                                                                                                                                         |
| CNS effects                           | Routine risk minimisation measures: SmPC sections 4.2, 4.4, 4.7, and 4.8 Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Follow up questionnaire Additional pharmacovigilance activities: None |
| Interstitial lung disease/pneumonitis | Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: None                     | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                    |
| Important Potential Risks             | Important Potential Risks                                                                                            | Important Potential Risks                                                                                                                                          |
| Atrioventricular block                | Routine risk minimisation measures: SmPC sections 4.2, 4.4 Additional risk minimisation measures: None               | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance                                     |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                      | Risk Minimisation Measures                                                                                  | Pharmacovigilance Activities                                                                                                                                                              |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                                                             | activities: None                                                                                                                                                                          |
| Pancreatitis                                        | Routine risk minimisation measures: SmPC section 4.4, 4.8 Additional risk minimisation measures: None       | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                           |
| Embryo-foetal toxicity                              | Routine risk minimisation measures: SmPC sections 4.4, 4.6, 5.3 Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                           |
| Missing Information                                 | Missing Information                                                                                         | Missing Information                                                                                                                                                                       |
| Patients with moderate or severe hepatic impairment | Routine risk minimisation measures: SmPC sections 4.2, 5.2 Additional risk minimisation measures: None      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Lorlatinib Hepatic Impairment Trial (B7461009) |
| Patients with severe renal impairment               | Routine risk minimisation measures: SmPC sections 4.2, 5.2 Additional risk minimisation measures: None      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional Pharmacovigilance activities: Lorlatinib Renal Impairment Trial (B7461010)   |

## Conclusion

The CHMP and Pharmacovigilance Risk Assessment Committee (PRAC) considered that the risk management plan version 1.0 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the Periodic

<div style=\"page-break-after: always\"></div>

Safety Update Report (PSUR) cycle with the international birth date (IBD). The IBD is 21.09.2018. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. New Active Substance

The  applicant  compared  the  structure  of  lorlatinib  with  active  substances  contained  in  authorised medicinal  products  in  the  European  Union  and  declared  that  it  is  not  a  salt,  ester,  ether,  isomer, mixture of isomers, complex or derivative of any of them.

The CHMP, based on the available data, considers lorlatinib to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Lorviqua  (lorlatinib)  is  included  in  the additional monitoring list as:

-  It contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU;
-  It is approved under a conditional marketing authorisation [REG Art 14(7)]

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The indication is as follows:

' Lorlatinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase  (ALK)  positive  advanced  non  small  cell  lung  cancer  (NSCLC)  whose  disease  has  progressed after:

- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or

<div style=\"page-break-after: always\"></div>

## · crizotinib and at least one other ALK TKI'.

The aim of therapy is to prolong survival and improve overall response rate (ORR), especially for in the CNS, as brain metastases are a major clinical problem in this patient population. The primary endpoint of the pivotal trial is ORR by investigator and can be considered an early surrogate for clinical benefit.

## 3.1.2. Available therapies and unmet medical need

ALK-inhibitors are currently the main treatment options for ALK-positive NSCLC. The first ALK inhibitor to be approved was crizotinib in 2012, but since then alectinib and ceritinib have been approved as first- and second-line therapies.

There is an unmet medical need for further targeted therapy in patients who have already received the approved ALK-inhibitors (crizotinib, ceritinib, and alectinib) as few treatment options are available once patients become resistant to approved therapies. Currently, there are no standard of care for patients in  the  second-line  after  alectinib or  ceritinib  nor  in  the  third-  or  later  line  setting  as  treatment  with chemotherapy has a very modest efficacy in both settings in addition to poor penetrance to the CNS. There  is  a  particular  need  for  therapies  active  in  the  CNS,  as  brain  metastases  is  a  major  clinical problem in this patient population, reflected by an incidence of brain metastases of 75% of patients in cohort  EXP-4  and  5  of  the  pivotal  study.  Therefore  there  is  a  high  unmet  medical  need  for  further treatment  options  in  patients  with  CNS  metastases.  The  data  is  currently  limited  on  the  use  of checkpoint inhibitors in the second- and third line setting (small sample sizes) in patients with ALKpositive  NSCLC  and  represented  in  small  subgroups  of  larger  randomised  trials.  In  addition,  the efficacy  results  with  immunotherapy  are  not  of  high  clinical  relevance  in  this  setting.  In  conclusion, there is currently no effective standard of care for patients neither in the proposed second-line setting after alectinib or ceritinib nor in the third-or later line setting.

The unmet medical need also includes prevention of CNS metastases as this is a potential risk for all patients with ALK-positive advanced NSCLC, who have received available targeted therapies.

## 3.1.3. Main clinical studies

Data  from  a  pivotal  Phase  1-2  study  are  provided.  Both  parts  of  the  study  were  open-label,  nonrandomised, single-arm study with no comparator. In the Phase 1 part, 41 patients were included, and in the Phase 2 part, 197 patients with ALK-positive NSCLC were included across 5 cohorts. However, the relevant study population for the sought indication were cohort 3B-5, which consisted of patients with:

-  Diagnosis of advanced ALK-positive NSCLC;
-  Previously treated with a prior second-generation ALK-TKI with or without chemotherapy (EXP3B);
-  Previously treated with 2 or more ALK-TKIs (pooled cohorts EXP-4 and EXP-5)

## 3.2. Favourable effects

Primary  endpoint:  Confirmed  ORR  by  IRC  was  42.9%  (95%CI:  54.5,  62.8)  in  cohort  EXP-3B  and among patients treated with 2 or 3 prior ALK-TKIs (pooled cohort EXP-4:EXP-5), the ORR was 38.7% (95%CI: 29.6, 48.5). Per cohort, the ORRs were 41.5% (CI 29.4, 54.4) in EXP-4 and 37.0% (23.2, 52.5) in EXP-5. A partial response was obtained in 39.3% in cohort EXP-3B and 37.8% in cohort EXP4-5, while complete responses were observed in 3.6% and 1.8% of the patients, respectively.

<div style=\"page-break-after: always\"></div>

Key secondary endpoints: Intracranial ORR by IRC, and results are also presented by cohort. Among the 9 patients with baseline brain metastases in EXP-3B, the IC ORR was 66.7% (95%CI: 29.9, 92.5) and among the 48 patients with baseline brain metastases in EXP-4:EXP-5, the IC ORR was 52.1% (95%CI: 37.2, 66.7). The CR/PR rates were 22.2/44.4% and 20.8/31.3%, respectively. Two patients (22.2%) and 8.3% of the patients from these subgroups, respectively, had progressive disease and no and 35.4%, respectively, had stable disease.

Median duration of response was 5.6 months (4.17-NR) in cohort EXP-3B and 9.9 months (5.65-24.44) in  the  pooled  cohorts  EXP-4  and  5,  while  time  to  tumour  response  were  approximately  1.4  months across the cohorts. Median PFS by ICR was 5.5 months (95%CI: 2.9, 8.2) for EXP-3B and 6.9 months (95%CI: 5.4, 9.5) for EXP-4:EXP-5. The median OS for the 28 patients with ALK-positive NSCLC in EXP-3B  was  19.5  months  (95%CI:  18.3,  21.0)  while  it  was  20.5  months  (95%CI:  19.6,  23.3  for EXP-4:EXP-5.

There were no detrimental effects on quality of life in the pivotal study.

## 3.3. Uncertainties and limitations about favourable effects

Although  the  results  from  the  presented  study  are  considered  mature,  they  are  not  considered comprehensive as based on uncontrolled data with limited sample size. Thus confirmatory studies are needed.

The ongoing confirmatory Phase 3 study compares lorlatinib to crizotinib in the first-line treatment of ALK-positive  NSCLC  and  results  will  be  available  by  Q4  2021.  This  proposed  confirmatory  study  is considered  acceptable  for  confirming  the  overall  efficacy  and  safety  of  lorlatinib.  In  view  of  the preliminary  evidence  for  the  benefit  of  lorlatinib  in  the  proposed  second-line  setting  in  patients progressing  on/resistant  to  currently  approved  second-generation  ALK-inhibitors,  an  observational efficacy study adequately powered to confirm the observed results in the limited sample size from EXP3B will be conducted as a specific obligation to the CMA. The PAES will confirm the efficacy of lorlatinib in  the  second-line setting after disease progression on alectinib or ceritinib. The primary endpoint is ORR, the estimated sample size is 70 patients, and the results will be available in Q2 2024.

## 3.4. Unfavourable effects

All of the patients experienced at least one AE, and most of these were treatment-related. The most common  TEAEs  were  hypercholesterolemia/hypertriglyceridemia,  oedema,  peripheral  neuropathy, fatigue,  cognitive  and  mood effects, dyspnoea, and increased weight. The most  common Grade 3-4 events were also hypercholesterolemia/hypertriglyceridemia.

Adverse  events  of  special  interest  include  hyperlipidaemia,  oedema,  peripheral  neuropathy,  CNS effects, weight gain, and vision disorders.

Less than 10% of the patients discontinued lorlatinib permanently, but it is noted that only a third of the  discontinuations  were  assessed  to  be  treatment-related  and  these  AEs  were  mostly  related  to cognitive effects, even at the 100 mg dose.

## 3.5. Uncertainties and limitations about unfavourable effects

There are inherent limitations to the interpretation of the safety profile  based on a single arm noncomparative trial. The safety data from the ongoing controlled Phase 3 study 1006 will be important to further characterise the safety of lorlatinib post authorisation (see Annex II).

<div style=\"page-break-after: always\"></div>

The CNS effects include e.g. mood effects, speech effects, and cognitive effects and looking at each effect  individually  may  cause  an  underestimation  of  the  overall  risk  of  CNS  effects  with  lorlatinib. Despite the relatively low rate of Grade 3 events, the reported cognitive disorders (neurological and psychiatric) may impact the patient's quality of life. CNS effects and their origin are very complex and challenging  both  to  diagnose  and  evaluate,  and  the  impact  on  patient  functioning  may  be  equally difficult to estimate. Therefore, safety results from the ongoing confirmatory Phase 3 study comparing lorlatinib to crizotinib in the first-line treatment of ALK-positive NSCLC (see Annex II) are especially important  regarding  the  assessment  of  CNS  effects  in  the  first-line  setting  as  fewer  patients  would have metastases to the CNS at that point in time.

## 3.6. Effects Table

Table 105: Effects Table for lorlatinib (data cutoff: 02 February 2018).

| Effect                                          | Short Description                                                   | Unit                                            | Treatment                                       | Control                                         | Uncertainties/ Strength of evidence             | Referen ces                                     |
|-------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Favourable Effects                              | Favourable Effects                                                  | Favourable Effects                              | Favourable Effects                              | Favourable Effects                              | Favourable Effects                              | Favourable Effects                              |
| ORR by IRC                                      | Proportion of patients with a confirmed CR or PR                    | %                                               | EXP-3B: 42.9% EXP-4:EXP-5: 38.7%                | N/A                                             |                                                 |                                                 |
| ORR IC                                          | CR or PR in the CNS                                                 | %                                               | EXP-3B: 66.7% EXP-4:EXP-5: 52.1%                | N/A                                             |                                                 |                                                 |
| TTR                                             | Time to tumour response                                             | Months                                          | EXP-3B: 1.4 EXP-4:EXP-5: 1.4                    | N/A                                             |                                                 |                                                 |
| DOR                                             | Duration of response in patients with a RECIST Version 1.1 CR or PR | Months                                          | EXP-3B: 5.6 EXP-4:EXP-5: 9.9                    | N/A                                             |                                                 |                                                 |
| PFS                                             | Progression free survival                                           | Months                                          | EXP-3B: 5.5 EXP-4:EXP-5: 6.9                    | N/A                                             |                                                 |                                                 |
| OS                                              | Overall survival                                                    | Months                                          | EXP-3B: 19.5 EXP-4:EXP-5: 20.5                  | N/A                                             |                                                 |                                                 |
| Unfavourable Effects: safety population (n=295) | Unfavourable Effects: safety population (n=295)                     | Unfavourable Effects: safety population (n=295) | Unfavourable Effects: safety population (n=295) | Unfavourable Effects: safety population (n=295) | Unfavourable Effects: safety population (n=295) | Unfavourable Effects: safety population (n=295) |
| Treatment- related Grade ≥ 3 TEAE               |                                                                     | %                                               | 38.6                                            | N/A                                             |                                                 |                                                 |
| Hypercholeste rolemia                           | Treatment-related All grades                                        | %                                               | 84.4                                            | N/A                                             |                                                 |                                                 |
| Hypertriglycer idemia                           | Treatment-related All grades                                        | %                                               | 67.1                                            | N/A                                             |                                                 |                                                 |
| Oedema                                          | Treatment-related All grades                                        | %                                               | 54.6                                            | N/A                                             |                                                 |                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                | Short Description            | Unit   |   Treatment | Control   | Uncertainties/ Strength of evidence   | Referen ces   |
|-----------------------|------------------------------|--------|-------------|-----------|---------------------------------------|---------------|
| Peripheral neuropathy | Treatment-related All grades | %      |        47.8 | N/A       |                                       |               |
| Cognitive effects     | Treatment-related All grades | %      |        28.8 | N/A       |                                       |               |
| Fatigue               | Treatment-related All grades | %      |        28.1 | N/A       |                                       |               |
| Mood effects          | Treatment-related All grades | %      |        22.7 | N/A       |                                       |               |
| Weight increased      | Treatment-related All grades | %      |        26.4 | N/A       |                                       |               |
| Diarrhoea             | Treatment-related All grades | %      |        22.7 | N/A       |                                       |               |
| Vision disorders      | Treatment-related All grades | %      |        15.3 | N/A       |                                       |               |

Abbreviations: TAE: Treatment Emergent Event.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

There  is  a  recognised  unmet  medical  need  in  ALK-positive  NSCLC  patients  who  progressed  after currently available ALK-targeted agents (crizotinib, alectinib, and ceritinib).

Treatment with lorlatinib results in clinically relevant response rates and duration of response in the proposed  second-  and  third  or  later  line  indication.  The  efficacy  in  brain  metastases  is  clinically meaningful  and  lorlatinib is considered an effective  treatment  option for patients with brain metastases.

A major therapeutic advantage of lorlatinib over treatment alternatives (platinum-based chemotherapy and immunotherapies, etc.) can therefore be agreed upon for the proposed indication.

Although the number of patients included in the cohort EXP-3B supporting the 2 nd  line indication is limited, the totality of the data in the post 2 nd  generation ALK-inhibitors setting can support a positive B/R in that indication. The pivotal study is a single arm study with no comparator. However, as ALK is a driver mutation in ALK-positive NSCLC and lorlatinib is a targeted treatment against a well-known target,  a  randomisation  to  chemotherapy,  immunotherapy  or  placebo  is  not  considered  ethical  in  a situation,  when  the  disease  progresses  after  use  of  the  available  ALK-inhibitors,  due  to  the  poor efficacy  of  these  treatment  options.  Furthermore,  all  of  the  developed  ALK-inhibitors  have  been superior in efficacy compared to chemotherapy and immunotherapy so far, both regarding ORR and duration  of  response  and  there  is  an  unmet  medical  need  in  patients  who  progressed  after  second generation ALKi in the 2 nd or 3 rd  line setting. However, given the limited sample size the applicant will conduct and submit an efficacy study post authorisation to further confirm the positive B/R in the 2 nd line post 2 nd  generation ALK-inhibitor setting (see Section 3.7.3). The applicant's proposal for the study design is considered acceptable and results from approximately 70 patients treated in the proposed second-line setting will be available in Q2 2024.

Efficacy  data  presented  according  to  the initial  lines  of  ALK-targeted  therapy  from  the  EXP-4  and  5 cohorts show that almost all of the patients had crizotinib as first-line therapy and that lorlatinib as 3 rd line treatment only induced responses in patients, who have had previous treatment with crizotinib and this is reflected in the wording of the indication. Time to tumour response of 1.4 months is in line with other ALK-inhibitors and is also considered clinically meaningful. It is also noted that the median OS was 20.5 months in the EXP4-5 cohort, which is considered highly clinically relevant in the third-or

<div style=\"page-break-after: always\"></div>

later  line  setting.  There  was  no  obvious  selection  bias  of  subsequent  therapies,  the  results  are therefore considered clinically relevant and meaningful.

Reported adverse reactions appear manageable and for the most part reversible and unlikely to affect the  tolerability  of  lorlatinib  in  the  proposed  dose.  Lorlatinib  causes  multiple  CNS  effects  which  may have a negative impact on the patient's quality of life. However, it should be noted that only 7.1% of patients discontinued lorlatinib at the proposed dose regimen.

Finally,  as  part  of  the  requirements  for  granting  CMA,  the  applicant  will  provide  results  from  an ongoing  confirmatory  Phase  3  trial  in  Q4  2021  at  the  earliest.  Such  data  will  confirm  the  overall efficacy and further characterise the safety profile of lorlatinib in the authorised indication. In addition, the  applicant  will  conduct  a  PAES  in  the  2 nd line  post  2 nd generation  ALK  inhibitors  to  confirm  the efficacy of lorlatinib in that setting. The results will be submitted by Q2 2024 (see Annex II).

## 3.7.2. Balance of benefits and risks

The B/R is positive in the claimed indication. It is agreed that lorlatinib represents a major therapeutic advantage  in  patients  who  have  been  previously  treated  with  the  2 nd   generation  ALK-inhibitors alectinib or ceritinib and/or crizotinib who currently have very limited treatment options with limited efficacy and no standard of care. The ORR and DOR are considered clinically relevant in this setting and outweigh the risks related to the use of lorlatinib. Lorlatinib is a valuable treatment option with clinically meaningful efficacy in the CNS and results show similar response rates both systemically and in the CNS.

## 3.7.3. Additional considerations on the benefit-risk balance

## Conditional marketing authorisation

As comprehensive data on the  product are not available, a conditional marketing authorisation was requested by the applicant in the initial submission.

The  product  falls  within  the  scope  of  Article  14-a  of  Regulation  (EC)  No  726/2004  concerning conditional  marketing  authorisations,  as  it  aims  at  the  treatment  of  advanced  ALK-positive  NSCLC which is a life-threatening disease.

Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation:

-  The benefit-risk balance is positive, as discussed. Treatment with lorlatinib has demonstrated a positive  benefit-risk  balance  for  the  treatment  of  ALK-positive  NSCLC  in  the  proposed indication.
-  It is likely that the applicant will be able to provide comprehensive data. The data package is not considered comprehensive and the applicant will submit a  Phase 3 confirmatory study in the  1 st line  setting  to  further  characterise  the  overall  efficacy  and  safety  profile  of  lorlatinib. Although  the  Phase 3  study  will  be  conducted  in  the  1L  setting  it  will  provide  additional evidence to support the overall efficacy of lorlatinib in ALK-positive NSCLC and will allow putting safety data into context. In addition, in view of the limited sample size of cohort EXP-3B, the applicant will conduct and submit the results from an efficacy study to confirm efficacy in the proposed 2L ALK-positive NSCLC post 2 nd  generation ALKi setting. These are specific obligations to the CMA. The SOB is considered feasible as there is a high unmet medical need and to date no  standard  of  care  is  available  in  the  proposed  second-line  setting  i.e.  after  alectinib  and ceritinib and results are awaited by Q2 2024. The confirmatory Phase 3 trial is also considered

<div style=\"page-break-after: always\"></div>

feasible as it is almost fully recruited and results are awaited in Q4 2021.

-  Unmet medical needs will be addressed, as to date there is no standard of care in the proposed second- or later line setting. Patients who have progressed after a second generation ALKi in the 2L or 3L setting patients have a poor long-term prognosis. Lorlatinib represents a major therapeutic advantage over potential alternative treatment options for the proposed indication i.e. chemotherapy and immunotherapy. No targeted therapies (ALK-TKIs) have been approved for the applied indication.
-  The benefits to public health of the immediate availability outweigh the risks inherent in the fact  that  additional  data  are  still  required,  as  the  available  data  show  that  lorlatinib  is  an effective  CNS-penetrative  therapy  option  in  patients  who  progressed  after  treatment  with  a second  generation  ALK-inhibitors  such  as  alectinib  and  ceritinib,  a  clinical  setting  where currently no treatments are authorised.

## 3.8. Conclusions

The  overall  B/R  of  lorlatinib  for  the  treatment  of  adult  patients  with  ALK  positive  advanced  NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK TKI therapy; or crizotinib and at least one other ALK-TKI is positive.

A divergent position is appended to this report.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by  majority decision that the benefit-risk balance of Lorviqua is favourable in the following indication:

Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase  (ALK)-positive  advanced  non-small  cell  lung  cancer  (NSCLC)  whose  disease  has  progressed after:

-  alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
-  crizotinib and at least one other ALK TKI.

The CHMP therefore recommends the granting of the conditional marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, Section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out  in  the  list  of  Union  reference  dates  (EURD  list)  provided  for  under  Article  107c(7)  of  Directive

<div style=\"page-break-after: always\"></div>

2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

-  At the request of the European Medicines Agency;
-  Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

Not applicable

## Specific Obligation to complete post-authorisation measures for the conditional marketing authorisation

This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

| Description                                                                                                                                                                                                                                                                                                                                                      | Due date         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| In order to further confirm the efficacy and safety of lorlatinib in the treatment of patients with ALK-positive NSCLC, the MAH should submit the clinical study report of the phase III study CROWN (1006) comparing lorlatinib versus crizotinib for the first- line treatment of advanced ALK-positive NSCLC. The clinical study report will be submitted by: | 31 December 2021 |
| In order to further confirm the efficacy of lorlatinib in patients who progressed after alectinib or ceritinib as the first ALK-TKI therapy, the MAH should conduct a prospective single arm study investigating patients in that same setting. The clinical study report will be submitted by:                                                                  | 30 June 2024     |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

<div style=\"page-break-after: always\"></div>

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that lorlatinib is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## APPENDIX

DIVERGENT POSITION DATED 28 February 2019

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 28 February 2019

## Lorviqua EMEA/H/C/004646/0000

The undersigned members  of  the  CHMP  did  not agree with the CHMP's  positive opinion recommending the granting of the marketing authorisation of Lorviqua indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) whose disease has progressed after:

- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
- crizotinib and at least one other ALK TKI.

The reason for divergent opinion was the following:

## Divergent position

The undersigned members of the CHMP did not agree with the CHMP's positive opinion recommending the granting of the conditional marketing authorisation of Lorviqua 25 &amp; 100 mg film-coated tablets indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) after treatment with at least one second-generation ALK tyrosine kinase inhibitor (TKI).

In line with the requirements for a conditional marketing authorisation, the applicant must ensure that a major therapeutic advantage has been shown for the product applied for. In the view of the divergent CHMP members, these requirements have not been fulfilled for the following reasons:

-  Major therapeutic advantage has not been shown for the entire claimed indication, as efficacy in the second-line setting (i.e. after a previous treatment with a second-generation ALK tyrosine kinase inhibitor) is currently not sufficiently established. The number of patients in the second line (n=28) does not allow for a proper evaluation of the efficacy data.
-  The major therapeutic advantage shown in terms of efficacy in third or further lines cannot be extrapolated to the second-line setting, as the Applicant has not provided (non)-clinical data in support for such extrapolation approach.

Thus, the efficacy of Lorviqua 25 &amp; 100 mg film-coated tablets in the claimed indication has not been sufficiently demonstrated rendering the B/R relationship of this product undetermined.

## CHMP Members expressing a divergent opinion:

-  HR - Katarina Vučić
-  ES - Concepcion Prieto Yerro
-  FR - Alexandre Moreau
-  NL - Johann Lodewijk Hillege
-  Co-opted member - Sol Ruiz